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The study of the synthesis of highly functionalized heterocyclic compounds represents an 
important subset of synthetic organic transformations leading to target compounds with a wide 
set of applications in medicinal chemistry, biological chemistry, materials sciences and natural 
product synthesis.  Through this work, synthetic strategies leading to a novel set of ester linked 
substituted quinoline – uracil scaffolds have been developed and the resulting products were 
found to be inhibitors of MPK1, an important target in cancer research.  This work has also led to 
the development and implementation of novel synthetic strategies toward highly functionalized, 
traditionally pharmacologically important 6-amino-, 6-hydroxy- and 6-oxo-uracil and 4,6-
dihydroxypiperidone scaffolds.  A novel Plk1-PBD inhibitor from this series would be important 
to probe the mechanism of this enzyme during mitosis and to develop a clinical candidate for this 
validated cancer target.  The Plk1-PBD research endeavor also documents a case for a tandem 
synthetic/analytical structure determination study.  The structure of an initially elusive compound 
from a high throughput screening of 97,090 compounds was determined by this approach.  
 
     Finally, the utility of novel heterocyclic sulfonyl and sulfinyl nitrogen protecting 
groups has been demonstrated through the addition of organometallic reagents to 2-
methylthiadiazole-, 2-benzothiazolesulfonylbenzaldimines and 2-pyridylsulfinylbenzaldimines.  
It was found that these addition reactions proceeded with a variety of organometallic 
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 v 
nucleophiles including Gringnard reagents, organozinc and organocuprates.  The heterocyclic 
sulfonyl protecting groups were easily cleaved from the α-branched amines, affording a useful 
protecting group strategy for the synthesis of this important class of compounds.    
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1.0  SYNTHESIS AND BIOLOGICAL ACTIVITY OF A FOCUSED LIBRARY OF 
MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE INHIBITORS1 
1.1 INTRODUCTION 
The synthesis of a small library of mitogen-activated protein kinase phosphatase-1 (MKP-1) 
inhibitors and their resultant biological activity will be discussed.  After a brief biological 
discussion, the background for the project is presented and the library design is introduced.  The 
discussion focuses on the routes used for the synthesis of the library and the resulting biological 
data.  The work in this chapter has appeared in reference 1. 
1.1.1 Brief biological background 
The family of mitogen-activated protein kinases (MAPKs) represents a class of evolutionary 
conserved enzymes which are involved in highly regulated signaling pathways within the cell.2  
Mitogen-activated protein kinases play a crucial role in the regulation of cellular processes such 
as gene expression, cell proliferation, cell survival and cell death.2   In the MAPK signaling 
pathway, MKP-1 has been identified as a crucial regulatory enzyme whose function affects the 
outcome of many of these cellular processes, a result which has supported the role of MKP-1 as 
an important target for biological research.3   Resent studies have also shown MKP-1 to be a 
potentially significant target for cancer therapy since the gene is overexpressed in human lung, 
prostate, gastric, breast and pancreatic cancers.4,5 
 2 
1.1.2  Project background 
Over the last two decades, the increasing biological importance of MKP-1 as a crucial regulatory 
enzyme in MAPK signaling cascades and as a potentially important therapeutic target has 
spurred the search for a potent and selective MKP-1 inhibitor.  Unfortunately, to this date, there 
is no crystal structure of the MKP-1 enzyme available to guide rational inhibitor design.  
Therefore, the identification of MKP-1 inhibitors has been the result of high throughput 
screening (HTS) efforts in conjunction with secondary MKP-1 cellular assays.6,7   
 
     In 2005, the University of Pittsburgh Department of Pharmacology reported 
sanguinarine as the first selective inhibitor of MKP-1, (1, Figure 1).  Sanguinarine was identified 
via a high-content analysis of 720 natural products and was shown to selectively inhibit MKP-1 
in vitro with an IC50 = 17.3 µM in comparison with other related dual-specificity phosphatases 
such as MKP-3 (IC50 >>100 µM), Cdc25B (IC50 = 57.8 µM), VHR (IC50 = 74.0 µM) and PTP1B 
(IC50 = 67.9 µM).7 Sanguinarine was also found to preferentially inhibit MKP-1 over MKP-3 in 
intact HeLa cells, showing 1 to be active at the cellular level.7  Selective inhibition of MKP-1 
over MKP-3 is a good criteria for general MKP-1 selectivity, given the structural homology 
between the catalytic domains of these two dual-specificity phosphatases in which the amino 
acid sequence is 82% identical.6  Utilizing the scaffold of sanguinarine, the authors investigated 
the inhibitory effect on MKP-1 of five other structurally similar compounds: chelerythrine 2, 
hydroxychelidonine 3, berberine 4, tetrahydroberberine 5 and protopine 6 (Figure 1), but only 2 
was found to inhibit MKP-1 with comparable potency (IC50 = 16.2 µM).7  
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Figure 1. Structure of sanguinarine and related analogues tested for MKP-1 inhibition.7 
 
In 2006, a second paper demonstrated the potency of novel benzofuran based inhibitors 
of MKP-1, such as NU-126 (7, Figure 2).6  The potency of 7 was similar to that of 1, inhibiting 
MKP-1 with an in vitro IC50 value of 28.2 µM.6  The selectivity of 7 for MKP-1 versus other 
dual-specificity phosphatases was enhanced over that of 1, as demonstrated by the in vitro IC50 
values of 7 for MKP-3 (IC50 > 400 µM), Cdc25B (IC50 > 400 µM), VHR (IC50 = 38.1 µM) and 
PTP1B (IC50 > 100 µM).6 
 
N
H
O
NC
CN
7
IC50: 28.2 µM  
Figure 2. Structure of NU-126 (7).6 
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In 2007, a high throughput screen of 13,309 compounds was conducted by the Pittsburgh 
Molecular Libraries Screening Center (PMLSC) to identify small molecule inhibitors of MKP-
1.1   Among the hits, a compound containing a linked quinoline-uracil scaffold was identified as 
an inhibitor of MKP-1 with an average IC50 value of 19.2 + 5.6 µM (8, Figure 3).1  The structure 
of 8 was unique among the HTS hits since it was the only quinoline-uracil based scaffold that 
was tested in this screen.1  This fact, along with the low µM in vitro potency of 8 and its 
relatively easily accessible structure encouraged the synthesis of analogues designed to 
systematically probe favorable binding interactions with MKP-1. 
 
N
N OO
NH2O
O
O
N
O
8
N-1
N-3
2
8
quinoline domain
uracil domain
 
Figure 3. Structure of MKP-1 inhibitor 8. 
 
1.1.3 Library design 
It was envisioned that the dual-domain nature of scaffold 8 could be used to generate a small 
library of compounds in which the points of derivatization would be the uracil N-1 and N-3 
positions and the quinoline 2 and 8 positions.  Augmentation of alkyl substituent size at the 
uracil N-1 and N-3 positions was chosen to probe steric effects and possible hydrophobic 
interactions within the MKP-1 inhibitor binding domain.   Variation at the uracil N-1 position 
 5 
included methyl, methylcyclopropyl, iso-butyl and benzyl substituents.  Variation at the uracil N-
3 position included methyl and benzyl substituents.  Derivatization at the quinoline 2 and 8 
positions was intended to probe electronic and steric requirements.  Variations at the 2-quinoline 
position included hydrogen, trifluormethyl, cyclopropyl, furanyl and phenyl substituents, while 
variation at the 8-quinoline position was chosen to include hydrogen and trifluoromethyl groups.   
This choice of substituents leads to a library of 26 compounds, including the original HTS hit 8.  
 
N N
O
R3
OH2N
R4
O
O O
N
R1
R2
N N
O
R3
OH2N
R4
O
Cl
+
+Na-O O
N
R1
R2
9:   R1 = H, R2 = H
10: R1 = H, R2 = CF3
11: R1 = H, R2 = cyclopropyl
12: R1 = H, R2 = furan
13: R1 = H, R2 = Ph
14: R1 = CF3, R2 = CF3
15: R3 = CH3, R4 = CH3
16: R3 = CH3, R4 = benzyl
17: R3 = methylcyclopropane, R4 = CH3
18: R3 = iso-butyl, R4 = CH3
19: R3 = benzyl, R4 = CH3
quinoline uracil
 
Scheme 1. Main retrosynthetic disconnection for the library analogues. 
1.2 LIBRARY SYNTHESIS 
1.2.1 Synthesis of 2,8-substituted quinolinecarboxylic acid sodium salts 
The 2,8-substituted quinolinecarboxylic acid sodium salts 9, 10, 11, 12, 13, and 14 were 
synthesized from their precursor quinolinecarboxylic acids 20, 21, 22, 23, 24 and 25 by reaction 
 6 
with 1 equiv. of a 10% NaOH solution according to Scheme 2.8   The resulting 2,8-substituted 
quinolinecarboxylic acid sodium salts were isolated in yields ranging from 97 – 100%. 
 
N R2
COOH
R1
NaOH
9:   R1 = H, R2 = H: 100%
10: R1 = H, R2 = CF3: 99%
11: R1 = H, R2 = cyclopropyl: 100%
12: R1 = H, R2 = furan: 100%
13: R1 = H, R2 = Ph: 99%
14: R1 = CF3, R2 = CF3: 97%
+Na-O O
N
R1
R2
20: R1 = H, R2 = H
21: R1 = H, R2 = CF3
22: R1 = H, R2 = cyclopropyl
23: R1 = H, R2 = furan
24: R1 = H, R2 = Ph
25: R1 = CF3, R2 = CF3  
Scheme 2. Synthesis of the quinolinecarboxylic acid sodium salts 9, 10, 11, 12, 13, and 14. 
 
The quinoline-4-carboxylic acid 20 and the 2-phenylquinoline-4-carboxylic acid 24 were 
purchased from commercial sources.  The 2-(trifluoromethyl)quinoline-4-carboxylic acid 21 and 
the 2,8-bis(trifluoromethyl)quinoline-4-carboxylic acid 25 were synthesized according to the 
route shown in Scheme 3. 
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R2
OO
ONH2
+
26: R1 = H
27: R1 = CF3
R1
75 to 150 oC
PPA
N
H
R2
O
R1
75 to 150 oC
POBr3
N R2
Br
R1
2) CO2
3) HCl
1) n-BuLi, THF, -78 oC
N R2
COOH
R1
28: R2 = CF3
29: R1 = H, R2 = CF3: 58%  
30: R1 = CF3, R2 = CF3: 32%
31: R1 = H, R2 = CF3: 50%  
32: R1 = CF3, R2 = CF3: 88%
21: R1 = H, R2 = CF3: 53%  
25: R1 = CF3, R2 = CF3: 53%  
Scheme 3. Synthesis of the mono- and bis-(trifluoromethyl)-4-quinoline carboxylic acids 21 and 25. 
 
The synthesis of 21 and 25 began with the PPA condensation and subsequent cyclization 
of ethyl 4,4,4-trifluoro-3-oxobutanoate 28 with either aniline 26 or 2-(trifluoromethyl)aniline 27 
to generate 29 and 30 in 58% and 32% yield, respectively.9   Quinolines 29 and 30 were then 
reacted with POBr3 at 150 oC, forming the corresponding 4-bromo-(trifluoromethyl)quinolines 
31 and 32 in 50% and 88% yield, respectively.9  In the last step, a lithium-halogen exchange 
reaction was performed on the 4-bromo-(trifluoromethyl)quinoline compounds 31 and 32 by 
reacting them with a solution of 1.34 M butyllithium in THF at -78 oC. This reaction generated 
the corresponding 4-lithium-(trifluoromethyl)quinoline reagents, which were then carboxylated 
with CO2 (dry ice) and protonated with HCl to generate the final mono- and bis-
(trifluoromethyl)-4-quinolinecarboxylic acids 21 and 25 in 53% yield.9 
 
     The remaining two quinolinecarboxylic acids, 2-cyclopropylquinoline-4-carboxylic 
acid 22 and 2-(furan-2-yl)quinoline-4-carboxylic acid 23, were synthesized by using the 
 8 
Pfitzinger reaction.10  Reaction of isatin 33 with either 1-cyclopropylethanone 34 or 2-
acetylfuran 35 in an 8.75 M solution of KOH at reflux, followed by subsequent acidification with 
concentrated HCl, generated 22 and 23 in 78% and 34% yield, respectively.11 
 
N
H
O
O +
R2
O
 22: R1 = H, R2 = cyclopropyl: 78% 
 23: R1 = H, R2 = furan: 34%
R1
1) KOH, H2O
    100 oC, 4.5 h
2) HCl N R2
COOH
R1
33:  R1 = H 34: R2 = cyclopropyl
35: R2 = furan  
Scheme 4. Synthesis of quinolinecarboxylic acids 22 and 23. 
 
1.2.2 Synthesis of 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 
The 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 15, 16, 17, 18 and 19 were synthesized 
from their precursor 1-N-alkyl-3-N-alkyl-6-aminouracils 36, 37, 38, 39 and 40 by reaction with 
2-chloroacetyl chloride 41 in a mixture of pyridine and chloroacetic acid heated at 90–95 oC 
(Scheme 5).12  1-N-Alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils were precipitated from the 
reaction mixtures at 0 oC with deionized water and recrystallized from ethyl acetate and hexanes, 
affording the products 15, 16, 17, 18 and 19 in 53%, 67%, 47%, 35% and 72% yield, 
respectively.   
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+ Cl
O
Cl
N N
O
R3
OH2N
R4
N N
O
R3
OH2N
R4
O
Cl
Pyridine
Chloroacetic acid
90-95 oC
15: R3 = CH3, R4 = CH3: 53%
16: R3 = CH3, R4 = benzyl: 67%
17: R3 = methylcyclopropane, R4 = CH3: 47%
18: R3 = iso-butyl, R4 = CH3: 35%
19: R3 = benzyl, R4 = CH3: 72%
36: R3 = CH3, R4 = CH3
37: R3 = CH3, R4 = benzyl
38: R3 = methylcyclopropane, R4 = CH3
39: R3 = iso-butyl, R4 = CH3
40: R3 = benzyl, R4 = CH3
41
 
Scheme 5. Synthesis of 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 15, 16, 17, 18 and 19. 
 
The 1,3-N,N-dimethyl-6-aminouracil 36 and the 1-N-iso-butyl-3-N-methy-6-aminouracil 
39 were purchased from commercial sources.  The remaining three 1-N-alkyl-3-N-alkyl-6-
aminouracils 37, 38 and 40 were synthesized according to the reaction sequence shown in 
Schemes 6 and 7, which was chosen to control the positioning of the alkyl substituents around 
the uracil ring. 
 
R3 NH2
42: R3 = benzyl  
43: R3 = methylcyclopropane
1) 1M HCl
2) KOCN
    H2O, rt
R3
N
H
O
N
H
H +
HO
CN
O Ac2O
77 oC
R3
N
H
O
N
H
O
CN
44: R3 = benzyl: 58%  
45: R3 = methylcyclopropane: 76%
46
47: R3 = benzyl: 75%  
48: R3 = methylcyclopropane: 56%
1) 10% NaOH
     H2O/EtOH, 95 oC
2) 1M HCl
N NH
O
R3
OH2N
49: R3 = benzyl: 50%  
50: R3 = methylcyclopropane: 36%  
Scheme 6. Synthesis of 1-N-alkyl-6-aminouracils 49 and 50. 
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For the synthesis of the 1-N-alkyl-6-aminouracils 49 and 50, benzylamine hydrochloride 
42 and methylcyclopropylamine hydrochloride 43 were reacted with KOCN in aqueous media to 
afford 1-benzylurea 44 and 1-(cyclopropylmethyl)urea 45 in 58% and 76% yield, respectively.13  
The urea products 44 and 45 were then condensed with 2-cyanoacetic acid 46 at 77 oC in acetic 
anhydride to produce the corresponding cyanoacetylureas 47 and 48 in 75% and 56% yields.14  
The products 47 and 48 cyclized by treatment with 10% NaOH in ethanol and water at 95 oC, 
affording the 1-N-alkyl-6-aminouracils 49 and 50 in 50% and 36% yield upon acidification.14 
 
N NH
O
R3
OH2N
49: R3 = benzyl
50: R3 = methylcyclopropane
51: R3 = CH3
DMF-DMA
DMF, 40 oC
N NH
O
R3
ONN
52: R3 = benzyl: 76%
53: R3 = methylcyclopropane: 
      93%
54: R3 = CH3: 65%
DBU, MeI
MeCN/DMF
25 oC
DBU, BnBr
MeCN/DMF
80 oC
N N
O
R3
ONN
N N
O
R3
ONN
R4
R4
55: R3 = benzyl, R4 = CH3: 51%
56: R3 = methylcyclopropane, 
      R4 = CH3: 46%
57: R3 = CH3, R4 = benzyl: 15%
N N
O
R3
ONN
R4 NH3 (aq)
MeOH, rt
N N
O
R3
O
R4
H2N
55, 56, 57 40: R3 = benzyl, R4 = CH3: 77%
38: R3 = methylcyclopropane, R4 = CH3: 80%
37: R3 = CH3, R4 = benzyl: 73%  
Scheme 7. Synthesis of 1-N-alkyl-3-N-alkyl-6-aminouracils 37, 38 and 40. 
 
The route for the synthesis of the 1-N-alkyl-3-N-alkyl-6-aminouracils 37, 38 and 40 is 
shown in Scheme 7.  The 1-N-methyl-6-aminouracil 51 was purchased from a commercial 
source.   The amino functionality of 1-N-alkyl-6-aminouracils 49, 50 and 51 was protected by the 
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way of DMF-DMA in DMF at 40 oC, generating the 1-N-alkyl-6-
[(dimethylamino)methylene]uracils 52, 53 and 54 in 76%, 93% and 65% yield, respectively.15 
The 1-N-alkyl-6-[(dimethylamino)methylene]uracils 52 and 53 were alkylated at the N-3 position 
by reaction with DBU and MeI in a mixture of MeCN and DMF at room temperature over a 2 d 
period, affording the 1-N-alkyl-3-N-methyl-6-[(dimethylamino)methylene] uracils 55 and 56 in 
51% and 46% yield.15  The 1-N-methyl-6-[(dimethylamino)methylene]uracil 54 was alkylated at 
the N-3 position by reaction with DBU and BnBr in a mixture of MeCN and DMF at 80 oC over 
a 5 h period, affording the 1-N-methyl-3-N-benzyl-6-[(dimethylamino)methylene]uracil 57 in 
15% yield.  Following the synthesis of 55, 56 and 57, the (dimethylamino)methylene group was 
removed by a solution of aqueous ammonia in methanol at room temperature over several days, 
affording the final 1-N-alkyl-3-N-alkyl-6-aminouracils 40, 38 and 37 in 77%, 80% and 73% 
yield, respectively.15  
1.2.3 Synthesis of the final library compounds 
Segment assembly followed the route shown in Scheme 8.  A convergent strategy for the final 
library of analogues was based on reacting six 2,8-substituted-4-quinolinecarboxylic acid sodium 
salts 9, 10, 11, 12, 13 and 14 with five 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 15, 16, 
17, 18 and 19 through an SN2 reaction in DMF at reflux.8  The products were precipitated from 
the reaction mixture by the slow addition of deionized water while cooling to 0 oC over a 1 h 
period.  The resulting library analogues were then dried in a Genevac solvent evaporator to 
remove residual traces of DMF.  The 23 library components 58 – 80 were synthesized in yields 
ranging from 31 – 74% (Scheme 8).  All of the final products were analyzed by 1H NMR and RP 
LC/MS and were found to be >85% pure by UV detection at 210 nm or >90% pure by ELSD 
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with the exception of 63 which was found to be >95% pure by 1H NMR analysis.1  A total of 12 
compounds were fully characterized by Mp, IR, 1H NMR, 13C NMR and HRMS.  At least one 
compound containing each unique quinoline or uracil subunit was chosen for full 
characterization.   
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68: R1 = CF3, 53%
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58: R1 = H, 74% 
      R2 = H
59: R1 = H, 45%
      R2 = CF3
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      R2 = cyclopropyl
61: R1 = H, 70%
      R2 = furan
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63: R1 = CF3, 56%
      R2 = CF3
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76: R1 = H, 51% 
      R2 = CF3
77: R1 = H, 48%
      R2 = cyclopropyl
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      R2 = furan
79: R1 = H, 39%
      R2 = Ph
80: R1 = CF3, 58% 
      R2 = CF3
71: R1 = H, 58% 
      R2 = CF3
72: R1 = H, 31%
      R2 = cyclopropyl
73: R1 = H, 61%
      R2 = furan
74: R1 = H, 60%  
      R2 = Ph
75: R1 = CF3, 55% 
      R2 = CF3
N N
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N
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Scheme 8. Synthesis of the final MKP-1 inhibitor library. 
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Among the five 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils, only the 1,3-N,N-
dimethyl-5-chloroacetyl-6-aminouracil 15 was reacted with quinoline-4-carboxylic acid sodium 
salt 9.   The resulting derivative 58 represents the simplest analogue used to probe the MKP-1 
inhibitor binding domain.  Analogue 58 was also readily constructed from commercially 
available starting materials (20 and 51) as a way to test the methodology proposed for 
synthesizing the 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils and the final library 
analogues.  Only four of the 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 15, 16, 18 and 
19 were reacted with the five 2,8-(substituted)quinoline-4-carboxylic acid sodium salts 10, 11, 
12, 13 and 14.  This was the result of a low overall yield for the synthesis of 17 (2% yield over 7 
steps), which generated only enough material for the synthesis of two final library analogues.  
Therefore, 17 was reacted with 12 to allow for a direct biological activity comparison to the 
original hit 8, and was also reacted with 14 due to the known biological activity of the 2,8-
bis(trifluoromethy)quinoline substructure found in mefloquine, an antimalarial agent.16   
1.3 BIOLOGICAL RESULTS FOR MKP-1 INHIBITORS 
A total library of 47 compounds comprised of 23 fully-assembled analogues and 24 intermediate 
quinolines or uracils was submitted to the University of Pittsburgh Molecular Libraries 
Screening Center (UPMLSC) for testing against MKP-1.  The 47-compound library was also 
registered on PubChem and the PubChem DMA-xyz compound names have been retained in the 
experimental section of this document.17  None of the quinoline- or uracil-based precursors were 
found to be active inhibitors of MKP-1, suggesting that both the quinoline and uracil subunits are 
 16 
necessary for activity.  The results of the enzyme assays have been published and are 
summarized in Table 1.1 
 
Table 1. Biological Resultsa Against MKP-1 and MKP-3.1 
 
 
Curiously, the resynthesized 73 suffered from an almost three-fold loss of potency with 
an IC50 value of 50 µM, versus 19.2 µM for the original hit 8.  The reasons for this loss of 
potency are unclear.  The analogues 61, 65, 66, 69 and 78 showed an IC50 value comparable to 
                                                 
a Assays performed in the laboratory of professor John S. Lazo. 
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the original hit 8 (Figure 4).  These five analogues also demonstrated selectivity for MKP-1 
when compared to MKP-3.  Analogues 61, 65, 66, 69 and 78 all inhibited MKP-3 with IC50 
values >50 µM. 
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         78
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           66
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Figure 4. Library analogues found to inhibit MKP-1 with a similar potency as to the original hit. 
 
A comparison of the structures for the five library analogues found to selectively inhibit 
MKP-1 shows some interesting trends leading to valuable structure activity relationship (SAR) 
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information about the binding of this novel class of quinoline-uracil based MKP-1 inhibitors.   
The alkyl substituents on the uracil N-1 and N-3 positions have only a modest effect on binding, 
with bulkier substituents, such as benzyl, being favored.  Interestingly, both isomeric forms 78 
and 66 of the benzyl-substituted aminouracil demonstrated tight inhibitor binding.  This result 
suggests that a maximization of hydrophobic interactions at the position where the N-1 and N-3 
alkyl substituents on the aminouracil sit in the inhibitor binding domain of MKP-1 may lead to a 
second generation library of more potent inhibitors.    
 
     The nature of the substituents on the quinoline ring system plays an important role in a 
tight binding of the quinoline-uracil analogues to MKP-1.  Substitution at the 4-quinoline 
position was found to greatly decrease the IC50, as shown for analogues 63, 68, 70, 75 and 80.  
As seen in Figure 4, four of the five most potent inhibitors of MKP-1 retained the furan 
substituent at the 2-quinoline position.   This result, in comparison to the 2-phenyl substituted 
quinoline analogues 62, 67, 74 and 79, suggests that, at the position where the quinoline 
substructure rests in the inhibitor binding domain of MKP-1, potentially both steric and 
electronic effects govern inhibitor binding.  This result suggests that a second-generation library 
of quinoline-uracil based MKP-1 inhibitors may be extended to include other heteroaromatic 
substituents at the 2-quinoline position such as thiophene, pyrrole, benzofuran, thiazole and 
pyridine. 
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1.4 CONCLUSIONS 
Collaborative research efforts have exposed a novel class of quinoline-uracil based MKP-1 
inhibitors, which were found to be selective for MKP-1 over MKP-3.  The active inhibitors were 
found to inhibit MKP-1 with low µM IC50 values comparable to those of the known inhibitors 
sanguinarine and NU-126.6,7   A library of analogs provided valuable SAR data for the design of 
this class of phosphatase inhibitors.  These results can guide the development of new quinoline-
uracil based MKP-1 inhibitors. 
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2.0  ADDITION OF ORGANOMETALLIC REAGENTS TO NOVEL 
HETEROCYCLIC SULFONYL AND SULFINYL BENZALDIMINES 
2.1 INTRODUCTION 
This chapter explores the reactivity of heterocyclic sulfonyl- and sulfinylbenzaldimines towards 
a variety of organometallic nucleophiles.  The synthesis of these uniquely protected aldimines 
and cleavage of the resulting heterocyclic protecting groups to generate the corresponding α-
branched primary amine products are also discussed. 
2.1.1 Overview of imines 
The addition of organometallic carbon-based nucleophiles to the C=N bond of imines represents 
an important class of carbon-carbon bond forming reactions that has been heavily investigated 
throughout the past fifty years.  More recently, developments in this field have focused on the 
synthesis of α-chiral amines through the asymmetric addition of organometallic reagents to 
imines.  These asymmetric addition reactions have been shown to proceed effectively through 
the use of chiral auxiliaries and with both stoichiometric and catalytic amounts of chiral ligands.  
The success of these organometallic addition reactions is highly dependent on both the reactivity 
of the imine and on the nature of the organometallic reagent.   
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     Imine reactivity is often mediated through the electron-withdrawing effects of the 
nitrogen atom substituent, a result which has led to the development of several classes of 
functionalized imines (Figure 5).18,19  It has been reported that, in general, the relative reactivities 
of these imines decreases in the order of N-acyliminium ions > N-acylimines >> N-
sulfonylimines > N-phosphinoylimines > N-alkyl and N-arylimines.18,19   While the nature of the 
imine nitrogen atom substituent mediates the reactivity of the imine by controlling the 
electrophilicity of the C=N carbon terminus, it also serves as a protecting group for the resulting 
amine products.18  Accordingly, it is important to be able to easily remove these protecting 
groups after the addition reaction.  
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O O
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O
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R2O
-
R2
N-acyliminium ions N-acylimines N-sulfonylimines
N-sulfinylimines N-phosphinoylimines N-alkylimines
 N-arylimines
81 82 83
84 85 86
 
Figure 5. Representation of several known classes of imines.18,19 
 
Deprotection of N-acylamines such as the N-Boc and N-formyl amines, as well as N-
phosphinoylamides and N-sulfinamides, can be generally accomplished under acidic conditions 
with HCl in protic solvents such as methanol.20-23  The deprotection of N-sulfonamides has 
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traditionally been performed under much harsher reaction conditions, by reactions with reagents 
such as sodium in liquid ammonia, sodium naphthalene in 1,2-dimethoxyethane, and with SmI2 
and DMPU in THF at reflux.24-26   A milder method for the deprotection of primary N-
arylsulfonylamides requires the conversion of these products to their corresponding t-butyl N-
arylsulfonylcarbamates by a DMAP-catalyzed reaction with Boc2O.27  The N-arylsulfonyl group 
can then be cleaved by reaction with Mg metal in methanol resulting in the corresponding N-Boc 
amines.27 
 
N
R1
R
S+N
R1
RS
+
O-O
-
87 88  
Figure 6. Structures of Davis (87) and Ellman (88) N-sulfinylimines. 
 
Among the several classes of imines shown in Figure 5, the N-sulfinylimines are unique 
in their ability to both activate the imine C=N bond towards nucleophilic addition and, when 
synthesized enantiomerically pure, serve as chiral auxiliaries to direct the diastereofacial 
selectivity for the nucleophilic addition reaction.28  The most widely utilized N-sulfinylimines 
are the N-p-toluenesulfinyl imines 87, pioneered by Davis, and the N-tert-butanesulfinyl imines 
explored by Ellman (88, Figure 6).  Recently, a general procedure for the synthesis of 
enantiopure N-sulfinamides 91 from enantiomerically pure N-sulfonyl-1,2,3-oxathiazolidine-2-
oxides 89 has emerged (Scheme 9).29  The resulting N-sulfinamides can be condensed with a 
variety of aldehydes or ketones in the presence of Ti(OEt)4 to form the enantiopure N-
sulfinylimines.28 
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Scheme 9. Asymmetric synthesis of N-sulfinamides.29 
2.1.2 Addition of organometallic reagents to imines 
The chemistry surrounding the addition of organometallic reagents to the imines listed above is 
rich in both scope and utility.  Indeed, over the last few decades, many of these imines have been 
demonstrated to be excellent reaction partners for the addition of lithium, magnesium, zinc, 
copper, rhodium and aluminum based organometallic reagents.  Also, more recently, asymmetric 
variants have been explored. 
 
2.1.2.1 Organolithium and Grignard reagents 
Organolithium and organomagnesium reagents have the dual properties of being good 
nucleophiles and strongly basic.  The addition of these reagents to unactivated imines such as N-
alkyl or N-arylimines is often difficult due to low imine reactivity and competitive α-
deprotonation of imines that can form metalated enamines.30  However, activated imines such as 
N-acylimines, N-sulfonylimines, N-phosphonylimines and N-sulfinylimines react quickly.   
 
     As a result of the high reactivity of N-acylimines, they are often unstable and cannot be 
isolated.19  This has led to the development of many procedures for their in situ preparation.18   A 
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nice example has been demonstrated by Petrini, which utilizes both the nucleophilic and basic 
characteristics of organolithium and organomagnesium reagents for the in situ preparation and 
tandem nucleophilic addition to a variety of alkyl and aryl aldehyde based α-amidosubstituted 
sulfones 92 (Scheme 10).30 
 
HN O
R1 SO2Ph R1 H
N
O
O
R1 R2
HN
O
O
O
R1 = Ph, i-Bu,
        phenethyl
R2MgBr
or
R2Li
R2MgBr
or
R2Li
92 93 94
R2MgBr:  R2 = vinyl
R2Li:  R2 = phenethynyl, hexynyl,
                  trimethylsilylethynyl
yield 63-93%
 
Scheme 10. Organometallic additions to in situ prepared N-acylimines.30 
 
Along similar lines, methodology for the in situ preparation of alkyl and aryl aldehyde 
based N-sulfonylimines followed by the addition of organolithium or Grignard reagents has also 
been developed.  Weinreb demonstrated a nice example through the use of the Kresze reaction 
(Scheme 11).31  Aldehydes 95 were reacted with N-sulfinyl p-toluenesulfonamide 96 to generate 
the corresponding N-tosylimines 97 in situ, which were then reacted with a variety of alkyl, 
vinyl, allyl and alkynyl organolithium or Grignard reagents.31  
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Scheme 11. Organometallic additions to in situ prepared N-sulfonylimines.31 
 
Zwierazk demonstrated that α-arylalkylamines could also be generated by the addition of 
alkyl, vinyl, allyl and aryl Grignard reagents to N-(diethoxyphosphoryl)aldimines 99 (Scheme 
12).23  The deprotected α-arylalkylamines 101 were generated in moderate to good yields over 
the two step addition/deprotection sequence.23 
 
R1 H
N
P
OEt
O
OEt R2MgBr
R1 R2
HN
P
OEt
O
OEt
HCl
R1 R2
+NH3Cl-
R1 = Ph, p-BrPh, p-MeOPh, 
        2-thienyl, 1-naphthyl
R2 = Me, Et, i-Pr, vinyl, Ph, allyl
2 step yields of 42-82%
99 100 101
 
Scheme 12. Addition of organometallics to N-phosphinoylimines.23 
 
As a result of the high reactivity of organolithium and organomagnesium reagents, 
asymmetric addition reactions have generally been performed using stoichiometric amounts of 
chiral ligands or chiral auxiliaries attached directly to the imine or to the organometallic 
reagent.18,19  An interesting example of the use of a stoichiometric amount of ligand has been 
demonstrated by Toru.  Grignard reagents were found to asymmetrically add to N-(2-
pyridylsulfonyl) aldimines 102 in the presence of a chiral phenyl-bis(oxazoline) ligand (Scheme 
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13).32  The asymmetric induction for these reactions is rationalized by invoking a ligand-bound 
tetrahedral Mg(II) complex 103, where the metal chelates with the oxygen atom and the nitrogen 
atom of the 2-pyridylsulfonyl protecting group.32,33  
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O
O
N
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O
O
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O
N
Toluene, -95 oC HN
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 Ligand
79% yield, 99% ee
 
Scheme 13. Asymmetric addition of MeMgBr to N-(2-pyridylsulfonyl)aldimines.32 
 
Ellman demonstrated that both aliphatic and aromatic N-tert-butanesulfinyl aldimines 
105 reacted with Grignard reagents in non-coordinating solvents to produce the corresponding N-
tert-butanesufinamides 107 in good yields and with excellent diastereoselectivities (Scheme 
14).34  Since the diastereoselectivities for these reactions decreased in the presence of 
coordinating solvents, a cyclic six membered transition state 106 was proposed.34 
 
S+
N
O-
R1
H R2MgBr
R1 = Et, i-Pr, Ph,
        Bn, p-MeOPh
S
O M R2
Nt-Bu
H
R1 S
+
N
H
O-
R1
R2
R2 = Me, Et, i-Pr, 
         vinyl, Ph
105 106 107
yield 79-100%
dr of 88:12 to 99:1
DCM
-45 oC
 
Scheme 14. Addition of Grignard reagents to N-tert-butylsulfinyl imines.34 
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Moreau demonstrated that aromatic N-p-toluenesulfinyl aldimines reacted with BnMgCl 
in toluene at -30 oC to give the corresponding N-p-toluenesulfinamides in moderate yields and 
diastereoselectivities.35  However, reactions performed under the same conditions with MeMgBr 
and 108 resulted in the formation of the sulfur addition products 109 and 110 (Scheme 15).35  In 
light of Moreau’s findings, Chan demonstrated that the addition of a stoichiometric amount of 
CuI to the reaction mixture containing two equivalents of MeMgBr and 108 at -15 oC helped to 
suppress the formation of the sulfur adduct 109.  This reaction gave the desired N-p-
toluenesulfinamide product in 49% yield and the sulfoxide 109 in only 21% yield.36   
 
N
H
S
1. MeMgBr
S +
O
H
2. H2O
108 109 110
O O
 
Scheme 15. Addition of MeMgBr to the N-p-toluenesulfinyl aldimine 108.35 
2.1.2.2 Dialkylzinc reagents 
The lower nucleophilicity of dialkylzinc reagents has hindered their direct addition to less 
activated imines such as N-alkyl and N-arylimines, as well as N-phosphinolyimines.  This was 
demonstrated in a paper by Qian who studied the effects of diethylzinc coordination in reactions 
with N-tosylimines.37  Qian reported that neither (E)-N-benzylidene-P,P-diphenylphosphinic 
amide nor (E)-N-benzylideneaniline reacted with Et2Zn after 24 h in toluene at room 
temperature.37  However, after 1 h in toluene, (E)-N-benzylidenebenzenesulfonamide 111 was 
shown to react with Et2Zn to give the reduction product 113 (Scheme 16).37  The product was 
proposed to arise from transfer of a β-hydrogen atom from one of the ethyl groups on zinc to the 
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carbon terminus of the imine C=N bond via the cyclic six-membered transition state 112 shown 
in Scheme 16.37  This transition state is supported by a solvent study which showed that when 
coordinating solvents such as THF are used, the ethyl adduct becomes the predominant product 
for the reaction.37 
 
N
H
S
O
O
Et2Zn
Toluene, rt H N
Zn
Ph S
O
Op-Tol
Et
HN
S
O
O
111 112 113
98% yield
 
Scheme 16. Reduction of N-tosylimines with Et2Zn.37 
 
Carretero demonstrated that N-(2-pyridinesulfonyl)aldimines 102 react with alkyl zinc 
bromides under copper catalyzed conditions to give the corresponding N-(2-
pyridinesulfonyl)amides in good to excellent yields.38  Primary and secondary alkyl zinc 
bromides containing alkene, ether, acetal, chloride, ester and nitrile groups were found to add 
efficiently to 102.38   The reactivity of N-(2-pyridinesulfonyl)aldimine was explained to arise 
from coordination of the imino and pyridyl nitrogen atoms to the copper catalyst, forming a five-
membered chelate ring.38  This metal coordination was used to explain the enhanced reactivity of 
N-(2-pyridinesulfonyl)aldimines over that of N-(heteroarylsulfonyl)imines which do not have the 
ability to form a bidentate chelate and were found not react under copper catalyzed conditions 
with organo zinc bromide reagents.38 
 
     As a result of the low nucleophilicity of dialkylzinc reagents, many asymmetric 
addition reactions have been reported which utilize Lewis basic chiral ligands to activate the zinc 
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reagent for addition to the imine.  For example, Andersson discovered that the use of a 
stoichiometric amount of the ((1S,3R,4R)-2-methyl-2-azabicyclo[2.2.1]heptan-3-yl)methanol 
ligand effectively activated Et2Zn for the asymmetric addition to (E)-N-benzylidene-P,P-
diphenylphosphinic amide 114 (Scheme 17).39  The proposed transition state 115 for this reaction 
is shown in Scheme 17.39 
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O
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Ph
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1 eq. Ligand
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Scheme 17. Ligand-activated asymmetric addition of Et2Zn to N-phosphinoyl imine 114.39 
 
Charette has found that dialkylzinc reagents can be asymmetrically added to both alkyl 
and aryl N-phosphinoylaldimines, generated in situ, using a catalytic amount of Cu(OTf)2 and 
the chiral BozPHOS ligand (119, Scheme 18).40,41  
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O
117 118
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R = Me, i-Pr, i-Bu, Ph, 
         phenethyl, n-hexyl
yield 87-98%
ee 90-97%  
Scheme 18. Copper-catalyzed asymmetric addition of Et2Zn to N-phosphinoyl aldimines.41 
2.1.2.3 Hydrozirconation and transmetallation 
Hydrozirconation of alkenes and alkynes by the use of Schwartz’s reagent (Cp2Zr(H)Cl, 120) is a 
well established way to prepare alkyl and alkenylzirconocenes.42  While these species are 
nucleophilic, the steric shielding of the cyclopentadienyl ligands on zirconium often prevents 
nucleophilic addition of the alkyl or alkenyl group to bulky elecrophiles.42  As a result, 
transmetallation of these groups from zirconium to other metal centers such as zinc, rhodium and 
aluminum has led to the generation of a variety of organometallic nucleophiles capable of 
addition to electrophiles such as imines.  Organometallic reagents generated from 
transmetallation of organozirconocenes have been effectively added to N-acyl, N-sulfonyl, N-
phosphinoyl and N-sulfinylimines.  
 
     In 2002, Wipf reported that the organometallic reagents derived from 
hydrozirconation of alkynes followed by transmetallation with Me2Zn effectively added to N-
sulfonyl and N-phosphinoylaldimines.43  Scheme 19 illustrates the hydrozirconation of 1-hexyne 
121 with Schwartz’s reagent 120 to generate the alkenylzirconocene species 122.  The alkenyl 
substituent is then transmetallated from 122 with Me2Zn to form the vinylzinc reagent 123, 
which can then be added to the N-phosphionylimine 114 to form the final allylic N-
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phosphinoylamide 124.  This work showed that a range of vinylzinc reagents could be prepared 
in situ from symmetrical internal alkynes and terminal alkynes containing silyl ether, silyl ester, 
sulfonamide and carbamate functionality.43  These zinc reagents were found to add in good 
overall yields (35-90%) to both aryl N-phosphinoylaldimines and alkyl and aryl N-
sulfonylaldimines if the addition reactions were conducted in toluene.43  
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N
H
P
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O
Ph
Ph
HN
P
Ph
O
Ph
C4H9
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121 122 123
123 124
Toluene, rt
76% yield
 
Scheme 19. In situ preparation of vinylzinc reagents and addition to aldimines.43 
 
If the aldimine 114 was added to the vinylzinc reagent 123 in CH2Cl2, then the 
predominant product of the reaction was the C-cyclopropylalkylamide 128.43  This product was 
proposed to arise from the reaction pathway shown in scheme 20.  The reaction was found to be 
general for a number of aldimines, preferentially producing the anti diastereoisomer of the C-
cyclopropylalkylamide products in good overall yields (45-91%).43 
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Scheme 20. Reaction pathway for the synthesis of C-cyclopropylalkylamides.43 
 
It was later reported by Hanzawa that [RhCl(cod)]2 132 could catalyze the addition of 
alkenylzirconocene chlorides 130 to both aryl and alkyl N-sulfonylaldimines (131, Scheme 21).44 
The proposed catalytic cycle for these reactions is shown in Scheme 22.44 
 
R1
CH2Cl2
Cp2Zr(H)Cl
R1
ZrCp2
Cl
+
R2 H
NTs
2 mol%
[RhCl(cod)]2
Dioxane, rt R
1 R2
NHTs
R1 = t-Bu, Ph, OEt,
        n-C4H9, BnOCH2
R2 = Ph, p-CF3Ph, p-MeOPh,
        cyclohexyl, t-Bu
129 130 131 133
yield 75-99%
 
Scheme 21. Rhodium catalyzed addition of alkenylzirconocenes to aldimines.44 
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Scheme 22. Proposed catalytic cycle for the rhodium-catalyzed addition of alkenylzirconocenes to aldimines.44 
 
The catalytic enantioselective addition of alkenylzirconocenes through zirconocene-zinc 
transmetallation has been well-established for the synthesis of chiral allylic alcohols resulting 
from addition into aldehydes.45  However, similar methodology for the synthesis of chiral allylic 
amines is still lacking.  An interesting discovery was made in the Wipf group, demonstrating that 
alkenylzirconocenes, prepared via hydrozirconation of alkynes with Cp2Zr(H)Cl, could be 
transmetallated to alane 135 and added to N-tert-butanesulfinylaldimines 136 (Scheme 23).46  A 
four-membered chelate transition state 137 was proposed to explain the stereochemistry of the 
resulting products.46 
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Scheme 23. Addition of vinylalanes to N-tert-butanesulfinylaldimines.46 
2.1.3 Introduction to Bts and Ths sulfonyl protecting groups 
In 1996, Vedejs introduced benzothiazole-2-sulfonyl chloride (139, BtsCl) and 5-methyl-
1,3,4-thiadiazole-2-sulfonyl chloride (140, ThsCl) as efficient nitrogen atom protecting reagents 
for use in peptide coupling reactions.47  He reported that these protecting groups could be 
removed from amino acids in high yields without racemization under a variety of conditions, 
including treatment with Zn and acetic acid in ethanol, Al and HgCl2 in water and THF, and 
H3PO2 in THF at reflux (Scheme 24).47  The electron-withdrawing effects of the heteroaromatic 
group on the sulfone activate it for reduction with a variety of reagents, including SmI2, Mg(0) 
and thiolate nucleophiles.24,32,48  Many of these deprotection conditions are much more mild than 
those traditionally used for the cleavage of more electron rich sulfones. 
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Scheme 24. Protection and deprotection conditions for the Ths and Bts groups.47 
2.2 RESULTS AND DISCUSSION 
We sought to explore the reactivity of N-Bts- and N-Ths-benzaldimines with a variety of 
organometallic carbon-based nucleophiles.  This section will discuss the synthesis of these 
aldimines and their reactivity towards a number of organometallic reagents including lithium-, 
magnesium-, zinc-, aluminum-, rhodium- and copper-based nucleophiles.   
2.2.1 Synthesis of N-Bts- and N-Ths-benzaldimines 
N-Bts- and N-Ths-benzaldimines were synthesized according to the route shown in Scheme 25.  
Initially, benzo[d]thiazole-2-thiol 142 and 5-methyl-1,3,4-thiadiazole-2-thiol 143 were converted 
to their corresponding sulfonyl chlorides 139 and 140 by oxidative chlorination with Cl2(g) in 
33% aqueous acetic acid according to the procedure described by Vedejs.47  While the yields for 
these products varied considerably, the average yields were 45% for Bts-Cl and 52% for Ths-Cl.   
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The sulfonyl chlorides 139 and 140 were further reacted with liquid NH3 to form the 
sulfonamides 144 and 145 in 73% and 68% yield. 
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143: Ar = Methylthiadiazole
139: 45%
140: 52%
144: Ar = Benzothiazole, 73%
145: Ar = Methylthiadiazole, 68%
146: Ar = Benzothiazole, 82%
147: Ar = Methylthiadiazole, 79%110  
Scheme 25. Synthesis of N-Bts- and N-Ths-benzaldimines. 
 
Initial attempts to synthesize N-Ths-benzaldimine 147 by TiCl4 mediated condensation of 
benzaldehyde 110 with 5-methyl-1,3,4-thiadiazole-2-sulfonamide 145 resulted only in recovery 
of the starting materials.  The failure of this reaction was attributed to rapid hydrolysis of the 
highly activated N-Ths-benzaldimine product.  Further attempts to synthesize the α-
amidosubstituted sulfone precursor by Petrini’s methodology again resulted in unreacted starting 
material.  It was found, however, that stock solutions of N-Ths-benzaldimine 147 could be 
prepared reproducibly by the reaction of 145 with one equivalent of benzaldehyde 110 in toluene 
under Dean-Stark conditions in the presence of 5.0 mol% of PTSA.  These stock solutions were 
prepared in 0.16 M concentration by filtering reaction mixtures into a dry volumetric flask and 
diluting them with toluene or THF.  The yields for these reactions were determined by 1H-NMR 
integration using 1,2-dimethoxybenzaldehyde as the internal standard.  It was found that the 
average yield for these reactions was 79% based on 12 individually prepared solutions with a 
 37 
range of 76-82%.  All attempts to isolate the N-Ths-benzaldimine 147 from the reaction mixture 
led to rapid decomposition.  The N-Bts-benzaldimine 146 was synthesized from 
benzo[d]thiazole-2-sulfonamide 144 and benzaldehyde 110 under the same reaction conditions 
as 147; however, Bts-benzaldimine 146 was found to be isolable as a stable crystalline solid.  
The average yield for the synthesis of 146 was 82% over 6 reactions within a range of 80–87%. 
2.2.2 Addition of organometallic reagents to the N-Bts- and N-Ths-benzaldimines 
2.2.2.1 Lithium reagents 
The addition of organolithium reagents to both N-Bts- and N-Ths-benzaldimines resulted in 
either poor yields or multiple decomposition products.  As shown in Table 2, only the addition of 
MeLi to the N-Ths-benzaldimine 147 resulted in the formation of the desired product 148 in 23% 
yield.  The addition of t-BuLi to the N-Ths-benzaldimine and MeLi to the N-Bts-benzaldimine 
resulted in multiple decomposition products by TLC analysis with no evidence of the desired 
product. 
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THF, -78 oC, 2 h
2.5 eqiv. RLi
H
N
S
O
O Ar
R
HN
S
O
O Ar
 
Table 2. Addition of Organolithium Reagents to 146 and 147. 
 
2.2.2.2 Grignard reagents 
In contrast to the results obtained for the addition of organolithium reagents, Grignard reagents 
were found to be suitable nucleophiles for addition to both N-Ths- and N-Bts-benzaldimines.  
For the addition of i-PrMgX to 147, neither the coordinating ability of the solvent nor the nature 
of the halogen on the Grignard reagent had an appreciable effect on the yield of the product 
(Table 3, entries 1, 2 and 4).  However, it was found that the reaction temperature was important 
and must be kept at -78 oC for the duration of the reaction (Table 3, entry 3).  Under optimized 
reaction conditions, methyl, vinyl, 1-propynyl and phenyl magnesium bromide were reacted with 
147 in THF at -78 oC to afford the corresponding sulfonamide products in moderate yields (46-
61%) after recrystallization. 
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1 - 2.5 h
 
        Table 3. Addition of Grignard Reagents to N-Ths-Benzaldimine 147. 
 
Grignard reagents were found to add more effectively to the N-Bts-benzaldimine 146.  As 
shown in Table 4, MeMgBr, i-PrMgCl, vinylMgBr, 1-propynylMgBr and PhMgBr were reacted 
with 146 in THF at -78 oC to afford the corresponding sulfonamide products in good yields (71-
87%). 
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N
THF, -78 oC
146  
       Table 4. Addition of Grignard Reagents to N-Bts-Benzaldimine 146. 
 
2.2.2.3 Diethylzinc reactions 
The addition of diethylzinc to both the N-Ths-benzaldimine and the N-Bts-benzaldimine 
succeeded with some surprising results.  It was found that the addition of Et2Zn to the N-Ths-
benzaldimine 147 proceeded best in non-coordinating solvents, such as toluene, when 2.5 
equivalents of Et2Zn were added at room temperature (Table 5, entries 1, 2 and 3).  Interestingly, 
it was also found that Et2Zn added to the N-Ths-benzaldimine 147 at -78 oC in moderate yield 
over extended reaction times (Table 5, entry 4).  A similar effect in the coordinating ability of the 
solvent was found for the addition of Et2Zn to the N-Bts-benzaldimine 146 (Table 5, entries 5 
and 6). 
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Table 5. Addition of Diethylzinc Reagents to 146 and 147. 
 
These results are different from what was reported by Qian for the reaction of (E)-N-
benzylidenebenzenesulfonamide 111 with Et2Zn, which primarily gave the reduced product 113 
in non-coordinating solvents.  This interesting difference is most likely due to the higher 
reactivity of the N-Bts- and N-Ths-benzaldimines resulting from the greater electron-
withdrawing effect of the heterocyclic sulfonyl activating groups. 
2.2.2.4 Hydrozirconation – transmetallation reactions 
The alkenylzinc reagents derived from hydrozirconation of 1-hexyne and 3-hexyne with 
Cp2Zr(H)Cl (120) followed by in situ transmetallation to zinc, were added in moderate to good 
yields to both N-Bts- and N-Ths-benzaldimines (Table 6).  Even though these reactions were 
conducted in the presence of CH2Cl2, the corresponding C-cyclopropylalkylamides were not 
detected.  The methyl addition product was, however, isolated in 13% yield from the reaction of 
N-Bts-benzaldimine 146 with 1-hexyne derived alkenylzinc reagent (Table 6, entry 3). 
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R1 R2
1. Cp2Zr(H)Cl, CH2Cl2
2. Me2Zn, -78 oC→ rt
3.
Ph H
N
S
ArO
O
N
S
ArO
O
H
R2
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Table 6. Addition of Alkenylzinc Reagents to 146 and 147. 
 
Multiple attempts were made to effect an asymmetric addition of either diethylzinc or the 
alkenylzinc reagent derived from hydrozirconation of 1-hexyne to N-Bts- and N-Ths-
benzaldimines.  However, after screening a wide range of Lewis basic chiral ligands and 
exploring the asymmetric copper-catalyzed systems popularized by Charette, the enantiomeric 
excesses for these reactions were never >12%.  This result is presumably due to high levels of 
competitive background reactions for the addition of the zinc reagents to the N-Bts- and N-Ths-
benzaldimines.  In the absence of chiral ligands, addition to aldimines proceeds in moderate 
yields at low temperatures over extended reaction times (Table 5, entry 4 and Table 6, entry 2). 
 
     The addition of the vinylalane, resulting from the hydrozirconation of 1-hexyne 
followed by transmetallation to aluminum with Me3Al, to the N-Bts-benzaldimine was also 
briefly explored.   As shown in Scheme 26, this reaction was found to be sluggish in toluene at 
room temperature, affording the product 164 in only 16% yield after 20 h. 
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1. Cp2Zr(H)Cl, CH2Cl2
2. Me3Al, 0 oC → rt, 1h
3. 146, Toluene, rt, 20 h
N
H Bts
164: 16% Yield  
Scheme 26. Vinylalane addition to the N-Bts-benzaldimine 146. 
 
In light of the work reported by Hanzawa, we decided to investigate asymmetric 
rhodium(I) catalyzed addition reactions of alkenylzirconocenes to the N-Bts-benzaldimine 146 
using the commercially available R,R-MeDUPHOS ligand 167 and chiral diene 168 (Table 7).  
As shown in Table 7, the rhodium-catalyzed addition of the 1-hexyne derived 
alkenylzirconocene succeeded with moderate enantiomeric excess in dioxane with both the chiral 
ligand 167 and the chiral diene 168 (Table 7, entry 3 versus entries 1 and 2).  Unfortunately, the 
catalytic turnover for these reactions remained low, with yields of 164 never increasing above 
19%. 
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1. Cp2Zr(H)Cl, CH2Cl2
2. Rh(I) catalyst, ligand/diene
3. 146, rt
N
H Bts
164
P
P
MeO
Ph
167 168
 
Table 7. Asymmetric Rh(I) Catalyzed Addition Reactions to 146. 
 
 
Along with rhodium(I)-catalyzed additions of alkenylzirconocenes to the N-Bts-
benzaldimine, we also explored the use of the Cu(CH3CN)4BF4 catalyst 169 for these addition 
reactions.  An interesting result was found with a protocol for the in situ preparation of 
Cp2Zr(H)Cl by the reaction of Cp2ZrCl2 with DIBAL-H as recently reported by Negishi.49  We 
found that the Cu(CH3CN)4BF4 catalyst did not effectively catalyze the addition of the 1-
hexenylzirconocene to N-Bts-benzaldimine 146 at room temperature in THF after 48 h (Table 8, 
entry 1).  However, upon an attempt to activate the N-Bts-benzaldimine 146 with BF3•OEt2, we 
discovered that the Cu(CH3CN)4BF4 catalyst catalyzed the addition of the iso-butyl group from i-
Bu2AlCl to generate the product 170 in 63% yield (Table 8, entry 2).  In the absence of the 
copper(I) catalyst, no reaction occurred (Table 8, entry 3).  
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1. Cp2ZrCl2, DIBAL-H, THF
2. 10 mol% Cu(CH3CN)4BF4
     146, THF, rt
3. Additive
N
H Bts
164
N
H Bts
170
+
 
Table 8. Copper(I)-Catalyzed Addition Reactions of Alkenylzirconocenes to 146.  
 
2.2.3 Deprotection of N-Ths and N-Bts-sulfonamides 
After exploring the addition of organometallic nucleophiles to the N-Ths and N-Bts-
benzaldimines, several deprotection reactions were investigated for the removal of the 
heteroaromatic sulfonyl groups from the sulfonamide products.  Utilizing the procedure reported 
by Vedejs, it was found after some optimization that the slow addition of a 50% H3PO2 solution 
to a mixture of either sulfonamides 148, 154 or 153 in refluxing THF efficiently produced the 
corresponding amines.   These amines were isolated crude and then converted to their more 
stable Boc-protected derivatives 171, 172 and 173 in good yields over the two step reaction 
sequence (Table 9). 
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Table 9. H3PO2 Deprotection and Boc Protection of Crude Amines. 
 
 
The use of SmI2 was also investigated for the deprotection of the N-Bts- and N-Ths-
sulfonamides 148 and 155 (Table 10).  These reactions proceeded efficiently at room 
temperature after in the presence of excess SmI2 to generate the corresponding 1-
phenylethanamines.  These amines were again isolated crude and then converted to their more 
stable Boc-protected derivatives 171 in good yields over the two-step reaction sequence. 
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    rt, 8 h
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Table 10. SmI2 Deprotection and Boc Protection of Crude Amines. 
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2.2.4 Addition of organometallic reagents to heterocyclic benzothiazole- and pyridyl-2-
sulfinylbenzaldimines. 
As a result of the low enantiomeric excess obtained for the asymmetric addition reactions of 
organometallic reagents to N-Bts- and N-Ths-benzaldimines, we decided to explore the novel 
benzo[d]thiazole-2-sulfinyl (Bt-2-sulfinyl) and pyridyl-2-sufinyl (Py-2-sulfinyl) protecting 
groups as chiral auxiliaries for the diastereomeric addition of organometallic reagents to the 
respective heterocyclic sulfinylbenzaldimines.  Racemic benzothiazole- and pyridyl-2-
sulfinylbenzaldimines were synthesized as shown in Scheme 27.  Initially, benzo[d]thiazole-2-
thiol 142 or pyridine-2-thiol 174 was reacted with NBS in EtOH/CH2Cl2 at room temperature to 
produce the corresponding sulfinates 175 and 176 in 77% and 83% yield, respectively.50  These 
sulfinates were then reacted with LiHMDS at -78 oC in THF to generate the corresponding 
sulfinamides 177 and 178 in 57% and 20% yields after aqueous workup.51  Sulfinamides 177 and 
178 were then condensed with benzaldehyde 110 in the presence of Ti(OEt)4 in CH2Cl2 at room 
temperature to form the desired heterocyclic-2-sulfinylbenzaldimines 179 and 180 in 79% and 
89% yields. 
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Scheme 27. Synthesis of heterocyclic-2-sulfinylbenzaldimines 179 and 180. 
 
The addition of organometallic reagents to benzothiazole-2-sulfinylbenzaldimine 179 was 
met with difficulty.   The addition of MeMgBr to 179 gave results similar to those reported by 
Moreau for the reaction of N-p-toluenesulfinyl aldimines, with methylation taking place 
predominately at the sulfur atom of the sulfoxide, resulting in only trace amounts of the desired 
methylated product 181 (Scheme 28).  The addition of 1 equivalent of CuI to the reaction 
mixture according to Chan’s protocol unfortunately did not enhance the chemoselectivity for 
methylation, again resulting in only trace amounts of 181.   Imine 179 was also found to be 
unreactive toward dialkylzinc, vinylzinc and vinylaluminum reagents in DCM or toluene at room 
temperature over extended periods of time. 
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Scheme 28. Addition of MeMgBr to 179. 
 
Similarly, pyridyl-2-sulfinylbenzaldimine 180 was found in general to be unreactive 
toward vinylzirconocenes under copper- or rhodium-catalyzed conditions, vinylzinc reagents and 
vinylalanes.  However, aldimine 180 did show moderate reactivity toward diethylzinc, 
cyclohexylzinc bromide and 1-propynylzinc halides under copper-catalyzed conditions as shown 
in Table 11.   
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180 183-185  
Table 11. Reaction of 180 with Organometallic Reagents. 
 
 
As can be seen from Table 11, the reaction of aldimine 180 with various organozinc 
reagents under copper-catalyzed conditions could be optimized to afford moderate yields of the 
desired amines over reaction times of approximately 1 d.  Variations of both solvent and 
temperature showed that the diastereomeric ratio for the addition of diethyl zinc to 180 was 
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highest in polar, non-coordinating solvents at 0 oC.  Interestingly, lowering the reaction 
temperature from room temperature to 0 oC had no observable influence on the diastereomeric 
ratio for the addition of cyclohexylzincbromide to 180.  Comparing the addition reactions of 1-
propynylzinc halides to 180, the highest diastereomeric ratios could be achieved from the 
(MeCN)4CuBF4 catalyzed addition of 1-propynylzinc bromide to 180 at room temperature, 
affording a dr of 3.5:1.  Overall, pyridyl-2-sulfinylbenzaldimines have been shown to be 
moderately reactive towards the copper-catalyzed addition of organozinc reagents over the 
narrow substrate scope explored.  The ability of this interesting class of chiral auxiliaries to 
chelate metal centers bodes well for their utility in the synthesis of α-branched amines. 
2.3 CONCLUSION 
N-Bts and N-Ths-benzaldimines were viable substrates for the addition of several organometallic 
reagents, including alkyl, vinyl, propynyl and aromatic organomagnesium reagents, dialkyl and 
alkenylzinc reagents, and alkylcuprates.  The product sulfonamides were smoothly converted to 
the corresponding amines by reaction with either SmI2 or H3PO2.  Further exploration into the 
use of the pyridyl-2-sulfinyl protecting group as a heterocyclic auxiliary for the synthesis of 
chiral amines from the corresponding imines has led to promising results for the addition of 
organozinc reagents under copper catalysis.  This interesting class of heterocyclic sulfonyl- and 
sulfinyl-benzaldimines has displayed good and in some cases unique reactivities toward a variety 
of organometallic reagents.  They are therefore potential alternatives to conventional protecting 
groups in the synthesis of α-branched amines. 
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3.0  STRUCTURE ELUCIDATION AND SYNTHESIS OF A PUTATIVE POLO LIKE 
KINASE – POLO BOX DOMAIN (PLK1-PBD) INHIBITOR 
3.1 OVERVIEW  
This chapter will present the discovery of a novel Plk1-PBD inhibitor resulting from a HTS 
effort conducted by the PMLSC.  The synthetic and analytical procedures utilized to identify the 
correct chemical structure of the biologically active substance are discussed.  The composition of 
the initially unknown substance and the decomposition pathways of this substance are 
characterized.  Finally, the synthesis of a library of 56 analogues targeted to the discovery of the 
biologically active species (scaffold) in the initially tested HTS sample is reported. 
3.2 INTRODUCTION 
Polo-like kinases (Plks) are named after the discovery of the polo gene of Drosophila 
melanogaster.52,53  Mammalian Plks represent a unique family of four serine/threonine (S/T) 
kinases (Plk1-4) as they contain both an N-terminal kinase domain and a C-terminal polo-box 
domain (PBD); two structural features evolutionary conserved from yeast to mammals.54,55   
Investigations into the roles of Plks 1-4 as regulatory enzymes during cell division have shown 
Plks are active during mitosis, meiosis and cytokinesis.55  Of the four mammalian Plks, the 
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biological functions of Plk1 are the best understood.  Plk1 is expressed mainly during the late G2 
and M phases of the cell cycle and is a key enzyme involved in regulation and progression of 
mitotic events including mitotic entry, centrosome maturation and separation, bipolar spindle 
formation, chromosome segregation and cytokinesis.56  Critical to the function of Plk1 is the 
PBD which serves as a (pSer/pThr) phosphopeptide binding domain that regulates the subcellular 
location of Plk1 during mitosis and stimulates the activity of the kinase domain through a 
conformational switching mechanism that releases the kinase domain from an inhibitory 
interaction with the PBD upon phosphopeptide binding.57,58  The PBD of Plk1 serves to localize 
Plk1 to mitotic structures including chromosomes, kinetochores and the spindle midzone during 
mitosis.59   In a study by Hanisch, overexpression of the PBD of Plk1 in HeLa S3 cells was 
shown to displace endogenous Plk1 from chromosomes and kinetochores resulting in spindle 
checkpoint-dependent mitotic arrest due to interference with proper chromosome congression.60 
 
 
     In adult tissues, Plk1 expression has been found to be highest in actively proliferating 
cell populations (spleen, ovary and testis) and very low in the liver, kidney, brain, thymus, 
intestine, lung, pancreas, heart, stomach and skin.61,62  The important function of Plk1 in 
maintaining genomic stability during cell division suggests that the levels of Plk1 must be tightly 
regulated during mitotic progression.  It has been found that either overexpression or down-
regulation of Plk1 in vivo induced tumorigenesis in mice.61,63,64   Plk1 overexpression has been 
reported in many cancers, including: lung, pancreases, endometrium, brain, breast, ovary, colon, 
skin, head and neck, esophagus, gastric tract and prostate; and overexpression of Plk1 often 
correlates with tumor aggressiveness and poor patient prognoses.61,62,65  Plk1 is a validated target 
for cancer therapies as several studies using RNA interference-based strategies have shown that 
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the depletion of Plk1 in different cancer cell lines led to cell death in vitro and tumor suppression 
in mice with human xenograft tumors.66-69  The development of drugs targeting Plk1 is inspired 
by an approach designed to target key enzymes active during mitosis as a way to inhibit the 
hyperproliferative state of tumor cells and induce apoptosis.70,71 
 
      Several small molecule inhibitors of Plk1 have been identified which generally target 
Plk1 in one of two ways: a) ATP-competitive inhibition at the kinase domain or b) inhibition at 
the PBD.  Inhibition of Plk1 at the kinase domain has led to the identification of several potent 
and selective ATP-competitive inhibitors including BI 2536, BI 6727 and GSK 461364A, which 
are currently in clinical trials as chemotherapeutics for non-small-cell lung cancer, leukemia and 
solid cancer (Figure 7, top).62,72-76  Less well known are Plk1 small molecule inhibitors that 
target the PBD (Figure 7, bottom).  Inhibitors of the PBD may have the advantage of being 
highly selective for Plks vs. other related protein kinases containing structurally similar catalytic 
domains.77  Furthermore, specific inhibition of Plk1-PBD among the other mammalian Plks 
represents an important challenge for the development of small molecule PBD based inhibitors, 
since all Plks are active with nonoverlapping functions during the cell cycle and in tumor 
progression.78  To date, three small molecule inhibitors of Plk1-PBD have been identified; 
purpurogallin IC50 ~ 0.3 µM, poloxin IC50 4.8 ± 1.3 µM and thymoquinone IC50 1.14 ± 0.04 
µM.79,80  Inhibition of Plk1-PBD by these small molecule inhibitors of the PBD showed the 
hallmarks of PBD overexpression found by Hanisch, resulting in Plk1 mislocation, chromosomal 
congression defects and mitotic arrest, suggesting that small molecule inhibitors of Plk1-PBD 
have the potential to become valuable anticancer drugs.79,80 
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Figure 7. Selected inhibitors of Plk1: ATP-competitive inhibitors currently in clinical trials (top) and PBD selective 
inhibitors (bottom). 
3.2.1 Project Background 
The potential for kinase selectivity coupled with the important roles of Plk1-PBD during mitosis 
peaked our interest in the identification of PBD based Plk1 inhibitors.  An HTS campaign 
conducted by the PMLSC of 97,090 samples provided by the NIH SMR identified 11 hits 
(0.011% of the originally screened compounds) as concentration-dependent inhibitors of 
phosphopeptide binding to Plk1-PBD with an IC50 < 50 µM (Figure 8).81  A fluorescence 
polarization assay with recombinant Plk1-PBD was used to monitor for inhibition of Plk1.  This 
assay was developed by the Yaffe group at MIT and was submitted to the MLSCN for this HTS 
campaign.82  Of the 11 hits, SID 861574 was found to be a 2.41 ± 0.71 µM inhibitor of Plk1-
PBD and was chosen for further chemical hit-to-probe development as it’s structure could be 
readily modified.  SID 861574 also did not have the undesirable electrophilic or hydrolytic 
structural features present in the remaining active compounds. 
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Figure 8. Validated inhibitors of phosphopeptide binding to Plk1-PBD with their corresponding PubChem SID 
numbers.17 
 
Several rounds of medicinal chemistry optimizations led to the generation of a novel 
library of 38 analogues, including a synthetic sample of SID 861574 (205, Scheme 29).  
However, all of these showed no affinity to Plk1-PBD in follow up assays.83   The lack of 
affinity to Plk1-PBD of the resynthesized hit (205) as well as its 38 analogues from the first 
round of medicinal chemistry led us to examine the nature of the original sample of SID 861574.  
Low resolution EI mass spectral data demonstrated a strong molecular ion of m/z 319 (M+, 57), 
consistent with the expected mass of SID 861574.  The 1H NMR spectra strongly supported the 
presence of an ethyl ester, a para-substituted aromatic ring system, and at least one 
heteroaromatic proton with a chemical shift similar to that found for a 6-amino or 6-
hydroxyuracil ring system.  An ATR-IR spectrum of SID 861574 indicated the presence of a 
carboxylic acid functionality (peaks at 2863 (very broad) and 1644 cm-1). 
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Scheme 29. Synthesis of 205, the originally proposed compound/structure of SID 861574. 
3.3 IDENTIFICATION OF THE STRUCTURE OF SID 861574 
3.3.1 Initial synthetic attempts toward the identification of SID 861574 
The results from the above spectral analyses of SID 861574 guided us in the preparation of a set 
of analogues that would be consistent with both the mass and the structural features of the 
original SID 861574 sample.  We chose an approach in which the 6-amino or 6-hydroxyuracil 
ring system remained intact and the positions of the para-substituted aromatic ring and the ethyl 
ester, amide or carboxylic acid groups were varied along the uracil core.  This strategy led to the 
synthesis of five isomers of the original hit (Figure 9).  The synthetic routes utilized to generate 
these isomeric analogues as well as the carboxylic acid derivative of 205 are shown in Schemes 
30-34 and are summarized below. 
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Figure 9. Isomeric analogues of SID 861574.  
3.3.1.1 Synthesis of the carboxylic acid analogue of 205 
Compound 205 was converted to its carboxylic acid derivative by saponification with LiOH 
followed by acidification with HCl to produce 211 in 88% yield (Scheme 30).  This derivative 
was synthesized as an analogue of the originally proposed structure of the HTS hit for further 
biological testing against Plk1-PBD. 
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Scheme 30. Synthesis of carboxylic acid analogue 211. 
3.3.1.2 Synthesis of the isomeric 6-aminouracils 206 and 207 
Analogues 206 and 207 were synthesized according to the route shown in Scheme 31.  Initially, 
four 5-substituted-6-methylthiouracil intermediates 216, 217, 218 and 219 were synthesized by 
the cyclization of malonates 212, 213 or 214, with 215 according to the literature.84  Direct 
aminolysis of these intermediates with 5 equivalents of either 4-aminobenzoic acid or ethyl 4-
aminobenzoate under microwave conditions (120 – 150 oC) in DMF led to poor isolated yields of 
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the respective 6-aminouracils.  It was found, however, that the m-CPBA oxidation of 
intermediates 216 and 217 followed by aminolysis of the corresponding sulfoxides at 95-100 oC 
in dioxane produced the 6-aminouracil intermediate 224 and analogue 206 in 76% and 50% 
yield, respectively.85  Compound 224 was converted to the final product, carboxylic acid 207, by 
palladium-catalyzed hydrogenolysis of the benzyl ester in 73% yield. 
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Scheme 31. Synthesis of SID 861574 isomers 206 and 207. 
3.3.1.3 Synthesis of 6-aminouracil analogues 208 and 209 
Compound 208 was synthesized according to the route shown in Scheme 32.  In light of further 
SAR analyses, the three 6-aminouracils 227, 228 and 229 were synthesized by aminolysis of 6-
chlorouracil (226) with either 4-aminobenzoic acid, 4-ethylaminobenzoate or 4-
benzylaminobenzoate in variable yields.  Of these three 6-aminouracils, 228 was further 
converted to the corresponding carbamate 230 by reaction with diethyl pyrocarbonate in 18% 
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yield.  Intermediate 230 was converted in 36% yield to the isomeric carboxylic acid analogue 
208 by hydrogenolysis of the benzyl ester using Pearlman’s catalyst. 
 
NH2
RO
+
N
H
NH
O
OCl
155-160 oC
222: R = -OEt
225: R = -OBn
223: R = -OH
227: R = -OEt (72%)
228: R = -OBn (19%)
229: R = -OH (71%)
DMF
N
H
NH
O
OHN
RO
8% Pd(OH)2/C 
H2 (1 atm)N
H
NH
O
ON
OBnO
EtO
O
230 (18%)
THF
N
H
NH
O
ON
OHO
EtO
O
208 (36%)
228, O(CO2Et)2, Et3N
226
DMF
 
Scheme 32. Synthesis of isomeric analogue 208. 
 
Analogue 209 was synthesized according to the route shown in Scheme 33.  The requisite 
precursor, urea 231, was obtained in 79% yield by a reaction of 4-aminobenzoate with potassium 
cyanate.  The urea 231 was condensed with cyanoacetic acid under microwave conditions, 
producing 232, which was cyclized by heating at reflux in HMDS in the presence of 15% 
TMSCl to furnish the 6-aminouracil 233 in 77% yield.86,87  Saponification of the 6-aminouracil 
derivative with LiOH followed by acidification with HCl produced the corresponding acid 234 in 
95% yield.  This carboxylic acid intermediate was protected as the benzyl ester 235 by 
deprotonation with Cs2CO3 followed by reaction with benzyl bromide according to a literature 
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procedure.88  The benzyl protected 6-aminouracil was then deprotonated with excess LiHMDS 
and reacted with ethyl chloroformate, generating a mixture of products from which the 6-
carboethoxyaminouracil derivative 236 was isolated crude in 20% yield.  This intermediate was 
then converted to the final analogue 209 in moderate yield and in ~87% purity based on 1H 
NMR. 
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Scheme 33. Synthesis of isomeric analogue 209. 
3.3.1.4 Synthesis of the 6-hydroxyuracil analogue 210 
Analogue 210 was synthesized according to the route shown in Scheme 34.  Initially, the urea 
231 was cyclized with diethyl malonate in the presence of NaOEt in ethanol at reflux.89  The 
reaction mixture was acidified to a pH of 6-7 with HCl, furnishing the sodium salt of the 
corresponding 6-hydroxyuracil 237 in 49% yield.  The isolated sodium salt was then either 
acidified to a pH of 1.5, generating the ethyl ester intermediate 238, or further saponified with 
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LiOH and subsequently treated with HCl to produce the carboxylic acid 239.  The ethyl ester 
intermediate 238 was condensed with ethyl isocyanate, producing 240, which was saponified 
with LiOH to reach the final analogue, 210, upon acidification with HCl in 46% yield.83 
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Scheme 34. Synthesis of isomeric 6-hydroxyuracil analogue 210. 
3.3.1.5 Conclusions of the initial synthetic attempt to identify the structure of SID 861574 
In this round of synthetic analoging, 25 new samples were synthesized including five analogues 
isomeric with the major component of the original HTS hit.  Unfortunately, none of the five 
isomers prepared in this study were spectroscopically identical to SID 861574 by 1H or 13C 
NMR.  Consequently, the identity of this substance remained unknown. 
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3.3.2 Structure elucidation of SID 861574: Development of a controlled synthesis of 
N1,N3-differentially-substituted 5-methylene-6-hydroxy uracils 
A breakthrough regarding the identity and structural connectivity of SID 861574 came about via 
isolation of an X-ray quality crystal after slow evaporation of a 1:1 solution of MeOH:ACN at 5 
oC, revealing the structure 241 shown in Figure 10.  This surprising result showed a structure for 
SID 861574 bearing the molecular formula C14H12N2O7 that contained an N3-carbethoxy-
substituted-6-hydroxy uracil core substituted in the N1 position with a p-substituted benzoic acid 
moiety.  In light of the differences between the X-ray structure and the originally proposed 
structure for SID 861574, evident by different atom connectivity’s and molecular 
formulas/weights C14H13N3O6 (m/z 319 (M+)) vs. C14H12N2O7 (m/z 320 (M+)), a 1H NMR (300 
MHz, DMSO-d6) was taken of a small set of the crystals sent for X-ray crystallography which 
showed no evidence of sample degradation/contamination.  A second crystal from this set was 
also submitted for X-ray crystallographic analysis, giving an identical result to the first 
submission. 
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Figure 10. Originally obtained X-ray structure (241) for SID 861574. 
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Our initial synthetic approach to access the proposed structure of SID 861574 was 
through a cyclization strategy.  Urea 243 would be cyclized with a highly reactive electrophile 
such as malonyl chloride or carbon suboxide (C3O2) directly furnishing the appropriately N1,N3-
subsituted-6-hydroxy uracil core.  Subsequently, benzyl ester cleavage would unveil the requisite 
carboxylic acid (Scheme 35).  Secondary urea 243 was synthesized by the initial conversion of 
amine 225 to the primary urea 242 by reaction with KOCN.  Deprotonation of 242 with 
LiHMDS and subsequent reaction with Mander’s reagent at -78 °C generated 243 in 63% 
yield.90,91  Attempts to cyclize 243 by reaction with malonyl chloride in the presence of Et3N, 
DIPEA or NaH in DCM or THF at 0 °C or room temperature resulted only in recovery of the 
starting urea.  Similarly, the reaction of 243 with carbon suboxide in THF, Et2O or DCM at -78 
or 0 °C resulted in the isolation of 243 with no evidence of formation of 244.92  It was found, 
however, that the primary urea 242 could be cyclized with malonyl chloride in the presence of 
Hünig’s base to furnish the N1-subsituted-6-oxo-uracil 245 in 39% yield.  Further elaboration of 
245 to carbamate 244 was met with difficulty, as the reaction of 245 with ethyl chloroformate in 
the presence of triethylamine resulted in a selective O-carbethoxylation reaction forming 
carbonate 246 in 64% isolated yield (Scheme 35).  The carbonate 246 was found to be stable 
upon storage at -5 °C under nitrogen gas for months; however, 246 was found to decompose by 
~50% after approximately 20 h in DMSO-d6 at room temperature.  Similar acylation reactions 
are known for piperidine-3,5-dione which was reported to undergo N,O-dicarbethoxylation upon 
reaction with excess ethyl chloroformate in the presence of Et3N.93 
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Scheme 35. Attempted synthesis of carbamate 244.  Synthesis of carbonate 246. 
 
Further, reaction of 246 in THF with 20 mol% of Pearlman’s catalyst under a hydrogen 
gas atmosphere (1 atm) successfully cleaved the benzyl ester and gave carboxylic acid 247 in 
61% yield.  Efforts toward the conversion of carbonate 246 to carbamate 244 were investigated 
under thermodynamic reaction conditions by reacting 246 with 20 mol% DMAP in THF at room 
temperature (Scheme 36).  After 4 h, this reaction resulted in the conversion of 246 to a 4:1 
mixture of 248:245 by 1H NMR analysis, demonstrating an interesting O- to C-carbethoxy 
transfer reaction catalyzed by DMAP and driven by the thermodynamic stability of the product 
ethyl ester 248.  It was found that while the conversion for this reaction was respectable, 
compound 248 was difficult to purify from the ~20% of 245 contaminating the final reaction 
mixture.  Accordingly, an alternative cyclization reaction was developed in which 248 was 
prepared by the initial reaction of 242 with ethyl malonyl chloride generating intermediate 251 
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which was then cyclized over the N1-C5-uracil ring positions by reaction with CDI in the 
presence of triethylamine.  This new cyclization strategy for uracil synthesis generated 248 in 
66% isolated yield.  The independently prepared products 248 from both routes were converted 
to their corresponding carboxylic acids 249 by hydrogenolysis of the benzyl esters.  Product 
samples of 249 from both reaction pathways were combined and found to be identical by 1H 
NMR (300 MHz, DMSO-d6), offering further confirmation to the assigned structure of 248 
isolated from the thermodynamic equilibration study.  The spectral data for compounds 247 and 
249 again proved these products to be distinct from the original HTS hit SID 861574. 
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Scheme 36. Synthesis of O- and C-carbethoxylated derivatives 247 and 249. 
 
The results above indicate that while O- and C-carbethoxylation of 245 can be readily 
achieved, selective N3-carbethoxylation is complicated by both the thermodynamic stability of 
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the C5-carbethoxy substitution and the lack of nucleophilicity of the N3-nitrogen of the 6-oxo-
uracil scaffold.  As a result, we sought to develop a protecting group strategy for the uracil C5-
ring position.  Initially, we attempted to implement this strategy by protecting the C5-position of 
substrate 245 through a reaction with trimethylene dithiotosylate (TsS(CH2)3STs, 254) to 
produce the corresponding dithiane 256 (see Scheme 37 for structure).94,95  Unfortunately, the 
reaction of 245 with trimethylene dithiotosylate using KOAc as a base in absolute ethanol at 
reflux or using triethylamine as a base in either ACN or DCM at room temperature led to 
complex reaction mixtures, affording only slight evidence of product formation by 1H NMR 
analysis.96,97  The lack of efficiency for the formation of dithiane 256 from the cyclic precursor 
245 led us to try a more stepwise approach to the formation of this compound (Scheme 37).  In 
the first step, primary urea 242 was reacted with methyl malonyl chloride in THF at room 
temperature to afford 253 in 92% yield.  After reaction optimization, it was found that 253 could 
be smoothly converted to 255 in 94% yield by reaction with trimethylene dithiotosylate in the 
presence of 2.5 equivalents of triethylamine in DCM at room temperature.  Dithiane 255 was 
then cyclized by treatment with excess K2CO3 in ACN at reflux over 4 h to afford the desired C5-
protected-6-oxo-uracil intermediate 256 in 67% yield. 
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Scheme 37. Synthesis of the C5-protected-6-oxouracil intermediate 256. 
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Initial attempts to introduce the ethyl ester at the N3-position of 256 by reaction with a 
large excess of both triethylamine and ethyl chloroformate in DCM surprisingly afforded the 
ethyl adduct 257 in 71% yield (Scheme 38).  This interesting reagent combination allows for a 
relatively mild method for N3-ethylation of N1-substituted-C5-disubstituted-6-oxo-uracil 
scaffolds.98,99  The scope and mechanism of this alkylation reaction has not been further 
investigated.  It was found, however that 256 could be successfully N3-carbethoxylated by 
reaction with ethyl chloroformate using pyridine as a base to form the carbamate 258 in 91% 
yield. 
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Scheme 38. Synthesis of N3-ethyl / N3-carbethoxy-6-oxouracils 257 and 258. 
 
Utilizing 257 as a model substrate to optimize the reaction conditions for cleavage of the 
dithiane, it was found that common desulfurization conditions including reaction with activated 
Raney nickel under a hydrogen gas atmosphere (1 atm) or reaction with nickel or cobalt 
borohydride failed to produce the desired desulfurized product.100  Reductive cleavage of the 
dithiane was ultimately accomplished via a modification of a procedure reported by Holton 
which demonstrated the efficiency of activated zinc to reductively desulfurize α-phenylthio 
ketones and esters under mild reaction conditions.101-103  Thus, the reaction of 257 in a 1:1 
solution of aqueous NH4Cl:THF with 10 equivalents of nano-zinc at room temperature followed 
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by an acidification of the reaction mixture to pH 1.0 – 1.5 with a 1.0 M HCl solution furnished 
259 in 62% yield (Scheme 39).  Gratifyingly, the application of this methodology to intermediate 
258 smoothly cleaved the dithiane, forming carbamate 244 in 66% yield.  Hydrogenolysis of the 
benzyl ester from 244 proceeded cleanly in 77% yield to the desired carboxylic acid 241.  This 
reaction represents the first example of the use of a dithiane protecting group strategy to 
synthesize C5-unsubstituted-N1,N3-differentially-substituted-6-oxo-uracil scaffolds and should be 
beneficial for the development of barbiturates containing this unique and synthetically 
challenging substitution pattern. 
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Scheme 39. Synthesis of the originally proposed X-ray structure 241. 
 
To test the structural equivalency of 241 with the original HTS hit, a 1:1 mixture of 241 
and SID 861574 was prepared in DMSO-d6 for 1H NMR analysis.  As can be clearly seen from 
the 1H NMR spectrum shown in Figure 11, these two compounds were found not to be identical, 
allowing us to rule out the structure of 241 as that of SID 861574.  In fact, in contrast to SID 
861574, compound 241 was found to form exclusively the keto-tautomer in DMSO-d6, as 
evidenced by the methylene peak at δ 3.97 ppm.  While the structure of SID 861574 remained 
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elusive, this work allowed for the generation of a series of closely related SID 861574 analogues 
and ultimately illuminate the structure of SID 861574. 
 
 
Figure 11. 1H NMR (300 MHz, DMSO-d6) stack plot of a) SID 861574 b) compound 241 and c) a 1:1 
mixture of SID 861574 and 241. 
 
The X-ray crystal structure of SID 861574 provided valuable information about the 
overall atom connectivity present in the molecular scaffold; however, the spectral inequivalency 
of SID 861574 and 241 suggested an inconsistency between one or more assignments in the 
crystal structure and the atoms present in SID 861574.  A close comparison of the 13C NMR data 
of SID 861574 and analogues 247, 249 and 241 provided important insight regarding the nature 
of the core heterocycle and the point of attachment of the ethyl ester (Figure 12).  First, the C2-
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carbonyl functionality in the 6-hydroxy uracil ring of substrates 247, 249 and 241 consistently 
falls within the chemical shift range of δ 149.3 – 150.0.  The closest carbonyl resonance found 
for SID 861574 was well outside this range at δ 159.5, suggesting that the core heterocycle was 
not a 6-hydroxy uracil.  Second, as can be seen from ethyl carbonate 247 and ethyl carbamate 
241, the chemical shift for the respective carbonyl resonances are found within a range of δ 
148.9 – 150.4, signaling that the ethyl ester functionality of SID 861574 was not attached to a N- 
or O-heteroatom but more likely to a C-atom as can be see by comparison with the ethyl ester 
analogue 249.  These two points together supported a structure in which the ethyl ester was 
attached to a carbon atom on the core heterocycle, which appeared to be a 4,6-dihydroxy-2-
piperidone and not a 6-hydroxy uracil (Figure 12, compound 260).   Further evidence for this 
observation came about via a re-refinement of the original X-ray crystallography data in which 
the N3-6-hydroxy uracil nitrogen atom was replaced with a carbon atom; hence, producing the 
4,6-dihydroxy-2-piperidone core of 260 and decreasing the R-value for the original data set from 
0.0809 to 0.0750.  On the basis of this information, we sought to synthesize compound 260 and 
directly compare it to SID 861574.   
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Figure 12. a) Numbering scheme for the 6-oxouracil scaffold.  b) Numbering scheme for the 4,6-
dihydroxy-2-piperidone scaffold.  c) 13C NMR chemical shift assignments in DMSO-d6 for compounds 247, 249, 
241 and SID 861574 (260). 
 
3.3.3 Positive identification of the structure of SID 861574 and biological testing results 
against Plk1-PBD 
The synthesis of 260 was based on a procedure reported by Mee which demonstrated that 
reaction of sodium diethyl 3-oxoglutarate with phenyl isocyanate in ether at reflux produced as 
the major product ethyl 2,4,6-trioxo-1-phenylpiperidine-3-carboxylate.104  Utilizing Mee’s 
protocol, it was found that reaction of sodium diethyl 3-oxoglutarate with benzyl 4-
isocyanatobenzoate 262 at 0 °C followed by heating in ether produced the uncyclized adduct 263 
as the major product (Scheme 40).105  Cyclization of 263 took place in the presence of NaH (2.0 
equiv.) by heating in THF for 45 min to give 264 as the major product in 50% crude yield after 
acidification.  These two reactions were then combined into one step by performing the reaction 
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in THF at reflux in the presence of NaH (2.5 equiv.) to furnish 264 in 39% yield and 90-95% 
purity by 1H NMR (Scheme 40).  While the original synthetic plan was to selectively cleave the 
benzyl ester of intermediate 264 through a palladium-catalyzed hydrogenolysis, exquisite 
chemoselectivity was found for the cleavage of the benzyl ester via saponification with 1.0 M 
NaOH, leading to the desired compound 260 in 78% yield.  A simplified one-pot reaction was 
developed in which a mixture of diethyl 3-oxoglutarate and readily available ethyl 4-
isocyanatobenzoate 203 in THF were reacted in the presence of excess NaH at 0 °C to cleanly 
generate in situ the ethyl ester analog of 263.  Cyclization and saponification of this intermediate 
was accomplished by the addition of an equal volume of 1.0 M NaOH to THF with stirring at 
room temperature for 1 h.  The resulting product was easily purified from this biphasic reaction 
mixture by removal of the THF layer and acidification of the aqueous layer with concentrated 
HCl (pH 0.0 - 0.5) at 0 °C, which cleanly precipitated 260 in 87% yield. 
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Scheme 40. Optimization of a one-pot synthesis of 260 (SID 861574). 
 
Upon isolation, a 1:1 solution of 260 and SID 861574 was prepared in DMSO-d6 for 1H 
NMR (300 MHz) analysis.  This NMR analysis demonstrated that 260 and SID 861574 were 
spectroscopically equivalent and hence identical compounds.  Compound 260 and SID 861574 
were also found to be identical by 13C NMR, IR, MS and X-ray crystallography.  A sample of the 
newly synthesized compound 260 was tested against Plk1-PBD.  Interestingly, unlike the initial 
assay results of the original HTS screen which showed SID 861574 to inhibit Plk1-PBD with an 
IC50 of 2.41 ± 0.71 µM, freshly prepared 260 was found to be inactive against Plk1-PBD (IC50 > 
50 µM). 
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3.4 INVESTIGATIONS INTO THE SAMPLE COMPOSITION OF                            
SID 861574 
As of 3/3/10, samples of two lots of SID 861574 were obtained for analysis.  The first lot, 
STOCK4S-15512 was the lot from which the originally tested sample of SID 861574, provided 
by the NIH SMR originated.  The second lot PHAR065456 was obtained later and both batches 
are/were available from Ambinter.  Samples from these lots were directly compared by 1H NMR 
(300 MHz) analysis in DMSO-d6 and it was found that both lots were identical in composition 
(Figure 13a, 13b and 13c).  Further NMR analysis of these two lots (now referred to collectively 
as SID 861574) showed the major contaminant of the sample to be NH4Cl (Figure 13d). 
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Figure 13. 1H NMR (300 MHz, DMSO-d6) stack plot of a) STOCK4S-15512, b) PHAR065456, c) 1:1 
mixture of STOCK4S-15512 and PHAR065456, d) PHAR065456 with NH4Cl added. 
 
An LC/MS/UV analysis was performed on SID 861574, which showed 260 (retention 
time = 10.91 min, MS (ESI+) m/z 320 [M + H]+) to be the major component of the sample along 
with two other impurities (< 5% by 1H NMR) having retention times of 13.31 and 16.51 min 
(Figure 14).   While the peak at 13.31 min ionized (ESI+) poorly and its origin remains 
unknown, the peak at 16.51 min was found to have a m/z = 411.  This mass was consistent with a 
compound having the structure of 266 (m/z = 411 [M + H]+), which was synthesized by the 
reaction of 265 (see Scheme 42 for synthesis) with ethyl 4-isocyanatobenzoate in the presence of 
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DIPEA (Scheme 41).  A direct LC/MS/UV comparison of 266 with SID 861574 showed a match 
between 266 and the impurity at 16.51 min in SID 861574 by both retention time and mass 
(Figure 14c).  As a result, 266 is very likely an impurity contained in the original sample of SID 
861574, and, therefore, the biological activity of 266 against Plk1-PBD is also of interest. 
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Scheme 41. Synthesis of 266, a likely impurity in SID 861574. 
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Figure 14. Direct LC/MS/UV comparison for a) SID 861674, b) compound 266 and c) a 3:1 mixture of 
SID 861574 and compound 266.a 
3.5 INVESTIGATIONS INTO THE DECOMPOSITION OF 260 AND                       
SID 861574 
As a result of the differences in biological activity against Plk1-PBD of SID 861574 and 260, 
along with a thorough analysis of the composition of SID 861574, it was also important to 
analyze the decomposition patterns of SID 861574 and 260 in wet DMSO.  It is plausible that the 
                                                 
a LC/MS analysis performed by Peter Chambers. 
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originally tested sample of SID 861574, prepared in an aqueous DMSO solution, may have 
partially decomposed prior to testing against Plk1-PBD and that a decomposition product of this 
sample was actually responsible for the initial positive assay result. 
3.5.1 High temperature decomposition of SID 861574 
A high temperature 1H NMR (300 MHz) decomposition experiment was performed on SID 
861574 by heating a sample of this compound to 90 °C for 3 h in DMSO-d6. The experiment 
showed decomposition of the sample to predominately yield one product.  We suspected that this 
decomposition product had the structure 265 as shown in Scheme 42.  To confirm this structure, 
compound 265 was synthesized by an independent route, initially forming the allyl ester 267 via 
the one pot reaction of diallyl 3-oxopentanedioate (268) with ethyl 4-isocyanatobenzoate as 
described above.106  Allyl ester 267 was then reacted with 5.0 mol% Pd(PPh3)4 in the presence of 
excess morpholine to cleave the allyl ester, following which decarboxylation was found to be 
spontaneous, forming 265 in 74% yield after acidification.  Compound 265 was found to exist as 
a 4:1 mixture of tautomers in DMSO-d6 by 1H NMR.  The most characteristic peaks for this 
tautomeric pair are the C5-H resonances at δ 5.36 and 5.25 (Figure 15b and 15d). 
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Scheme 42. Synthesis of thermal decomposition fragment 265. 
 
To confirm that compound 265 was the genuine high temperature decomposition product 
of 260, a 3:2 mixture of 260:265 was prepared in DMSO-d6.  This mixture was heated to 110 °C 
for 30 min.  After cooling to room temperature, 1H NMR showed a nearly complete 
decomposition of 260 to 265 and EtOH, confirming the structure of 265 as the thermal 
decomposition product of 260 (and therefore SID 861574) in DMSO (Figure 15).  Compound 
265 is thought to arise via the decomposition pathway shown in Scheme 43, in which an initial 
retro [4+2] reaction of 260 generates the corresponding α-oxo ketene intermediate 269, which 
then either reacts with the eliminated EtOH to reform 260 or with H2O (present in DMSO) to 
form the dicarboxylic acid intermediate 270.107,108  Intermediate 270, may then either undergo a 
retro [4+2] reaction to reform 269 or irreversibly decarboxylate to form the final product 265. 
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Figure 15. 1H NMR (300 MHz, DMSO-d6) stack plot of: a) compound 260, b) compound 265, c) a 2:3 mixture of 
260 and 265 at room temperature, and d) a mixture after heating to 110 °C for 30 min, showing the thermal 
decomposition of 260 to 265. 
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Scheme 43. Proposed high temperature decomposition pathway for 260 to 265 in wet DMSO. 
 
3.5.2 Room temperature decomposition of 260 vs. SID 861574 
The room temperature decomposition of a concentrated sample of compound 260 in wet DMSO-
d6 was monitored over 6 weeks (Figure 16a).  It was found that over this time period 260 
underwent a hydrolytic decomposition relatively cleanly to afford predominantly two products.  
The structure of the first decomposition product was found through synthesis and 1H NMR 
comparison to be that of 271 (Figure 16b, Scheme 44a).  Compound 272 was also synthesized 
via a modification of a procedure reported by Pericas et. al. for 1H NMR comparison due to the 
expected similarity in the 1H NMR resonances for compound 272 vs. 271.106  This experiment 
ruled out the possibility of the 1H NMR resonances in Figure 16a to arise from 272 (Scheme 
44b).  The second room temperature decomposition product was found to be consistent with the 
high temperature decomposition product 265 (Figure 16c). 
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Figure 16. 1H NMR (300 MHz, DMSO-d6) stack plot for the room temperature decomposition of 260 over 6 weeks 
into compounds 271, 265 and ethanol. 
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Scheme 44. Synthesis of possible decomposition products of 260, 271 and 272. 
 
A control 1H NMR (300 MHz) experiment of the room temperature decomposition of 
two samples of 260 was performed over 9 weeks (Figure 17).  Both samples contained 2.5 mg of 
260 in 1.0 mL of DMSO-d6 containing 2.0 µL deionized water, however, one sample was doped 
with 1.3 equiv. NH4Cl (Figure 17b) and the other was not (Figure 17a).  As can be inferred by 
comparison with Figure 16a, both the rate and complexity of the decomposition of 260 appears 
to be enhanced in DMSO solutions heavily saturated with water.  While 271 and 265 were 
detected in these spectra, the identities of the other decomposition products remain unknown.  A 
comparison of the NMR spectra between the NH4Cl doped sample and the non-doped sample 
shows only slight differences in both the rate and extent of decomposition of 260 over the period 
studied.  After 9 weeks, both samples were stored at -20 oC to suppress further decomposition 
before biological testing against Plk1-PBD.  The 1H NMR decomposition profile of a sample of 
SID 861574 stored under similar conditions was found to match the results of this control 
experiment (Figure 17c).  These experiments reveal the instability of SID 861574 in wet DMSO 
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solutions and may provide a possible link between the decomposition of SID 861574 and the 
biological activity against Plk1-PBD. 
 
 
Figure 17. Comparison of the room temperature decomposition patterns in wet DMSO-d6 of a) compound 
260, b) a mixture of 260 and NH4Cl and c) SID 861574. 
3.6 INITIAL BIOLOGICAL TESTING RESULTS AGAINST PLK1-PBD 
Initially, three compounds were submitted for biological testing against Plk1-PBD (Figure 18, 
Table 12): a) compound 260, batch DMA-NB205-92, a resynthesis of SID 861574, b) compound 
267, batch DMA-NB245-4, the allyl ester analogue of 260 and c) compound 265, batch DMA-
NB245-3, the freshly synthesized high temperature decomposition product of 260.  Of these 
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three compounds, only 265 was found to inhibit Plk1-PBD with an IC50 of 2.079 µM.  Following 
this result, an optimized synthesis of 265 was developed and the product of this reaction DMA-
NB245-24 was submitted along with the previous samples and two additional closely structurally 
related compounds 234 and 239 for biological testing against Plk1-PBD.  Curiously, of these 
samples again only compound 265 batch DMA-NB245-3 and not compound 265 batch DMA-
NB245-24 was active against Plk1-PBD.  This result strongly suggested that an impurity in the 
sample 265 batch DMA-NB245-3 (~90% pure) and not in DMA-NB245-24 (> 95% pure) was 
responsible for the positive assay result.  As can be seen from table 12, it was also found that 265 
batch DMA-NB245-3 slightly decreased in potency from the first to the second testing.  This 
decrease in potency may reflect the stability of the active agent in the sample over a storage 
period of 3 months. 
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Figure 18. Samples submitted for biological testing against Plk1-PBD. 
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Table 12. Biological Testing Results from Two Trials for Inhibitors of Plk1-PBD. 
 
3.7 IDENTIFICATION AND SYNTHESIS OF PUTATIVE IMPURITIES FOUND IN 
THE BIOLOGICALLY ACTIVE BATCH OF COMPOUND 265,                                 
DMA-NB245-3 
As a result of the large difference in biological activities between 265, batches DMA-NB245-3 
and DMA-NB245-24, a thorough analysis of these samples by LC/MS/UV and 1H NMR was 
conducted.  The LC/MS/UV analysis (Figure 19) reveals a predominant impurity at 12.70 min 
having a mass of m/z 335 (M+H)+ in the active sample DMA-NB245-3.  However, this impurity 
was absent in the inactive sample DMA-NB245.  A 1H NMR (300 MHz, DMSO-d6) of 265 batch 
DMA-NB245-3 showed this sample to contain ~5-7% of an impurity having distinctive aromatic 
resonances at δ 7.89 (d) and 7.68 (m) (see figure 21a for 1H NMR).  Initially, we sought to 
identify this potentially active impurity through synthesis and isolation, by scaling up the 
synthetic route used to synthesize 265 batch DMA-NB245-3 200-fold (Scheme 45). 
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Figure 19. LC/MS/UV comparison of compound 265: a) batch DMA-NB245-24 (inactive), b) batch DMA-NB245-
3 (active) and c) MS (ESI+) trace for impurity peak at 12.70 min.  Samples prepared as 1 mg substrate in 1 mL 
MeOH.a 
 
In the first step of this scale up synthesis, the sodium salt of 268 was generated and 
reacted with isocyanate 203 to form adduct 273, which was cyclized by heating in THF to give 
an approximately 2:1:0.5:trace mixture of 274a: 274b: 274c: 274d after acidification and 
recrystallization.106  This mixture was then subjected to the deallylation conditions used for the 
synthesis of 265, batch DMA-NB245-3.  A mixture of 247a-d was reacted with Pd(PPh3)4 in the 
presence of 10 equiv. morpholine in THF at room temperature for 1.5 h, followed by 
saponification of the ethyl ester by reaction with 1.0 M NaOH, providing 1.89 g of 265 in 62% 
yield (~90% purity by 1H NMR) after acidification with HCl.  This sample contained the 
identical impurity peaks by 1H NMR as seen in batch DMA-NB245-3.  After five 
recrystallizations from THF or EtOAc and hexanes, the majority of 265 was removed from the 
sample and the ratio of the impurity to 265 was enriched from 7:93 to 32:68 as judged by 1H 
                                                 
a LC/MS analysis performed by Peter Chambers. 
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NMR.  However, other unidentified impurities also remained in the sample.  Following this 
series of recrystallizations, other methods were utilized to separate the remaining 32 mg of 
enriched sample.  Unfortunately, isolation attempts by column chromatography, prep TLC, 
semiprep SFC, MPLC and HPLC failed to produce any pure samples.   A sample from the 
remainder of this mixture was saved for further biological testing against Plk1-PBD (265, batch 
DMA-NB245-38).  The identities of many of the impurities in this sample were finally 
determined after an elaborate series of experiments designed to optimize the synthesis of 265 
with respect to the unknown but desired impurity(s).   The interesting impurity profile of this 
sample will be discussed shortly. 
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Scheme 45. Scale up synthesis of 265 batch DMA-NB245-3. 
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Trials toward the optimization of the reaction conditions for the synthesis of 265 with 
respect to the desired impurity(s) identified by 1H NMR in the biologically active sample of 265, 
batch DMA-NB245-3, are depicted in Table 13.  As can be seen from entries 1-4, the 
deallylation of 274 in the presence of high loadings of Pd(0) catalyst and morpholine (10 equiv.) 
led to higher percentages of the desired impurity(s) in the crude reaction mixtures as determined 
by 1H NMR (DMSO-d6).  Entry 3 demonstrates that in the absence of an amine, the reaction 
product 265 acts as an allyl scavenging agent, forming a high percentage of the allylated reaction 
byproducts 277 and 278 in the crude reaction mixtures.  The appearance of the impurity(s) of 
interest was also ruled out as arising from a side reaction of N-allylmorpholine (276), formed as 
a necessary byproduct in these reactions (Table 13, entries 4 and 7).   
 
     As a result of the correlation between higher percentages of the impurity in the crude 
reaction product mixtures with higher loadings of the Pd(0) catalyst, it was thought that possibly 
the Pd(II) formed in these reaction mixtures was responsible for catalyzing the reaction to the 
desired impurity(s).  To test this hypothesis, the deallylation of 274 in the presence of Pd(OAc)2 
was explored with different catalyst loadings.  The reaction succeeded at 60 °C, and catalyst 
loadings between 50-100 mol% were necessary for maximizing (32-35%) the percentage of the 
desired impurity(s) in these crude mixtures (Table 13, entries 5-9).   Interestingly, entries 10-11 
show that heating mixtures of 267 or 265 to 60 °C in the presence of Pd(OAc)2 and morpholine 
also led to the formation of the desired impurity(s).  Attempts to run this reaction in the presence 
of ZnCl2 or in the absence of a Lewis acidic catalyst resulted in a large decrease in the formation 
of the desired impurity(s) by 1H NMR (Table 13, entries 12 and 13).  Finally, the optimized 
reaction conditions were found.  The reaction of 265 in the presence of one equivalent of 
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Pd(OAc)2 at 60 oC, in the absence of morpholine, generated a 1:1 mixture of 265:279 as 
determined by 1H NMR integration (Table 13, entry 14 vs.15).  These results suggest that the 
impurity(s) observed in sample 265 batch DMA-NB245-3 originate from a nucleophilic (H2O, 
morpholine) ring opening reaction of product 265 that takes place in the presence of Lewis acidic 
palladium (II) salts. 
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Impurity(s)
           Heterocycle
274: R1 =  -CO2Allyl, R2 =  -OEt
267: R1 =  -CO2Allyl, R2 =  -OH
265: R1 = -H, R2 = -OH
275
276
279 280
 
Table 13. Optimization of Reaction Conditions to Enhance the Ratio of the Major Impurity Found in the 
Biologically Active Sample of 265 (DMA-NB245-3). 
 
 
The structure of the putative impurity 279 formed in Table 13, entry 15 was confirmed 
after scaling up the reaction and carefully recrystallizing the products until the “impurity” was 
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isolated in ~85-95% purity by 1H NMR (300 MHz, DMSO-d6).  The product of this reaction was 
then directly compared to a genuine sample of 279 synthesized according to the route shown in 
Scheme 46.104  Initial attempts to synthesize 279 by the reaction of ethyl 4-aminobenzoate with 
anhydride 282, prepared according to a known literature procedure,  were unsuccessful due to the 
spontaneous decarboxylation of 283 to form 284 which was isolated in 28% yield.109,110  The 
reaction of anhydride 282 with 4-aminobenzoic acid 223, however, resulted in the formation of 
the desired dicarboxylic acid 279 which was found to be more stable toward decarboxylation 
than the ethyl ester analogue 283.  A 1H NMR (DMSO-d6) comparison of 279 (isolated from 
Table 13, entry 15) and the freshly synthesized sample of 279 showed these samples to be 
identical.  For further 1H NMR comparisons and biological testing purposes, 279 was heated in 
toluene to form the decarboxylated analogue 285 in 86% yield. 
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279 (44%) 285 (86%)  
Scheme 46. Synthesis of putative impurities 279 and 285 thought to be contained in 265 batch DMA-NB245-3. 
 
This analysis provided an optimized procedure, resulting in the isolation of 279 as a 
possible impurity contained in the original sample of 265 batch DMA-NB245-3.  Compound 
279, while a good match by 1H NMR to the major impurity resonances in DMA-NB245-3, was 
found to differ by LC/MS from the major impurity contained in this sample.  Consistent with 
both the 1H NMR and LC/MS data for the major impurity in 265 batch DMA-NB245-3 is 
compound 280 (Scheme 47).  Compound 280 may arise in 265 batch DMA-NB245-3 via a 
similar mechanism to that leading to compound 279, with morpholine acting as the nucleophile 
opening the ring in compound 265. 
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Scheme 47. Synthesis of the putative impurity 280 contained in 265 batch DMA-NB245-3. 
 
Compound 280 was synthesized according to the route shown in Scheme 47.  Initially, 
1.5 equiv. of 286 were reacted with ethyl 4-aminobenzoate 222 in the presence of ZnO at reflux 
in toluene to afford the amide 287 in 63% yield.  Reaction of 287 with morpholine under the 
same reaction conditions generated 288 in 44% yield.  The ethyl ester of 288 was then saponified 
in the presence of 3.0 M LiOH, affording 280 in 61% yield following acidification and 
recrystallization from MeOH.  A direct LC/MS/UV comparison of 280 and 265 batch DMA-
NB245-3 was performed.  As can be seen in Figure 20, compound 280 was identical in terms of 
both mass and retention time to the major impurity contained in 265 batch DMA-NB245-3.  
Compound 280 was also found to match the major impurity peaks found within 265 batch DMA-
NB245-3 by 1H NMR  (Figure 21). 
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Figure 20. LC/MS/UV comparison of a) compound 265 batch DMA-NB245-3, and b) compound 280.  Samples 
prepared as 1 mg substrate in 1 mL DMSO.a 
 
                                                 
a LC/MS analysis performed by Peter Chambers. 
 98 
 
Figure 21. 1H NMR (300 MHz, DMSO-d6) stack plot of a) compound 265 batch DMA-NB245-3 and b) putative 
impurity 280. 
 
A 1H NMR (DMSO-d6) comparison of compounds 265, 280, 277, 285, 279 and 260 with 
265 batch DMA-NB245-38 (scaled up synthesis of DMA-NB245-3) showed that sample 265 
batch DMA-NB245-38 was ~90% composed of a 51:22:9:8:6:4 ratio of 
265:280:277:285:279:260 solvated with ~10% MeOH.  This observation is also supported by 
LC/MS/UV analysis.  The results of this analysis indicate that all of the compounds reported 
above in sample 265 batch DMA-NB245-38 are likely constituents of the biologically active 
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sample 265 batch DMA-NB245-3 and are worthy candidates for biological testing against Plk1-
PBD. 
3.8 FURTHER SYNTHESIS OF ANALOGUES FOR BIOLOGICAL TESTING 
AGAINST PLK1-PBD 
The different compound structures revealed through the synthesis and decomposition studies of 
SID 861574 inspired the generation of an additional small set of analogues for biological testing 
against Plk1-PBD.  Through these syntheses, several analogues were constructed in which either 
the ethyl 4-aminobenzoate or 4-aminobenzoic acid moieties were symmetrically linked over a 
diarylurea, diarylmalonamide or tricarbonyl framework as shown in Schemes 48 - 50.  Pending 
further biological testing, these analogues may complement the findings of the above studies and 
generate a set of SAR data for this class of compounds at the PBD of Plk1. 
 
O
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O OEt O OEt
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O
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O OH O OH
,
286
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Scheme 48. Synthesis of tricarbonyl analogues 289 and 290. 
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Scheme 49. Synthesis of diarylmalonamide analogues 292 and 293. 
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Scheme 50. Synthesis of diaylurea analogues 294 and 295. 
3.9 SUMMARY 
Through the utilization of a fluorescence polarization assay with recombinant Plk1-PBD to 
monitor for inhibition of Plk1 via PBD binding by small molecules, a HTS campaign was 
conducted by the PMLSC and 97,090 compounds were screened as potential Plk1-PBD 
inhibitors.  A total of 11 hits were identified as Plk1 inhibitors with IC50 < 50 µM, and one (SID 
861574, IC50 = 2.41 ± 0.71 µM) was chosen for further hit-to-probe development.  Medicinal 
chemistry studies resulted in the synthesis of a library of 38 novel analogues based on the 
assigned structure of SID 861574, all of which where found to be biologically inactive against 
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Plk1-PBD.  A resynthesized sample of the initially proposed structure of SID 861574 was found 
to be spectroscopically nonequivalent with the originally tested material and inactive against 
Plk1-PBD.  Guided by NMR, IR, MS and X-ray crystallography data, a series of synthetic 
strategies led to uniquely functionalized 6-hydroxy- and 6-aminouracil scaffolds, all of which 
were spectroscopically nonequivalent to the originally tested sample of SID 861574.  However, 
due to the characteristic structural features of these compounds as observed through rigorous 
spectroscopic analysis, the structure of the original HTS hit SID 861574 could be identified.  
Following an independent synthesis of this compound (260), biological testing again revealed a 
lack of activity against Plk1-PBD. 
 
Consequently, a thorough investigation of both the synthesis and decomposition profiles 
of the original SID 861574 sample was conducted.  These studies resulted in: a) the 
identification and synthesis of an impurity (266) contained in the original biologically active 
sample, b) the synthesis of compounds 265 and 271 resulting from the degradation of this 
sample, and c) a new set of potentially active analogues revealed through the synthesis of the 
strongly supported decomposition product 265 of SID 861574, which was found to be transiently 
active against Plk1-PBD.  Testing of two different batches indicated that a separate agent formed 
during the synthesis of this compound was most likely responsible for the positive assay result.  
This work culminated in the synthesis of 56 compounds for biological testing against Plk1-PBD.  
It is hoped that a potent inhibitor of Plk1-PBD may be realized on the backdrop of several 
closely related analogues.  SAR data for the binding of these compounds to Plk1-PBD could 
afford a scaffold for further hit-to-probe development. 
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4.0  EXPERIMENTAL PART 
4.1 GENERAL EXPERIMENTAL 
All moisture-sensitive reactions were performed under an atmosphere of nitrogen gas and all 
glassware was either dried in an oven at 140 oC or flame dried under high vacuum prior to use.  
THF and Et2O were dried by distillation from Na/benzophenone ketyl, and CH2Cl2 and toluene 
were purified using an alumina column filtration system.  Reactions were monitored by either 1H 
NMR at 300 MHz in DMSO-d6 or by TLC analysis (EM Science pre-coated silica gel 60 F254 
plates, 250 m (layer thickness) and visualization was accomplished with a 254 nm UV light and 
by staining with a p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 
mL of conc. H2SO4 in 100 mL of 95% EtOH) and a KMnO4 solution (1.5 g of KMnO4 and 1.5 g 
of K2CO3 in 100 mL of a 0.1% NaOH solution).  Flash chromatography on SiO2 was used to 
purify the crude reaction mixtures.  Melting points were determined using a Laboratory Devices 
Mel-Temp II.  Infrared spectra were determined on a Smiths Detection IdentifyIR FT-IR 
spectrometer.  1H and 13C NMR spectra were obtained on a Bruker Avance 300 instrument in 
CDCl3 unless otherwise noted.  Chemical shifts were reported in parts per million with the 
residual solvent peak used as an internal standard.  1H NMR spectra were recorded at 300 MHz 
and are tabulated as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad), number of protons, and coupling constant(s).  13C NMR 
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spectra were recorded at 76 MHz using a proton-decoupled pulse sequence with a d1 of 3 sec, 
and are tabulated by observed peak.  Mass spectra were obtained on a Micromass Autospec 
double focusing instrument. 
4.2 LIBRARY SYNTHESIS 
4.2.1 Synthesis of 2,8-substituted-quinolinecarboxylic acid sodium salts 
N CF3
COO- Na+
10
1
2
3
4567
8
9 10
11
 
General procedure A. Sodium 2-(trifluoromethyl)quinoline-4-carboxylate (10).  A 
suspension of 2-(trifluoromethyl)quinoline-4-carboxylic acid 21 (224 mg, 0.927 mmol) in an 
aqueous NaOH solution (0.371 mL, 0.926 mmol, 10%) was heated at 40-50 oC.  After 1 h, the 
solution turned homogenous and the water was removed in vacuo. The resulting product 10 (242 
mg, 99%) was isolated as a white solid: 1H-NMR (acetone-d6, 300 MHz) δ 9.03 (d, 1 H, J = 8.5 
Hz, H-6), 8.15 (s, 1 H, H-3), 8.05 (d, 1 H, J = 8.4 Hz, H-9), 7.73 (dt, 1 H, J = 8.4, 1.3 Hz, H-8), 
7.44 (t, 1 H, J = 8.3 Hz, H-7). 
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N
COO- Na+
9
1
2
345
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Sodium quinoline-4-carboxylate (9).  According to general procedure A, 20 (50.0 mg, 0.289 
mmol) and aqueous NaOH (0.563 mL, 0.289 mmol, 0.513 M) were stirred at room temperature 
for 30 min. The resulting product 9 (56.4 mg, 100%) was isolated as a white solid: 1H-NMR 
(methanol-d4, 300 MHz) δ 8.85 (br, 1 H, H-1), 8.47 (br, 1 H, H-5), 8.04 (br, 1 H, H-8), 7.76 (br, 
1 H, H-7), 7.61 (br, 2 H, H-6, H-2). 
 
N
COO- Na+
11
1
23
4
5
6789
10
11
12
13
 
Sodium 2-cyclopropylquinoline-4-carboxylate (11).  According to general procedure A, 22 
(400 mg, 1.88 mmol) and aqueous NaOH (0.750 mL, 1.88 mmol, 10%) were heated at 40-50 oC 
for 1 h.  The product 11 (440 mg, 100%) was isolated as a white solid: 1H-NMR (methanol-d4 
300 MHz) δ 8.18 (dd, 1 H, J = 8.2, 0.8 Hz, H-8), 7.79 (d, 1 H, J = 8.4 Hz, H-11), 7.53 (dt, 1 H, J 
= 8.1, 1.4 Hz, H-10), 7.35 (dt, 1 H, J = 7.5, 1.2 Hz, H-9), 7.10 (s, 1 H, H-5), 2.21–2.12 (m, 1 H, 
H-3), 1.05–0.99 (m, 4 H, H-1, H-2). 
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Sodium 2-(furan-2-yl)quinoline-4-carboxylate (12). According to general procedure A, 23 
(400 mg, 1.67 mmol) and aqueous NaOH (0.699 mL, 1.67 mmol, 10%) were heated at 40–50 oC 
for 1 h. The product 12 (435 mg, 100%) was isolated as a light brown solid: 1H-NMR (methanol-
d4, 300 MHz) δ 8.35 (d, 1 H, J = 8.3 Hz, H-9), 8.04 (d, 1 H, J = 8.3 Hz, H-12), 7.98 (s, 1 H, H-
6), 7.76–7.69 (m, 2 H, H-11, H-1), 7.54 (t, 1 H, J = 7.5 Hz, H-10), 7.33 (d, 1 H, J = 3.4 Hz, H-3), 
6.66 (dd, 1 H, J = 3.3, 1.7 Hz, H-2). 
 
N
COO- Na+
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1
2
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5
6
7
8
910
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14 15
16
 
Sodium 2-phenylquinoline-4-carboxylate (13).75  According to general procedure A, 24 (500 
mg, 2.01 mmol) and aqueous NaOH (1.60 mL, 2.01 mmol, 5.0%) were combined over a 1 h 
period, affording 13 (540 mg, 99%) as a light yellow solid: 1H-NMR (methanol-d4, 300 MHz) δ 
8.91 (d, 1 H, J = 8.1 Hz, H-11), 8.46 (s, 1 H, H-8), 8.15–8.13 (m, 2 H, H-1, H-5), 8.00 (d, 1 H, J 
= 8.3 Hz, H-14), 7.56 (t, 1 H, J = 7.0 Hz, H-13), 7.27–7.21 (m, 4 H, H-2, H-3, H-4, H-12). 
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Sodium 2,8-bis(trifluoromethyl)quinoline-4-carboxylate (14).  According to general 
procedure A, 25 (279 mg, 0.901 mmol) and aqueous NaOH (0.360 mL, 0.91 mmol, 10%) were 
heated at 40-50 oC for 1 h.  The product 14 (210 mg, 97%) was isolated as a white solid: 1H-
NMR (acetone-d6, 300 MHz) δ 9.28 (d, 1 H, J = 8.6 Hz, H-8), 8.26 (s, 1 H, H-3), 8.05 (d, 1 H, J 
= 7.1 Hz, H-6), 7.40 (t, 1 H, J = 7.7 Hz, H-7). 
4.2.2 Synthesis of 1-N-alkyl-3-N-alkyl-5-chloroacetyl-6-aminouracils 
N
N
O
O NH2
Cl
O
15
1
2
3
4
5 6 7
8
9
 
General procedure B.  6-Amino-5-(2-chloroacetyl)-1,3-dimethylpyrimidine-2,4(1H,3H)-
dione (15, DMA-P77).11  To a mixture of 36 (1.00 g, 6.45 mmol), chloroacetic acid (1.00 g, 10.6 
mmol) and pyridine (0.512 mL, 6.46 mmol) was added 2-chloroacetyl chloride 41 (0.513 mL, 
6.45 mmol) at room temperature.  The reaction mixture was heated to 95 oC for 1 h under a 
nitrogen atmosphere.  After 1 h, the mixture was cooled to 50 oC and deionized water (20.0 mL) 
was slowly added, with vigorous stirring, while cooling the mixture to 0 oC for 1 h.  A white 
precipitate formed which was isolated by vacuum filtration, washed with additional H2O (15.0 
mL) and recrystallized from a 3:2 solution of EtOAc and hexanes.  The resulting product 15 (789 
mg, 53%) was isolated as a yellow crystalline solid: Mp 189–190 oC; IR (KBr) 3339, 3154, 
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1718, 1659, 1608, 1529, 1369, 1150, 781, 651 cm-1; 1H-NMR (DMSO-d6 300 MHz) δ 10.79 (br, 
1 H, H-1), 8.44 (br, 1 H, H-1), 4.91 (s, 2 H, H-9), 3.31 (s, 3 H, H-5), 3.14 (s, 3 H, H-3); 13C-
NMR (DMSO-d6, 75 MHz) δ 189.0 (C-8), 161.2 (C-6), 158.1 (C-2), 149.4 (C-4), 89.3 (C-7), 
51.5 (C-9), 29.7 (C-3), 27.6 (C-5); MS (EI) m/z 231 (M+, 9), 196 (100), 182 (77), 166 (23), 137 
(27), 121 (68), 57 (92); HRMS (EI) m/z calculated for C8H10N3O3Cl 231.0411, found 231.0411. 
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6-Amino-3-benzyl-5-(2-chloroacetyl)-1-methylpyrimidine-2,4(1H,3H)-dione (16, DMA-
P150).  According to general procedure B, 37 (400 mg, 1.73 mmol) and 2-chloroacetyl chloride 
41 (0.138 mL, 1.73 mmol) were combined to yield 16 (357 mg, 67%) as an off white crystalline 
solid: Mp 213.5–215 oC; IR (KBr) 3436, 3179, 3061, 1714, 1600, 1512, 1433, 1236, 1139, 778, 
715, 649 cm-1; 1H-NMR (DMSO-d6 300 MHz) δ 10.84 (br, 1 H, H-1), 8.52 (br, 1 H, H-1), 7.28–
7.21 (m, 5 H, H-7, H-8, H-9, H-10, H-11), 4.97 (s, 2 H, H-5), 4.92 (s, 2 H, H-15), 3.32 (s, 3 H, 
H-3); 13C-NMR (DMSO-d6, 75 MHz) δ 189.2 (C-14), 161.0 (C-12), 158.2 (C-2), 149.4 (C-4), 
137.3 (C-6), 128.2 (C 2, C-8, C-10), 127.4 (2 C, C-7, C-11), 126.9 (C-9), 89.3 (C-13), 51.3 (C-
15), 43.6 (C-5), 29.8 (C-3); MS (EI) m/z 307 (M+, 13), 271 (100), 258 (43), 231 (58), 180 (17), 
132 (26), 106 (26), 65 (42); HRMS (EI) m/z calculated for C14H14N3O3Cl 307.0724, found 
307.0718. 
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6-Amino-5-(2-chloroacetyl)-1-(cyclopropylmethyl)-3-methylpyrimidine-2,4 (1H,3H)-dione 
(17, DMA-P164).  According to general procedure B, 38 (220 mg, 1.12 mmol) and 2-
chloroacetyl chloride 41 (0.0895 mL, 1.12 mmol) were combined to yield 17 (145 mg, 47%) as a 
yellow crystalline solid: Mp 185–186 oC;  IR (KBr) 3317, 3066, 3010, 1723, 1655, 1603, 1523, 
1387, 1144, 1019, 827 cm-1; 1H-NMR (DMSO-d6 300 MHz) δ 10.96 (br, 1 H, H-1), 8.54 (br, 1 
H, H-1), 4.93 (s, 2 H, H-12), 3.88 (d, 2 H, J = 6.8 Hz, H-3), 3.15 (s, 3 H, H-8), 1.15 (m, 1 H, H-
4), 0.47–0.39 (m, 4 H, H-5, H-6); 13C-NMR (DMSO-d6, 75 MHz) δ 189.4 (C-11), 161.1 (C-9), 
157.4 (C-2), 149.6 (C-7), 89.2 (C-10), 51.3 (C-12), 45.8 (C-3), 27.6 (C-8), 9.2 (C-4), 3.5 (2 C, C-
5, C-6); MS (EI) m/z 271 (M+, 9), 236 (74), 206 (71), 168 (82), 139 (42), 80 (51); HRMS (EI) 
m/z calculated for C11H14N3O3Cl 271.0724, found 271.0731. 
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6-Amino-5-(2-chloroacetyl)-1-isobutyl-3-methylpyrimidine-2,4(1H,3H)-dione (18, DMA-
P92).  According to general procedure B, 39 (250 mg, 1.27 mmol) and 2-chloroacetyl chloride 
41 (0.101 mL, 1.27 mmol) were combined to yield 18 (122 mg, 35%) as a white crystalline solid: 
Mp 184–185 oC; IR (KBr) 3488, 3219, 3155, 2970, 1712, 1655, 1611, 1522, 1375, 1231, 773 cm-
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1; 1H-NMR (DMSO-d6 300 MHz) δ 11.00 (br, 1 H, H-1), 8.44 (br, 1 H, H-1), 4.92 (s, 2 H, C-12), 
3.78 (d, 2 H, J = 7.8 Hz, H-3), 3.14 (s, 3 H, H-8), 2.04–1.97 (m, 1 H, H-4), 0.85 (d, 6 H, J = 6.6 
Hz, H-5, H-6); 13C-NMR (DMSO-d6, 75 MHz) δ 189.3 (C-11), 161.2 (C-9), 157.6 (C-2), 149.6 
(C-7), 89.2 (C-10), 51.5 (C-12), 48.0 (C-3), 27.6 (C-8), 26.0 (C-4), 19.3 (2 C, C-5, C-6); MS (EI) 
m/z 273 (M+, 16), 238 (95), 224 (39), 182 (53), 168 (100); HRMS (EI) m/z calculated for 
C11H16N3O3Cl 273.0880, found 273.0881. 
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6-Amino-1-benzyl-5-(2-chloroacetyl)-3-methylpyrimidine-2,4(1H,3H)-dione (19, DMA-
P143).  According to general procedure B, 40 (365 mg, 1.58 mmol) and 2-chloroacetyl chloride 
41 (0.126 mL, 1.58 mmol) were combined to yield 19 (350 mg, 72%) as a white crystalline solid: 
Mp 247–248.5 oC; IR (KBr) 3471, 3215, 3157, 1709, 1655, 1616, 1513, 1379, 1236, 772 cm-1; 
1H-NMR (DMSO-d6 300 MHz) δ 10.92 (br, 1 H, H-1), 8.44 (br, 1 H, H-1), 7.37–7.21 (m, 5 H, 
H-5, H-6, H-7, H-8, H-9), 5.21 (s, 2 H, H-3), 4.95 (s, 2 H, H-15), 3.18 (s, 3 H, H-11); 13C-NMR 
(DMSO-d6, 75 MHz) δ 189.4 (C-14), 161.2 (C-12), 157.6 (C-2), 149.6 (C-10), 135.0 (C-4), 
128.5 (2 C, C-5, C-9), 127.3 (C-7), 126.2 (2 C, C-6, C-8), 89.4 (C-13), 51.4 (C-15), 44.8 (C-3), 
27.7 (C-11); MS (EI) m/z 307 (M+, 19), 272 (100), 258 (40), 139 (7); HRMS (EI) m/z calculated 
for C14H14N3O3Cl 307.0724, found 307.0719. 
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4.2.3 Synthesis of the 2,8-substituted-4-quinoline carboxylic acids 
N
H
CF3
O
29
1
2
3
456
7
8
9
11
10
 
General procedure C. 2-(Trifluoromethyl)quinoline-4(1H)-one (29).9  To a vigorously stirred 
solution of aniline 26 (0.456 mL, 5.00 mmol) in polyphosphoric acid (6.30 g) was added 4,4,4-
trifluoro-3-oxobutanoate 28 (0.731 mL, 5.00 mmol) over a 2 min period at 100 oC.  The reaction 
mixture was heated to 150 oC for 2 h under a nitrogen atmosphere.  After 2 h of heating, the 
reaction mixture was cooled to room temperature and neutralized with an aqueous NaOH 
solution (16.0 mL, 5.0 %).  A precipitate formed which was isolated by vacuum filtration, 
washed with excess deionized water and re-dissolved in an aqueous NaOH solution (8.00 mL, 10 
%) with gentle heating.  The basic solution was filtered and then acidified to a pH of 4.5 with 
concentrated HCl.  The white precipitate which formed was isolated by vacuum filtration, 
washed with deionized water and recrystallized from a 2:1 solution of ethanol and water.  The 
resulting product 29 (515 mg, 46%) was isolated as a clear crystalline solid: 1H-NMR (acetone-
d6 300 MHz) δ 11.19 (br, 1 H, H-11), 8.30 (dd, 1 H, J = 8.3, 1.0 Hz, H-6), 7.96 (d, 1 H, J = 8.4 
Hz, H-9), 7.85 (td, 1 H, J = 6.9, 1.5 Hz, H-8), 7.62 (t, 1 H, J = 7.1 Hz, H-7), 7.04 (s, 1 H, H-3). 
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2,8-Bis(trifluoromethyl)quinolin-4(1H)-one (30, DMA-P104).17  According to general 
procedure C, 2-(trifluoromethyl)aniline 27 (3.72 mL, 30.0 mmol) and 4,4,4-trifluoro-3-
oxobutanoate 28 (4.38 mL, 30.0 mmol) were reacted over a 2 h period at 150 oC.  An alternative 
workup was preformed in which the product was extracted from the aqueous acidified mixture 
(pH = 5) with ether (4 x 100 mL) and chromatographed on SiO2 (1:1 EtOAc: hexanes).  The 
product was recrystallized from hexanes to afford 30 (2.66 g, 32%) as a white crystalline solid: 
Mp 133-134 oC; 1H-NMR (acetone-d6 300 MHz) δ 11.75 (s, 1 H, H-11), 8.60 (d, 1 H, J = 8.4 Hz, 
H-8), 8.29 (d, 1 H, J = 7.5 Hz, H-6), 7.84 (t, 1 H, J = 7.8 Hz, H-7), 7.37 (s, 1 H, H-3); MS (EI) 
m/z 281 (M+, 100), 261 (66), 233 (63), 214 (24), 183 (16), 75 (7). 
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General Procedure D. 4-Bromo-2-(trifluoromethyl)quinoline (31).17   To a melt of POBr3 
(1.35 g, 4.69 mmol) at 75 oC, under a nitrogen atmosphere, was added 29 (1.00 g, 4.69 mmol) 
over a 15 min period.  After the addition, the reaction mixture was heated to 150 oC for 2 h and 
then cooled to room temperature.  At room temperature, the reaction was quenched by the 
addition of deionized water (20.0 mL).  A white precipitate formed which was extracted from the 
aqueous mixture with CH2Cl2 (3 x 100 mL).  The combined organic extracts were washed with a 
saturated brine solution (50.0 mL), dried (Na2SO4), filtered through a plug of SiO2 and 
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concentrated by rotary evaporation.  The resulting crude solid was recrystallized from ethanol 
and water to yield 31 (652 mg, 50%) as a slightly impure white solid: 1H-NMR (chloroform-d, 
300 MHz) δ 8.22 (m, 2 H, H-6, H-9), 8.01 (s, 1 H, H-3), 7.89-7.73 (m, 2 H, H-7, H-8). 
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4-Bromo-2,8-bis(trifluoromethyl)quinoline (32, DMA-P108).17  According to general 
procedure D, 30 (2.01 g, 7.13 mmol) and POBr3 (2.05 g, 7.13 mmol) were combined to yield 32 
(2.15 g, 88%) as a white crystalline solid: Mp 60-62 oC; 1H-NMR (chloroform-d, 300 MHz) δ 
8.48 (d, 1 H, J = 8.4 Hz, H-6), 8.23 (d, 1 H, J = 7.3 Hz, H-8), 8.12 (s, 1 H, H-3), 7.83 (t, 1 H, J = 
7.9 Hz, H-7); MS (EI) m/z 343 (M+, 97), 345 (100), 267 (29), 169 (18), 84 (94). 
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General procedure E. 2-(Trifluoromethyl)quinoline-4-carboxylic acid (21, DMA-P114). 17  
To a solution of n-butyl lithium in hexanes (0.825 mL, 1.11 mmol, 1.34 M) in THF (2.00 mL) 
was added, over a 15 min period at -78 oC, a solution of  4-bromo-2-(trifluoromethyl)quinoline 
31 (305 mg, 1.11 mmol) in THF (0.50 mL).  The reaction mixture was stirred under a nitrogen 
atmosphere for 2 h and then slowly poured into an Erlenmeyer flask containing an excess of 
powdered dry ice.  This mixture was stirred for 15 min while warming to room temperature and 
was then diluted with deionized water (28.0 mL).  The resulting aqueous solution was washed 
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with ether (3 x 10.0 mL), acidified to a pH of 3-4 with an HCl solution (1.18 M) and extracted 
with EtOAc (3 x 30.0 mL).  The EtOAc extracts were combined and concentrated by rotary 
evaporation.  The resulting crude solid was recrystallized from EtOAc and hexanes to afford 21 
(142 mg, 53%) as a white crystalline solid: Mp 195.5–197 oC; IR (KBr) 3113, 2946, 1728, 1358, 
1256, 1199, 1103, 901, 767, 663 cm-1; 1H-NMR (acetone-d6 300 MHz) δ 8.96 (d, 1 H, J = 8.6 
Hz, H-6), 8.36 (s, 1 H, H-3), 8.28 (d, 1 H, J = 8.4 Hz, H-9), 8.02 (t, 1 H, J = 8.3 Hz, H-8), 7.95–
7.89 (m, 1 H, H-7); 13C-NMR (acetone-d6, 75 MHz) δ 166.6 (C-11), 149.0 (C-8), 147.9 (q, JCF = 
34.6 Hz, C-2), 138.8 (C-6), 132.0, 131.1 (2 C), 126.8, 126.7, 122.4 (q, JCF = 272.8 Hz, C-1), 
118.8 (C-3); MS (EI) m/z 241 (M+, 100), 223 (12), 196 (20), 185 (9), 176 (7), 128 (5); HRMS 
(EI) m/z calculated for C11H6NO2F3 241.0351, found 241.0349. 
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2,8-Bis(trifluoromethyl)quinoline-4-carboxylic acid (25, DMA-P115).18  According to general 
procedure E, 32 (300 mg, 0.872 mmol), n-butyl lithium (0.65 mL, 0.87 mmol, 1.34 M) and CO2 
(excess dry ice)  were converted to 25 (144 mg, 53%).  The product was obtained as a white 
crystalline solid: Mp 226–228 oC; IR (KBr) 3027, 1710, 1519, 1430, 1361, 1311, 1148, 1036, 
781, 687 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 12.32 (s, 1 H), 9.12 (d, 1 H, J = 8.7 Hz), 8.36 
(s, 1 H), 8.28 (d, 1 H, J = 7.1 Hz), 7.91 (t, 1 H, J = 7.9 Hz); 13C-NMR (acetone-d6, 75 MHz) δ 
166.1, 148.5 (q, JCF = 35.5 Hz), 145.0, 139.3, 131.4, 130.6 (q, JCF = 5.6 Hz), 129.9, 129.0 (q, JCF 
= 30.0 Hz), 127.5, 124.6 (q, JCF = 271.4 Hz), 122.0 (q, JCF = 273.1 Hz), 119.1; MS (EI) m/z 309 
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(M+, 100), 290 (21), 264 (28), 240 (17), 214 (17), 176 (30); HRMS (EI) m/z calculated for 
C12H5NO2F6 309.0224, found 309.0216. 
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2-Cyclopropylquinoline-4-carboxylic acid (22, DMA-P121).19  A solution of indoline-2,3-
dione 33 (1.00 g, 6.80 mmol) in aqueous KOH (4.00 mL, 35.0 mmol, 8.75 M) was stirred for 10 
min at room temperature.  The solution changed color from black to transparent yellow.  To this 
mixture was added 1-cyclopropylethanone 34 (1.01 mL, 10.2 mmol) and ethanol (2.5 mL).  The 
reaction mixture was heated at reflux for 4.5 h, cooled to 0 oC and acidified to pH of 5-6 with 
glacial acetic acid.  A precipitate developed which was isolated by vacuum filtration and was 
recrystallized from a 10:1 solution of EtOAc and hexanes to afford 22 (1.13 g, 78%) as a white 
crystalline solid: Mp 214–214.8 oC; IR (KBr) 3448, 3095, 3007, 1667, 1616, 1405, 1338, 882, 
772 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 8.74 (dd, 1 H, J = 8.6, 0.8 Hz, H-11), 7.97–7.94 (m, 
2 H, H-5, H-8), 7.74 (dt, 1 H, J = 7.6, 1.4 Hz, H-10), 7.57 (dt, 1 H, J = 7.7, 1.4 Hz, H-9), 2.43–
2.34 (m, 1 H, H-3), 1.23–1.07 (m, 4 H, H-1, H-2); 13C-NMR (acetone-d6, 75 MHz) δ 169.7 (C-
13), 164.9 (C-4), 147.6 (C-12), 142.3 (C-6), 131.9 (C-10), 128.2 (C-11), 127.4 (C-9), 127.3 (C-
5), 124.9 (C-8), 120.1 (C-7), 18.1 (C-15), 11.6 (C 2, C-1, C-2); MS (EI) m/z 213 (M+, 60), 212 
(100), 187 (14), 167 (63), 128 (12); HRMS (EI) m/z calculated for C13H11NO2 213.0790, found 
213.0784. 
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2-(Furan-2-yl)quinoline-4-carboxylic acid (23, DMA-P117).20  A solution of indoline-2,3-
dione 33 (1.00 g, 6.80 mmol) in aqueous KOH (4.00 mL, 35.0 mmol, 8.75 M) was stirred for 10 
min at room temperature.  The solution turned from black to transparent yellow.  To this mixture 
was added 1-(furan-2-yl)ethanone 35 (1.02 mL, 10.2 mmol). The reaction mixture was heated at 
reflux for 4.5 h, cooled to room temperature and acidified to pH of 3-4 with concentrated 
hydrochloric acid (36 %).  A precipitate developed which was isolated by vacuum filtration, 
dissolved in a solution of 10:1 EtOAc:MeOH and filtered through a plug of silica gel.  The 
solvents were then removed by rotary evaporation and the resulting orange solid was 
recrystallized three times from a 3:1 solution of ethanol and water to afford 23 (548 mg, 34 %) as 
a brown solid: Mp 234–237 oC (dec.); IR (KBr) 3435, 3141, 1714, 1600, 1372, 1232, 1018, 761 
cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 8.82 (dd, 1 H, J = 8.5, 0.8 Hz, C-12), 8.44 (s, 1 H, C-6), 
8.11 (dd, 1 H, J = 8.5, 0.6 Hz, C-9), 7.85–7.64 (m, 2 H, H-1, H-11), 7.66 (dt, 1 H, J = 7.8, 1.3 
Hz, H-10), 7.40 (dd, 1 H, J = 3.4, 0.7 Hz, H-3), 6.72 (dd, 1H, J = 3.4, 1.6 Hz, H-2); 13C-NMR 
(acetone-d6, 75 MHz) δ 167.4 (C-14), 154.2 (C-4), 150.0 (C-5), 149.5 (C-13), 145.7 (C-1), 137.0 
(C-7), 131.0 (C-11), 130.5 (C-12), 128.4 (C-10), 126.6 (C-9), 124.8 (C-6), 119.3 (C-8), 113.4 (C-
3), 111.3 (C-2); MS (EI) m/z 239 (M+, 100), 211 (16), 166 (25), 140 (20), 110 (26); HRMS (EI) 
m/z calculated for C14H9NO3 239.0582, found 239.0590. 
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4.2.4 Synthesis of the 1-N-alkyl-3-N-alkyl-6-aminouracils 
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1-Benzylurea (44, DMA-P105).21   Neat phenylmethanamine 42 (5.00 g, 46.7 mmol) was added 
to an aqueous HCl solution (39.4 mL, 46.5 mmol, 1.18 M) at room temperature.  This solution 
was stirred for 5 min, diluted with deionized water (100 mL) and then mixed with an aqueous 
solution of potassium cyanate (40.0 mL, 70.0 mmol, 1.75 M).  The reaction mixture was stirred 
for 30 h and the resulting precipitate was removed by vacuum filtration.  The isolated solid was 
then recrystallized from a 1:3 solution of ethanol and water affording 44 (4.04 g, 58%) as large 
colorless crystals: Mp 151-152 oC; 1H-NMR (acetone-d6, 300 MHz) δ 7.49–7.17 (m, 5 H, H-6, 
H-7, H-8, H-9, H-10), 6.07 (br, 1 H, H-3), 5.22 (br, 2 H, H-1), 4.27 (d, 2 H, J = 12.0 Hz, H-4). 
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1-(Cyclopropylmethyl)urea (45, DMA-P126).22  To a solution of cyclopropylmethanamine 
hydrochloride 43 (3.00 g, 27.9 mmol) in deionized water (60.0 mL) was added an aqueous 
solution of potassium cyanate (20.0 mL, 41.8 mmol, 2.10 M) at room temperature.  The reaction 
mixture was stirred for 44 h and then extracted with EtOAc (11 x 100 mL).  The combined 
organic layers were dried (Na2SO4) and concentrated by rotary evaporation.  The resulting solid 
was recrystallized from a 9:1 solution of EtOAc and hexanes affording 45 (2.31 g, 76%) as 
colorless crystals: Mp 121-122 oC; 1H-NMR (acetone-d6, 300 MHz) δ 5.84 (br, 1 H, H-3), 5.25 
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(br, 2 H, H-1), 2.97 (t, 2 H, J = 6.0 Hz, H-4), 0.87–0.96 (m, 1 H, H-5), 0.12–0.42 (m, 4 H, H-6, 
H-7). 
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N-(Benzylcarbamoyl)-2-cyanoacetamide (47).23  A solution of 1-benzylurea 44 (3.84 g, 25.6 
mmol) and 2-cyanoacetic acid 46 (2.40 g, 28.2 mmol) in acetic anhydride (30.0 mL) was heated 
to 77 oC for 1.25 h.  After 1.25 h, the reaction mixture was cooled to room temperature and a 
pale yellow precipitate formed.  The reaction mixture was then diluted with ether (50.0 mL) and 
cooled to 0 oC for 30 min.  The resulting precipitate was isolated by vacuum filtration, washed 
with ether (30.0 mL) and dried in vacuo.  The crude product 47 (4.18 g, 75%) was used for the 
next step without further purification: 1H-NMR (acetone-d6, 300 MHz) δ 9.83 (br, 1 H, H-4), 
8.50 (br, 1 H, H-6), 7.26-7.37 (m, 5 H, H-9, H-10, H-11, H-12, H-13), 4.48 (d, 2 H, J = 12.0 Hz, 
H-7), 3.93 (s, 2 H, H-2).  
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2-Cyano-N-(cyclopropylmethylcarbamoyl)acetamide (48, DMA-P130).22  A solution of 1-
(cyclopropylmethyl)urea 45 (2.28 g, 20.0 mmol) and 2-cyanoacetic acid 46 (1.87 g, 22.0 mmol) 
in acetic anhydride (23.0 mL) was heated to 77 oC for 1 h.  The reaction mixture was then cooled 
to room temperature and the solvent was removed by rotary evaporation.  The resulting crude 
residue was recrystallized twice from a 5:1 solution of EtOAc and hexanes affording 48 (2.02 g, 
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56%) as a light orange crystalline solid: Mp 162-163 oC; 1H-NMR (acetone-d6, 300 MHz) δ 9.62 
(br, 1 H, H-4), 8.12 (br, 1 H, H-6), 3.93 (s, 2H, H-2), 3.11–3.16 (m, 2 H, H-7), 0.97-1.10 (m, 1 
H, H-8), 0.21-0.50 (m, 4 H, H-9, H-10); MS (EI) m/z 181 (M+, 8), 166 (9), 153 (58), 97 (67), 85 
(100), 70 (99), 54 (79). 
 
NHN
O
OH2N
49
1
2
3
4
5
6
7
8
9
11
12
10
13  
6-Amino-1-benzylpyrimidine-2,4(1H,3H)-dione (49, DMA-P111).13  A suspension of 47 (4.15 
g, 19.1 mmol) in deionized water (25.0 mL) and ethanol (2.50 mL) was heated to 85–90 oC.  To 
this mixture was added a NaOH solution (4.89 mL, 10%) and the reaction mixture was heated for 
1 h.  A white precipitate developed.  After 1 h of heating, the reaction mixture was cooled to 
room temperature and acidified to pH 7 with an HCl solution (1.18 M).  The neutralized reaction 
mixture was then diluted with deionized water (30.0 mL) and cooled to 0 oC.  The resulting 
white precipitate was isolated by vacuum filtration, washed with deionized water (30.0 mL) and 
recrystallized from a 1:10 solution of methanol and EtOAc.  The resulting product 49 (2.08 g, 
50%) was obtained as a white crystalline solid: Mp 283-284 oC; 1H-NMR (DMSO-d6, 300 MHz) 
δ 10.50 (br, 1 H, H-11), 7.17–7.36 (m, 5 H, H-5, H-6, H-7, H-8, H-9), 6.78 (br, 2 H, H-1), 5.02 
(s, 2 H, H-3), 4.60 (s, 1 H, H-13); MS (EI) m/z 217 (M+, 25), 91 (100), 78 (55), 63 (75). 
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6-Amino-1-(cyclopropylmethyl)pyrimidine-2,4(1H,3H)-dione (50, DMA-P132).24  A 
suspension of 48 (1.99 g, 11.0 mmol) in deionized water (20.0 mL) and ethanol (1.50 mL) was 
heated to 85–90 oC.  To this mixture was added a NaOH solution (2.80 mL, 10%).  The reaction 
mixture was heated for 1 h, cooled to room temperature and acidified to pH 7 with an HCl 
solution (1.18 M).  The neutralized reaction mixture was then cooled to 0 oC and a light orange 
crystalline precipitate formed which was isolated by vacuum filtration and dried in vacuo.  The 
resulting product 50 (0.71 g, 36%) was obtained as a light orange crystalline solid: Mp 265-266 
oC; 1H-NMR (DMSO-d6, 300 MHz) δ 10.29 (br, 1 H, H-8), 6.77 (br, 2 H, H-1), 4.53 (s, 1 H, H-
10), 3.66 (d, 2 H, J = 6.6 Hz, H-3), 1.07–1.15 (m, 1 H, H-4), 0.33–0.45 (m, 4 H, H-5, H-6); MS 
(EI) m/z 181 (M+, 43), 152 (14), 127 (87), 68 (31), 55 (100). 
 
NHN
O
ONN
52
15
1
2
3 4
5
6
7
8
9
11
12
10
13
14
 
General procedure F.  (E)-N'-(3-Benzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin -4-yl)-N,N-
dimethylformimidamide (52, DMA-P113).14  To a suspension of 49 (1.50 g, 6.91 mmol) in 
DMF (34.0 mL) was added DMF-DMA (3.72 mL, 27.7 mmol).  The reaction mixture was heated 
to 40 oC for 24 h under a nitrogen atmosphere.  After 24 h, the solvent was removed by rotary 
evaporation and the crude residue was dissolved in a minimum amount of hot DMSO.  The 
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product was crystallized by slowly adding a 2:1 mixture of hexanes to EtOAc, followed by 
cooling at 0 oC for 5 h. The resulting precipitate was isolated by vacuum filtration and dried 
under high vacuum affording 52 (1.42 g, 76%) as a white crystalline solid: Mp 220–221 oC; IR 
(KBr) 3489, 3126, 2980, 2846, 1651, 1609, 1552, 1347, 1226, 1127 cm-1; 1H- NMR (DMSO-d6 
300 MHz) δ 10.70 (br, 1 H, H-13), 8.01 (s, 1 H, H-3), 7.27–7.16 (m, 5 H, H-7, H-8, H-9, H-10, 
H-11), 5.04 (s, 2 H, H-5), 4.99 (s, 1 H, H-15), 3.02 (s, 3 H, H-2), 2.88 (s, 3 H, H-1); 13C-NMR 
(DMSO-d6, 75 MHz) δ 163.2 (C-14), 160.3 (C-3), 156.0 (C-4), 151.8 (C-12), 138.5 (C-6), 128.2 
(2 C, C-8, C-10), 127.1 (2 C, C-7, C-11), 126.8 (C-9), 82.2 (C-15), 44.2 (C-5), 40.3 (C-2), 34.4 
(C-1); MS (EI) m/z 272 (M+, 24), 256 (6), 192 (15), 108 (100), 91 (54), 69 (64); HRMS (EI) m/z 
calculated for C14H16N4O2 272.1273, found 272.1274. 
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(E)-N'-(3-(Cyclopropylmethyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-N,N-
dimethylformimidamide (53, DMA-P139).  According to general procedure F, 50 (673 mg, 
3.71 mmol) and DMF-DMA (19.7 mL, 14.9 mmol) were heated in DMF (18.0 mL) at 40 oC for 
14 h.  The resulting product 53 (819 mg, 93%) was isolated as an orange crystalline solid: Mp 
248.7–250 oC; IR (KBr) 3416, 3325, 3182, 3035, 2812, 1634, 1584, 1491, 1384, 1285, 1115, 
1021, 835, 803 cm-1; 1H-NMR (methanol-d4, 300 MHz) δ 7.89 (s, 1 H, H-3), 4.97 (s, 1 H, H-12), 
3.81 (d, 2 H, J = 7.1 Hz, H-5), 3.09 (s, 3 H-2), 2.99 (s, 3 H, H-1), 1.24–1.12 (m, 1 H, H-6), 0.40–
0.26 (m, 4 H, H-7, H-8); 13C-NMR (methanol-d4, 75 MHz) δ 167.2 (C-11), 164.0 (C-3), 157.3 
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(C-4), 154.0 (C-9), 83.5 (C-12), 47.6 (C-5), 41.2 (C-1), 35.4 (C-2), 11.5 (C-6), 4.2 (2 C, C-7, C-
8); MS (EI) m/z 236 (M+, 100), 207 (17), 181 (24), 152 (28), 138 (16), 123 (23), 99 (46), 84 (42), 
73 (56), 55 (81); HRMS (EI) m/z calculated for C11H16N4O2 236.1273, found 236.1274. 
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(E)-N,N-Dimethyl-N'-(3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl) 
formimidamide (54, DMA-P128).14  According to general procedure F, 51 (1.50 g, 10.6 mmol) 
and DMF-DMA (5.70 mL, 42.4 mmol) were heated in DMF (45.0 mL) at 40 oC for 8 h.  The 
resulting product 54 (1.37 g, 65%) was isolated as a white crystalline solid: Mp 254-256 oC; IR 
(KBr) 3155, 3024, 1689, 1655, 1618, 1557, 1359, 1227, 1109, 996 cm-1; 1H-NMR (DMSO-d6, 
300 MHz) δ 10.61 (s, 1 H, H-7), 8.02 (s, 1 H, H-3), 4.96 (s, 1 H, H-9), 3.33 (s, 3 H, H-5), 3.13 (s, 
3 H, H-2), 2.98 (s, 3 H, H-1); 13C-NMR (DMSO-d6, 75 MHz) δ 163.1 (C-8), 160.8 (C-3), 155.8 
(C-4), 151.8 (C-6), 82.2 (C-9), 40.3 (C-5), 34.4 (C-2), 28.6 (C-3); MS (EI) m/z 196 (M+, 100), 
152 (5), 99 (21), 82 (43), 55 (26). 
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General Procedure G. (E)-N'-(3-Benzyl-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-
yl)-N,N-dimethylformimidamide (55, DMA-P129).  A suspension of 52 (797 mg, 2.93 mmol) 
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in acetonitrile (13.0 mL) and DMF (2.00 mL) was reacted with DBU (0.882 mL, 5.85 mmol) at 
50 oC for 1 h under a nitrogen atmosphere.  After 1 h, the reaction mixture became homogenous 
and was cooled to room temperature.  After addition of iodomethane (0.911 mL, 14.6 mmol), the 
reaction mixture was stirred at room temperature for 2 d and then glacial acetic acid (8 drops) 
was added.  The solvents were removed by rotary evaporation and the crude yellow oil was 
added to a saturated NaHCO3 solution (20.0 mL).  The aqueous phase was extracted with EtOAc 
(4 x 50.0 mL) and the organic layers were combined, dried (Na2SO4) and concentrated by rotary 
evaporation.  The resulting residue was chromatographed on SiO2 (20:1 EtOAc: methanol).  The 
crude product was recrystallized from a 1:1 solution of EtOAc and hexanes and 55 (429.1 mg, 
51%) was obtained as a white crystalline solid: Mp 163-164 oC; 1H-NMR (methanol-d4, 300 
MHz) δ 7.85 (s, 1 H, H-3), 7.19–7.11 (m, 5 H, H-7, H-8, H-9, H-10, H-11), 5.18 (s, 2 H, H-5), 
5.11 (s, 1 H, H-15), 3.19 (s, 3 H, H-13), 3.04 (s, 3 H, H-2), 2.94 (s, 3 H, H-1); MS (EI) m/z 286 
(M+, 98), 242 (37), 186 (36), 91 (100). 
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(E)-N'-(3-(Cyclopropylmethyl)-1-methyl-2,6-dioxo-1,2,3,6 tetrahydropyrimidin-4-yl)-N,N-
dimethylformimidamide (56, DMA-P142).  According to general procedure G, 53 (785 mg, 
3.32 mmol), DBU (2.50 mL, 16.6 mmol) and iodomethane (2.06 mL, 33.2 mmol) were reacted 
for 3 d.  The resulting product 56 (382 mg, 46%) was isolated as a colorless crystalline solid:  
Mp 176-177 oC; 1H-NMR (methanol-d4, 300 MHz) δ 7.88 (s, 1 H, H-3), 5.07 (s, 1 H, H-12), 3.86 
(d, 2 H, J = 7.1 Hz, H-5), 3.18 (s, 3 H, H-10), 3.08 (s, 3 H, H-2), 3.02 (s, 3 H, H-1), 1.22–1.14 
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(m, 1 H, H-6), 0.40–0.27 (m, 4 H, H-7, H-8); MS (EI) m/z 250 (M+, 100), 221 (14), 195 (19), 152 
(23), 122 (31), 99 (36), 69 (49), 55 (59); HRMS (EI) m/z calculated for C12H18N4O2 250.1430, 
found 250.1433. 
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(E)-N'-(1-Benzyl-3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-N,N-
dimethylformimidamide (57, DMA-P131).25   According to general procedure G, 54 (1.10 g, 
5.61 mmol), DBU (1.69 mL, 11.2 mmol) and (bromomethyl)benzene (1.33 mL, 11.2 mmol) 
were heated at 80 oC for 5 h.  The resulting product 57 (192 mg, 15%) was isolated as a white 
solid: Mp 201–202 oC; IR (KBr) 3079, 2966, 1683, 1650, 1619, 1573, 1410, 1363, 1112, 760, 
694 cm-1; 1H-NMR (DMSO-d6 300 MHz) δ 8.08 (s, 1 H, H-3), 7.25 (s, 5 H, H-9, H-10, H-11, H-
12, H-13), 5.18 (s, 1 H, H-15), 4.94 (s, 2 H, H-7), 3.29 (s, 3 H, H-5), 3.11 (s, 3 H, H-2), 3.00 (s, 3 
H, H-1); 13C-NMR (DMSO-d6, 75 MHz) δ 161.9 (C-14), 159.4 (C-3), 156.0 (C-4), 151.9 (C-6), 
138.0 (C-8), 128.1 (2 C, C-10, C-12), 127.4 (2 C, C-9, C-13), 126.8 (C-11), 81.7 (C-15), 43.1 (C-
7), 34.4 (C-2), 29.6 (C-5) (one signal buried in DMSO-d6, C-1); MS (EI) m/z 286 (M+, 100), 269 
(6), 181 (9), 111 (13), 99 (22), 82 (32), 73 (24); HRMS (EI) m/z calculated for C15H18N4O2 
286.1430, found 286.1440. 
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General procedure H.  6-Amino-1-benzyl-3-methylpyrimidine-2,4(1H,3H)-dione (40, DMA-
P136).26  An aqueous ammonia solution was prepared by slowly bubbling ammonia gas through 
deionized water (250 mL) at 0 oC for 30 min.  A portion of the ammonia solution (20.0 mL) was 
added to 55 (658 mg, 2.30 mmol) dissolved in methanol (20.0 mL).  This mixture was stirred at 
room temperature in a stoppered flask.  After 3 d, the solvents were removed by rotary 
evaporation and the resulting residue was chromatographed on SiO2 (EtOAc, with a few drops of 
Et3N).  The product was recrystallized from a 1:1 solution of EtOAc and hexanes to afford 40 
(417 mg, 77%) as a white crystalline solid: Mp 171–172 oC; IR (KBr) 3357, 3213, 1693, 1663, 
1626, 1498, 1454, 1431, 1379, 1283, 1130, 783, 696 cm-1; 1H-NMR (methanol-d4, 300 MHz) δ 
7.25–7.11 (m, 5 H, H-5, H-6, H-7, H-8, H-9), 5.04 (br, 2 H, H-1), 4.87 (s, 1 H, H-13), 3.15 (s, 3 
H, H-11); 13C-NMR (methanol-d4, 75 MHz) δ 165.6 (C-12), 157.1 (C-10), 153.7 (C-2), 137.1 
(C-4), 129.9 (C 2, C-6, C-8), 128.8 (C-7), 127.5 (2 C, C-5, C-9), 77.1 (C-13), 46.8 (C-3), 28.3 
(C-11); MS (EI) m/z 231 (M+, 100), 173 (7), 145 (9), 111 (7), 106 (11); HRMS (EI) m/z 
calculated for C12H13N3O2 231.1008, found 231.1005. 
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6-Amino-1-(cyclopropylmethyl)-3-methylpyrimidine-2,4(1H,3H)-dione (38).27  According to 
general procedure H, 56 (350 mg, 1.40 mmol) was reacted with an aqueous ammonia solution 
(20 mL) for 4 d.  The crude product 38 (220 mg, 80%) was isolated as white solid and was used 
for the next step without further purification: 1H-NMR (DMSO-d6 300 MHz) δ 6.79 (br, 2 H, H-
1), 4.68 (s, 1 H, H-10), 3.72 (d, 2 H, J = 7.1 Hz, H-3), 3.06 (s, 3 H, H-8), 1.16–1.11 (m, 1 H, H-
4), 0.43–0.32 (m, 4 H, H-5, H-6).  
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6-Amino-3-benzyl-1-methylpyrimidine-2,4(1H,3H)-dione (37, DMA-P137).28 According to 
general procedure H, 57 (756 mg, 2.64 mmol) was reacted with an aqueous ammonia solution 
(20 mL) for 3 d.  The concentrated crude reaction mixture was chromatographed on SiO2 (9:1 
CH2Cl2: methanol).  The product 37 (446 mg, 73%) was isolated as a white solid: Mp 202-203 
oC; 1H-NMR (DMSO-d6 300 MHz) δ 7.29–7.21 (m, 5 H, H-7, H-8, H-9, H-10, H-11), 6.87 (br, 2 
H, H-1), 4.90 (s, 2 H, H-5), 4.73 (s, 1 H, H-13), 3.23 (s, 3 H, H-3); MS (EI) m/z 231 (M+, 42), 
220 (52), 205 (100), 145 (19), 99 (15). 
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General procedure I. 2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro- pyrimidin-5-
yl)-2-oxoethyl 2,8-bis(trifluoromethyl) quinoline-4-carboxylate (63, DMA-P146).  A solution 
of 15 (40.5 mg, 0.175 mmol) and 14 (60.8 mg, 0.184 mmol) in DMF (5.00 mL) was heated to 
reflux under a nitrogen atmosphere for 1 h, then cooled to room temperature.  The product was 
precipitated by the slow addition of deionized water (20 mL) over 1 h while the mixture was 
cooled to 0 oC.  The resulting precipitate was isolated by vacuum filtration, washed with 
deionized water (40 mL), and dried in a Genevac for 17 h at 40 oC followed by 19 h at 50 oC to 
remove residual DMF.  The product 63 (49.6 mg, 56%) was isolated as a white solid:  1H-NMR 
(acetone-d6, 300 MHz) δ 11.04 (br, 1 H, H-17), 9.23 (d, 1 H, J = 8.6 Hz, H-8), 8.52 (s, 1 H, H-3), 
8.45 (d, 1 H, J = 7.1 Hz, H-6), 8.07 (t, 1 H, J = 8.0 Hz, H-7), 7.70 (br, 1 H, H-17), 5.69 (s, 2 H, 
H-13), 3.54 (s, 3 H, H-20), 3.28 (s, 3 H, H-18). 
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2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl quinoline-
4-carboxylate (58, DMA-P78).  According to general procedure I, 15 (47.0 mg, 0.203 mmol) 
and 9 (44.0 mg, 0.225 mmol) were converted to 58 (55.0 mg, 74 %) as a tan solid: Mp 249–250 
oC; IR (KBr) 3416, 3137, 1712, 1639, 1605, 1531, 1448, 1247, 1152, 775 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 10.73 (s, 1 H, H-15), 9.10 (d, 1 H, J = 4.4 Hz, H-1), 8.72 (d, 1 H, J = 
8.7 Hz, H-8), 8.46 (br, 1 H, H-15), 8.15 (d, 1 H, J = 8.5 Hz, H-5), 8.02 (d, 1 H, J = 4.3 Hz, H-2), 
7.87 (t, 1 H, J = 7.2 Hz, H-7), 7.75 (t, 1 H, J = 7.2 Hz, H-6), 5.55 (s, 2 H, H-11), 3.33 (s, 3 H, H-
18), 3.19 (s, 3 H, H-16); 13C-NMR (DMSO-d6, 75 MHz) δ 189.8 (C-12), 165.6 (C-10), 161.4 (C-
19), 158.0 (C-14), 150.3 (C-17), 149.5 (C-1), 148.3 (C-9), 135.1 (C-3), 129.9 (C-7), 129.6 (C-8), 
128.1 (C-6), 125.4 (C-4), 124.0 (C-5), 122.0 (C-2), 88.9 (C-13), 69.9 (C-11), 29.6 (C-16), 27.4 
(C-18); MS (EI) m/z 368 (M+, 8), 212 (60), 182 (100), 157 (89), 129 (56), 101 (23), 57 (56); 
HRMS (EI) m/z calculated for C18H16N4O5 368.1120, found 368.1126. 
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2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl                
2-(trifluoromethyl)quinoline-4-carboxylate (59, DMA-P145).  According to general procedure 
I, 15 (53.3 mg, 0.230 mmol) and 10 (66.6 mg, 0.253 mmol) were converted to 59 (45.6 mg, 
45%) as a tan solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.06 (br, 1 H, H-16), 8.96 (d, 1 H, J = 
7.8 Hz, H-9), 8.39 (s, 1 H, H-3), 8.30 (d, 1 H, J = 8.2 Hz, H-6), 8.04 (t, 1 H, J = 7.3 Hz, H-8), 
7.93 (t, 1 H, J = 7.1 Hz, H-7), 7.68 (br, 1 H, H-16), 5.67 (s, 2 H, H-12), 3.54 (s, 3 H, H-19), 3.28 
(s, 3 H, H-17). 
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2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl                
2-cyclopropylquinoline-4-carboxylate (60, DMA-P140).  According to general procedure I, 15 
(57.9 mg, 0.250 mmol) and 11 (64.7 mg, 0.275 mmol) were converted to 60 (59.8 mg, 59%) as a 
white crystalline solid: Mp 241–242 oC; IR (KBr) 3399, 3294, 3094, 3009, 1716, 1647, 1621, 
1513, 1446, 1243, 1024, 696, 774 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.78 (br, 1 H, H-18), 
8.67 (d, 1 H, J = 8.2 Hz, H-11), 8.48 (br, 1 H, H-18), 7.99–7.97 (m, 2 H, H-5, H-8), 7.79 (t, 1 H, 
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J = 7.0 Hz, H-9), 7.63 (t, 1 H, J = 7.1 Hz, H-10), 5.57 (s, 2 H, H-14), 3.36 (s, 3 H, H-21), 3.22 (s, 
3 H, H-19), 2.55–2.42 (m, 1 H, H-3), 1.17–1.12 (m, 4 H, H-1, H-2); 13C-NMR (DMSO-d6, 75 
MHz) δ 189.8 (C-15), 165.8 (C-13), 162.8 (C-22), 161.4 (C-17), 158.0 (C-4), 149.5 (C-20), 
148.2 (C-12), 135.1 (C-6), 129.8 (C-10), 128.9 (C-11), 126.6 (C-9), 125.3 (C-5), 122.6 (C-8), 
121.4 (C-7), 88.9 (C-16), 69.8 (C-14), 29.6 (C-19), 27.5 (C-21), 17.3 (C-3), 10.8 (2 C, C-1, C-2); 
MS (EI) m/z 408 (M+, 10), 212 (100), 195 (66), 167 (79), 139 (20), 101 (15); HRMS (EI) m/z 
calculated for C21H20N4O5 408.1434, found 408.1445. 
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2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-(furan-
2-yl)quinoline-4-carboxylate (61, DMA-P138).  According to general procedure I, 15 (46.3 mg, 
0.200 mmol) and 12 (57.5 mg, 0.220 mmol) were converted to 61 (61.5 mg, 70%) as a brown 
solid: Mp 272–273 oC; IR (KBr) 3366, 3100, 1710, 1619, 1530, 1459, 1383, 1238, 1169, 973, 
780 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.73 (br, 1 H, H-19), 8.67 (d, 1 H, J = 8.3 Hz, H-
12), 8.46 (br, 1 H, H-19), 8.38 (s, 1 H, H-6), 8.11 (d, 1 H, J = 8.3 Hz, H-9), 7.99 (br, 1 H, H-1), 
7.86 (t, 1 H, J = 7.6 Hz, H-11), 7.70 (t, 1 H, J = 7.7 Hz, H-10), 7.45 (d, 1 H, J = 3.4 Hz, H-3), 
6.76 (dd, 1 H, J = 3.4, 1.8 Hz, H-2), 5.58 (s, 2 H, H-15), 3.34 (s, 3 H, H-22), 3.20 (s, 3 H, H-20); 
13C-NMR (DMSO-d6, 75 MHz) δ 189.8 (C-16), 165.4 (C-14), 161.4 (C-23), 158.0 (C-18), 152.3 
(C-4), 149.5 (C-5), 148.3 (C-21), 148.0 (C-13), 145.5 (C-1), 136.3 (C-7), 130.6 (C-12), 129.3 (C-
11), 127.7 (C-10), 125.5 (C-9), 123.0 (C-6), 118.0 (C-8), 112.8 (C-3), 111.2 (C-2), 88.9 (C-17), 
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70.0 (C-15), 29.6 (C-20), 27.5 (C-22); MS (EI) m/z 434 (M+, 54), 365 (9), 239 (100), 212 (34), 
195 (98), 182 (53), 166 (34), 139 (14), 101 (10); HRMS (EI) m/z calculated for C22H18N4O6 
434.1226, found 434.1221. 
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2-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl                
2-phenylquinoline-4-carboxylate (62, DMA-P100).  According to general procedure I, 15 (52.0 
mg, 0.225 mmol) and 13 (67.1 mg, 0.246 mmol) were converted to 62 (66.0 mg, 66%) as a tan 
solid: Mp 270–272 oC (dec); IR (KBr) 3381, 3097, 2951, 1713, 1619, 1529, 1460, 1234, 1165, 
970, 777, 695 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.75 (br, 1 H, H-21), 8.71 (d, 1 H, J = 
8.7 Hz, H-14), 8.54 (s, 1 H, H-8), 8.47 (br, 1 H, H-21), 8.29 (d, 2 H, J = 6.8 Hz, H-1, H-5), 8.20 
(d, 1 H, J = 8.0 Hz, H-11), 7.89 (t, 1 H, J = 7.8 Hz, H-13), 7.74 (t, 1 H, J = 7.8 Hz, H-12), 7.57 
(m, 3 H, H-2, H-3, H-4), 5.59 (s, 2 H, H-17), 3.34 (s, 3 H, H-24), 3.20 (s, 3 H, H-22); 13C-NMR 
(DMSO-d6, 75 MHz) δ 189.8 (C-18), 165.7 (C-16), 161.5 (C-25), 158.0 (C-20), 155.7 (C-7), 
149.5 (C-23), 148.3 (C-15), 137.7 (C-9), 136.6 (C-6), 130.4 (C-13), 130.0 (C-14), 129.8 (C-12), 
129.0 (2 C, C-2, C-4), 127.9 (C-3), 127.1 (2 C, C-1, C-5), 125.4 (C-11), 123.2 (C-8), 119.3 (C-
10), 88.9 (C-19), 70.0 (C-17), 29.6 (C-22), 27.5 (C-24); MS (ESI) m/z 445 ([M + H]+); HRMS 
(ESI) m/z calculated for C24H21N4O5  (M+H) 445.1512, found 445.1502. 
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2-(6-Amino-3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-(trifluoromethyl)quinoline-4-carboxylate (64, DMA-P158). According to general procedure 
I, 16 (56.9 mg, 0.185 mmol) and 10 (51.1 mg, 0.194 mmol) were converted to 64 (58.9 mg, 
62%) as a tan solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.09 (br, 1 H, H-16), 8.95 (d, 1 H, J = 
8.0 Hz, H-9), 8.39 (s, 1 H, H-3), 8.30 (d, 1 H, J = 8.2 Hz, H-6), 8.03 (t, 1 H, J = 6.9 Hz, H-8), 
7.92 (t, 1 H, J = 7.1 Hz, H-7), 7.74 (br, 1 H, H-16), 7.44 (d, 2 H, J = 7.1 Hz, H-21, H-25), 7.34–
7.25 (m, 3 H, H-22, H-23, H-24), 5.68 (s, 2 H, H-12), 5.13 (s, 2 H, H-19), 3.55 (s, 3 H, H-17). 
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2-(6-Amino-3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-cyclopropylquinoline-4-carboxylate (65, DMA-P161).  According to general procedure I, 16 
(60.3 mg, 0.196 mmol) and 11 (48.4 mg, 0.206 mmol) were converted to 65 (47.5 mg, 50%) as 
an orange solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.12 (br, 1 H, H-18), 8.74 (d, 1 H, J = 7.9, 
H-11), 7.98–7.95 (m, 2 H, H-5, H-8), 7.77–7.72 (m, 2 H, H-10, H-18), 7.57 (t, 1 H, J = 7.7 Hz, 
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H-9), 7.45–7.25 (m, 5 H, H-23, H-24, H-25, H-26, H-27), 5.62 (s, 2 H, H-14), 5.13 (s, 2 H, H-
21), 3.54 (s, 3 H, H-19), 2.44–2.36 (m, 1 H, H-3), 1.25–1.10 (m, 4 H, H-1, H-2). 
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2-(6-Amino-3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl        
2-(furan-2-yl)quinoline-4-carboxylate (66, DMA-P160).  According to general procedure I, 16 
(57.3 mg, 0.186 mmol) and 12 (51.0 mg, 0.195 mmol) were converted to 66 (57.7 mg, 59%) as a 
brown solid: Mp 143–146 oC (dec.); IR (KBr) 3378, 3116, 2961, 1717, 1623, 1531, 1435, 1232, 
1190, 1012, 775 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.11 (br, 1 H, H-19), 8.80 (d, 1 H, J = 
8.1 Hz, H-12), 8.48 (s, 1 H, H-6), 8.11 (d, 1 H, J = 8.0 Hz, H-9), 7.84–7.81 (m, 2 H, H-1, H-11), 
7.72 (br, 1 H, H-19), 7.66 (t, 1 H, J = 7.7 Hz, H-10), 7.44 (d, 2 H, H-24, H-28), 7.40 (d, 1 H, J = 
3.3 Hz, H-3), 7.34-7.25 (m, 3 H, H-25, H-26, H-27), 6.72 (dd, 1 H, J = 3.4, 1.6 Hz, H-2), 5.67 (s, 
2 H, H-15), 5.13 (s, 2 H, H-22), 3.54 (s, 3 H, H-20); 13C-NMR (acetone-d6, 75 MHz) δ 191.7 (C-
16), 166.7 (C-14), 162.6 (C-29), 160.0 (C-18), 154.4 (C-4), 150.8 (C-5), 150.0 (C-21), 149.6 (C-
13), 145.8 (C-1), 138.8 (C-23), 137.8 (C-7), 131.2 (C-11), 130.5 (C-12), 129.1 (C 4, C-24, C-25, 
C-27, C-28), 128.4 (C-10), 128.1 (C-9), 126.8 (C-26), 124.7 (C-6), 119.1 (C-8), 113.5 (C-3), 
111.4 (C-2), 90.3 (C-17), 71.1 (C-15), 44.8 (C-22), (C-20, buried in solvent peak). MS (EI) m/z 
510 (M+, 100), 288 (24), 239 (15), 195 (17), 91 (26); HRMS (EI) m/z calculated for C28H22N4O6 
510.1539, found 510.1554. 
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2-(6-Amino-3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-phenylquinoline-4-carboxylate (67, DMA-P162).  According to general procedure I, 16 (59.1 
mg, 0.192 mmol) and 13 (54.7 mg, 0.202 mmol) were converted to 67 (46.5 mg, 47%) as a tan 
solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.13 (br, 1 H, H-21), 8.84 (d, 1 H, J = 7.8 Hz, H-14), 
8.63 (s, 1 H, H-8), 8.37–8.35 (m, 2 H, H-1, H-5), 8.23 (d, 1 H, J = 8.4 Hz, H-11), 7.87 (t, 1 H, J 
= 7.6 Hz, H-13), 7.73–7.67 (m, 2 H, H-12, H-21), 7.62–7.54 (m, 3 H, H-2, H-3, H-4), 7.46–7.43 
(m, 2 H, H-26, H-30), 7.34-7.26 (m, 3 H, H-27, H-28, H-29), 5.68 (s, 2 H, H-17), 5.14 (s, 2 H, 
H-24), 3.55 (s, 3 H, H-22).  
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2-(6-Amino-3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2,8-
bis(trifluoromethyl)quinoline-4-carboxylate (68, DMA-P159).  According to general 
procedure I, 16 (47.7 mg, 0.155 mmol) and 14 (53.8 mg, 0.165 mmol) were converted to 68 
(47.9 mg, 53%) as a yellow solid: Mp 116–118 oC (dec.); IR (KBr) 3391, 3115, 1720, 1624, 
1534, 1437, 1313, 1244, 1199, 1145, 1108, 949, 776, 690 cm-1; 1H-NMR (acetone-d6, 300 MHz) 
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δ 11.08 (br, 1 H, H-17), 9.23 (d, 1 H, J = 8.8 Hz, H-8), 8.52 (s, 1 H, H-3), 8.45 (d, 1 H, J = 7.4 
Hz, H-6), 8.07 (t, 1 H, J = 8.0 Hz, H-7),  7.78 (br, 1 H, H-17), 7.43 (d, 2 H, J = 7.0 Hz, H-22, H-
26), 7.34–7.25 (m, 3 H, H-23, H-24, H-25), 5.70 (s, 2 H, H-13), 5.13 (s, 2 H, H-20), 3.55 (s, 3 H, 
H-18); 13C-NMR (acetone-d6, 150 MHz) δ 190.2 (C-14), 164.5 (C-12), 161.6 (C-27), 159.0 (C-
16), 149.7 (C-10), 147.6 (q, JCF = 34.5 Hz, C-2), 144.1 (C-19), 139.5 (C-21), 137.7 (C-4), 130.8 
(C-6), 130.1 (q, JCF = 6.0 Hz, C-8), 129.2 (C-7), 128.1 (C 4, C-22, C-23, C-25, C-26), 128.0 (q, 
JCF = 30.0 Hz, C-9), 127.0 (C-24), 126.3 (C-5), 123.7 (q, JCF = 270.0 Hz, C-1), 121.1 (q, JCF = 
271.5 Hz, C-11), 118.5 (C-3), 89.2 (C-15), 70.6 (C-13), 43.8 (C-20), 29.4 (C-18); MS (EI) m/z 
580 (M+, 100), 309 (26), 214 (6), 132 (6), 91 (17); HRMS (EI) m/z calculated for C26H18F6N4O5 
580.1181, found 580.1191.  
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2-(6-Amino-1-(cyclopropylmethyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-
oxoethyl 2-(furan-2-yl)quinoline-4-carboxylate (69, DMA-P165).  According to general 
procedure I, 17 (54.3 mg, 0.200 mmol) and 12 (54.9 mg, 0.210 mmol) were converted to 69 
(53.3 mg, 56%) as a brown solid: Mp 138–142 oC (dec); IR (KBr) 3399, 6116, 2960, 1716, 1651, 
1617, 1525, 1458, 1277, 1148, 962, 776 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.26 (br, 1 H, 
H-19), 8.81 (d, 1 H, J = 8.3 Hz, H-12), 8.49 (s, 1 H, H-6), 8.11 (d, 1 H, J = 8.3 Hz, H-9), 7.85–
7.81 (m, 2 H, H-1, H-11), 7.71 (br, 1 H, H-19), 7.66 (t, 1 H, J = 7.2 Hz, H-10), 7.40 (d, 1 H, J = 
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3.3 Hz, H-3), 6.73 (dd, 1 H, J = 3.3, 1.6 Hz, H-2), 5.66 (s, 2 H, H-15), 4.04 (d, 2 H, J = 7.0 Hz, 
H-20), 3.29 (s, 3 H, H-25), 1.29 (m, 1 H, H-21), 0.57–0.49 (m, 4 H, H-22, H-23); 13C-NMR 
(acetone-d6, 75 MHz) δ 191.8 (C-16), 166.6 (C-14), 162.6 (C-26), 159.1 (C-18), 154.3 (C-4), 
151.0 (C-5),  149.9 (C-24), 149.5 (C-13), 145.7 (C-1), 137.7 (C-7), 131.1 (C-11), 130.5 (C-12), 
128.3 (C-10), 126.7 (C-9), 124.6 (C-6), 119.0 (C-8), 113.4 (C-3), 111.3 (C-2), 90.2 (C-17), 71.0 
(C-15), 46.8 (C-20), 28.0 (C-25), 10.0 (C-21), 4.2 (C-22, C-23); MS (EI) m/z 474 (M+, 57), 239 
(100), 206 (66), 139 (41), 91 (41); HRMS (EI) m/z calculated for C25H22N4O6 474.1539, found 
474.1519. 
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2-(6-Amino-1-(cyclopropylmethyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-
oxoethyl 2,8-bis(trifluoromethyl)quinoline-4-carboxylate (70, DMA-P166).  According to 
general procedure I, 17 (40.7 mg, 0.150 mmol) and 14 (52.2 mg, 1.575 mmol) were converted to 
70 (44.7 mg, 55%) as a tan solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.22 (br, 1 H, H-15), 9.24 
(d, 1 H, J = 9.1 Hz, H-8), 8.53 (s, 1 H, H-3), 8.45 (d, 1 H, J = 6.6 Hz, H-6), 8.08 (t, 1 H, J = 8.1 
Hz, H-7), 7.77 (br, 1 H, H-15), 5.70 (s, 2 H, H-11), 4.05 (d, 2 H, J = 7.1 Hz, H-17), 3.29 (s, 3 H, 
H-22), 1.29 (m, 1 H, H-18), 0.56–0.48 (m, 4 H, H-19, H-20). 
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2-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-
(trifluoromethyl)quinoline-4-carboxylate (71, DMA-P151).  According to general procedure I, 
18 (57.2 mg, 0.209 mmol) and 10 (57.9 mg, 0.220 mmol) were converted to 71 (33.4 mg, 58%) 
as an orange solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.25 (br, 1 H, H-16), 8.95 (d, 1 H, J = 8.5 
Hz, H-9), 8.39 (s, 1 H, H-3), 8.30 (d, 1 H, J = 8.5 Hz, H-6), 8.03 (dt, 1 H, J = 7.7, 1.4 Hz, H-8), 
7.92 (dt, 1 H, J = 7.8, 1.3 Hz, H-7), 7.65 (br, 1 H, H-16), 5.68 (s, 2 H, H-12), 3.98 (d, 2 H, J = 
7.9, H-17), 3.29 (s, 3 H, H-22), 2.29–2.20 (m, 1 H, H-18), 0.97 (d, 6 H, J = 6.7 Hz, H-19, H-20). 
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2-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-
cyclopropylquinoline-4-carboxylate (72, DMA-P149).  According to general procedure I, 18 
(75.0 mg, 0.274 mmol) and 11 (67.7 mg, 0.288 mmol) were converted to 72 (37.8 mg, 31%) as 
an orange solid: Mp 124.5–126 oC (dec); IR (KBr) 3413, 3138, 2961, 1718, 1655, 1613, 1520, 
1459, 1243, 1145, 968, 772 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.29 (br, 1 H, H-18), 8.75 
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(d, 1 H, J = 8.7 Hz, H-11), 7.98–7.94 (m, 2 H, H-5, H-8), 7.75 (dt, 1 H, J = 7.6, 1.4 Hz, H-10), 
7.60 (br, 1 H, H-18), 7.57 (dt, 1 H, J = 7.7, 1.4 Hz, H-9), 5.62 (s, 2 H, H-14), 3.98 (d, 2 H, J = 
7.9 Hz, H-19), 3.29 (s, 3 H, H-24), 2.44–2.36 (m, 1 H, H-3), 2.30–2.20 (m, 1 H, H-20), 1.25–
1.08 (m, 4 H, H-1, H-2), 0.97 (d, 6 H, J = 6.7 Hz, H-21, H-22); 13C-NMR (acetone-d6, 75 MHz) 
δ 190.2 (C-15), 165.8 (C-13), 162.8 (C-25), 161.4 (C-17), 157.6 (C-4), 149.8 (C-23), 148.2 (C-
12), 135.1 (C-6), 129.9 (C-10), 128.8 (C-11), 126.6 (C-9), 125.3 (C-5), 122.6 (C-8), 121.4 (C-7), 
88.8 (C-16), 69.9 (C-14), 47.9 (C-19), 27.6 (C-24), 26.0 (C-20), 19.3 (2 C, C-21, C-22), 17.3 (C-
3), 10.8 (2 C, C-1, C-2); MS (EI) m/z 450 (M+, 8), 254 (35), 212 (100), 197 (21), 182 (76), 168 
(78), 139 (28); HRMS (EI) m/z calculated for C24H26N4O5 450.1903, found 450.1900. 
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2-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-
(furan-2-yl)quinoline-4-carboxylate (73, DMA-P153).  According to general procedure I, 18 
(54.7 mg, 0.200 mmol) and 12 (57.5 mg, 0.210 mmol) were converted to 73 (57.7 mg, 61%) as a 
brown solid: Mp 148–149 oC (dec); IR (KBr) 3410, 3137, 2962, 1718, 1654, 1614, 1522, 1459, 
1231, 1190, 993, 775 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.27 (br, 1 H, H-19), 8.81 (d, 1 
H, J = 8.5 Hz, H-12), 8.49 (s, 1 H, H-6), 8.11 (d, 1 H, J = 8.2 Hz, H-9), 7.85–7.81 (m, 2 H, H-1, 
H-11), 7.67 (t, 2 H, J = 7.1 Hz, H-10, H-19), 7.40 (d, 1 H, J = 3.4 Hz, H-3), 6.73 (dd, 1 H, J = 
3.3, 1.7 Hz, H-2), 5.66 (s, 2 H, H-15), 3.98 (d, 2 H, J = 7.9 Hz, H-20), 3.29 (s, 3 H, H-25), 2.27–
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2.23 (m, 1 H, H-21), 0.97 (d, 6 H, J = 6.6 Hz, H-22, H-23); 13C-NMR (acetone-d6, 75 MHz) δ 
190.1 (C-16), 165.4 (C-14), 161.4 (C-26), 157.6 (C-18), 152.3 (C-4), 149.8 (C-24), 148.3 (C-5), 
148.0 (C-13), 145.5 (C-1), 136.3 (C-7), 130.6 (C-12), 129.3 (C-11), 127.8 (C-10), 125.5 (C-9), 
123.0 (C-6), 118.1 (C-8), 112.8 (C-3), 111.2 (C-2), 88.8 (C-17), 70.1 (C-15), 47.9 (C-20), 27.5 
(C-25), 26.0 (C-21), 19.3 (2 C, C-22, C-23); MS (EI) m/z 476 (M+, 68), 254 (77), 239 (96), 224 
(49), 195 (100), 182 (81), 168 (78), 139 (36), 101 (19); HRMS (EI) m/z calculated for 
C25H24N4O6 476.1696, found 476.1709. 
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2-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-
phenylquinoline-4-carboxylate (74, DMA-P101).  According to general procedure I, 18 (54.7 
mg, 0.200 mmol) and 13 (59.6 mg, 0.220 mmol) were converted to 74 (58.5 mg, 60%) as a white 
crystalline solid: Mp 233–234 oC; IR (KBr) 3481, 3055, 2958, 1722, 1654, 1633, 1512, 1392, 
1233, 1145, 995, 770 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.95 (br, 1 H, H-21), 8.72 (d, 1 
H, J = 8.2 Hz, H-14), 8.55 (s, 1 H, H-8), 8.46 (br, 1 H, H-21), 8.30 (d, 2 H, J = 7.0 Hz, H-1, H-
5), 8.20 (d, 1 H, J = 8.6 Hz, H-11), 7.89 (t, 1 H, J = 7.2 Hz, H-13), 7.74 (t, 1 H, J = 7.3 Hz, H-
12), 7.58 (m, 3 H, H-2, H-3, H-4), 5.61 (s, 2 H, H-17), 3.81 (d, 2 H, J = 7.5 Hz, H-22), 3.20 (s, 3 
H, H-27), 2.05 (m, 1 H, H-23), 0.88 (d, 6 H, J = 6.5 Hz, H-24, H-25); 13C-NMR (DMSO-d6, 75 
MHz) δ 190.1 (C-18), 165.7 (C-16), 161.4 (C-28), 157.6 (C-20), 155.7 (C-7), 149.8 (C-26), 
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148.4 (C-15), 137.7 (C-9), 136.6 (C-6), 130.4 (C-13), 130.1 (C-14), 129.8 (C-12), 129.0 (2 C, C-
2, C-4), 128.0 (C-3), 127.2 (2 C, C-1, C-5), 125.4 (C-11), 123.2 (C-8), 119.3 (C-10), 88.8 (C-19), 
70.1 (C-17), 47.9 (C-22), 27.6 (C-27), 26.0 (C-23), 19.3 (2 C, C-24, C-25); MS (ESI) m/z 487 
([M + H]+); HRMS (ESI) m/z calculated for C27H27N4O5 (M+H) 487.1981, found 487.1943. 
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2-(6-Amino-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2,8-
bis(trifluoromethyl)quinoline-4-carboxylate (75, DMA-P152). According to general 
procedure I, 18 (45.1 mg, 0.165 mmol) and 14 (57.3 mg, 0.173 mmol) were converted to 75 
(49.3 mg, 55%) as a tan solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.25 (br, 1 H, H-17), 9.24 (d, 
1 H, J = 9.3 Hz, H-8), 8.52 (s, 1 H, H-3), 8.45 (d, 1 H, J = 7.3 Hz, H-6), 8.07 (t, 1 H, J = 8.0 Hz, 
H-7), 7.66 (br, 1 H, H-17), 5.70 (s, 2 H, H-13), 3.99 (d, 2 H, J = 7.9 Hz, H-18), 3.29 (s, 3 H, H-
23), 2.30–2.20 (m, 1 H, H-19), 0.97 (d, 6 H, J = 6.7 Hz, H-20, H-21).  
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2-(6-Amino-1-benzyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl 2-
(trifluoromethyl)quinoline-4-carboxylate (76, DMA-P154).  According to general procedure I, 
19 (54.1 mg, 0.176 mmol) and 10 (48.6 mg, 0.185 mmol) were converted to 76 (46.2 mg, 51%) 
as an orange solid: Mp 113–116 oC (dec.); IR (KBr) 3435, 3067, 2962, 1718, 1654, 1618, 1523, 
1454, 1198, 1142, 1002, 779 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.15 (br, 1 H, H-16), 8.94 
(d, 1 H, J = 8.8 Hz, H-9), 8.38 (s, 1 H, H-3), 8.29 (d, 1 H, J = 8.0 Hz, H-6), 8.03 (t, 1 H, J = 8.5 
Hz, H-8), 7.91 (t, 1 H, J = 7.1 Hz, H-7), 7.48 (br, 1 H, H-16), 7.40–7.32 (m, 5 H, H-19, H-20, H-
21, H-22, H-23), 5.70 (s, 2 H, H-12), 5.41 (s, 2 H, H-17), 3.34 (s, 3 H, H-25); 13C-NMR 
(acetone-d6, 150 MHz) δ 191.5 (C-13), 165.8 (C-11), 162.6 (C-26), 159.2 (C-15), 151.0 (C-24), 
149.0 (C-10), 147.9 (q, JCF = 34.5 Hz, C-2), 139.5 (C-18), 135.6 (C-4), 132.3 (C-8), 131.2 (2 C, 
C-7, C-9), 129.6 (2 C, C-22, C-20), 128.5 (C-5), 127.2 (2 C, C-19, C-23), 126.9 (C-21), 126.6 
(C-6), 122.4 (q, JCF = 273.0 Hz, C-1), 118.5 (C-3), 90.2 (C-14), 71.3 (C-12), 45.9 (C-17), 28.1 
(C-25); MS (EI) m/z 512 (M+, 6), 493 (2), 288 (87), 258 (80), 241 (17), 225 (44), 196 (58), 146 
(16), 101 (46), 91 (100); HRMS (EI) m/z calculated for C25H19F3N4O5 512.1308, found 
512.1331. 
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2-(6-Amino-1-benzyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-cyclopropylquinoline-4-carboxylate (77, DMA-P157).  According to general procedure I, 19 
(57.2 mg, 0.186 mmol) and 11 (45.9 mg, 0.195 mmol) were converted to 77 (43.2 mg, 48%) as 
an orange solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.18 (br, 1 H, H-18), 8.73 (d, 1 H, J = 8.4 
Hz, H-11), 7.97–7.94 (m, 2 H, H-5, H-8), 7.74 (dt, 1 H, J = 7.6, 1.4 Hz, H-10), 7.56 (dt, 1 H, J = 
7.7, 1.3 Hz, H-9), 7.40–7.32 (m, 6 H, H-18, H-21, H-22, H-23, H-24, H-25), 5.64 (s, 2 H, H-14), 
5.41 (s, 2 H, H-19), 3.34 (s, 3 H, H-27), 2.43–2.35 (m, 1 H, H-3), 1.24–1.07 (m, 4 H, H-1, H-2). 
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2-(6-Amino-1-benzyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-(furan-2-yl)quinoline-4-carboxylate (78, DMA-P156).  According to general procedure I, 19 
(54.2 mg, 0.176 mmol) and 12 (48.3 mg, 0.185 mmol) were converted to 78 (48.9 mg, 54%) as a 
brown solid: Mp 146–150 oC (dec.); IR (KBr) 3435, 3116, 1717, 1653, 1618, 1522, 1454, 1233, 
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1149, 962, 776 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 11.18 (br, 1 H, H-19), 8.78 (d, 1 H, J = 
8.5 Hz, H-12), 8.47 (s, 1 H, H-6), 8.10 (d, 1 H, J = 8.5 Hz, H-9), 7.83–7.79 (m, 2 H, H-1, H-11), 
7.65 (t, 1 H, J = 7.6 Hz, H-10), 7.39–7.32 (m, 7 H, H-3, H-19, H-22, H-23, H-24, H-25, H-26), 
6.72 (dd, 1 H, J = 3.4, 1.7 Hz, H-2), 5.68 (s, 2 H, H-15), 5.40 (s, 2 H, H-20), 3.34 (s, 3 H, H-28); 
13C-NMR (acetone-d6, 75 MHz) δ 191.8 (C-16), 166.6 (C-14), 162.5 (C-29), 159.2 (C-18), 154.3 
(C-4), 151.0 (C-27), 149.9 (C-5), 149.5 (C-13), 145.7 (C-1), 137.7 (C-7), 135.7 (C-21), 131.1 (C-
11), 130.5 (C-12), 129.6 (2 C, C-23, C-25), 128.5 (C-10), 128.3 (C-9), 127.2 (C 2, C-22, C-26), 
126.7 (C-24), 124.6 (C-6), 119.0 (C-8), 113.4 (C-3), 111.3 (C-2), 90.1 (C-17), 71.0 (C-15), 45.9 
(C-20), 28.1 (C-28); MS (EI) m/z 510 (M+, 100), 288 (25), 271 (17), 239 (20), 195 (23), 166 
(15), 91 (93); HRMS (EI) m/z calculated for C28H22N4O6 510.1539, found 510.1524. 
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2-(6-Amino-1-benzyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl       
2-phenylquinoline-4-carboxylate (79, DMA-P148).  According to general procedure I, 19 (56.2 
mg, 0.182 mmol) and 13 (54.5 mg, 0.201 mmol) were converted to 79 (36.5 mg, 39%) as an 
orange solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.19 (br, 1 H, H-21), 8.83 (d, 1 H, J = 8.5 Hz, 
H-14), 8.62 (s, 1 H, H-8), 8.36–8.34 (m, 2 H, H-1, H-5), 8.21 (d, 1 H, J = 8.4 Hz, H-11), 7.86 (t, 
1 H, J = 6.9 Hz, H-13), 7.69 (t, 1 H, J = 7.4 Hz, H-12), 7.62–7.51 (m, 3 H, H-2, H-3, H-4), 7.36–
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7.32 (m, 6 H, H-21, H-24, H-25, H-26, H-27, H-28), 5.69 (s, 2 H, H-17), 5.41 (s, 2 H, H-22), 
3.34 (s, 3 H, H-30). 
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2-(6-Amino-1-benzyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-2-oxoethyl    
2,8-bis(trifluoromethyl)quinoline-4-carboxylate (80, DMA-P155). According to general 
procedure I, 19 (47.7 mg, 0.155 mmol) and 14 (53.9 mg, 0.163 mmol) were converted to 80 
(52.5 mg, 58%) as a tan solid: 1H-NMR (acetone-d6, 300 MHz) δ 11.14 (br, 1 H, H-17), 9.22 (d, 
1 H, J = 8.8 Hz, H-8), 8.51 (s, 1 H, H-3), 8.44 (d, 1 H, J = 7.3 Hz, H-6), 8.06 (t, 1 H, J = 7.9 Hz, 
H-7), 7.49 (br, 1 H, H-17), 7.36–7.33 (m, 5 H, H-20, H-21, H-22, H-23, H-24), 5.71 (s, 2 H, H-
13), 5.41 (s, 2 H, H-18), 3.34 (s, 3 H, H-26). 
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4.3 ADDITION OF ORGANOMETALLIC REAGENTS TO BENZOTHIAZOLE AND 
METHYLTHIADIAZOLE ALDIMINES 
4.3.1 Synthesis of N-Bts- and N-Ths-benzaldimines 
N N
S S Cl
O
O140  
General procedure J. 5-Methyl-1,3,4-thiadiazole-2-sulfonyl chloride (140).56   To a solution 
of acetic acid (45.0 mL, 33%) cooled to -5-5 oC (internal thermometer) was introduced a 
vigorous stream of Cl2 gas.  After 5 min, the solution became yellow and a yellow solid 
precipitated.  At this time, 5-methyl-1,3,4-thiadiazole-2-thiol 143 (5.00 g, 37.8 mmol) was 
slowly added to the reaction mixture over a 30 min period, carefully keeping the temperature of 
the reaction mixture <5 oC and the solution thoroughly saturated with Cl2 gas at all times.  The 
reaction mixture was stirred for an additional 15 min after all of 143 was added.   The resulting 
white precipitate which formed during the course of the reaction was quickly isolated by vacuum 
filtration through an ice cooled Buchner funnel and was washed with ice cold deionized water 
(30.0 mL).  The solid was then dissolved in cold ether (125 mL) and the ether solution was 
washed with a cold saturated NaHCO3 solution (1 X 75.0 mL) followed by a cold saturated brine 
solution (1 X 50.0 mL).   The ether solution was dried (Na2SO4), concentrated by rotary 
evaporation (10 oC), and the resulting white solid was recrystallized from ether (50.0 mL) at -78 
oC, isolated by vacuum filtration and dried under high vacuum for 2 h.  The product 140 (3.94 g, 
53%) was isolated as a white crystalline solid: Mp 48-49 oC (dec); 1H-NMR (CDCl3, 300 MHz) 
δ 2.97 (s, 3 H). 
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Benzo[d]thiazole-2-sulfonyl chloride (139).56  According to general procedure J, 
benzo[d]thiazole-2-thiol 142 (4.00 g, 23.9 mmol) was slowly added over a 1.5 h period to a 
mixture of acetic acid (45 mL, 33%) and Cl2 gas (large excess).  The reaction mixture was stirred 
for an additional 30 min after all of 142 was added.  A modified work up procedure was 
performed in which the crude reaction product was isolated by vacuum filtration, washed with 
ice cooled deionized water (40.0 mL), dissolved in cold CH2Cl2 (100 mL) and washed with a 
cold saturated NaHCO3 solution (1 X 50.0 mL), followed by a cold saturated brine solution (1 X 
50.0 mL).  The CH2Cl2 solution was then filtered through a 1 in plug of celite, concentrated by 
rotary evaporation (13 oC) and the crude orange solid was recrystallized from ether (20.0 mL) at 
-78 oC.  The product 139 (3.24 g, 56%) was isolated as a white crystalline solid: Mp 104.5-108 
oC; 1H-NMR (CDCl3, 300 MHz) δ 8.33 (d, 1 H, J = 7.5 Hz), 8.08 (d, 1 H, J = 6.9 Hz), 7.74-7.73 
(m, 2 H). 
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Benzo[d]thiazole-2-sulfonamide (144).76  To a solution of 139 (2.46 g, 10.5 mmol) in CH2Cl2 
(25.0 mL) cooled to -78 oC under a nitrogen atmosphere, was added condensed NH3 (5 drops, 
acetone/dry ice condenser) over a 15 min period.  The reaction mixture was then slowly warmed 
to room temperature.  After 17 h, the heterogeneous reaction mixture was cooled to 0 oC and 
diluted with hexanes (25.0 mL).  The resulting white precipitate was isolated by vacuum 
filtration, washed with a 1:1 solution of CH2Cl2 and hexanes, and added to a boiling solution of 
 146 
EtOAc (100 mL) with stirring for 20 min.   After 20 min, the EtOAc solution was cooled to room 
temperature, filtered through a 1.5 in plug of SiO2 and concentrated by rotary evaporation.  The 
resulting white solid was recrystallized from a 5:1 solution of hexanes and EtOAc.  The 
recrystallized product was isolated by vacuum filtration, washed with hexanes (40 mL) and dried 
under high vacuum for 10 h.  The product 144 (1.64 g, 73%) was isolated as a white crystalline 
solid: Mp 179-180 oC, IR (KBr) 3312, 3151, 3039, 1472, 1356, 1164, 929, 765 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 8.33 (s, 2 H), 8.27 (d, 1 H, J = 7.8 Hz), 8.17 (d, 1 H, J = 8.1 Hz), 7.70-
7.60 (m, 2 H, J = 7.8 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 169.4, 151.7, 135.6, 127.5, 127.4, 
124.2, 123.2; MS (EI) m/z 214 (M+, 85), 150 (100), 135 (94), 108 (80), 90 (74), 80 (58), 68 (88); 
HRMS (EI) m/z calculated for C7H6N2O2S2 213.9871, found 213.9874.   
 
 
N N
S S NH2
O
O145  
5-Methyl-1,3,4-thiadiazole-2-sulfonamide (145).77  To a solution of 140 (3.57 g, 18.0 mmol) in 
CH2Cl2 (40.0 mL) cooled to -78 oC under a nitrogen atmosphere, was added condensed NH3 (7-8 
drops, acetone/dry ice condenser) over a 5 min period.  The reaction mixture was then slowly 
warmed to room temperature.  After 16 h, the heterogeneous reaction mixture was cooled to 0 oC 
and the white precipitate was isolated by vacuum filtration.  The solid was stirred in boiling 
EtOAc (100 mL) for 20 min to dissolve the sulfonamide.  The resulting heterogeneous mixture 
was cooled to room temperature and the remaining ammonium salts were removed by vacuum 
filtration.  The EtOAc solution was concentrated by rotary evaporation and the resulting white 
solid was recrystallized from a 1:1 solution of EtOAc and hexanes.  The precipitate was isolated 
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by vacuum filtration, washed with hexanes (40.0 mL) and dried under high vacuum for 2 h.  The 
product 145 (2.20 g, 68%) was isolated as a white crystalline solid: Mp 164.5-166 oC; IR (KBr) 
3319, 3148, 3035, 1418, 1358, 1209, 1175, 930 cm-1; 1H-NMR (acetone-d6, 300 MHz) δ 7.59 (s, 
2 H), 2.85 (s, 3 H); 13C-NMR (acetone-d6, 75 MHz) δ 171.3, 170.5, 15.7; MS (EI) m/z 179 (M+, 
17), 115 (100), 99 (71), 80 (25), 59 (15); HRMS (EI) m/z calculated for C3H5N3O2S2 178.9823, 
found 178.9831. 
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(E)-N-Benzylidenebenzo[d]thiazole-2-sulfonamide (146).  To a suspension of 144 (500 mg, 
2.33 mmol) and p-TsOH (22.3 mg, 0.117 mmol) in toluene (20.0 mL) was added freshly distilled 
benzaldehyde 110 (0.237 mL, 2.33 mmol).  The reaction mixture was heated at reflux under a 
nitrogen atmosphere for 20 h.  Water formed during the course of the reaction was azeotropically 
removed via a Dean-Stark trap.  After 20 h, the reaction mixture was cooled to room temperature 
and filtered through a flame-dried piece of glass wool contained inside a disposable 9 in pipette.  
The toluene was removed in vacuo and the resulting crude yellow oil was recrystallized from a 
7:1 mixture of hexanes to EtOAc.  The precipitate was isolated by vacuum filtration, washed 
with hexanes (30.0 mL) and dried under high vacuum for 15 h.  The product 146 (614 mg, 87%) 
was isolated as an off-white crystalline solid: Mp 128-129 oC (dec); IR (KBr) 3067, 1596, 1566, 
1313, 1338, 1161, 870, 769 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 9.24 (s, 1 H), 8.20 (d, 1 H, J = 
7.7 Hz), 8.06-8.01 (m, 3 H), 7.76-7.60 (m, 5 H); 13C-NMR (CD2Cl2, 75 MHz) δ 175.5, 164.2, 
 148 
153.2, 137.6, 136.7, 132.6, 132.5 (2), 129.9 (2), 128.6, 128.2, 125.9, 122.9; MS (EI) m/z 302 
(M+, 1.7), 237 (5), 214 (12), 150 (18), 135 (100), 105 (33); HRMS (EI) m/z calculated for 
C14H10N2O2S2 302.0184, found 302.0180. 
 
H
N
S
O
O
N
N
S
147
 
Representative procedure for the synthesis of (E)-N-benzylidene-5-methyl-1,3,4-
thiadiazole-2-sulfonamide stock solutions (147).  To a suspension of 145 (179 mg, 1.00 mmol) 
and PTSA (9.50 mg, 0.0500 mmol) in toluene (8.0 mL) was added freshly distilled benzaldehyde 
110 (0.102 mL, 1.00 mmol).  The reaction mixture was heated at reflux under a nitrogen 
atmosphere.  Water formed during the course of the reaction was azeotropically removed via a 
Dean-Stark trap.  After 21 h, the reaction mixture was cooled to room temperature and filtered 
through a flame dried piece of glass wool, contained inside a disposable 9 in pipette, into a dry 
5.0 mL volumetric flask.  The resulting solution was immediately sealed with a septum under 
nitrogen gas and then diluted to the 5.0 mL mark with dry toluene.  An aliquot (0.500 mL, 0.100 
mmol) of the aldimine stock solution was removed and added to a dry NMR tube containing a 
98% pure sample of 2,3-dimethoxybenzladehyde (17.5 mg, 0.103 mmol) dissolved in dry 
CD2Cl2 (0.50 mL).  The 2,3-dimethoxybenzaldehyde served as an internal standard for 1H-NMR 
(300 MHz, pulse delay = 10.00 s) integration.  Integration of the Ths-benzaldimine proton (δ 
9.54, area = 1.00) versus the internal standard aldehyde proton (δ 10.84, area = 1.31) showed the 
reaction yield to be 79%. 
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4.3.2 Organometallic additions to N-Bts- and N-Ths-benzaldimines 
N
S
O
O
N
N
S
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5-Methyl-N-(1-phenylethyl)-1,3,4-thiadiazole-2-sulfonamide (148) by reaction of 147 with 
MeLi.  To a solution of MeLi (0.36 mL, 0.40 mmol, 1.1 M) in THF (1.50 mL) was added a 
solution of 147 (1.00 mL, 0.160 mmol, 0.160 M) at -78 oC under a nitrogen atmosphere.  The 
reddish-brown reaction mixture was stirred at -78 oC for 2 h, was quenched by the addition of a 
saturated NH4Cl solution (5.0 mL) and was warmed to room temperature.  After stirring for 10 
min, the quenched reaction mixture was partitioned between a saturated brine solution (10.0 mL) 
and ether (10.0 mL).  The ether layer was removed and the aqueous layer was extracted with 
ether (2 X 10.0 mL).  The ether layers were combined, dried (Na2SO4) and concentrated by 
rotary evaporation.  The resulting crude residue was chromatographed on SiO2 (1:1 EtOAc: 
hexanes).  The product was recrystallized from EtOAc and hexanes, isolated by vacuum 
filtration, washed with hexanes (15.0 mL) and dried under high vacuum for 1 h to give 148 (10.4 
mg, 23%) as a white crystalline solid: Mp 130-131 oC; IR (KBr) 3065, 2981, 2866, 1468, 1447, 
1350, 1208, 1169, 1095, 1016, 768 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.27-7.21 (m, 5 H), 
5.85 (s, 1 H), 4.74 (q, 1 H, J = 6.9 Hz), 2.75 (s, 3 H), 1.55 (d, 3 H, J = 7.2 Hz); 13C-NMR 
(CD2Cl2, 75 MHz) δ 170.9, 169.7, 142.1, 128.9 (2), 127.9, 126.9 (2), 55.3, 23.4, 15.8; HRMS 
(TOF MS ES+) m/z calculated for C11H13N3O2S2Na (M+Na) 306.0347, found 306.0328. 
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General procedure K. Grignard reactions.  5-Methyl-N-(2-methyl-1-phenylpropyl)-1,3,4-
thiadiazole-2-sulfonamide (151, Table 3 entry 2).  To a solution of 147 (0.385 mL, 0.237 
mmol, 0.615 M) in THF (2.00 mL) cooled to -78 oC under a nitrogen atmosphere, was added a 
solution of i-PrMgCl in ether (0.30 mL, 0.60 mmol, 2.0 M).  The resulting red-orange solution 
was stirred at -78 oC for 2 h and then quenched with a saturated NH4Cl solution (5.0 mL).  After 
stirring for 10 min, the quenched reaction mixture was partitioned between a saturated brine 
solution (10.0 mL) and ether (10.0 mL).  The ether layer was removed and the aqueous layer was 
extracted with ether (2 X 10.0 mL).  The ether layers were combined, dried (Na2SO4) and 
concentrated by rotary evaporation.  The resulting crude residue was chromatographed on SiO2 
(1:1 EtOAc: hexanes).  The isolated product was recrystallized from a 1:10 mixture of EtOAc 
and hexanes, washed with hexanes (15.0 mL) and dried under high vacuum for 1 h to give 151 
(43.5 mg, 59%) as a white crystalline solid: Mp 164-165 oC; IR (KBr) 3118, 2975, 2870, 1452, 
1352, 1097, 1051, 922, 705 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.20-7.18 (m, 3 H), 7.07-7.04 
(m, 2 H), 5.90 (d, 1 H, J = 8.7 Hz), 4.24 (t, 1 H, J = 8.3 Hz), 2.67 (s, 3 H), 2.01 (m, 1 H, J = 6.8 
Hz), 1.03 (d, 3 H, J = 6.6 Hz), 0.76 (d, 3 H, J = 6.6 Hz); 13C-NMR δ 170.1, 169.6, 140.0, 128.6 
(2), 127.9 (2), 127.6, 65.9, 34.4, 19.6, 19.4, 15.8; HRMS (TOF MS EI+) m/z calculated for 
C13H18N3O2S2 (M+H) 312.0840, found 312.0835. 
 
5-Methyl-N-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (151, Talbe 3 entry 
1).  According to general procedure K, a solution of 147 (0.385 mL, 0.237 mmol, 0.615 M) and 
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i-PrMgCl in THF (0.30 mL, 0.60 mmol, 2.0 M) were reacted in CH2Cl2 (2.00 mL) at -78 oC for 
2.5 h.  The same workup procedure was followed except CH2Cl2 was used in place of ether.  The 
product 151 (41.9 mg, 57%) was isolated as a white crystalline solid.  
 
5-Methyl-N-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (151, Table 3 entry 
3).  According to general procedure K, a solution of 147 (0.358 mL, 0.237 mmol, 0.666 M) and 
i-PrMgCl in THF (0.30 mL, 0.60 mmol, 2.0 M) were reacted in THF (2.00 mL) initially at -78 
oC.  The reaction mixture was warmed to room temperature for 1.5 h following the addition of i-
PrMgCl.  The product 151 (13.9 mg, 19%) was isolated as a white crystalline solid.  
 
5-Methyl-N-(2-methyl-1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (151, Table 3 entry 
4).  According to general procedure K, a solution of 147 (0.358 mL, 0.316 mmol, 0.883 M) and 
i-PrMgBr in THF (0.40 mL, 0.80 mmol, 2.0 M) were reacted in CH2Cl2 (2.00 mL) at -78 oC for 
2.5 h.  The same workup procedure was followed except CH2Cl2 was used in place of ether.  The 
product 151 was isolated as a white crystalline solid (60.2 mg, 61%). 
 
5-Methyl-N-(1-phenylethyl)-1,3,4-thiadiazole-2-sulfonamide (148, Table 3 entry 5).  
According to general procedure K, a solution of 147 (1.00 mL, 0.160 mmol, 0.160 M) and 
MeMgBr in ether (0.13 mL, 0.40 mmol, 3.0 M) were reacted in THF (2.00 mL) at -78 oC for 2 h.  
The resulting product 148 (27.7 mg, 61%) was isolated as a white crystalline solid. 
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5-Methyl-N-(1-phenylallyl)-1,3,4-thiadiazole-2-sulfonamide (152, Table 3 entry 6).  
According to general procedure K, a solution of 147 (1.00 mL, 0.160 mmol, 0.160 M) and 
vinylMgBr in THF (0.40 mL, 0.40 mmol, 1.0 M) were reacted in THF (1.50 mL) at -78 oC for 2 
h.  The resulting product 152 (21.8 mg, 46%) was isolated as a white crystalline solid: Mp 122-
123 oC; IR (KBr) 3141, 3024, 2870, 1443, 1360, 1172, 1054, 939, 702 cm-1; 1H-NMR (CD2Cl2, 
300 MHz) δ 7.32-7.21 (m, 5 H), 6.05-5.94 (m, 1 H), 5.86 (d, 1 H J = 7.2 Hz), 5.23-5.17 (m, 3 H), 
2.77 (s, 3 H); 13C-NMR (CD2Cl2, 75 MHz) δ 170.2, 169.0, 139.0, 136.7, 129.1 (2), 128.5, 127.7 
(2), 117.8, 61.1, 16.0; HRMS (TOF MS ES+) m/z calculated for C12H14N3O2S2 (M+H) 296.0527, 
found 296.0506.  
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5-Methyl-N-(1-phenylbut-2-ynyl)-1,3,4-thiadiazole-2-sulfonamide (153, Table 3 entry 7).  
According to general procedure K, a solution of 147 (1.00 mL, 0.160 mmol, 0.160 M) and 1-
propynylMgBr in THF (0.80 mL, 0.40 mmol, 0.50 M) were reacted in THF (1.50 mL) at -78 oC 
for 2 h.  The resulting product 153 (23.9 mg, 49%) was isolated as a white crystalline solid: Mp 
169-170 oC; IR (KBr) 3055, 2858, 1455, 1351, 1211, 1173, 1019, 734 cm-1; 1H-NMR (CD2Cl2, 
300 MHz) δ 7.50-7.46 (m, 2 H), 7.39-7.33 (m, 3 H), 5.67 (d, 1 H, J = 8.4 Hz), 5.43 (dd, 1 H, J = 
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6.6, 2.1 Hz), 2.84 (s, 3 H), 1.72 (d, 3 H, J = 2.4 Hz); 13C-NMR (CD2Cl2, 75 MHz) δ 170.5, 
168.8, 137.8, 129.3 (2), 129.2, 128.0 (2), 84.7, 75.5, 51.0, 16.2, 3.7; HRMS (TOF MS ES+) m/z 
calculated for C13H13N3O2S2Na (M+Na) 330.0347, found 330.0345.   
 
N
S
O
O
N
N
S
H
154
 
N-Benzhydryl-5-methyl-1,3,4-thiadiazole-2-sulfonamide (154, Table 3 entry 8).  According 
to general procedure K, a solution of 147 (1.00 mL, 0.160 mmol, 0.160 M) and PhMgBr in ether 
(0.13 mL, 0.40 mmol, 3.0 M) were reacted in THF (1.50 mL) at -78 oC for 2 h.  The resulting 
product 154 (35.2 mg, 64%) was isolated as a white crystalline solid: Mp 185-186 oC; IR (KBr) 
3174, 3066, 2869, 1447, 1359, 1174, 1045, 702 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.33-7.21 
(m, 10 H), 6.08 (d, 1 H, J = 6.9 Hz), 5.85 (d, 1 H, J = 7.5 Hz ), 2.73 (s, 3 H); 13C-NMR (CD2Cl2, 
300 MHz) δ 170.3, 168.8, 140.1 (2), 129.1 (4), 128.3 (2), 127.8 (4), 62.5, 15.9; HRMS (TOF MS 
ES+) m/z calculated for C16H16N3O2S2 (M+H) 346.0684, found 346.0671. 
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N-(1-Phenylethyl)benzo[d]thiazole-2-sulfonamide (155, Table 4 entry 1).  According to 
general procedure K, 146 (90.7 mg, 0.300 mmol) and MeMgBr in ether (0.20 mL, 0.60 mmol, 
3.0 M) were reacted in THF (1.80 mL) at -78 oC for 2.5 h.  The same workup procedure was 
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performed except that the product was isolated by chromatography on SiO2 (3:1 hexanes: 
EtOAc).  The product 155 (83.2 mg, 87%) was isolated as a white crystalline solid: Mp 144-145 
oC; IR (KBr) 3116, 2973, 2874, 1477, 1350, 1163, 1062, 982, 764 cm-1; 1H-NMR (CD2Cl2, 300 
MHz) δ 8.07 (dd, 1 H, J = 8.0, 1.5 Hz), 7.92 (dd, 1 H, J = 8.1, 1.2 Hz), 7.57 (dt, 2 H, J = 7.4, 1.2 
Hz), 7.24 (d, 2 H, J = 6.9 Hz), 7.15-7.04 (m, 3 H), 6.35 (d, 1 H, J = 7.2 Hz), 4.80 (quintet, 1 H, J 
= 7.1 Hz), 1.53 (d, 3 H, J = 6.9 Hz); 13C-NMR (CD2Cl2, 75 MHz) δ 167.3, 152.8, 142.2, 137.0, 
128.9 (2), 128.1, 128.0, 127.8, 126.9 (2), 125.3, 122.6, 55.3, 23.7; HRMS (TOF MS ES+) m/z 
calculated for C15H14N2O2S2Na (M+Na) 341.0394, found 341.0389. 
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N-(2-Methyl-1-phenylpropyl)benzo[d]thiazole-2-sulfonamide (156, Table 4 entry 2).  
According to general procedure K, 146 (90.7 mg, 0.300 mmol) and i-PrMgCl in ether (0.30 mL, 
0.60 mmol, 2.0 M) were reacted in THF (1.70 mL) at -78 oC for 2.5 h.  The same workup 
procedure was performed except that the product was isolated by chromatography on SiO2 (3:1 
hexanes: EtOAc) to give 156 (90.1 mg, 87%) as a white crystalline solid: Mp 157-158 oC; IR 
(KBr) 3265, 2959, 2872, 1455, 1336, 1041, 915, 771 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.99 
(dd, 1 H, J = 8.1, 1.2 Hz), 7.87 (dd, 1 H, J = 7.8, 1.2 Hz), 7.53 (dt, 2 H, J = 7.2, 1.2 Hz), 7.02-
6.93 (m, 5 H), 5.58 (d, 1 H, J = 8.7 Hz), 4.26 (t, 1 H, J = 8.1 Hz), 2.01 (m, 1 H, J = 6.9 Hz), 1.00 
(d, 3 H, J = 6.6 Hz), 0.75 (d, 3 H, J = 6.6 Hz); 13C-NMR (CD2Cl2, 75 MHz) δ 166.7, 152.8, 
 155 
140.0, 137.0, 128.4 (2), 127.9, 127.7, 127.6 (2), 125.3, 122.5, 65.8, 34.8, 19.7, 19.3; HRMS 
(TOF MS ES+) m/z calculated for C17H19N2O2S2 (M+H) 347.0888, found 347.0862. 
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N-(1-Phenylallyl)benzo[d]thiazole-2-sulfonamide (157, Table 4 entry 3).  According to 
general procedure K, 146 (90.7 mg, 0.300 mmol) and vinylMgBr in THF (0.60 mL, 0.60 mmol, 
1.0 M) were reacted in THF (1.20 mL) at -78 oC for 3 h.  The same workup procedure was 
performed except that the product was isolated by chromatography on SiO2 (3:1 hexanes: 
EtOAc) to give 157 (84.5 mg, 85%) as a white crystalline solid: Mp 141-142 oC; IR (KBr) 3117, 
2872, 1450, 1346, 1161, 1039, 930, 765 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.07 (d, 1 H, J = 
8.1 Hz), 7.90 (d, 1 H, J = 7.2 Hz), 7.54 (dt, 2 H, J = 7.2, 1.5 Hz), 7.16-7.12 (m, 5 H), 5.93 (m, 1 
H), 5.52 (s, 1 H), 5.27-5.12 (m, 3 H); 13C-NMR (CD2Cl2, 75 MHz) δ 167.1, 152.9, 139.5, 137.2, 
137.0, 129.1 (2), 128.5, 128.1, 127.9 (3), 125.4, 122.7, 117.8, 61.4; HRMS (TOF MS ES+) m/z 
calculated for C16H15N2O2S2 (M+H) 331.0575, found 331.0549. 
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N-(1-Phenylbut-2-ynyl)benzo[d]thiazole-2-sulfonamide (158, Table 4 entry 4).  According to 
general procedure K, 146 (90.7 mg, 0.300 mmol) and 1-propynylMgBr in THF (1.2 mL, 0.60 
mmol, 0.50 M) were reacted in THF (1.30 mL) at -78 oC for 3 h.  The same workup procedure 
was performed except that the product was isolated by chromatography on SiO2 (3:1 hexanes: 
EtOAc) to give 158 (72.8 mg, 71%) as a white crystalline solid: Mp 155.5-156.5 oC; IR (KBr) 
3073, 2866, 1454, 1351, 1168, 1038, 764 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 8.14 (d, 1 H, J = 
7.2 Hz), 8.00 (d, 1 H, J = 7.5 Hz), 7.61-7.55 (m, 2 H), 7.48 (d, 2 H, J = 6.6 Hz), 7.28-7.25 (m, 3 
H), 6.18 (s, 1 H), 5.46 (s, 1 H), 1.29 (s, 3 H); 13C-NMR (CD2Cl2, 75 MHz) δ 166.6, 153.2, 138.0, 
137.3, 129.2 (2), 129.1, 128.3, 128.0 (3), 125.5, 122.8, 84.5, 75.3, 51.0, 3.3; HRMS (TOF MS 
ES+) m/z calculated for C17H14N2O2S2Na (M+Na) 365.0394, found 365.0358. 
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N-Benzhydrylbenzo[d]thiazole-2-sulfonamide (159, Table 4 entry 5).  According to general 
procedure K, 146 (90.7 mg, 0.300 mmol) and PhMgBr in ether (0.20 mL, 0.60 mmol, 3.0 M) 
were reacted in THF (1.80 mL) at -78 oC for 3 h.  The same workup procedure was performed 
except that the product was isolated by chromatography on SiO2 (3:1 hexanes: EtOAc).  The 
product was recrystallized from a 5:1 mixture of hexanes and EtOAc to afford 159 (88.4 mg, 
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77%) as a white crystalline solid: Mp 187-188 oC; KBr (IR) 3156, 3068, 1448, 1350, 1167, 1045, 
945 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 8.06 (dd, 1 H, J = 8.4, 1.2 Hz), 7.93 (dd, 1 H, J = 8.1, 
1.2 Hz), 7.58 (dt, 2 H, J = 7.5, 1.2 Hz), 7.19-7.15 (m, 10 H), 5.87 (s, 2 H); 13C-NMR (CDCl3, 
300 MHz) δ 166.3, 152.4, 139.9 (2), 136.7, 128.7 (4), 128.0 (2), 127.7 (5), 127.4, 125.2, 122.1, 
62.3; HRMS (TOF MS ES+) m/z calculated for C20H16N2O2S2Na (M+Na) 403.0551, found 
403.0520. 
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General procedure L. Diethylzinc Reactions. 5-Methyl-N-(1-phenylpropyl)-1,3,4-
thiadiazole-2-sulfonamide (160, Table 5 entry 2).  To a solution of 147 (2.00 mL, 0.312 mmol, 
0.156 M) in toluene (2.50 mL) was slowly added a solution of Et2Zn in toluene (0.48 mL, 0.48 
mmol, 1.0 M).  The resulting dark red-orange reaction mixture was stirred at room temperature 
for 2.5 h and quenched with a saturated NH4Cl solution (5.0 mL).  After stirring for 10 min, the 
quenched mixture was partitioned between a saturated NH4Cl solution (10.0 mL) and ether (20.0 
mL).  The aqueous layer was extracted with ether (2 X 20.0 mL).  The combined ether layers 
were washed with a saturated brine solution (5.0 mL), dried (Na2SO4) and concentrated by rotary 
evaporation.  The resulting crude residue was chromatographed on SiO2 (1:1 EtOAc: hexanes).  
The product was recrystallized from a 1:10 mixture of EtOAc and hexanes, isolated by vacuum 
filtration, washed with hexanes (15.0 mL) and dried under high vacuum for 1 h to give 160 (48.8 
mg, 53%) as a white crystalline solid: Mp 144-145 oC; IR (KBr) 3105, 2941, 2864, 1458, 1350, 
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1167, 1100, 1011, 913, 760 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.23-7.13 (m, 5 H), 6.23 (d, 1 
H, J = 7.2 Hz), 4.45 (q, 1 H, J = 7.4 Hz), 2.70 (s, 3 H), 2.01-1.72 (m, 2 H, J = 7.3 Hz), 0.85 (t, 3 
H, J = 7.2 Hz); 13C-NMR (CD2Cl2, 75 MHz) δ 170.3, 169.8, 140.9, 129.1 (2), 128.1, 127.7 (2), 
61.6, 30.8, 16.0, 10.9; HRMS (TOF MS ES+) m/z calculated for C12H15N3O2S2Na (M+Na) 
320.0503, found 320.0493. 
 
5-Methyl-N-(1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (160, Table 5 entry 1).  
According to general procedure L, a solution of 147 in THF (2.00 mL, 0.312 mmol, 0.156 M) 
and a solution of Et2Zn in toluene (0.48 mL, 0.48 mmol, 1.0 M) were reacted in THF (2.00 mL) 
at room temperature for 4 h.  The product 160 (39.9 mg, 43%) was isolated as a white crystalline 
solid. 
 
5-Methyl-N-(1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (160, Table 5 entry 3).  
According to general procedure L, a solution of 147 in toluene (2.00 mL, 0.316 mmol, 0.158 M) 
and a solution of Et2Zn in toluene (0.80 mL, 0.80 mmol, 1.0 M) were reacted in toluene (2.80 
mL) at room temperature for 2.5 h.  The product 160 (65.7 mg, 70%) was isolated as a white 
crystalline solid. 
 
5-Methyl-N-(1-phenylpropyl)-1,3,4-thiadiazole-2-sulfonamide (160, Table 5 entry 4).   
According to general procedure L, a solution of 147 in toluene (1.00 mL, 0.158 mmol, 0.158 M) 
and a solution of Et2Zn in toluene (0.20 mL, 0.20 mmol, 1.0 M) were reacted in toluene (2.20 
mL) at -78 oC for 33 h.  The product 160 (28.6 mg, 61%) was isolated as a white crystalline 
solid. 
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N-(1-Phenylpropyl)benzo[d]thiazole-2-sulfonamide (161, Table 5 entry 5).  According to 
general procedure L, 146 (90.7 mg, 0.300 mmol) and a solution of Et2Zn in toluene (0.60 mL, 
0.60 mmol, 1.0 M) were reacted in THF (1.40 mL) at room temperature for 4 h.  The same 
workup procedure was followed except the crude reaction mixture was chromatographed on SiO2 
(3:1, hexanes: EtOAc).  The product was recrystallized from a 5:1 mixture of hexanes and 
CH2Cl2 to afford 161 (39.6 mg, 40%) as a white crystalline solid: Mp 126.5-127.5 oC; IR (KBr) 
3171, 2967, 2873, 1456, 1357, 1163, 1037, 766 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.00 (d, 1 
H, J = 7.4 Hz), 7.82 (d, 1 H, J = 7.2 Hz), 7.50 (dt, 2 H, J = 7.6, 1.8 Hz), 7.09-6.95 (m, 5 H), 5.97 
(s, 1 H), 4.48 (d, 1 H, J = 4.2 Hz ), 1.97-1.73 (m, 2 H, J = 7.5 Hz), 0.81 (t, 3 H, J = 7.5 Hz); 13C-
NMR δ 166.6, 152.1, 139.8, 136.4, 128.2 (2), 127.4, 127.3, 127.1, 126.7 (2), 124.8, 121.9, 60.8, 
30.3, 10.5; HRMS (TOF MS ES+) m/z calculated for C16H16N2O2S2Na (M+Na) 355.0551, found 
355.0557. 
 
N-(1-Phenylpropyl)benzo[d]thiazole-2-sulfonamide (161, Table 5 entry 6).  According to 
general procedure L, 146 (90.7 mg, 0.300 mmol) and a solution of Et2Zn in toluene (0.60 mL, 
0.60 mmol, 1.0 M) were reacted in toluene (1.40 mL) at room temperature for 4 h.  The same 
workup procedure was followed except that the crude reaction mixture was chromatographed on 
SiO2 (3:1, hexanes: EtOAc).  The product was recrystallized from a 5:1 mixture of hexanes and 
CH2Cl2 to afford 161 (57.8 mg, 58%) as a white crystalline solid. 
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Preparation of zirconocene hydrochloride from LiAlH4 (120).58  To a solution of Cp2ZrCl2 
(5.00g, 17.1 mmol) in THF (45.0 mL) under a nitrogen atmosphere was added a solution of 
LiAlH4 in ether (4.4 mL, 4.4 mmol, 1.0 M) slowly via a syringe pump over a 45 min period.  The 
reaction mixture was stirred for an additional 30 min.  The resulting heterogeneous solution was 
filtered through a Schlenk filter under vacuum and the resulting solid was sequentially washed 
with THF (4 X 10 mL), CH2Cl2 (1 X 10 mL), THF (1 X 10 mL) and ether (1 X 5.0 mL).  The 
product was then dried under high vacuum in the dark for 15 h to yield 120 (3.16 g, 72%) as a 
white solid. 
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General procedure M. Addition of alkenylzinc reagents. (E)-5-Methyl-N-(1-phenylhept-2-
enyl)-1,3,4-thiadiazole-2-sulfonamide (163, Table 6 entry 1).   To a suspension of Cp2Zr(H)Cl 
(163.8 mg, 0.636 mmol) in CH2Cl2 (2.00 mL) under a nitrogen atmosphere was added 1-hexyne 
(0.0820 mL, 0.720 mmol) at room temperature.  After 15 min, the resulting clear pale yellow 
solution was cooled to -78 oC and a Me2Zn solution in toluene (0.30 mL, 0.60 mmol, 2.0 M) was 
added.  This mixture was warmed to room temperature for 1 h and then slowly added to a 
solution of 147 in toluene (2.00 mL, 0.316 mmol, 0.158 M).  The resulting dark red-orange 
reaction mixture was stirred at room temperature for 2.5 h and then quenched by the addition of a 
saturated NH4Cl solution (5.0 mL).  After stirring for 1 h, the quenched mixture was partitioned 
between a saturated NH4Cl solution (10.0 mL) and ether (20.0 mL).  The aqueous layer was 
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extracted with ether (2 X 20.0 mL).  The ether layers were combined, washed with a saturated 
brine solution (5.0 mL), filtered through a 1 in pad of SiO2 which was washed with additional 
EtOAc (20.0 mL), dried (Na2SO4) and concentrated by rotary evaporation.  The resulting crude 
residue was chromatographed on SiO2 (1:2 EtOAc: hexanes).  The product was recrystallized 
from a 5:1 mixture of hexanes and CH2Cl2, isolated by vacuum filtration, washed with hexanes 
(15.0 mL) and dried under high vacuum for 10 h to give 163 (38.4 mg, 35%) as a white 
crystalline solid: Mp 88.5-90 oC; IR (KBr) 3106, 2956, 2927, 2871, 1453, 1354, 1172, 1085, 979 
cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.33-7.21 (m, 5 H), 6.30 (d, 1 H, J = 7.8 Hz), 5.58 (m, 2 
H), 5.15 (dt, 1 H, J = 6.3, 2.7 Hz), 2.75 (s, 3 H), 1.95 (m, 2 H), 1.26 (septet, 4 H, J = 3.6 Hz), 
0.86 (t, 3 H, J = 6.9 Hz); 13C-NMR (CD2Cl2, 75 MHz) δ 170.3, 169.6, 140.2, 135.5, 129.2 (2), 
128.5, 128.3, 127.8 (2), 61.2, 32.3, 31.5, 22.7, 16.1, 14.2; HRMS (TOF MS ES+) m/z calculated 
for C16H21N3O2S2Na (M+Na) 374.0937, found 374.0964. 
 
(E)-5-Methyl-N-(1-phenylhept-2-enyl)-1,3,4-thiadiazole-2-sulfonamide (163, Table 6 entry 
2).  According to general procedure M, Cp2Zr(H)Cl (163.8 mg, 0.636 mmol), 1-hexyne (0.0820 
mL, 0.720 mmol), Me2Zn (0.30 mL, 0.60 mmol, 2.0 M) and a solution of 147 in toluene (2.00 
mL, 0.320 mmol, 0.160 M) were combined in CH2Cl2 (2.00 mL) for 10 h.  The same workup 
procedure was performed except that the crude reaction mixture was chromatographed on SiO2 
(3:1 hexanes: EtOAc) to give 163 (64.4 mg, 57%) as a white crystalline solid. 
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(E)-N-(1-Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 6 entry 3).  
According to general procedure M, Cp2Zr(H)Cl (123.0 mg, 0.477 mmol), 1-hexyne (0.0620 mL, 
0.540 mmol), Me2Zn (0.225 mL, 0.450 mmol, 2.0 M), and 146 (90.7 mg, 0.300 mmol) were 
combined in CH2Cl2 (1.50 mL) for 4.5 h. The same workup procedure was performed except that 
the crude reaction mixture was chromatographed on SiO2 (4:1 hexanes: EtOAc). The methyl 
addition product 146 (12.0 mg, 13%) was isolated as a white solid.  The desired product 164 
(82.3 mg, 71%) was isolated as a white crystalline solid: Mp 98.5-99.5 oC; IR (KBr) 3131, 2923, 
2872, 1452, 1351, 1168, 1036, 986, 756 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.11 (d, 1 H, J = 
7.8 Hz), 7.92 (d, 1 H, J = 7.5 Hz), 7.57 (quintet, 2 H, J = 8.4 Hz), 7.27-7.14 (m, 5 H), 5.60-5.50 
(m, 3 H), 5.20 (t, 1 H, J = 6.8 Hz), 1.78 (q, 2 H, J = 6.3 Hz), 1.12-1.02 (m, 4 H), 0.75 (t, 3 H, J = 
6.6 Hz); 13C-NMR (CDCl3, 75 MHz) δ 167.5, 152.9, 140.1, 137.1, 135.3, 129.1 (2), 128.3 (2), 
128.0, 127.8, 127.7 (2), 125.5, 122.5, 61.1, 32.2, 31.3, 22.7, 14.4; HRMS (TOF MS ES+) m/z 
calculated for C20H22N2O2S2Na (M+Na) 409.1020, found 409.1022. 
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(E)-N-(2-Ethyl-1-phenylpent-2-enyl)-5-methyl-1,3,4-thiadiazole-2-sulfonamide (165, Table 
6 entry 4).  According to general procedure M, Cp2Zr(H)Cl (81.9 mg, 0.138 mmol), 1-hexyne 
 163 
(0.0410 mL, 0.360 mmol), Me2Zn (0.15 mL, 0.15 mmol, 1.0 M) and a solution of 147 in toluene 
(1.00 mL, 0.150 mmol, 0.150 M) were combined in CH2Cl2 (1.00 mL) for 2 h.  The same 
workup procedure was performed except that the crude reaction mixture was chromatographed 
on SiO2 (1:1 hexanes: EtOAc) to give 165 (25.1 mg, 47%) as a white solid: Mp 98.5-99.5 oC; IR 
(KBr) 3122, 2965, 2872, 1455, 1357, 1170, 1043, 940 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 7.29-
7.81 (m, 5 H), 5.80 (d, 1 H, J = 8.1 Hz), 5.31 (t, 1 H, J = 7.1 Hz), 5.19 (d, 1 H, J = 8.1 Hz), 2.77 
(s, 3 H), 2.13-1.86 (m, 4 H), 0.90 (dt, 6 H, J = 7.5, 3.0 Hz); 13C-NMR (CDCl3, 75 MHz) δ 169.5, 
168.9, 138.9, 138.5, 130.8, 128.7 (2), 127.9, 127.8 (2), 62.9, 22.1, 21.1, 15.9, 14.3, 13.7; HRMS 
(TOF MS ES+) m/z calculated for C16H21N3O2S2Na (M+Na) 374.0973, found 374.0951. 
 
Synthesis of (E)-N-(1-phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164) by the 
addition of (E)-hex-1-enyldimethylaluminum.  To a suspension of Cp2Zr(H)Cl (87.7 mg, 
0.340 mmol) in CH2Cl2 (1.00 mL) under a nitrogen atmosphere was added 1-hexyne (0.0402 
mL, 0.350 mmol) at room temperature.  After 15 min, the volatiles were removed from the 
zirconocene solution under high vacuum and the resulting yellow oil was dissolved in toluene 
(1.00 mL).  This mixture was cooled to 0 oC and a solution of Me3Al in toluene (0.34 mL, 0.34 
mmol, 1.0 M) was added.  The reaction mixture was warmed to room temperature for 1 h and 
then canulated under nitrogen gas into a solution of 146 (45.5 mg, 0.150 mmol) in toluene (0.50 
mL).  The resulting yellow mixture was stirred at room temperature for 20 h and then quenched 
by the addition of a saturated NH4Cl solution (5.0 mL).  After 30 min, the quenched mixture was 
partitioned between a saturated brine solution (10.0 mL) and ether (20.0 mL).  The aqueous layer 
was extracted with ether (2 X 20.0 mL).  The combined ether layers were filtered through a 1 in 
pad of SiO2 which was washed with additional EtOAc (20.0 mL), dried (Na2SO4) and 
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concentrated by rotary evaporation.  The resulting crude residue was chromatographed on SiO2 
(1:3 EtOAc: hexanes) to give 164 (9.4 mg, 16%) as a clear oil.     
 
General procedure N.  Rhodium(I) catalyzed additions of alkenyl- zirconocnes.  (E)-N-(1-
Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 7 entry 3).   To a suspension 
of Cp2Zr(H)Cl (87.7 mg, 0.340 mmol) in CH2Cl2 (1.00 mL) under a nitrogen atmosphere was 
added 1-hexyne (0.0402 mL, 0.350 mmol) at room temperature.  After 15 min, the volatiles were 
removed from the zirconocene solution under high vacuum and the resulting yellow oil was 
dissolved in degassed dioxane (0.50 mL).  The zirconocene solution was then canulated under 
nitrogen gas into a premixed solution of (1S,4S,8S)-5-benzyl-8-methoxy-1,8-dimethyl-2-(2’-
methylpropyl)-bicyclo[2.2.2]octa-2,5-diene 168 (4.66 mg, 0.0150 mmol) and [RhCl(ethylene)2]2 
(2.9 mg, 0.0075 mmol) in degassed dioxane (0.50 mL) at room temperature.  To this mixture was 
then added, via cannulation under nitrogen gas, a solution of R,R-MeDUPHOS 167 (4.6 mg, 
0.015 mmol) and 146 (45.4 mg, 0.150 mmol) in degassed dioxane (0.50 mL).  The reaction 
mixture was stirred under nitrogen gas for 20 h and then quenched with a saturated NH4Cl 
solution (5.0 mL) with stirring for 50 min.  The quenched mixture was partitioned between a 
saturated brine solution (10.0 mL) and ether (20.0 mL).  The aqueous layer was extracted with 
ether (2 X 20.0 mL).  The combined ether layers were filtered through a 2 in pad of SiO2 which 
was washed with additional EtOAc (25.0 mL), dried (Na2SO4) and concentrated by rotary 
evaporation.  The resulting crude residue was chromatographed on SiO2 (1:3 EtOAc: hexanes) to 
give 164 (4.30 mg, 7.0%) as a slightly impure yellow oil.  A sample of this product was 
dissolved in a 99:1 mixture of hexanes and i-PrOH for chiral HPLC (chiralcel-OD column; 99:1 
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hexanes : i-PrOH; flow rate 1.0 mL/min; UV detection at 258 nm; product enantiomer retention 
times of 39.3 and 59.7 min and areas of 61.4 and 16.2) which showed 58% ee. 
 
(E)-N-(1-Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 7 entry 2).  
According to general procedure N, a solution of Cp2Zr(H)Cl (58.0 mg, 0.225 mmol), 1-hexyne 
(0.0287 mL, 0.250 mmol), [RhCl(cod)]2 (2.9 mg, 0.0075 mmol), 168 (4.66 mg, 0.0150 mmol) 
and 146 (45.4 mg, 0.150 mmol) were combined in degassed dioxane for 24 h.  No product was 
detected by TLC. 
 
(E)-N-(1-Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 7 entry 2).  
According to general procedure N, a solution of Cp2Zr(H)Cl (87.7 mg, 0.340 mmol) and 1-
hexyne (0.0340 mL, 0.300 mmol) were combined, after a solvent switch to toluene (0.50 mL), 
with a solution of [RhCl(cod)]2 (3.7 mg, 0.0078 mmol), R,R-MeDUPHOS (4.6 mg, 0.015 mmol) 
and 146 (45.4 mg, 0.150 mmol) in toluene (1.00 mL) for 16 h.  The product 164 (11.0 mg, 19%) 
was obtained as a clear oil in 1% ee (determined by chiral HPLC analysis). 
 
Synthesis of Tetrakis[acetonitrile]copper(I) tetrafluoroborate (169).60  To a suspension of 
Cu2O (0.750 g, 5.24 mmol) in acetonitrile (14.0 mL) was slowly added a solution of HBF4 (2.77 
mL, 15.1 mmol, 48 %) over a 5 min period under a nitrogen atmosphere.  After 10 min, the 
reaction mixture was quickly filtered and transferred to a dry 50 mL round bottom flask.  This 
solution was then cooled to -30 oC for 20 min under nitrogen gas and a crystalline solid formed.  
The resulting solid was isolated by filtration, washed with ether (20 mL) and dried under high 
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vacuum for 3 h.  The resulting Cu(CH3CN)4BF4 (1.24 g, 75%) was isolated as a clear crystalline 
solid: Mp 160-162 oC. 
 
General procedure O. Copper(I) catalyzed additions of alkenylzirconocenes.   (E)-N-(1-
Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 8 entry 1).  To a solution of 
Cp2ZrCl2 (49.7 mg, 0.170 mmol) in THF (0.50 mL) cooled to 0 oC under a nitrogen atmosphere 
was added a solution of DIBAL-H in hexanes (0.17 mL, 0.17 mmol, 1.0 M) over a 15 min 
period.  After 30 min at 0 oC, a white Cp2Zr(H)Cl suspension formed and 1-hexyne (0.0172 mL, 
0.150 mmol) was added.  This mixture was warmed to room temperature and became 
homogenous after 1 h.  The mixture was then added to a premixed solution of 146 (45.4 mg, 
0.150 mmol) and Cu(CH3CN)4BF4 (2.40 mg, 0.00750 mmol) in THF (0.50 mL) at 0 oC under a 
nitrogen atmosphere.  The reaction mixture was warmed to room temperature and stirred for 2 d.  
The reaction was quenched by the addition of a saturated NH4Cl solution (5.0 mL) with stirring 
for 50 min, and partitioned between a saturated brine solution (10.0 mL) and ether (20.0 mL).  
The aqueous layer was extracted with ether (2 X 20.0 mL).  The combined ether layers were 
filtered through a 1 in pad of SiO2 which was washed with additional EtOAc (25.0 mL), dried 
(Na2SO4) and concentrated by rotary evaporation.  The resulting crude residue was 
chromatographed on SiO2 (1:3 EtOAc: hexanes) to give 164 (1.5 mg, 3%) as an impure clear oil. 
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N-(3-Methyl-1-phenylbutyl)benzo[d]thiazole-2-sulfonamide (170, Table 8 entry 2).  
According to general procedure O, Cp2ZrCl2 (99.4 mg, 0.340 mmol), DIBAL-H (0.34 mL, 0.34 
mmol, 1.0 M), 1-hexyne (0.0344 mL, 0.300 mmol), Cu(CH3CN)4BF4 (4.80 mg, 0.0150 mmol) 
and 146 (45.4 mg, 0.150 mmol) were combined, and then BF3•OEt2 (0.0565 mL, 0.450 mmol) 
was added.  The resulting purple reaction mixture was stirred at room temperature for 18 h to 
give 170 (34.0 mg, 63%) as a white crystalline solid: Mp 122-123 oC; IR (KBr) 3182, 2957, 
1455, 1426, 1356, 1170, 1052, 930, 763 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.01 (dd, 1 H, J = 
8.1, 1.2 Hz), 7.84 (dd, 1 H, J = 7.2, 1.5 Hz), 7.52 (dt, 2 H, J = 7.5, 1.2 Hz), 7.08 (dd, 2 H, J = 8.1, 
1.2 Hz), 7.01-6.93 (m, 3 H), 5.74 (d, 1 H, J = 8.1 Hz), 4.65 (q, 1 H, J = 7.5 Hz), 1.82-1.73 (m, 1 
H), 1.66-1.50 (m, 2 H), 0.88 (t, 6 H, J = 7.8 Hz); 13C-NMR (CDCl3, 75 MHz) δ 166.5, 152.1, 
140.3, 136.5, 128.2 (2), 127.4, 127.3, 127.1, 126.6 (2), 124.9, 121.9, 57.7, 46.5, 24.6, 22.3, 22.2; 
HRMS (TOF MS ES+) m/z calculated for C18H20N2O2S2Na (M+Na) 383.0864, found 383.0868. 
 
(E)-N-(1-Phenylhept-2-enyl)benzo[d]thiazole-2-sulfonamide (164, Table 8 entry 3).  
According to general procedure O, Cp2ZrCl2 (99.4 mg, 0.340 mmol), DIBAL-H (0.34 mL, 0.34 
mmol, 1.0 M), 1-hexyne (0.0344 mL, 0.300 mmol), and 146 (45.4 mg, 0.150 mmol) were 
combined and then BF3.OEt2 (0.0565 mL, 0.450 mmol) was added.  The reaction mixture was 
stirred at room temperature for 16 h after which time no product 164 or 170 was noted by TLC. 
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General procedure P.  Deprotection of sulfonamides with H3PO2 and re-protection with 
Boc2O. Tert-butyl 1-phenylethylcarbamate (171, Table 9 entry 1).78  To a solution of 
sulfonamide 148 (200 mg, 0.706 mmol) in refluxing THF (9.0 mL) was slowly added a H3PO2 
solution (2.3 mL, 21 mmol, 50%) via syringe pump over a 3.5 h period under a nitrogen 
atmosphere.  The reaction mixture was heated at reflux for an additional 1 h after all of the 
H3PO2 solution was added.  After this time, the reaction mixture was cooled to room 
temperature, diluted with deionized water (5.0 mL) and washed with hexanes (5.0 mL).  The 
hexane layer was then washed with an HCl solution (2.0 mL, 0.50 M) and the aqueous layers 
were combined, cooled to 0 oC, basified to a pH > 13 with a NaOH solution (10 mL, 5.0 M) and 
extracted with ether (3 X 30 mL).  The combined ether layers were washed with a saturated brine 
solution (5.0 mL), dried (Na2SO4) and concentrated by rotary evaporation.  The resulting clear 
oil was then dissolved in CH3CN (3.0 mL) and reacted with Boc2O (192 mg, 0.883 mmol) in the 
presence of Et3N (0.0980 mL, 0.760 mmol) under a nitrogen atmosphere.  The reaction mixture 
was stirred at room temperature for 1 h and the solvent was then removed by rotary evaporation.  
The crude residue was chromatographed on SiO2 (20:1, hexanes: EtOAc to remove the excess 
Boc2O followed by 5:1 hexanes: EtOAc) to give 171 (132 mg, 84%) as a clear crystalline solid: 
Mp 87-88 oC; IR (KBr) 3383, 2983, 1687, 1519, 1367, 1248, 1171, 1059, 756 cm-1; 1H-NMR 
(CD2Cl2, 300 MHz) δ 7.32-7.23 (m, 5 H) 4.95 (s, 1 H), 4.74 (s, 1 H), 1.43 (s, 3 H), 1.41 (s, 9 H); 
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13C-NMR (CD2Cl2, 75 MHz) δ 155.5, 145.2, 129.0 (2), 127.5, 126.4 (2), 79.6, 50.8, 28.7 (3), 
23.3; HRMS (TOF MS EI+) m/z calculated for C13H19NO2Na (M+Na) 244.1313, found 
244.1309. 
 
N
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Tert-butyl benzhydrylcarbamate (172, Table 9 entry 2).79  According to general procedure P, 
sulfonamide 154 (50.0 mg, 0.145 mmol) and H3PO2 (0.48 mL, 4.3 mmol, 50%) were combined 
in THF (2.0 mL) for 4.5 h.  The isolated crude amine was then combined with Boc2O (39.5 mg, 
0.181 mmol) and Et3N (0.020 mL, 0.145 mmol) in CH3CN (1.5 mL) for 1 h to give 172 (34.2 
mg, 83%) as a clear crystalline solid: Mp 123-124 oC;  IR (KBr) 3373, 2978, 1690, 1520, 1363, 
1173, 1022, 744 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 7.36-7.25 (m, 10 H), 5.93 (s, 1 H), 2.20 (s, 
1 H), 1.46 (s, 9 H); 13C-NMR (CDCl3, 75 MHz) δ 155.0, 142.1 (2), 128.6 (4), 127.3 (2), 127.2 
(4), 79.9, 58.5, 28.4 (3); HRMS (TOF MS ES+) m/z calculated for C18H21NO2Na (M+Na) 
306.1470, found 306.1468. 
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Tert-butyl 1-phenylbut-2-ynylcarbamate (173, Table 9 entry 3).  According to general 
procedure P, sulfonamide 153 (70.0 mg, 0.228 mmol) and H3PO2 (0.75 mL, 6.8 mmol) were 
combined in THF (5.0 mL) for 4.5 h.  The isolated crude amine was then combined with Boc2O 
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(59.7 mg, 0.274 mmol) and Et3N (0.0318 mL, 0.228 mmol) in CH3CN (3.0 mL) for 1 h to give 
173 (49.5 mg, 88%) as a white crystalline solid: Mp 90-91 oC; IR (KBr) 3318, 2978, 1713, 1682, 
1523, 1365, 1246, 1157, 1021, 880 cm-1; 1H-NMR (CD2Cl2, 300 MHz) δ 7.47 (d, 2 H, J = 6.0 
Hz), 7.38-7.27 (m, 3 H), 5.55 (s, 1 H), 5.18 (s, 1 H), 1.88 (s, 3 H), 1.44 (s, 9 H); 13C-NMR 
(CD2Cl2, 75 MHz) δ 155.1, 140.8, 128.9 (2), 128.1, 127.1 (2), 81.1, 80.1, 77.9, 46.8, 28.4 (3), 
3.6; HRMS (TOF MS ES+) m/z calculated for C15H19NO2Na (M+Na) 268.1313, found 268.1302.   
 
General procedure Q.  Deprotection of sulfonamides with SmI2 and re-protection with 
Boc2O.  Tert-butyl 1-phenylethylcarbamate (171, Table 10 entry 1).  To a solution of 
sulfonamide 148 (100 mg, 0.353 mmol) in degassed THF (1.0 mL) was added a solution of SmI2 
in THF (25 mL, 2.5 mmol, 0.10 M) slowly over a 1 h period at room temperature under a 
nitrogen atmosphere.  The reaction mixture turned from a dark blue color to yellow over 8 h.  
The mixture was quenched by pouring it into KOH (2.0 g) and ice (20 g).  This solution was 
warmed to room temperature and extracted with ether (3 X 50 mL).  The combined ether layers 
were concentrated by rotary evaporation (13 oC).  The resulting yellow residue was acidified 
with an HCl solution (10 mL, 1.0 M).  The aqueous solution was washed with hexanes (1 X 10 
mL), cooled to 0 oC and basified with a NaOH solution (5.0 mL, 5.0 M) to pH > 13.  The basic 
mixture was extracted with ether (3 X 25 mL).  The combined ether layers were washed with a 
saturated brine solution (1 X 5.0 mL), dried (Na2SO4) and concentrated by rotary evaporation (13 
oC).  The crude amine was then dissolved in CH3CN (1.5 mL) and reacted with Boc2O (96.3 mg, 
0.353 mmol) in the presence of Et3N (0.0490 mL, 0.353 mmol) under a nitrogen atmosphere.  
The reaction mixture was stirred at room temperature for 1.5 h and the solvent was then removed 
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by rotary evaporation.  The crude residue was chromatographed on SiO2 (10:1 hexanes: EtOAc) 
to give 171 (65.4 mg, 84%) as a clear crystalline solid. 
 
Tert-butyl 1-phenylethylcarbamate (171, Table 10 entry 2).  According to general procedure 
Q, sulfonamide 155 (100 mg, 0.314 mmol) and SmI2 (28 mL, 2.8 mmol, 0.10 M) were reacted in 
THF for 8 h.  The isolated crude amine was then combined with Boc2O (85.7 mg, 0.393 mmol) 
and Et3N (0.0438 mL, 0.314 mmol) in CH3CN (1.5 mL) for 1.5 h to give 171 (57.4 mg, 83%) as 
a white crystalline solid. 
4.3.4 Addition of organometallic reagents to (E)-N-benzylidenebenzo[d]thiazole-2-
sulfinamide and (E)-N-benzylidenepyridine-2-sulfinamide. 
S
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Ethyl benzo[d]thiazole-2-sulfinate (175).  To a solution of benzo[d]thiazole-2-thiol 142 (1.50 
g, 8.97 mmol) in EtOH (20 mL) and CH2Cl2 (20 mL) cooled to 0 oC was added NBS (3.19 g, 
17.9 mmol) in one portion.  The reaction mixture turned a dark red color, was warmed to room 
temperature for 4 h, and quenched by the addition of a saturated solution of NaHCO3 (40 mL).  
This mixture was diluted with CH2Cl2 (50 mL) and the organic layer was washed with a 
saturated brine solution (40 mL), dried (Na2SO4) and concentrated by rotary evaporation.  The 
resulting oily suspension was filtered and chromatographed on SiO2 (5:1 hexanes: EtOAc).  The 
isolated product was dried by rotary evaporation, followed by high vacuum for 5 h affording 175 
(1.57 g, 77%) as a tan oil: IR (salt plate) 2983, 2934, 1733, 1471, 1314, 1139, 1002, 883, 762 
cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.18 (d, 1 H, J = 8.4 Hz), 8.01 (d, 1 H, J = 7.8 Hz), 7.63-
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7.51 (m, 2 H), 4.43-4.36 (m, 1 H), 4.00-3.94 (m, 1 H), 1.39 (t, 3 H, J = 6.9 Hz); 13C-NMR 
(CDCl3, 75 MHz) δ 176.2, 154.1, 136.6, 127.7 (2), 125.4, 122.9, 63.4, 16.1; MS (EI) m/z 227 
(M+, 30), 183 (98), 162 (89), 151 (58), 135 (100), 108 (81), 90 (58), 69 (43); HRMS (EI) m/z 
calculated for C9H9NO2S2 227.0075, found 227.0079. 
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Ethyl pyridine-2-sulfinate (176).  To a solution of 174 (1.67 g, 14.7 mmol) in a 1:1 mixture of 
EtOH and DCM (60 mL) was added NBS (5.23 g, 29.4 mmol) in one portion at 0 °C.  The 
reaction mixture immediately turned orange in color, was warmed to room temperature over 1 h 
and was then diluted with a saturated NaHCO3 solution (50 mL) followed by DCM (50 mL).  
This mixture was stirred for 30 min, the aqueous layer was removed and the DCM layer was 
washed with a saturated brine solution (2 X 50 mL).  The DCM layer was then diluted with 
hexanes (50 mL), filtered through a plug of SiO2 (2 in), washed through with DCM (100 mL) and 
dried in vacuo to afford 176 as an orange oil (2.19 g, 83%).  This compound was used crude for 
the next step: 1H NMR (CDCl3, 300 MHz) δ 8.63 (d, 1 H, J = 4.2 Hz), 8.03-7.93 (m, 2 H), 7.49-
7.46 (m, 1 H), 4.27-4.17 (m, 1 H), 3.89-3.78 (m, 1 H), 1.32 (t, 3 H, J = 7.2 Hz); 13C NMR 
(CDCl3, 75 MHz) δ 163.8, 150.0, 137.8, 126.2, 119.8, 62.6, 15.6. 
S
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Benzo[d]thiazole-2-sulfinamide (177).  To a solution of 175 (250 mg, 1.10 mmol) in THF (5.0 
mL) cooled to -78 oC under a nitrogen atmosphere was added a solution of LiHMDS in THF 
(1.43 mL, 1.43 mmol, 1.00 M) dropwise over a 5 min period.  The reaction mixture turned a 
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deep red color, stirred at -78 oC for 2 h, and quenched by pouring it at -78 oC into an Erlenmeyer 
flask containing a saturated NH4Cl solution (20 mL).  This mixture was stirred for 30 min, while 
warming to room temperature, and then extracted with EtOAc (3 X 10 mL).  The combined 
EtOAc layers were washed with a saturated brine solution (10 mL), dried (Na2SO4), concentrated 
to 20 mL by rotary evaporation and filtered through a 1 in plug of SiO2 which was washed with 
additional EtOAc (50 mL).  The filtrate was concentrated by rotary evaporation and the resulting 
solids were recrystallized from a 2:1 solution of EtOAc and hexanes (30 mL).  The solid was 
washed with a 2:1 solution of EtOAc and hexanes (20 mL) and dried under high vacuum for 15 h 
to give 177 (125 mg, 57%) as a light yellow crystalline solid:  Mp 141-142 oC (dec); IR (KBr) 
3310, 3174, 3083, 1474, 1426, 1040, 892, 761 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 8.24 (d, 1 
H, J = 7.5 Hz), 8.12 (d, 1 H, J = 7.8 Hz), 7.59 (m, 2 H), 7.18 (s, 2 H); 13C-NMR (DMSO-d6, 75 
MHz) δ 179.5, 153.4, 136.2, 126.9, 126.3, 123.7, 122.8; MS (EI) m/z 198 (M+, 4.5), 182 (40), 
167 (14), 150 (81), 135 (100), 108 (86), 90 (67), 69 (86); HRMS (EI) m/z calculated for 
C7H6N2OS2 197.9922, found 197.9919. 
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Pyridine-2-sulfinamide (178).  To a solution of 176 (6.47 g, 34.4 mmol) in dry THF (100 mL) 
was added a solution of LiHMDS (37.8 mL, 37.8 mmol, 1.0 M) in THF, over 5 min at -65 oC.  
The reaction mixture turned a dark brown/red color during the addition, was stirred at -65 oC for 
1 h and was quenched by addition to a saturated NH4Cl solution (100 mL).  The resulting 
mixture was stirred at room temperature for 1 h and then diluted with EtOAc (50 mL).  The 
EtOAc layer was removed and the aqueous layer was extracted with EtOAc (2 X 100 mL).  The 
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EtOAc extracts were combined, dried (Na2SO4) and filtered through a plug of SiO2 (1 in) with 
additional EtOAc (200 mL).  The EtOAc was removed in vacuo and the resulting solids were 
recrystallized from a 1:2 mixture of hexanes to EtOAc (a seed crystal was added to initiate 
crystallization). The resulting light brown precipitate was isolated by vacuum filtration, washed 
with hexanes (20 mL) and dried in vacuo to afford 178 (985 mg, 20%):  Mp 108.0-109.5 oC 
(dec.); IR (KBr) 3226, 3075, 2699, 1580, 1451, 1426, 1086, 1056, 877 cm-1; 1H NMR (CDCl3, 
300 MHz) δ 8.71 (d, 1 H, J = 4.2 Hz), 7.97-7.89 (m, 2 H), 7.46-7.42 (m, 1 H), 7.47 (br-s, 2 H); 
13C NMR (CDCl3, 75 MHz) δ 164.4, 150.0, 138.0, 125.6, 120.6; MS (EI) m/z 142 (M+, 2.6), 126 
(4.7), 110 (4.5), 96 (36), 79 (100); HRMS (EI) m/z calculated for C5H6N2OS 142.0201, found 
142.0199. 
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(E)-N-Benzylidenebenzo[d]thiazole-2-sulfinamide (179).  To a suspension of 177 (200 mg, 
1.00 mmol) in CH2Cl2 (15.0 mL) under a nitrogen atmosphere was added benzaldehyde 110 
(0.102 mL, 1.00 mmol) and Ti(OEt)4 (0.418 mL, 2.02 mmol) at room temperature.  After 1.5 h, 
the solution turned a dark orange color and the reaction was quenched by the addition of SiO2 
(1.00 g) with stirring for 15 min.  The resulting suspension was filtered through a 1 in plug of 
SiO2 which was washed with additional CH2Cl2 (75 mL).  The filtrate was concentrated by rotary 
evaporation and the resulting pale yellow oil was placed under high vacuum for 12 h when it 
crystallized affording 179 (228 mg, 79%) as a pale yellow crystalline solid: Mp 101-102.5 oC; IR 
(KBr) 3055, 1604, 1569, 1312, 1097, 994, 760 cm-1; 1H-NMR (CDCl3, 300 MHz) δ 8.93 (s, 1 
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H), 8.22 (d, 1 H, J = 8.1 Hz), 7.96 (t, 3 H, J = 6.6 Hz), 7.61-7.48 (m, 5 H); 13C-NMR (CDCl3, 75 
MHz) δ 174.0, 163.7, 153.3, 136.3, 133.6, 133.4, 130.2 (2), 129.2 (2), 127.0, 126.9, 124.8, 122.1; 
MS (EI) m/z 286 (M+, 4.4), 183 (33), 167 (67), 135 (28), 103 (100), 76 (36); HRMS (EI) m/z 
calculated for C14H10N2OS2 286.0235, found 286.0242. 
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(E)-N-benzylidenepyridine-2-sulfinamide (180).  To a suspension of 178 (400 mg, 2.81 mmol) 
and 110 (0.286 mL, 2.81 mmol) in dry DCM (30 mL) was added Ti(OEt)4 (1.17 mL, 5.63 
mmol). The reaction mixture turned a deep orange color and cleared after 2 h.  After 2 h, SiO2 
(1.00 g) was added with stirring for 15 min.  The resulting slurry was vacuum filtered through a 
plug of SiO2 (1.5 in) and washed with additional DCM (150 mL).  The clear pale yellow filtrate 
was dried in vacuo to afford 180 as an off white solid (577 mg, 89%):  Mp 90.0 - 91.0 oC (dec.); 
IR (KBr) 3057, 1605, 1573, 1448, 1423, 1214, 1098, 1070, 756 cm-1; 1H NMR (CDCl3, 300 
MHz) δ 8.85 (s, 1 H), 8.75 (d, 1 H, J = 4.2 Hz), 7.94–7.88 (m, 4 H), 7.54–7.44 (m, 4 H); 13C 
NMR (CDCl3, 75 MHz) δ 164.1, 161.8, 150.1, 138.1, 133.8, 132.8, 129.8 (2 C), 128.9 (2 C), 
125.5, 119.2; MS (EI) m/z 230 (M+, 3), 181 (27), 152 (31), 127 (99), 103 (95), 79 (100); HRMS 
(EI) m/z calculated for C12H10N2OS 230.0514, found 230.0503. 
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General procedure R. N-(1-Phenylethyl)benzo[d]thiazole-2-sulfinamide (181).  To a solution 
of aldimine 179 (30.0 mg, 0.105 mmol) in THF (1.0 mL) at -78 oC was added dropwise a 
solution of MeMgBr in ether (0.070 mL, 0.21 mmol, 3.0 M) under a nitrogen atmosphere.  The 
reaction mixture was stirred for 1 h, quenched by adding a saturated NH4Cl solution (3.0 mL) at 
-78 oC, slowly warmed to room temperature over a 30 min period and partitioned between a 
saturated brine solution (10 mL) and ether (10 mL).  The aqueous layer was extracted with ether 
(2 X 10 mL), the combined ether extracts were dried (Na2SO4), condensed by rotary evaporation 
and dissolved in a minimum amount of EtOAc for chromatography on SiO2 (2:1 hexanes: 
EtOAc) to give two products (A and B).  These products were dried in vacuo to afford 181 
(Product A, 2.1 mg, 7%) isolated impure as an off white solid: 1H-NMR (CDCl3, 300 MHz) δ 
7.56 (d, 2 H, J = 8.1 Hz), 7.45-7.11 (m, 6 H), 7.09 (t, 1 H, J = 7.5 Hz), 5.76 (s, 1 H), 4.87 (q, 1 H, 
J = 6.0 Hz), 1.68 (d, 3 H, J = 6.6 Hz).  A 1H-NMR (CDCl3) of fraction B showed 182 (4.2 mg, 
24%) as clear oil. 
 
N
H
S
O
182
 
(E)-N-Benzylidenemethanesulfinamide (182).  According to general procedure R, aldimine 
179 (30.0 mg, 0.105 mmol) was combined with a solution of MeMgBr in ether (0.039 mL, 0.12 
mmol, 3.0 M) in CH2Cl2 (1.0 mL) at -78 oC.  The reaction mixture was warmed to 0 oC for 3 h.  
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The product 182 (9.8 mg, 56%) was isolated as a clear oil: 1H-NMR (CDCl3, 300 MHz) δ 8.66 
(s, 1 H), 7.89 (d, 2 H, J = 7.2 Hz), 7.57-7.51 (m, 3 H), 2.74 (s, 3 H); 13C-NMR (CDCl3, 75 MHz) 
δ 161.8, 133.9, 132.7, 129.5 (2), 129.0 (2), 42.9; MS (EI) m/z 167 (M+, 34), 156 (100), 104 (36), 
77 (73). HRMS (EI) m/z calculated for C8H9NOS 167.0405, found 167.0400. 
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General Procedure S.  N-(1-phenylpropyl)pyridine-2-sulfinamide (183, Table 11 entry 3).  
To a solution of 180 (23.0 mg, 0.100 mmol) and Cu(OTf)2 (3.6 mg, 0.010 mmol) in DCM (1.0 
mL) was added a solution of Et2Zn (0.200 mL, 0.200 mmol, 1.0 M) in DCM at 0 oC.  The 
reaction mixture turned from yellow to purple upon the addition, was stirred under nitrogen gas 
for 20 h and was quenched by the addition of a saturated NaHCO3 solution (5.0 mL) with stirring 
for 30 min.  The resulting mixture was partitioned between DCM (10 mL) and a saturated brine 
solution (10 mL).  The DCM layer was kept and the aqueous layer was extracted with DCM (2 X 
10 mL).  The combined DCM layers were dried (Na2SO4) and concentrated in vacuo.  The 
resulting yellow residue was dissolved in DCM (~ 0.5 mL) and chromatographed on SiO2 (3:1 
EtOAc:Hexanes).  The product was isolated (Rf = 0.32) and dried in vacuo to afford 183 as a 
clear oil (12.3 mg, 47% yield, 2:1 d.r.): IR (KBr) 3216, 2966, 2931, 2875, 1577, 1453, 1423, 
1089, 1041, 773 cm-1; 1H NMR (CDCl3, 300 MHz, 2:1 mixture of diastereoisomers) δ 8.75 (s, 
0.67 H), 8.50 (s, 0.34 H), 8.20-7.90 (m, 1.25 H), 7.86-7.83 (m, 0.33 H), 7.76-7.71 (m, 0.38 H), 
7.41-7.27 (m, 3.67 H), 7.25-7.23 (m, 0.34 H), 7.18-7.08 (m, 1.22 H), 4.85 (br-s, 0.66 H), 4.72 
(br-s, 0.34 H), 4.44-4.42 (m, 1 H), 2.07-1.96 (m, 0.45 H), 1.89-1.08 (m, 1.66 H), 0.89-0.84 (m, 3 
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H); 13C NMR (CDCl3, 75 MHz) δ 164.5, 163.8, 150.7, 150.3, 142.4, 141.9, 138.4, 137.9, 129.2 
(2 C), 128.8 (2 C), 128.3 (4 C), 127.8 (2 C), 126.2, 125.6, 121.7, 121.4, 60.2, 57.7, 31.6, 31.4, 
11.1, 11.0; HRMS (TOF MS ES+) m/z calculated for C14H16N2OSNa 283.0881, found 283.0901. 
 
N-(1-phenylpropyl)pyridine-2-sulfinamide (183, Table 11 entry 1).  According to general 
procedure S, 180 (23.0 mg, 0.100 mmol) and Et2Zn in DCM (0.200 mL, 0.200 mmol, 1.0 M) 
were reacted in DCM (1.0 mL) at room temperature for 24 h to afford 183 crude (6.0 mg, 17%, 
dr 1:1). 
 
N-(1-phenylpropyl)pyridine-2-sulfinamide (183, Table 11 entry 2).  According to general 
procedure S, 180 (23.0 mg, 0.100 mmol), Cu(OTf)2 (3.6 mg, 0.010 mmol) and Et2Zn in toluene 
(0.200 mL, 0.200 mmol, 1.0 M) were reacted in toluene (1.0 mL) at room temperature for 20 h to 
afford 183 (12.2 mg, 47%, dr 1:1). 
 
N-(1-phenylpropyl)pyridine-2-sulfinamide (183, Table 11 entry 4).  According to general 
procedure S, 180 (23.0 mg, 0.100 mmol), Cu(OTf)2 (3.6 mg, 0.010 mmol) and Et2Zn in THF 
(0.200 mL, 0.200 mmol, 1.0 M) were reacted in THF (1.0 mL) at 0 oC for 15 h to afford a trace 
amount of 183 by TLC (SiO2, 3:1 EtOAc:hexanes). 
 
 179 
HN
S
O
N
184
 
N-(cyclohexyl(phenyl)methyl)pyridine-2-sulfinamide (184, Table 11 entry 5).  According to 
general procedure S, 180 (23.0 mg, 0.100 mmol), Cu(OTf)2 (3.6 mg, 0.010 mmol) and 
cyclohexylzinc bromide in THF (0.400 mL, 0.200 mmol, 0.50 M) were reacted in DCM (1.0 
mL) at room temperature for 24 h.  The product was isolated by chromatography on SiO2 (2:1 
EtOAc:hexanes; Rf = 0.30) to afford 184 as a clear oil (20.1 mg, 64%, dr 3.5:1): IR (KBr) 3228, 
2926, 2852, 1577, 1451, 1423, 1089, 1039 cm-1; 1H NMR (CDCl3, 300 MHz, 3.5:1 mixture of 
diastereoisomers) δ 8.72 (br-s, 0.23 H), 8.63 (br-s, 0.77 H), 7.85-7.76 (m, 1.24 H), 7.68-7.63 (m, 
0.79 H), 7.42-7.34 (m, 1.24 H), 7.15-7.06 (m, 2.80 H), 6.94 (br-s, 1.56 H), 5.00 (br-s, 0.23 H), 
4.84 (br-s, 0.79 H), 4.23 (br-s, 1 H), 1.98-1.82 (m, 1.22 H), 1.79-1.75 (m, 1.44 H), 1.41 (d, 1.44 
H, J = 10.8 Hz), 1.26-1.00 (m, 5 H), 0.96-0.85 (m, 2 H); HRMS (TOF MS ES+) m/z calculated 
for C18H22N2OSNa 337.1351, found 337.1321. 
 
N-(cyclohexyl(phenyl)methyl)pyridine-2-sulfinamide (184, Table 11 entry 6).  According to 
general procedure S, 180 (23.0 mg, 0.100 mmol), Cu(OTf)2 (3.6 mg, 0.010 mmol) and 
cyclohexylzinc bromide in THF (0.400 mL, 0.200 mmol, 0.50 M) were reacted in DCM (1.0 
mL) at 0 oC for 24 h.  The product was isolated by chromatography on SiO2 (2:1 EtOAc:hexanes; 
Rf = 0.30) to afford 184 (19.9 mg, 63%, dr 4:1). 
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General Procedure T. N-(1-phenylbut-2-ynyl)pyridine-2-sulfinamide (185, Table 11 entry 
9).  To a solution of ZnBr2 (45.0 mg, 0.200 mmol) in THF (0.20 mL) cooled to 0 oC was added a 
solution of 1-propynylmagnesium bromide in THF (0.400 mL, 0.200 mmol, 0.50 M).  The 
resulting white suspension was slowly warmed to room temperature for 30 min and was then 
added via syringe to a yellow/orange homogenous mixture of 180 (23.0 mg 0.100 mmol) and 
(CH3CN)4CuBF4 (3.2 mg, 0.010 mmol) in DCM (1.0 mL).  The resulting green/yellow slightly 
heterogeneous reaction mixture was stirred at room temperature for 22 h and then a saturated 
NaHCO3 solution (5.0 mL) was added with stirring for 30 min.  The resulting mixture was 
diluted with DCM (10 mL), washed with a saturated brine solution (10 mL) and the aqueous 
layer was extracted with DCM (2 X 10 mL).  The combined organic layers were dried (Na2SO4), 
condensed in vacuo and dissolved in a minimum amount of DCM for chromatography on SiO2 
(2:1 EtOAc: hexanes; Rf = 0.33).  The product was isolated and dried in vacuo to afford 185 as a 
clear oil (13.4 mg, 50%, dr 3.5:1): IR (KBr) 3441, 3203, 2918, 1577, 1453, 1424, 1092, 1064, 
1040 cm-1; 1H NMR (CDCl3, 300 MHz, 3.5:1 mixture of diastereoisomers) δ 8.75 (d, 0.22 H, J = 
4.5 Hz), 8.62 (d, 0.78 Hz, J = 4.2 Hz), 8.04 (d, 0.22 H, J = 7.8 Hz), 7.94 (d, 0.78 H, J = 7.5 Hz), 
7.93-7.91 (m, 0.22 H), 7.83 (dt, 0.78 H, J = 7.4, 1.2 Hz), 7.58 (d, 0.44 H, J = 7.2 Hz), 7.44-7.20 
(m, 6 H), 5.39-5.33 (m, 0.22 H), 5.28-5.26 (m, 0.78 H), 4.93 (d, 0.78 H, J = 4.5 Hz), 4.79 (d, 
0.22 H, J = 4.8 Hz), 1.91 (d, 2.29 H, J = 2.1 Hz), 1.72 (d, 0.66 H, J = 2.4 Hz); 13C NMR (CDCl3, 
75 MHz) δ 163.6, 150.6, 150.5, 139.9, 138.3, 138.2, 129.3 (2 C), 129.1 (2 C), 128.9, 128.7, 
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128.5 (2 C), 128.1 (2 C), 126.0, 121.8, 121.6, 84.0, 78.0, 48.6, 47.8, 4.5, 4.3; HRMS (TOF MS 
ES+) m/z calculated for C15H14N2OSNa 293.0725, found 293.0732. 
 
N-(1-phenylbut-2-ynyl)pyridine-2-sulfinamide (185, Table 11 entry 7).  According to general 
procedure T, 180 (23.0 mg, 0.100 mmol) and 1-propynylmagnesium bromide in THF (0.300 mL, 
0.150 mmol, 0.50 M) were reacted in DCM (1.0 mL) at 0 oC for 3 h to afford 185 (12.9 mg, 
48%, dr 1:1). 
 
N-(1-phenylbut-2-ynyl)pyridine-2-sulfinamide (185, Table 11 entry 8).  According to general 
procedure T, 1-propynylmagnesium bromide in THF (0.400 mL, 0.200 mmol, 0.5 M) and ZnCl2 
in THF (0.200 mL, 0.200 mmol, 1.0 M) were mixed at -78 oC, warmed to room temperature and 
then reacted with 180 (23.0 mg, 0.100 mmol) and Cu(OTf)2 (3.6 mg, 0.010 mmol) in DCM (1.0 
mL) at room temperature for 21 h to afford 185 (3.6 mg, 13%, dr 1:1). 
 
N-(1-phenylbut-2-ynyl)pyridine-2-sulfinamide (185, Table 11 entry 10).  According to 
general procedure T, ZnI2 (63.8 mg, 0.200 mmol), 1-propynylmagnesium bromide in THF (0.400 
mL, 0.200 mmol, 0.5 M), 180 (23.0 mg, 0.100 mmol) and (CH3CN)4CuBF4 (3.2 mg, 0.010 
mmol) in DCM (1.0 mL) were reacted at room temperature for 17 h to afford 185 (16.3 mg, 
60%, dr 2.9:1). 
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4.4 SYNTHESIS OF SID 861574 AND RELATED PLK1-PBD                    
INHIBITORS 
4.4.1 First generation analogues of SID 861574 
N
H
NH
OH
OO
N
H
O
EtO2C
205
 
Ethyl 4-(6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido) benzoate (205, 
DMA-NB74-1).  To a solution of barbituric acid (124 mg, 0.970 mmol) in DMF (1.5 mL) was 
added dropwise Et3N (0.273 mL, 1.94 mmol) at room temperature.   A white precipitate formed 
during the addition.  The resulting suspension was stirred at room temperature for 30 min and 
then ethyl-4-isocyanatobenzoate (191 mg, 0.970 mmol) was added.  The suspension turned pale 
yellow following the addition and was stirred at room temperature for 15 h.  After 15 h, the 
reaction mixture was acidified with an HCl solution (~ 3.0 mL, 1.2 M, pH = 0).  The resulting 
white solids were isolated by vacuum filtration, washed with deionized water (30 mL) and 
heated in boiling EtOH (20 mL) for 15 min followed by cooling to room temperature.  The white 
precipitate was isolated by vacuum filtration, washed with EtOH (30 mL) and dried in vacuo to 
afford 205 as a white solid (223 mg, 72%): Mp 340-340.5 oC; IR (KBr) 3214, 2986, 2808, 1744, 
1705, 1637, 1603, 1495, 1417, 1280, 1111, 853 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 17.33 (s, 
1 H), 11.86 (s, 2 H), 11.71 (s, 1 H), 7.95 (d, 2 H, J = 8.4 Hz), 7.66 (d, 2 H, J = 8.4 Hz), 4.29 (q, 2 
H, J = 6.9 Hz), 1.32 (t, 3 H, J = 7.0 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 169.5, 165.5 (3 C), 
148.9, 141.0, 130.9 (2 C), 126.3, 120.7 (2 C), 81.5, 61.1, 14.6; MS (EI) m/z 319 (M+, 34), 165 
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(54), 137 (26), 120 (100), 69 (37); HRMS (EI) m/z calculated for C14H13N3O6 319.080435, found 
319.081014. 
 
N
H
NH
OH
OO
N
H
O
HO2C
211
 
General Procedure U. 4-(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbox-
amido)benzoic acid (211, DMA-NB74-83).  A mixture of 205 (40.0 mg, 0.125 mmol) in a 
LiOH solution (2.0 mL, 1.0 M) was stirred at room temperature for 2.5 h.  The reaction mixture 
was acidified with an aqueous HCl solution (1.0 M, pH=1-2) at 0 oC and the resultant carboxylic 
acid product precipitated.  The solid was isolated by vacuum filtration, washed with deionized 
water (15 mL) and dried in vacuo to afford 211 as a white solid (32.0 mg, 88%): Mp >380 oC; IR 
(ATR) 3245, 3038, 2855, 1718, 1671, 1592, 1528, 1414, 1254, 1174, 798 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 17.17 (s, 1 H), 12.85 (s, 1 H), 11.79 (s, 3 H), 7.95 (d, 2 H, J = 8.4 Hz), 
7.66 (d, 2 H, J = 8.7 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 169.3, 167.2 (3 C), 149.0, 140.9, 
131.1 (2 C), 127.3, 120.6 (2 C), 81.7; MS (EI) m/z 291 (M+, 18), 154 (34), 137 (100), 120 (79), 
68 (35); HRMS (EI) m/z calculated for C12H9N3O6 291.049135, found 291.048553. 
 
N
H
NH
O
OMeS
BnO
O
216
 
Benzyl 6-(methylthio)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (216, DMA-
NB74-6).  To a suspension of K2CO3 (2.55 g, 18.5 mmol) in DMSO (20 mL) was added dibenzyl 
malonate (2.91 mL, 13.0 mmol) followed by 3,3-dimethylthio-2-azaprop-2-enenitrile (1.50 g, 
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9.23 mmol).   The reaction mixture was stirred at room temperature for 5 h and was then slowly 
added to an ice cold HCl solution (50 mL, 10%).  A white precipitate formed.  After stirring for 
15 min, the precipitate was isolated by filtration, washed with deionized water (30 mL) and 
recrystallized from a 4:1 mixture of EtOH:water (50 mL).  The resulting crude product was 
recrystallized a second time from a 9:1 mixture of EtOAc:EtOH (65 mL) to afford 216 as a clear 
crystalline solid (921 mg, 34%):  Mp 215-216 oC; IR (ATR) 3453, 3030, 1718, 1650, 1411, 
1273, 1130 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 11.37 (s, 1 H), 10.94 (s, 1 H), 7.45-7.31 (m, 
5 H), 5.21 (s, 2 H), 2.55 (s, 3 H); 13C-NMR (DMSO-d6, 75 MHz) δ 163.9, 159.4, 158.9, 149.7, 
135.9, 128.3 (2 C), 127.9, 127.8 (2 C), 104.3, 66.1, 14.3; HRMS (TOF MS ES+) m/z calculated 
for C13H12N2O4SNa (M+Na) 315.0415 found 315.0414.  
 
N
H
NH
O
OMeS
EtO
O
217
 
Ethyl 6-(methylthio)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (217, DMA-
NB74-7).  To a suspension of K2CO3 (3.40 g, 24.6 mmol) in DMSO (27 mL) was added diethyl 
malonate (2.70 mL, 17.2 mmol) followed by 3,3-dimethylthio-2-azaprop-2-enenitrile (2.00 g, 
12.3 mmol). The reaction mixture was stirred at room temperature for 5 h and was then added to 
deionized water (125 mL) and acidified (pH = 0.5) by the slow addition of an HCl solution (~21 
mL, 10%).  A precipitate formed after cooling to 0 oC for 15 min and was removed by filtration.  
The filtrate was neutralized with KOH (pH = 7) and a white solid slowly formed over 15 h.  The 
solid was isolated by filtration and was dissolved in an aqueous HCl solution (15 mL, 10%) for 
15 min.  A white solid precipitated which was isolated by vacuum filtration, washed with water 
(30 mL) and recrystallized from EtOAc (20 mL) to afford 217 as a clear crystalline solid (522 
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mg, 18%): Mp  237-238.5 oC; IR (ATR) 3453, 3157, 3019, 2824, 1713, 1687, 1647, 1480, 1405, 
1285, 1103, 1021 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 11.35 (s, 1 H), 10.94 (s, 1 H), 4.17 (q, 
2 H, J = 6.9 Hz), 2.55 (s, 3 H), 1.22 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 164.3, 
159.9, 157.7, 150.2, 105.8, 61.2, 14.8, 14.5; MS (EI) m/z 230 (M+, 7), 184 (33), 125 (22), 111 
(29), 97 (53), 83 (54), 69 (88), 57 (100); HRMS (EI) m/z calculated for C8H10N2O4S 230.036129, 
found 230.036411. 
 
N
H
NH
O
OMeS
HO
O
218
N
H
NH
O
OMeS
t-BuO
O
219
 
6-(Methylthio)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (218, DMA-NB74-
14) and tert-butyl 6-(methylthio)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(219).  To a suspension of K2CO3 (1.70 g, 12.3 mmol) in DMSO (15 mL) was added ditert-butyl 
propane-1,3-dioate (2.70 mL, 7.69 mmol) followed by 3,3-dimethylthio-2-azaprop-2-enenitrile 
(1.00 g, 6.15 mmol).  The reaction mixture was stirred at room temperature for 18 h and was then 
added in small portions to an aqueous HCl solution (30 mL, 10%).  A precipitate formed which 
was isolated by vacuum filtration, washed with water (40 mL) and stirred in boiling EtOAc (100 
mL).   An insoluble white solid was filtered from the EtOAc solution.  The filtrate was 
concentrated and recrystallized three times from a minimum amount of boiling EtOAc to afford 
219 as a fluffy white solid (41.6 mg, 3.0%): Mp 327-328 oC (dec.); IR (ATR) 3381, 3151, 3038, 
1718, 1696, 1642, 1528, 1299, 1118 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 11.29 (s, 1 H), 
10.90 (s, 1 H), 2.56 (s, 3 H), 1.45 (s, 9 H); 13C-NMR (DMSO-d6, 75 MHz) δ 162.7, 159.6, 155.0, 
149.9, 107.4, 81.4, 27.7 (3 C), 14.3; HRMS (ESI) m/z calculated for C10H14N2O4SNa 281.0572, 
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found 281.0574.  The solid isolated from the filtration was purified by solid/liquid extraction 
using EtOAc (4 X 60 mL) to afford 218 as a white crystalline solid  (450 mg, 36%): Mp  329-
330 oC (dec.); IR (ATR) 3276, 3120, 1713, 1612, 1511, 1374, 1174 cm-1; 1H-NMR (DMSO-d6, 
300 MHz) δ 13.85 (s, 1 H), 12.18 (s, 1 H), 10.90 (s, 1 H), 2.58 (s, 3 H); 13C-NMR (DMSO-d6, 75 
MHz) δ 169.8, 166.5, 164.9, 148.7, 96.7, 14.7; MS (EI) m/z 202 (M+, 0.7), 158 (76), 115 (11), 68 
(100); HRMS (EI) m/z calculated for C6H6N2O4S 202.004829, found 202.004120. 
 
N
H
NH
O
OS
BnO
O
O
220
 
General procedure V. Benzyl 6-(methylsulfinyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (220, DMA-NB74-16).  To a suspension of 216 (292 mg, 1.00 mmol) in CH2Cl2 
(20 mL) was added m-CPBA (591 mg, 2.50 mmol, 73%) at room temperature.  After 15 min, the 
suspension cleared and after 30 min a white solid precipitated from the reaction mixture.  After 
1.5 h, the white precipitate was isolated by vacuum filtration, washed with CH2Cl2 (10 mL) and 
dried in vacuo to afford 220 as a fluffy white solid (247 mg, 80%): Mp 204-205 oC; IR (ATR) 
3524, 3038, 1739, 1715, 1681, 1666, 1394, 1301, 1124 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 
11.67 (s, 1 H), 10.34 (s, 1 H), 7.46-7.33 (m, 5 H), 5.27 (s, 2 H), 2.93 (s, 3 H); 13C-NMR (DMSO-
d6, 75 MHz) δ 168.0, 163.5, 159.8, 148.9, 136.2, 128.9 (2 C), 128.5, 128.3 (2 C), 101.4, 66.8, 
41.4; HRMS (ESI) m/z calculated for C13H12N2O5SNa (M+Na) 331.0365, found 331.0388. 
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Ethyl 6-(methylsulfinyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (221, DMA-
NB74-21).  According to general procedure V, 217 (150 mg, 0.651 mmol) and m-CPBA (385 
mg, 1.63 mmol, 73%) were mixed in CH2Cl2 (13 mL) at room temperature for 1.5 h.  The 
product was precipitated from the reaction mixture at 0 oC with hexanes (10 mL) and the 
resulting solid was isolated by vacuum filtration, washed with a 1:1 mixture of CH2Cl2:hexanes 
(10 mL) and dried in vacuo to afford 221 as a clear crystalline solid (115 mg, 72%): Mp  239-
240 oC; IR (ATR) 3174, 3055, 2831, 1735, 1705, 1674, 1592, 1400, 1314, 1120, 1006 cm-1; 1H-
NMR (DMSO-d6, 300 MHz) δ 11.64 (s, 1 H), 10.31 (s, 1 H), 4.21 (q, 2 H, J = 6.9 Hz), 2.96 (s, 3 
H), 1.25 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 167.2, 163.4, 159.8, 148.9, 101.7, 
61.6, 41.4, 14.5; MS (EI) m/z 246 (M+, 30), 200 (25), 155 (52), 140 (87), 112 (100), 94 (31); 
HRMS (EI) m/z calculated for C8H10N2O5S 246.031043, found 246.031121. 
 
N
H
NH
O
OHN
BnO
O
OEtO
224
 
General Procedure W.  Benzyl 6-(4-(ethoxycarbonyl)phenylamino)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate (224, DMA-NB74-19).  A suspension of 220 (200 mg, 
0.649 mmol) and ethyl 4-aminobenzoate (1.03 g, 6.17 mmol) in dioxane (2.0 mL) was heated to 
95-100 oC for 6 h.  A white solid precipitated from the reaction mixture during this time.  The 
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reaction mixture was cooled to room temperature, diluted with acetone (1.0 mL) and further 
cooled to 0 oC for 30 min.  The cold reaction mixture was vacuum filtered and the isolated white 
solid was washed with acetone (5.0 mL) and dried in vacuo to afford 224 as a white crystalline 
solid (202 mg, 76%): Mp  379-380 oC (dec.); IR (ATR) 3381, 3230, 3038, 1718, 1696, 1642, 
1528, 1299, 1118 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 11.08 (s, 1 H), 11.01 (s, 1 H), 10.80 
(s, 1 H), 7.97 (d, 2 H, J = 8.4 Hz), 7.48-7.44 (m, 4 H), 7.39-7.30 (m, 3 H), 5.24 (s, 2 H), 4.32 (q, 
2 H, J = 6.9 Hz), 1.32 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 168.3, 165.7, 161.0, 
156.8, 149.6, 141.2, 137.1, 131.0 (2 C), 128.7 (2 C), 128.0, 127.7 (2 C), 127.6, 124.8 (2 C), 83.1, 
65.5, 61.2, 14.7; MS (EI) m/z 409 (M+, 7), 365 (24), 301 (13), 275 (23), 256 (33), 91 (100); 
HRMS (EI) m/z calculated for C21H19N3O6 409.127386, found 409.127861. 
 
N
H
NH
O
OHN
EtO
O
OHO
206
 
4-(5-(Ethoxycarbonyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylamino)benzoic acid (206, 
DMA-NB74-25).  According to general procedure W, 221 (50.0 mg, 0.203 mmol) and 4-
aminobenzoic acid (264 mg, 1.90 mmol) were heated in dioxane (1.0 mL) at 95-100 oC for 5 h.  
The resulting product 206 was isolated as a light white solid (32.1 mg, 50%): Mp >380 oC; IR 
(ATR) 3217, 3172, 1743, 1705, 1666, 1634, 1575, 1420, 1301, 1204, 788 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 12.94 (s, 1 H), 11.02 (s, 2 H), 10.73 (s, 1 H), 7.95 (d, 2 H, J = 8.4 Hz), 
7.41 (d, 2 H, J = 8.4 Hz), 4.15 (q, 2 H, J = 7.2 Hz), 1.22 (t, 3 H, J = 7.2 Hz); 13C-NMR (DMSO-
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d6, 75 MHz) δ 168.5, 167.3, 161.0, 156.6, 149.6, 141.0, 131.1 (2 C), 128.4, 124.5 (2 C), 83.3, 
60.3, 14.8; MS (EI) m/z 319 (M+, 11), 273 (100), 163 (19), 91 (25), 57 (36); HRMS (EI) m/z 
calculated for C14H13N3O6 319.080435, found 319.080744. 
 
N
H
NH
O
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HO
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General procedure X. 6-(4-(Ethoxycarbonyl)phenylamino)-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylic acid (207, DMA-NB74-27).  To a solution of 224 (25.0 mg, 0.0611 
mmol) in a 1:1 mixture of dioxane:MeOH (15 mL) was added 20 wt% Pd(OH)2/C (10.7 mg, 
0.020 mmol/Pd).  The dark back suspension was placed under a H2 atmosphere (1 atm).  The 
reaction mixture was stirred for 3 h and filtered through a plug of celite (1.5 in, disposable 
pipette) with EtOAc (50 mL).  The filtrate was concentrated by rotary evaporation (40 oC) and 
the resulting white solid was purified by warming in a 3:1 solution of EtOAc:hexane (10 mL) for 
15 min.  The solid was isolated by vacuum filtration, washed with hexanes (10 mL) and dried in 
vacuo to afford 207 as a white crystalline solid (14.2 mg, 73%): Mp  324.5-326 oC (dec.); IR 
(ATR) 3161, 2991, 2823, 1722, 1681, 1625, 1575, 1390, 1286, 1128 cm-1; 1H-NMR (DMSO-d6, 
300 MHz) δ 14.52 (s, 1 H), 11.68 (s, 1 H), 11.59 (s, 1 H), 11.52 (s, 1 H), 8.00 (d, 2 H, J = 8.4 
Hz), 7.52 (d, 2 H, J = 8.4 Hz), 4.33 (q, 2 H, J = 7.2 Hz), 1.33 (t, 3 H, J = 7.2 Hz); 13C-NMR 
(DMSO-d6, 75 MHz) δ 169.5, 168.5, 165.7, 157.0, 148.8, 139.9, 131.0 (2 C), 128.6, 125.8 (2 C), 
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80.1, 61.3, 14.6; MS (EI) m/z 319 (M+, 1), 275 (100), 230 (63), 145 (16), 120 (24); HRMS (EI) 
m/z calculated for C14H13N3O6 319.080435, found 319.08111. 
 
NH2
OBnO
225
 
Benzyl 4-aminobenzoate (225, DMA-NB74-77).90 To a solution of 4-aminobenzoic acid (3.00 
g, 21.9 mmol) in MeOH (50 mL) was added Cs2CO3 (3.92 g, 12.0 mmol).  The reaction mixture 
was stirred at room temperature for 30 min, concentrated by rotary evaporation (40 oC) and dried 
in vacuo.  The resulting cesium salt was suspended in a 3:1 solution of CH3CN (30 mL): DMF 
(10 mL) and a solution of benzyl bromide (2.73 mL, 23.0 mmol) in CH3CN (10 mL) was added 
dropwise over 2 h.  The reaction mixture was stirred at room temperature for 17 h, concentrated 
by rotary evaporation (40 oC) and the resulting crude yellow oil was dissolved in EtOAc (150 
mL).  The EtOAc solution was washed with a saturated NaHCO3 solution (1 X 50 mL), followed 
by a saturated brine solution (1 X 50 mL).  The EtOAc layer was dried with Na2SO4, 
concentrated by rotary evaporation (40 oC) and the resulting yellow oil was recrystallized from a 
10:1 solution of hexanes:EtOAc (150 mL) to afford 225 as a fluffy white solid (2.23 g, 45%): 
Mp 87-88 oC; IR (ATR) 3453, 3354, 3222, 1681, 1631, 1597, 1277, 1169, 1114, 1075 cm-1; 1H-
NMR (DMSO-d6, 300 MHz) δ 7.67 (d, 2 H, J = 8.4 Hz), 7.43-7.32 (m, 5 H), 6.57 (d, 2 H, J = 8.7 
Hz), 6.31 (s, 2 H), 5.48 (s, 2 H); 13C-NMR (DMSO-d6, 75 MHz) δ 166.1, 154.1, 137.3, 131.7 (2 
C), 128.9 (2 C), 128.3, 128.2 (2 C), 116.0, 113.1 (2 C), 65.5; MS (EI) m/z 227 (M+, 54), 182 
(17), 120 (100), 91 (94); HRMS (EI) m/z calculated for C14H13NO2 227.094629, found 
227.094483. 
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General procedure Y. Ethyl 4-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylamino)benzoate 
(227, DMA-NB74-57).  A mixture of 6-chloro-1,3-dihydropyrimidine-2,4-dione (220 mg, 1.50 
mmol) and ethyl 4-aminobenzoate (991 mg, 6.00 mmol) was heated to 155-160 oC for 3 h.  The 
solids melted during heating forming a clear solution.  After 3 h, the reaction mixture was cooled 
to room temperature, diluted with acetone (4.0 mL) and stirred for 30 min.  The remaining solid 
was isolated by vacuum filtration and washed with acetone (10 mL).  The resulting solid was 
boiled in EtOAc (30 mL) for 30 min and the mixture was cooled to room temperature.  The 
purified solid was isolated by vacuum filtration, washed with acetone (10.0 mL) and dried in 
vacuo to afford 227 as a white solid (299 mg, 72%): Mp  363-365 oC (dec.); IR (ATR) 3086, 
3014, 1716, 1683, 1647, 1485, 1407, 1260, 1127 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.64 
(s, 1 H), 10.36 (s, 1 H), 8.79 (s, 1 H), 7.92 (d, 2 H, J = 8.7 HZ), 7.26 (d, 2 H, J = 8.7 Hz), 4.98 (s, 
1 H), 4.27 (q, 2 H, J = 6.9 Hz), 1.29 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 165.2, 
164.4, 150.8, 150.6, 143.2, 130.9 (2 C), 124.2, 120.0 (2 C), 78.9, 60.5, 14.2; MS (EI) m/z 275 
(M+, 100), 247 (6), 120 (32), 69 (41), 57 (53); HRMS (EI) m/z calculated for C13H13N3O4 
275.090606, found 275.090923. 
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Benzyl 4-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-ylamino)benzoate (228, DMA-NB74-55).  
According to general procedure Y, 225 (1.39 g, 6.12 mmol) and 6-chloro-1,3-dihydropyrimidine-
2,4-dione (225 mg, 1.54 mmol) were dissolved in DMF (1.0 mL) and heated to 155-160 oC for 1 
h.  The reaction mixture was worked up according to the general procedure.  The isolated 
product was further purified by dissolving in DMSO (10 mL) and adding distilled water (20 mL) 
slowly to re-precipitate the product.  The resulting solid was isolated by vacuum filtration, boiled 
in EtOAc (10 mL) for 5 min to remove residual DMSO, re-isolated by vacuum filtration, washed 
with hexanes (15 mL) and dried in vacuo to afford 228 as a pale yellow solid (98.7 mg, 19%): 
Mp 301-303 oC (dec.); IR (ATR) 3194, 3086, 2932, 1752, 1711, 1592, 1560, 1267, 1101, 751 
cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.64 (s, 1 H), 10.37 (s, 1 H), 8.82 (s, 1 H), 7.95 (d, 2 H, 
J = 8.4 Hz), 7.46-7.37 (m, 5 H), 7.27 (d, 2 H, J = 8.4 Hz), 5.32 (s, 2 H), 4.98 (s, 1 H); 13C-NMR 
(DMSO-d6, 75 MHz) δ 165.5, 164.9, 151.3, 151.1, 143.9, 136.7, 131.3 (2 C), 129.0 (2 C), 128.6, 
128.4 (2 C), 124.3, 120.5 (2 C), 79.5, 66.4; MS (EI) m/z 337 (M+, 25), 187 (12), 146 (18), 91 
(100), 65 (17); HRMS (EI) m/z calculated for C18H15N3O4 337.106256, found 337.105811. 
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4-(2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-ylamino)benzoic acid (229, DMA-NB74-5).  
According to general procedure Y, 6-chloro-1,3-dihydropyrimidine-2,4-dione (293 mg, 2.00 
mmol) and 4-aminobenzoic acid (1.02 g, 7.50 mmol) were dissolved in DMF (1.0 mL) and 
heated to 155-160 oC for 2 h to afford 229 as a light yellow solid (352 mg, 71%, ~90% pure by 
1H-NMR).  A 50.0 mg sample was further purified by recrystallization from a 3:1 solution of 
deionized water:DMSO initially heated to 90 oC then cooled to rt.  The recrystallized solid was 
isolated by vacuum filtration and heated in distilled water for 30 min at 90 oC two times to 
remove any residual DMSO.  After cooling to room temperature the solid was isolated by 
vacuum filtration, washed with additional water (5.0 mL) and dried under high vacuum for 24 h. 
Following the recrystallization, 229 was isolated as a white powder (33.2 mg, 66% recovery 
from recrystallization): Mp >380 oC; IR (KBr) 3354, 3012, 1719, 1600, 1398, 1276 cm-1; 1H-
NMR (DMSO-d6, 300 MHz) δ 12.79 (s, 1 H), 10.63 (s, 1 H), 10.35 (s, 1 H), 8.75 (s, 1 H), 7.91 
(d, 2 H, J = 8.7 Hz), 7.26 (d, 2 H, J = 8.7), 4.97 (s, 1 H); 13C-NMR (DMSO-d6, 75 MHz) δ 167.3, 
164.9, 151.3 (2 C), 143.2, 131.3 (2 C), 125.9, 120.6 (2 C), 79.0; MS (EI) m/z 247 (M+, 53), 155 
(64), 120 (40), 84 (77), 68 (100); HRMS (EI) m/z calculated for C11H9N3O4 247.059306, found 
247.057526. 
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Benzyl-4-((2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)(ethoxycarbonyl)amino)benzoate 
(230, DMA-NB108-3).  To a solution of 228 (70.0 mg, 0.208 mmol) and Et3N (32.1 µL, 0.228 
mmol) in DMF (1.0 mL) was added diethyl pyrocarbonate (33.7 µL, 0.228 mmol) at 0 oC.  The 
reaction mixture turned a light green color and was warmed to room temperature for 48 h.  After 
48 h, the reaction mixture was filtered through a 1 in plug of SiO2 (pretreated with a 99.9:0.1 
solution of EtOAc:Et3N) and the product was flushed through with a 99.9:0.1 solution of 
EtOAc:Et3N (85 mL). The filtrate was concentrated by rotary evaporation (30 oC) and the 
resulting orange residue was diluted with EtOAc (1.0 mL) followed by hexanes (30 mL) with 
cooling to 0 oC for 30 min.  The resulting solid was isolated by vacuum filtration, washed with 
hexanes (10 mL) and dried in vacuo.  This crystallization procedure was performed twice to 
afford 230 (15.2 mg, 16% crude yield, ~85% pure by 1H-NMR).  The mother liquors from the 
previous two recrystallizations were combined, concentrated by rotary evaporation (30 oC) and 
the resulting pale yellow oil was diluted with EtOAc (1.0 mL) followed by hexanes (30 mL) at 0 
oC. The resulting solid was isolated by vacuum filtration, washed with hexanes (5.0 mL) and 
dried in vacuo to afford pure 230 as a fluffy off-white solid (2.0 mg, 2.3%): Mp 171-172 oC; IR 
(ATR) 3196, 2987, 2789, 1715, 1647, 1591, 1418, 1273, 1223, 1107, 1016 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 11.55 (s, 1 H), 11.24 (s, 1 H), 8.02 (d, 2 H, J = 8.7 Hz), 7.54 (d, 2 H, J = 
8.7 Hz), 7.48-7.38 (m, 5 H), 5.36 (s, 3 H), 4.19 (q, 2 H, J = 6.9 Hz), 1.20 (t, 3 H, J = 7.2 Hz); 
13C-NMR (DMSO-d6, 75 MHz) δ 165.3, 164.6, 152.4, 151.3, 150.7, 144.2, 136.5, 130.7 (2 C), 
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129.0 (2 C), 128.6, 128.4 (2 C), 128.3, 126.5 (2 C), 98.4, 66.8, 63.5, 14.5; MS (EI) m/z 409 (M+, 
20), 302 (7), 230 (21), 91 (100); HRMS (EI) m/z calculated for C21H19N3O6 409.127386, found 
409.127299. 
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4-((2,6-Dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)(ethoxycarbonyl)amino)benzoic acid (208, 
DMA-NB108-6).  According to general procedure X, 230 (8.80 mg, 0.0183 mmol, 85% pure) 
and 20 wt% Pd(OH)2/C (0.8 mg, 0.0015 mmol/Pd) in distilled THF (0.50 mL) were stirred under 
a H2 gas (1.0 atm) atmosphere for 6 h at room temperature.  After filtration through celite, the 
resulting white solid was triturated with a 5:1 mixture of hexanes:EtOAc (10 mL) while cooling 
to 0 oC.  The resulting white solid was isolated by vacuum filtration, washed with hexanes (3.0 
mL), and dried in vacuo to afford 208 as a white powdery solid (2.1 mg, 36%): IR (ATR) 3492, 
3187, 2987, 2818, 1702, 1599, 1413, 1284, 1027 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 13.10 
(s, 1 H), 11.57 (s, 1 H), 11.24 (s, 1 H), 7.96 (d, 2 H, J = 8.7 Hz), 7.50 (d, 2 H, J = 8.7 Hz), 5.34 
(d, 1 H, J = 1.5 Hz), 4.19 (q, 2 H, J = 7.2 Hz), 1.20 (t, 3 H, J = 7.2 Hz); MS (EI) m/z 319 (M+, 
100), 275(13), 247 (52), 137 (33), 68 (87); HRMS (EI) m/z calculated for C14H13N3O6 
319.080435, found 319.081124. 
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Ethyl 4-ureidobenzoate (231, DMA-NB74-59).111 A solution of ethyl 4-aminobenzoate (3.00 g, 
17.8 mmol) in glacial acetic acid (30 mL) was stirred at room temperature for 30 min at which 
time the solution turned homogenous.  To this solution was added a solution of KOCN (2.17 g, 
26.7 mmol) in deionized water (20 mL).  The reaction mixture was heated to 70 oC for 14 h, 
cooled to room temperature and concentrated by rotary evaporation (80 oC).  The resulting clear 
oil was crystallized by stirring in deionized water (60 mL) at 0 oC for 30 min.  The resulting 
white solid was isolated by vacuum filtration, washed with water (40 mL) and recrystallized 
from a 2:1 solution of EtOAc:hexanes (65 mL) to afford 231 as a white crystalline solid (2.93 g, 
79%): Mp 180-181 oC; IR (ATR) 3405, 3358, 3181, 1705, 1675, 1586, 1528, 1286, 1174, 1019 
cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 8.94 (s, 1 H), 7.81 (d, 2 H, J = 8.7 Hz), 7.51 (d, 2 H, J = 
8.4 Hz), 6.04 (s, 2 H), 4.24 (q, 2 H, J = 7.2 Hz), 1.28 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 
75 MHz) δ 166.0, 156.0, 145.6, 130.7 (2 C), 122.4, 117.2 (2 C), 60.6, 14.7; HRMS (TOF MS 
ES+) m/z calculated for C10H12N2O3Na (M+Na) 231.0746, found 231.0762. 
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Ethyl 4-(3-(2-cyanoacetyl)ureido)benzoate (232, DMA-NB74-40).  A suspension of 231 (312 
mg, 1.50 mmol) and cyanoacetic acid (129 mg, 1.50 mmol) in Ac2O (0.50 mL) was heated in a 
microwave reactor for 30 min at 80 oC.  The heterogeneous reaction mixture was cooled to room 
temperature, diluted with a 3:1 mixture of EtOAc:hexanes (3.0 mL) and stirred vigorously for 20 
min.  The resulting solids were isolated by vacuum filtration, washed with a 1:1 mixture of 
EtOAc:hexanes (10 mL) and dried in vacuo to afford 232 as a white crystalline solid (299 mg, 
72%): Mp 232-233 oC; IR (ATR) 3248, 2987, 1713, 1694, 1685, 1593, 1507, 1273, 1174, 701 
cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.95 (s, 1 H), 10.23 (s, 1 H), 7.92 (d, 2 H, J = 8.7 Hz), 
7.67 (d, 2 H, J = 8.7 Hz), 4.28 (q, 2 H, J = 6.9 Hz), 4.06 (s, 2 H), 1.30 (t, 3 H, J = 6.9 Hz); 13C-
NMR (DMSO-d6, 75 MHz) δ 166.3, 165.7, 150.4, 142.3, 130.8 (2 C), 125.3, 119.6 (2 C), 115.3, 
61.0, 27.6, 14.7; MS (EI) m/z 275 (M+, 100), 57 (6); HRMS (EI) m/z calculated for C13H13N3O4 
275.090606, found 275.090412. 
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Ethyl 4-(6-amino-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoate (233, DMA-NB74-43).  
A suspension of 232 (663 mg, 2.41 mmol) and TMSCl (0.047 mL, 0.361 mmol) in HMDS (7.2 
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mL) was heated to reflux for 17 h.  After 17 h, the reaction mixture was cooled to room 
temperature and the solvent was removed by rotary evaporation (70 oC).  The crude orange 
residue was cooled to 0 oC and hydrolyzed with a saturated NaHCO3 solution (20 mL) with 
stirring for 30 min while warming to room temperature.  The resulting precipitate was isolated by 
vacuum filtration, washed with distilled water (30 mL), dried in vacuo and recrystallized from a 
1:1 solution of EtOAc:hexanes (50 mL) to afford 233 as a pale orange solid (512 mg, 77%): Mp 
268-269 oC (dec.); IR (ATR) 3414, 3319, 3085, 2963, 1713, 1698, 1627, 1575, 1366, 1284, 1101 
cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 10.54 (s, 1 H), 8.07 (d, 2 H, J = 8.4 Hz), 7.49 (d, 2 H, J 
= 8.4 Hz), 6.22 (s, 2 H), 4.66 (s, 1 H), 4.36 (q, 2 H, J = 7.2 Hz), 1.33 (t, 3 H, J = 6.9 Hz); 13C-
NMR (DMSO-d6, 75 MHz) δ 165.7, 163.2, 155.7, 151.2, 139.0, 131.0 (2 C), 130.9, 130.6 (2 C), 
75.6, 61.5, 14.6; MS (EI) m/z 275 (M+, 74), 232 (32), 165 (39), 146 (44), 120 (100), 65 (33); 
HRMS (EI) m/z calculated for C13H13N3O4 275.090606, found 275.090591. 
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4-(6-Amino-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoic acid (234, DMA-NB74-63). 
According to general procedure U, 233 (400 mg, 1.45 mmol) and an aqueous solution of LiOH 
(10.0 mL, 2.0 M) were combined at room temperature for 1.5 h to afford 234 as a light orange 
solid: (341 mg, 95%): Mp >380 oC; IR (ATR) 3435, 3333, 3200, 1694, 1620, 1605, 1473, 1263, 
1027 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 13.16 (s, 1 H), 10.53 (s, 1 H), 8.03 (d, 2 H, J = 8.4 
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Hz), 7.44 (d, 2 H, J = 8.1 Hz), 6.21 (s, 2 H), 4.65 (s, 1 H); 13C-NMR (DMSO-d6, 75 MHz) δ 
166.8, 162.7, 155.3, 150.8, 138.1, 131.6, 130.7 (2 C), 129.9 (2 C), 75.1; MS (EI) m/z 247 (M+, 
57), 204 (28), 163 (31), 137 (33), 120 (33), 83 (44), 68 (71), 53 (100); HRMS (EI) m/z calculated 
for C11H9N3O4 247.059306, found 247.059011. 
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Benzyl 4-(6-amino-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoate (235, DMA-NB74-
69). To a suspension of 234 (150 mg, 0.607 mmol) in MeOH (6.0 mL) was added Cs2CO3 (108.6 
mg, 0.333 mmol).  The suspension was stirred at room temperature for 30 min, concentrated by 
rotary evaporation (40 oC) and dried in vacuo.  The resulting off white cesium salt was dissolved 
in DMSO (3.0 mL) and benzyl bromide (90.6 µL, 0.758 mmol) was added.  The reaction mixture 
was stirred at room temperature for 2 h and then distilled water (15 mL) was added with cooling 
to 0 oC for 30 min.  The precipitate was isolated by vacuum filtration, washed with distilled 
water (15 mL) and dried in vacuo.  The resulting solid was boiled in a 1:1 mixture of 
EtOAc:hexanes (30 mL) for 15 min, isolated by vacuum filtration, washed with hexanes (30 mL) 
and dried in vacuo to afford 235 as a light orange solid (145 mg, 71%): Mp 256-257 oC (dec.); 
IR (ATR) 3424, 3322, 3239, 3086, 2762, 1698, 1627, 1603, 1575, 1474, 1267, 1093 cm-1; 1H-
NMR (DMSO-d6, 300 MHz) δ 10.54 (s, 1 H), 8.09 (d, 2 H, J = 8.4 Hz), 7.50-7.35 (m, 7 H), 6.21 
(s, 2 H), 5.39 (s, 2 H), 4.65 (d, 1 H, J = 1.8 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 165.5, 163.2, 
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155.7, 151.2, 139.2, 136.5, 131.1 (2 C), 130.7 (3 C), 129.0 (2 C), 128.7, 128.5 (2 C), 75.6, 66.7; 
MS (EI) m/z 337 (M+, 24),187 (13), 146 (19), 91 (100), 65 (18); HRMS (EI) m/z calculated for 
C18H15N3O4 337.106256, found 337.107044. 
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Benzyl-4-(6-(ethoxycarbonylamino)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoate    
(236).  To a suspension of 235 (55.0 mg, 0.163 mmol) in dry THF (0.50 mL) was added a 
solution of LiHMDS (42.2 mg, 0.245 mmol) in THF (0.75 mL) at 0 oC.  The reaction mixture 
was stirred at 0 oC for 30 min upon which time the suspension cleared and ethyl chloroformate 
(17.1 µL, 0.179 mmol) was added.  The reaction mixture was slowly warmed to room 
temperature and stirred for 5 h.  The product was isolated by column chromatography on SiO2  
(EtOAc; Rf = 0.63) and recrystallized from a 1:5 mixture of EtOAc:hexanes (15 mL) to afford 
236 as an off white solid (13.1 mg, 20%, ~80% pure by 1H-NMR). This product was used crude 
for the next step: 1H-NMR (DMSO-d6, 300 MHz) δ 11.43 (s, 1 H), 9.06 (s, 1 H), 8.04 (d, 2 H, J 
= 8.1 Hz), 7.48-7.34 (m, 7 H), 5.88 (s, 1 H), 5.38 (s, 2 H), 3.81 (q, 2 H, J = 6.9 Hz), 1.05 (t, 3 H, 
J = 6.9 Hz). 
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4-(6-(Ethoxycarbonylamino)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoic acid (209).  
According to general procedure X, 236 (9.0 mg, 0.0176 mmol, 80% pure) and 20 wt% 
Pd(OH)2/C (0.7 mg, 0.0013 mmol/Pd) in distilled THF (0.50 mL) were stirred under a H2 
atmosphere (1.0 atm) for 10 h at room temperature.  After filtration through celite, the resulting 
white solid was triturated with a 5:1 mixture of hexanes:EtOAc (10 mL) while cooling to 0 oC.  
The resulting white solid was isolated by vacuum filtration, washed with hexanes (3.0 mL), and 
dried in vacuo to afford 209 as a white solid (3.4 mg, 53%, ~87% pure by 1H-NMR): Mp 289-
290 oC (dec.); IR (ATR) 3399, 3214, 2987, 2791, 1755, 1705, 1702, 1639, 1610, 1522, 1377, 
1204, 1036 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 13.19 (s, 1 H), 11.42 (s, 1 H), 9.04 (s, 1 H), 
7.99 (d, 2 H, J = 8.4 Hz), 7.41 (d, 2 H, J = 8.1 Hz), 5.88 (d, 1 H, J = 1.8 Hz), 3.97 (q, 2 H, J = 6.9 
Hz), 1.06 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 175 MHz) δ 166.8, 163.1, 152.5, 150.5, 
147.4, 138.3, 131.2, 130.2 (2 C), 129.9 (2 C), 92.7, 61.5, 14.1; MS (EI) m/z 319 (M+, 29), 273 
(88), 230 (93), 188 (82), 68 (73), 53 (100); HRMS (EI) m/z calculated for C14H13N3O6 
319.080435, found 319.079582. 
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Sodium 3-(4-(ethoxycarbonyl)phenyl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-olate (237).  
A sodium ethoxide solution was freshly prepared by dissolving Na (280 mg, 12.2 mmol) in 
distilled EtOH (10 mL) under a nitrogen atmosphere.  This solution was cooled to 0 oC and then 
231 (1.00 g, 4.80 mmol) was added.  The heterogeneous solution was stirred at room temperature 
for 30 min and upon clearing, diethyl malonate (0.729 mL, 4.80 mmol) was added.  The 
homogenous reaction mixture was refluxed for 13 h, a white precipitate formed and the reaction 
mixture was cooled to room temperature.  The reaction mixture was diluted with EtOH (5.0 mL) 
and acidified to a pH = 6.0-7.0 with a concentrated HCl solution.  The solvent was removed by 
rotary evaporation (60 oC) and the product was dissolved in boiling EtOH (100 mL).  The 
remaining inorganic solids were removed by vacuum filtration and the filtrate was concentrated 
by rotary evaporation (40 oC).  The resulting clear oil was crystallized by boiling in acetone (75 
mL) for 15 min and the resulting solid was isolated by vacuum filtration, washed with acetone 
(50 mL) and dried in vacuo to afford 237 as a white solid (743 mg, 49%): 1H-NMR (DMSO-d6, 
300 MHz) δ 9.30 (s, 1 H), 7.91 (d, 2 H, J = 8.4 Hz), 7.22 (d, 2 H, J = 8.4 Hz), 4.32 (q, 2 H, J = 
7.2 Hz), 3.96 (d, 1 H, J = 2.1 Hz), 1.31 (t, 3 H, J = 7.2 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 
166.0, 164.5, 164.3, 152.9, 143.1, 130.7 (2 C), 129.2 (2 C), 128.3, 75.4, 61.1, 14.7. 
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Ethyl 4-(2,4,6-trioxotetrahydropyrimidin-1(2H)-yl)benzoate (238, DMA-NB74-61).112  To a 
solution of 237 (250 mg, 0.838 mmol) in distilled water (3.0 mL) was slowly added an aqueous 
HCl solution (1.0 M, pH = 1.5) dropwise over a 15 min period at 0 oC.  The reaction mixture was 
stirred at 0 oC for 30 min.  The resulting precipitate was isolated by vacuum filtration, washed 
with deionized water (10 mL) and dried in vacuo to afford 238 as a white solid (184 mg, 79%): 
Mp 224-225 oC; IR (ATR) 3252, 3086, 2987, 1702, 1687, 1411, 1275, 1100 cm-1; 1H-NMR 
(DMSO-d6, 300 MHz) δ 11.58 (s, 1 H), 8.05 (d, 2 H, J = 8.4 Hz), 7.40 (d, 2 H, J = 8.1 Hz), 4.34 
(q, 2 H, J = 7.2 Hz), 3.74 (s, 2 H), 1.33 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 
167.6 (2 C), 166.2, 152.3, 140.3, 130.8, 130.7 (2 C), 130.5 (2 C), 61.9, 15.1 (1 C in DMSO 
peak); MS (EI) m/z 276 (M+, 23), 248 (24), 231 (55), 163 (37), 146 (100), 84 (53); HRMS (EI) 
m/z calculated for C13H12N2O5 276.074622, found 276.074522. 
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4-(2,4,6-Trioxotetrahydropyrimidin-1(2H)-yl)benzoic acid (239, DMA-NB74-62). According 
to general procedure U, 237 (225 mg, 0.641 mmol) and an aqueous solution of LiOH (2.0 mL, 
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2.0 M) were combined at room temperature for 2 h to afford 239 as a white crystalline solid (120 
mg, 75%): Mp 303-304 oC (dec.); IR (ATR) 3390, 3219, 3086, 1716, 1690, 1685, 1606, 1351, 
1204, 1114 cm-1; 1H-NMR (DMSO-d6, 300 MHz) δ 13.11 (s, 1 H), 11.55 (s, 1 H), 8.01 (d, 2 H, J 
= 8.1 Hz), 7.35 (d, 2 H, J = 8.1 Hz), 3.73 (s, 2 H); 13C-NMR (DMSO-d6, 75 MHz) δ 167.2 (2 C), 
167.1, 151.8, 139.5, 131.2, 130.3 (2 C), 129.8 (2 C), (1 C in DMSO peak); MS (EI) m/z 248 (M+, 
45), 220 (15), 163 (100), 146 (70), 90 (23); HRMS (EI) m/z calculated for C11H8N2O5 
248.043322, found 248.042989. 
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Ethyl 4-(5-(ethylcarbamoyl)-6-hydroxy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoate 
(240, DMA-NB74-96).  To a solution of 238 (60.0 mg, 0.217 mmol) in acetonitrile (1.5 mL) was 
added Et3N (46.3 µL, 0.326 mmol) followed by ethanisocyanate (18.8 µL, 0.239 mmol).  The 
reaction mixture was stirred at room temperature for 5 h, cooled to 0 oC and acidified with an 
aqueous HCl solution (1.0 M, pH 2) over a 10 min.  The product precipitated and the mixture 
was stirred at 0 oC for an additional 30 min.  The precipitated product was isolated by vacuum 
filtration, washed with deionized water (5.0 mL), dried in vacuo and recrystallized from a 3:1 
mixture of hexanes:EtOAc (10 mL) to afford 240 as a fluffy white solid (33.8 mg, 45%): Mp 
241-242 oC; IR (ATR) 3209, 3086, 3002, 2829, 1718, 1709, 1685, 1592, 1446, 1282, 1096 cm-1; 
1H-NMR (DMSO-d6, 300 MHz) δ 17.43 (s, 1 H), 11.83 (s, 1 H), 9.69 (s, 1 H), 8.03 (d, 2 H, J = 
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8.4 Hz), 7.46 (d, 2 H, J = 8.4 Hz), 4.34 (q, 2 H, J = 7.2 Hz), 3.41-3.32 (m, 2 H), 1.33 (t, 3 H, J = 
6.9 Hz), 1.13 (t, 3 H, J = 7.2 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 170.3, 165.7 (3 C), 149.4, 
139.6, 130.3 (2 C), 130.2, 130.0 (2 C), 79.7, 61.4, 35.0, 14.9, 14.6; MS (EI) m/z 347 (M+, 100), 
274 (12), 257 (39), 231 (12); HRMS (EI) m/z calculated for C16H17N3O6 347.111736, found 
347.110260. 
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4-(5-(Ethylcarbamoyl)-6-hydroxy-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)benzoic-acid 
(210, DMA-NB108-1).  According to general procedure U, 240 (23.8 mg, 0.0685 mmol) and an 
aqueous LiOH solution (0.50 mL, 2.0 M) were combined at room temperature for 2 h to afford 
210 as a pale yellow crystalline solid (10.1 mg, 46%): Mp 296-297 oC (dec.); IR (ATR) 3576, 
3496, 3151, 2993, 2851, 1675, 1575, 1457, 1413, 1282, 1169, 1094 cm-1; 1H-NMR (DMSO-d6, 
300 MHz) δ 17.42 (s, 1 H), 13.13 (s, 1 H), 11.82 (s, 1 H), 9.69 (s, 1 H), 8.01 (d, 2 H, J = 8.1 Hz), 
7.43 (d, 2 H, J = 8.4 Hz), 3.39 (m, 2 H), 1.13 (t, 3 H, J = 7.2 Hz); 13C-NMR (DMSO-d6, 75 
MHz) δ 170.3, 167.2 (3 C), 149.4, 139.2, 131.1, 130.1 (4 C), 79.7, 35.0, 14.9; MS (EI) m/z 319 
(M+, 74), 275 (21), 248 (15), 163 (100), 146 (83), 137 (46), 69 (44), 57 (45); HRMS (EI) m/z 
calculated for C14H13N3O6 319.080435, found 319.079829. 
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4.4.2 Second generation analogues of SID 861574:  Synthesis of N1,N3-differentially-
substituted-5-methylene-6-hydroxy uracils. 
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Phenylmethyl 4-(aminocarbonylamino)benzoate (242).  A solution of 225 (1.25 g, 5.50 mmol) 
in AcOH (12.5 mL) was stirred at room temperature for 5 min until all of the amine dissolved.  A 
solution of KOCN (669 mg, 8.25 mmol) in distilled water (6.25 mL) was then added at room 
temperature and the resulting clear homogenous solution was warmed to 70 °C for 15 h.  The 
resulting suspension was cooled to room temperature, diluted with water (10 mL) and further 
cooled to 0 °C for 30 min.  The precipitate was isolated by vacuum filtration, washed with water 
(30 mL), dried in vacuo and recrystallized by dissolving in boiling EtOAc (50 mL) and slowly 
adding hexanes (50 mL) followed by cooling to 0 °C for 30 min.  The product was isolated by 
vacuum filtration, washed with hexanes (30 mL) and dried in vacuo to afford 242 as a white 
crystalline solid (1.15 g, 78%):  Mp 196.5-197.5 oC; IR (ATR) 3440, 3308, 3202, 1705, 1655, 
1580, 1530, 1265, 1109 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 8.98 (s, 1 H), 7.86 (d, 2 H, J = 
8.7 Hz), 7.53 (d, 2 H, J = 8.7 Hz), 7.46-7.34 (m, 5 H), 6.05 (s, 2 H), 5.30 (s, 2 H); 13C NMR 
(DMSO-d6, 75 MHz) δ 165.8, 156.0, 145.9, 136.9, 130.9 (2 C), 129.0 (2 C), 128.5, 128.4 (2 C), 
122.0, 117.3 (2 C), 66.1; MS (EI) m/z 270 (M+, 9), 163 (23), 120 (49), 91 (100), 65 (73); HRMS 
(EI) m/z calculated for C15H14N2O3 270.1004, found 270.1008. 
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Benzyl 4-(3-(ethoxycarbonyl)ureido)benzoate (243, DMA-NB139-67).  To a solution of 242 
(550 mg, 2.03 mmol) in THF (20 mL) was added, at -78 oC, a solution of LiHMDS (418 mg, 
2.42 mmol, 0.48 M) in THF, dropwise over 5 min.  The mixture was stirred at -78 oC for 30 min 
and then ethyl cyanoformate (0.219 mL, 2.24 mmol) was added.  The reaction mixture was 
slowly warmed to 0 oC over 5 h and was quenched by the addition of a saturated NH4Cl solution 
(10 mL) with stirring for 20 min.  The mixture was diluted with EtOAc (50 mL) and washed 
with a saturated NaHCO3 solution (1 X 50 mL).  The EtOAc layer was dried (Na2SO4), 
concentrated in vacuo and the yellow residue was chromatographed on SiO2 (2:1 
hexanes:EtOAc).  The isolated product was recrystallized from a 10:1 solution of hexane:EtOAc 
(40 mL) to afford 243 as a light yellow crystalline solid (438 mg, 63%): Mp 156-157 oC; IR 
(ATR) 3239, 3133, 2969, 1726, 1694, 1593, 1549, 1505, 1273, 1241, 1090 cm-1; 1H NMR 
(DMSO-d6, 300 MHz) δ 10.47 (s, 1 H), 10.12 (s, 1 H), 7.95 (d, 2 H, J = 8.7 Hz), 7.66 (d, 2 H, J = 
9.0 Hz), 7.47-7.34 (m, 5 H), 5.32 (s, 2 H), 4.18 (q, 2 H, J = 7.2 Hz), 1.24 (t, 3 H, J = 7.2 Hz); 13C 
NMR (DMSO-d6, 75 MHz) δ 165.0, 154.4, 150.2, 142.4, 136.2, 130.4 (2 C), 128.4 (2 C), 128.0, 
127.9 (2 C), 124.1, 118.8 (2 C), 65.9, 61.7, 14.1; MS (EI) m/z 342 (M+, 26), 235 (42), 146 (42), 
91 (100); HRMS (EI) m/z calculated for C18H18N2O5 342.1216, found 342.1202. 
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Phenylmethyl 4-(2,4,6-trioxo-1,3,5-trihydropyrimidinyl)benzoate (245, DMA-NB166-38).  
To a solution of malonyl dichloride (804 µL, 8.55 mmol) in distilled THF (55.0 mL) was added 
242 (1.10 g, 4.07 mmol) at room temperature.  The homogeneous light yellow reaction mixture 
was stirred for 5 min and then DIPEA (744 µL, 4.27 mmol) was added.  After 2 h, the reaction 
mixture was diluted with a saturated brine solution (150 mL) and extracted with DCM (2 X 150 
mL).  The extracts were combined, filtered through a 1 in plug of SiO2, washed through the plug 
with excess EtOAc (250 mL), dried (Na2SO4) and concentrated in vacuo.  The resulting orange 
solids were dissolved in boiling EtOAc (25 mL) and hexanes (150 mL) were slowly added to 
precipitate the product.  After cooling to 0 °C, the solid was isolated by vacuum filtration, 
washed with hexanes (50 mL) and dried in vacuo to afford 245 as a yellow/orange crystalline 
solid (532 mg, 39%): Mp 220.5-222.0 °C; IR (ATR) 3194, 3101, 2881, 1694, 1423, 1360, 1273, 
1114 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 11.60 (s, 1 H), 8.10 (d, 2 H, J = 7.8 Hz), 7.49-7.35 
(m, 7 H), 5.39 (s, 2 H), 3.75 (s, 2 H); 13C NMR (DMSO-d6, 175 MHz) δ 167.1 (2 C), 165.5, 
151.8, 140.0, 136.5, 130.3 (2 C), 130.1 (2 C), 130.0, 129.0 (2 C), 128.6, 128.4 (2 C), 66.8, 40.8; 
MS (EI) m/z 338 (M+, 8), 231 (27), 146 (23), 91 (100), 65 (44); HRMS (EI) m/z calculated for 
C18H14N2O5 338.0903, found 338.0902. 
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Phenylmethyl 4-(4-ethoxycarbonyloxy-2,6-dioxo-1,3-dihydropyrimidinyl)benzoate (246).  
To a homogeneous light orange solution of 245 (150 mg, 0.443 mmol) in THF (5.0 mL) was 
added ethyl chloroformate (48.1 µL, 0.488 mmol) followed by Et3N (68.5 µL, 0.488 mmol) at 0 
°C.  The reaction mixture turned heterogeneous and dark orange upon the addition of Et3N, was 
warmed to room temperature over 1 h, stirred at room temperature for 2 h, diluted with distilled 
water (5.0 mL) and acidified to a pH of 3-4 with an HCl solution (1.0 M, ~ 4 drops).   The 
acidified mixture was then diluted with DCM (50 mL) and washed with a saturated brine 
solution (2 X 50 mL).  The DCM layer was dried (Na2SO4), vacuum filtered through a 1 in plug 
of SiO2, washed through the plug with 3:1 EtOAc:hexanes (250 mL) and concentrated by rotary 
evaporation (30 °C).  The residue was triturated with a 3:1 solution of DCM:hexanes (75 mL), 
cooled to 0 °C for 15 h and the remaining solids were isolated by vacuum filtration, washed with 
hexanes (30 mL) and dried in vacuo to afford 246 as a light yellow solid (117 mg, 64%): Mp 
209.5-211.0 °C (dec); IR (ATR) 3183, 3096, 2969, 2831, 1787, 1713, 1644, 1260, 1196, 1103, 
1016 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 12.43 (s, 1 H), 8.08 (d, 2 H, J = 8.4 Hz), 7.50 – 
7.36 (m, 7 H), 5.82 (s, 1 H), 5.39 (s, 2 H), 4.33 (q, 2 H, J = 7.2 Hz), 1.31 (t, 3 H, J = 7.2 Hz); 13C 
NMR (DMSO-d6, 75 MHz) δ 165.1, 163.0, 154.4, 149.9, 149.5, 139.7, 136.1, 129.9 (2 C), 129.7 
(2 C), 129.5, 128.6 (2 C), 128.2, 127.9 (2 C), 89.5, 66.4 (2 C), 13.9; MS (EI) m/z 410 (M+, 100), 
 210 
338 (67), 303 (24), 146 (9), 91 (26); HRMS (EI) m/z calculated for C21H18N2O7 410.1114, found 
410.1113. 
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4-(4-Ethoxycarbonyloxy-2,6-dioxo-1,3-dihydropyrimidinyl)benzoic acid (247).  To a solution 
of 246 (50.0 mg, 0.122 mmol) in distilled THF (3.0 mL) was added 20 wt% Pd(OH)2/C (17.1 
mg, 0.0240 mmol) and the reaction mixture was placed under a hydrogen (1 atm) atmosphere at 
room temperature for 2 h.  At this time, the reaction mixture was directly filtered through a 1 in 
plug of SiO2, washed through with additional EtOAc (35 mL) and dried by rotary evaporation 
(25 °C).  The resulting light yellow solid was triturated with a 2:1 solution of hexanes:EtOAc (25 
mL), isolated by vacuum filtration, washed with hexanes (10 mL), triturated a second time with 
acetone (1.0 mL, 0 °C, 5 min), filtered and dried in vacuo to afford 247 as a white powdery solid 
(23.7 mg, 61%): Mp 210-211 °C (dec); IR (ATR) 3075, 2969, 2825, 2674, 1787, 1694, 1649, 
1423, 1260, 1185, 1016 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 13.12 (s, 1 H), 12.42 (s, 1 H), 
8.01 (d, 2 H, J = 8.1 Hz), 7.42 (d, 2 H, J = 8.1 Hz), 5.81 (s, 1 H), 4.33 (q , 2 H, J = 7.2 Hz), 1.32 
(t, 3 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 75 MHz) δ 167.2, 163.5, 154.9, 150.4, 150.0, 139.6, 
131.1, 130.3 (2 C), 129.8 (2 C), 89.8, 66.8, 14.3; MS (EI) m/z 320 (M+, 11), 248 (43), 163 (100), 
146 (71); HRMS (EI) m/z calculated for C14H12N2O7 320.0645, found 320.0650. 
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Ethyl 2-[N-(N-{4-[benzyloxycarbonyl]phenyl}carbamoyl)carbamoyl]acetate (251, DMA-
NB205-51).  To a solution of ethyl malonyl chloride (186 µL, 1.20 mmol) in THF (7.0 mL) was 
added 242 (270 mg, 1.00 mmol) in one portion at room temperature.  The resulting dark orange 
suspension cleared after 5 h. After 20 h, the reaction mixture was directly filtered through a 1 in 
plug of SiO2 and flushed through with EtOAc (75 mL).  The filtrate was concentrated in vacuo 
and the resulting orange solids were dissolved in boiling EtOAc (20 mL) to which hexanes (80 
mL) was slowly added to precipitate the product.  After slowly cooling to room temperature and 
then to 0 °C for 30 min, the precipitate was isolated by vacuum filtration, washed with hexanes 
(30 mL) and dried in vacuo to afford methyl 251 as light yellow crystalline needles (300 mg, 
78%): Mp 136.5-137.5 °C; IR (ATR) 3233, 3120, 2982, 1750, 1694, 1599, 1554, 1506, 1273, 
1247, 1154, 1096, 1021 cm-1; 1H NMR (CDCl3, 300 MHz) δ 10.62 (s, 1 H), 10.00 (s, 1 H), 8.06 
(d, 2 H, J = 8.7 Hz), 7.60 (d, 2 H, J = 8.7 Hz), 7.46-7.35 (m, 5 H), 5.36 (s, 2 H), 4.25 (q, 2 H, J = 
7.2 Hz), 3.52 (s, 2 H), 1.31 (t, 3 H, J = 7.2 Hz); 13C NMR (CDCl3, 75 MHz) δ 167.8, 167.4, 
166.1, 150.8, 141.5, 136.2, 131.2 (2 C), 128.8 (2 C), 128.4 (3 C), 126.1, 119.6 (2 C), 66.9, 62.5, 
42.5, 14.2; MS (EI) m/z 384 (M+, 57), 277 (27), 146 (100), 91 (80); HRMS (EI) m/z calculated 
for C20H20N2O6 384.1321, found 384.1323. 
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Phenylmethyl 4-[5-(ethoxycarbonyl)-4-hydroxy-2,6-dioxo-1,3-dihydropyrimidinyl]benzoate 
(248, DMA-NB205-60).  To a pale yellow solution of 251 (150 mg, 0.390 mmol) in DCM (8.0 
mL) was added Et3N (114 µL, 0.820 mmol) followed by CDI (94.8 mg, 0.585 mmol) at room 
temperature.  The reaction mixture was stirred for 36 h, diluted with deionized water (5.0 mL), 
acidified to a pH of 1.5 with an HCl solution (1.0 M) and then diluted with DCM (30 mL).  The 
aqueous layer was removed and the DCM layer was washed with an HCl solution (30 ml 
deionized water, 2 drops of 1.0 M HCl), dried (Na2SO4) and concentrated by rotary evaporation 
(20 °C).  The resulting tan solids were dissolved in EtOAc (20 mL) and hexanes (60 mL) were 
added to precipitate the product.  After cooling to 0 °C for 30 min, the resulting solid was 
isolated by vacuum filtration, washed with hexanes (20 mL) and dried in vacuo to afford 248 as a 
light tan solid (106 mg, 66%): Mp 214-216 °C (dec); IR (ATR) 3164, 2982, 1737, 1681, 1605, 
1517, 1415, 1277, 1150, 1105, 1005 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 12.50 (s, 1 H), 8.07 
(d, 2 H, J = 8.4 Hz), 7.50-7.36 (m, 7 H), 5.39 (s, 2 H), 4.27 (q, 2 H, J = 7.2 Hz), 1.24 (t, 3 H, J = 
7.2 Hz); 13C NMR (DMSO-d6, 75 MHz) δ 171.7, 168.5, 165.6, 160.1, 149.3, 140.4, 136.6, 130.4 
(2 C), 130.2 (2 C), 129.8, 129.0 (2 C), 128.6, 128.4 (2 C), 83.1, 66.8, 61.9, 14.5; MS (EI) m/z 
410 (M+, 2), 364 (57), 257 (88), 231 (57), 146 (78), 91 (100); HRMS (EI) m/z calculated for 
C21H18N2O7 410.1114, found 410.1100. 
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4-[5-(Ethoxycarbonyl)-4-hydroxy-2,6-dioxo-1,3-dihydropyrimidinyl]benzoic-acid          
(249, DMA-NB205-71).  To a solution of 248 (50.0 mg, 0.122 mmol) in THF (3.0 mL) was 
added Pd(OH)2/C (17.0 mg, 0.0244 mmol) at room temperature.  The resulting dark black 
suspension was stirred under hydrogen (1 atm) for 3 h and was then filtered through a plug of 
SiO2 (1 in, 5 3/4 in disposable glass pipette) with EtOAc (40 mL).  The filtrate was concentrated 
by rotary evaporation (25 °C) and the resulting solids were dried in vacuo to afford 249 as a light 
tan powder (32.3 mg, 83%): Mp 241-242 °C (dec); IR (ATR) 3233, 3101, 2974, 2894, 1750, 
1718, 1694, 1592, 1474, 1424, 1379, 1286, 1228, 1165 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 
13.09 (s, 1 H), 12.41 (s, 1 H), 8.00 (d, 2 H, J = 8.4 Hz), 7.37 (d, 2 H, J = 8.4 Hz), 4.27 (q , 2 H, J 
= 6.9 Hz), 1.24 (t, 3 H, J = 6.9 Hz); 13C NMR (DMSO-d6, 75 MHz) δ 171.7, 168.4, 167.3, 160.2, 
149.4, 139.9, 130.9, 130.2 (2 C), 130.1 (2 C), 83.2, 61.9, 14.5; MS (EI) m/z 320 (M+, 4.5), 303 
(42), 274 (20), 163 (57), 146 (63), 91 (76), 69 (80), 57 (100); HRMS (EI) m/z calculated for 
C14H12N2O7 320.0645, found 320.0633. 
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Benzyl 4-(3-(3-methoxy-3-oxopropanoyl)ureido)benzoate (253).  To a solution of methyl 
malonyl chloride (162 µL, 1.51 mmol) in THF (8.0 mL) was added 242 (370 mg, 1.37 mmol) in 
one portion at room temperature.  The resulting light brown suspension cleared after 5 h at room 
temperature and a precipitate reformed after 20 h.  The reaction mixture was then diluted with 
EtOAc (10 mL), filtered through a 1 in plug of SiO2, flushed through with EtOAc (100 mL) and 
concentrated in vacuo.  The resulting solids were dissolved in boiling EtOAc (20 mL) and 
hexanes (80 mL) was slowly added to precipitate the product.  After slowly cooling to room 
temperature and then to 0 °C for 30 min, the precipitate was isolated by vacuum filtration, 
washed with hexanes (50 mL) and dried in vacuo to afford 253 as a tan solid (467 mg, 92%): Mp 
163.5-164.5 °C; IR (ATR) 3233, 3144, 3000, 1756, 1731, 1726, 1700, 1599, 1411, 1265, 1236, 
1154 cm-1; 1H NMR (CDCl3, 300 MHz) δ 10.60 (s, 1 H), 9.91 (s, 1 H), 8.06 (d, 2 H, J = 8.4 Hz), 
7.60 (d, 2 H, J = 8.4 Hz), 7.47-7.35 (m, 5 H), 5.36 (s, 2 H), 3.81 (s, 3 H), 3.54 (s, 2 H); 13C NMR 
(CDCl3, 75 MHz) δ 167.6, 167.4, 165.9, 150.8, 141.2, 136.0, 131.0 (2 C), 128.6 (2 C), 128.3, 
128.2 (2 C), 125.9, 119.5 (2 C), 66.7, 53.0, 42.3; MS (EI) m/z 370 (M+, 15), 263 (13), 146 (77), 
91 (100); HRMS (EI) m/z calculated for C19H18N2O6 370.1165, found 370.1174. 
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Sodium 4-methylbenzenesulfonothioate (296).94  To a suspension of para-toluenesulfinic acid 
sodium salt (5.00 g, 28.1 mmol) in anhydrous pyridine (30.0 mL) was added sulfur (900 mg, 
28.1 mmol) at room temperature.  The initially pale yellow suspension began to clear and a 
heavy white precipitate formed after 16 h.  After 16 h, the reaction mixture was diluted with 
ether (30 mL) and was stirred at room temperature for 5 min before cooling to 0 oC for 30 min.  
The white precipitate was then isolated by vacuum filtration, washed with ether (4 X 25 mL) and 
dried in vacuo to afford 296 (5.43 g, 92%):  1H-NMR (CDCl3, 300 MHz) δ 7.65 (d, 2 H, J = 7.8 
Hz), 7.15 (d, 2 H, J = 7.5 Hz), 2.29 (s, 3 H); 13C-NMR (CDCl3, 75 MHz) δ 152.9, 138.9, 128.6 
(2 C), 124.5 (2 C), 21.3. 
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S,S'-propane-1,3-diyl bis(4-methylbenzenesulfonothioate) (254).94 To a suspension of KI 
(19.1 mg, 0.115 mmol) and 296 (5.00 g, 23.8 mmol) in 95% ethanol (20 mL) was added freshly 
distilled 1,3-dibromopropane (1.17 mL, 11.5 mmol) at room temperature.  The heterogeneous 
reaction mixture was heated to reflux for 5 h, cooled to room temperature and diluted with 
deionized water (30 mL) followed by DCM (75 mL). The DCM layer was removed, washed with 
a saturated brine solution (2 X 50 mL), dried (Na2SO4) for 30 min and concentrated by rotary 
evaporation (40 oC).  The resulting clear oil was dissolved in DCM (2.0 mL) for chromatography 
on SiO2 (gradient elution 1:1 hexanes:DCM -> DCM).  The isolated product fractions were 
combined, concentrated by rotary evaporation (40 oC), transferred to a preweighed 10 mL RBF 
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with DCM (2.0 mL), re-concentrated by rotary evaporation (40 oC) and dried in vacuo afford 254 
as a white crystalline solid (3.66 g, 73%, ~95% pure): 1H-NMR (CDCl3, 300 MHz) δ 7.79 (d, 4 
H, J = 8.1 Hz), 7.36 (d, 4 H, J = 8.1 Hz), 3.01 (t, 4 H, J = 6.9 Hz), 2.47 (s, 6 H), 2.06 (m, 2 H, J = 
6.9 Hz); 13C-NMR (CDCl3, 75 MHz) δ 145.2 (2 C), 141.5 (2 C), 130.0 (4 C), 127.1 (4 C), 34.1 
(2 C), 28.1, 21.7 (2 C).  
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Methyl-2-(4-(benzyloxycarbonyl)phenylcarbamoylcarbamoyl)-1,3-dithiane-2-carboxylate  
(255).  To a suspension of 253 (450 mg, 1.22 mmol) in DCM (12.0 mL) was added Et3N (423 
µL, 3.04 mmol) followed by 254 (557 mg, 1.34 mmol) at room temperature.  The reaction 
mixture cleared and turned light orange within 5 min.   After 3 h, the reaction mixture was 
diluted with DCM (50 mL), washed with a saturated brine solution (2 X 50 mL), dried (Na2SO4) 
and concentrated in vacuo.  The resulting yellow oil was dissolved in CH2Cl2 (1.5 mL) and 
chromatographed on SiO2 (gradient elution 3:1 -> 2:1 hexanes:EtOAc).  The product fractions 
were combined and concentrated in vacuo to afford 255 as a white solid (540 mg, 94%): Mp 
134-135 °C; IR (ATR) 3265, 3226, 3114, 2956, 1694, 1592, 1543, 1260, 1204, 1172, 1109 cm-1; 
1H NMR (CDCl3, 300 MHz) δ 10.46 (br-s, 1 H), 9.28 (br-s, 1 H), 8.08 (d, 2 H, J = 8.7 Hz), 7.63 
(d, 2 H, J = 8.7 Hz), 7.47-7.34 (m, 5 H), 5.36 (s, 2 H), 3.85 (s, 3 H), 3.11-2.94 (m, 4 H), 2.10-
2.06 (m, 2 H); 13C NMR (CDCl3, 75 MHz) δ 167.6, 166.4, 165.8, 149.6, 141.2, 136.1, 131.0 (2 
C), 128.6 (2 C), 128.3, 128.2 (2 C), 126.0, 119.4 (2 C), 66.7, 61.2, 54.6, 28.1 (2 C), 23.4; MS 
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(EI) m/z 474 (M+, 4), 253 (24), 227 (86), 177 (99), 91 (100); HRMS (EI) m/z calculated for 
C22H22N2O6S2 474.0919, found 474.0908. 
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Benzyl 4-(7,9,11-trioxo-1,5-dithia-8,10-diazaspiro[5.5]undecan-8-yl)benzoate (256, DMA-
NB166-96).  To a suspension of 255 (488 mg, 1.03 mmol) in ACN (50 mL) was added K2CO3 
(157 mg, 1.13 mmol) at room temperature.  The reaction mixture was heated to reflux for 4 h, 
cooled to room temperature, diluted with distilled water (30 mL) and acidified with an HCl 
solution (1.0 M, pH = 2-3).  The resulting cloudy solution was diluted with a saturated brine 
solution (150 mL) and was extracted with EtOAc (2 X 150 mL).  The extracts were combined, 
dried (Na2SO4) and concentrated by rotary evaporation (40 °C).  The resulting yellow solids were 
chromatographed on SiO2 (gradient elution 3:1 -> 2:1 hexanes:EtOAc) and the product fractions 
were combined and concentrated in vacuo to afford 256 as white solid (306 mg, 67%): Mp 
112.0-113.5 °C; IR (ATR) 3220, 3114, 2932, 1694, 1392, 1323, 1265 cm-1; 1H-NMR (CDCl3, 
300 MHz) δ 8.61 (br-s, 1 H), 8.22 (d, 2 H, J = 8.1 Hz), 7.46-7.27 (m, 7 H), 5.40 (s, 2 H), 3.36-
3.27 (m, 2 H), 3.18-3.10 (m, 2 H), 2.19-2.16 (m, 2 H); 13C-NMR (CDCl3, 75 MHz) δ 166.1, 
165.6, 164.7, 148.3, 137.7, 135.9, 131.3, 131.1 (2 C), 128.8 (4 C), 128.5, 128.4 (2 C), 67.3, 52.0, 
27.6 (2 C), 23.1; MS (EI) m/z 442 (M+, 7), 335 (13), 263 (21), 146 (93), 118 (81), 91 (100); 
HRMS (EI) m/z calculated for C21H18N2O5S2 442.065716, found 442.063885. 
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Benzyl 4-(10-ethyl-7,9,11-trioxo-1,5-dithia-8,10-diazaspiro[5.5]undecan-8-yl)benzoate (257, 
DMA-NB205-38).   To a clear solution of 256 (303 mg, 0.680 mmol) in DCM (20 mL) was 
added Et3N (474 µL, 3.40 mmol) followed by ethyl chloroformate (325 µL, 3.40 mmol) 
dropwise over 25 min at 0 °C.   The clear reaction mixture was stirred at 0 °C for 1 h, warmed to 
room temperature over 30 min and then filtered directly through a 1 in plug of SiO2 and washed 
through with a 3:1 mixture of hexanes:EtOAc (100 mL).  The filtrate was concentrated in vacuo 
and the resulting white solids were purified by recrystallization from a boiling 2:1 mixture of 
hexanes:EtOAc (30 mL) followed by cooling to 0 °C for 15 h.  The resulting solid was isolated 
by vacuum filtration, washed with hexanes (15 mL) and dried in vacuo to afford 257 as a clear 
crystalline solid (225 mg, 71%): Mp 161-162 °C; IR (ATR) 2974, 1713, 1681, 1398, 1385, 1314, 
1273, 1109, 846 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.22 (d, 2 H, J = 8.1 Hz), 7.47-7.31 (m, 7 
H), 5.40 (s, 2 H), 4.00 (q, 2 H, J = 6.9), 3.40-3.31 (m, 2 H), 3.15-3.07 (m, 2 H), 2.20-2.13 (m, 2 
H), 1.26 (t, 3 H, J = 6.9 Hz); 13C-NMR (CDCl3, 75 MHz) δ 165.6 (2 C), 164.9, 149.3, 138.6, 
135.9, 131.1 (3 C), 128.8 (2 C), 128.7 (2 C), 128.5, 128.3 (2 C), 67.2, 52.6, 38.9, 27.9 (2 C), 
23.3, 13.1; MS (EI) m/z 470 (M+, 2), 400 (93), 259 (49), 65 (100); HRMS (EI) m/z calculated for 
C23H22N2O5S2 470.0970, found 470.0973. 
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Phenylmethyl 4-(3-ethyl-2,4,6-trioxo-1,3,5-trihydropyrimidinyl)benzoate (259, DMA-
NB205-58).  To a solution of 257 (130 mg, 0.267 mmol) in THF (2.0 mL) was added nano-zinc 
(181 mg, 2.76 mmol) followed by a saturated NH4Cl solution (2.0 mL).  The heterogeneous 
biphasic black reaction mixture was stirred at room temperature for 45 min, carefully acidified to 
pH 1.5 with an HCl solution (1.0 M) and then filtered through a plug of celite (1 in) with EtOAc 
(75 mL).  The filtrate was washed with a saturated brine solution (2 X 50 mL), dried (Na2SO4) 
and concentrated by rotary evaporation (35 °C). The resulting pale yellow oil was re-filtered 
through a 1 in plug of celite (9 in disposable pipette) with EtOAc (25 mL) and the filtrate was 
concentrated by rotary evaporation (20 °C).  The resulting clear oil was dissolved in DCM (3.0 
mL) and hexanes (15 mL) were added.  The cloudy white solution was cooled to -78 °C for 30 
min and the resulting solid was isolated by vacuum filtration, washed with hexanes (30 mL) and 
dried in vacuo to afford 259 as a white powdery solid (62.8 mg, 62%): Mp 152.5-154.0 °C; IR 
(ATR) 2974, 2894, 1700, 1681, 1398, 1273, 1122, 1228, 1172 cm-1; 1H NMR (CDCl3, 300 MHz) 
δ 8.22 (d, 2 H, J = 8.4 Hz), 7.43-7.38 (m, 5 H), 7.29 (d, 2 H, J = 8.4 Hz), 5.39 (s, 2 H), 4.00 (q, 2 
H, J = 6.9 Hz), 3.86 (s, 2 H), 1.26 (t, 3 H, J = 6.9 Hz); 13C-NMR (CDCl3, 75 MHz) δ 165.6, 
164.4, 164.2, 150.9, 138.3, 135.9, 131.1 (3 C), 128.9 (2 C), 128.8 (2 C), 128.6, 128.4 (2 C), 67.2, 
40.2, 37.9, 13.4; MS (EI) m/z 366 (M+, 58), 259 (93), 146 (88), 91 (100); HRMS (EI) m/z 
calculated for C20H18N2O5 366.1216, found 366.1199. 
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Phenylmethyl 4-[4-(ethoxycarbonyl)-1,3,5-trioxo-7,11-dithia-2,4-diazaspiro[5.5]undec-2-
yl]benzoate (258, DMA-NB205-59).  To a solution of 256 (300 mg, 0.678 mmol) in dry DCM 
(7.0 mL) cooled to 0 °C was added anhydrous pyridine (274 µL, 3.39 mmol) followed by ethyl 
chloroformate (334 µL, 3.39 mmol).  The clear reaction mixture was stirred at 0 °C for 30 min 
and was slowly warmed to room temperature over 30 min.  The reaction mixture was then 
diluted with DCM (50 mL), washed with deionized water (4 X 50 mL), dried (Na2SO4) and 
concentrated by rotary evaporation (10-15 °C).  The resulting pale yellow oil was dissolved in 
DCM (5.0 mL) and hexanes (30 mL) were added at room temperature.  The cloudy solution was 
then cooled to -78 °C under nitrogen for 30 min.  A precipitate formed which was isolated by 
vacuum filtration, washed with hexanes (30 mL) and dried in vacuo to afford 258 as a white 
powdery solid (317 mg, 91%): Mp 147.5-148.5 °C; IR (ATR) 2987, 1787, 1705, 1694, 1398,  
1334, 1273, 1215, 1109, 1008 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.23 (d, 2 H, J = 8.7 Hz), 
7.47-7.33 (m, 7 H), 5.40 (s, 2 H), 4.51 (q, 2 H, J = 6.9 Hz), 3.27-3.19 (m, 4 H), 2.21-2.15 (m, 2 
H), 1.43 (t, 3 H, J = 6.9 Hz); 13C-NMR (CDCl3, 75 MHz) δ 165.5, 164.8, 162.6, 148.2, 146.6, 
137.5, 135.9, 131.5, 131.2 (2 C), 128.9 (2 C), 128.7 (2 C), 128.6, 128.4 (2 C), 67.3, 67.1, 52.6, 
27.8 (2 C), 23.1, 13.9; MS (EI) m/z 514 (M+, 100), 346 (29), 178 (33), 91 (48); HRMS (EI) m/z 
calculated for C24H22N2O7S2 514.0868, found 514.0852. 
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Ethyl 2,4,6-trioxo-3-{4-[benzyloxycarbonyl]phenyl}-1,3,5-trihydropyrimidinecarboxylate 
(244, DMA-NB245-23).  To a solution of 258 (90.0 mg, 0.175 mmol) in THF (3.0 mL) was 
added nano-zinc (229 mg, 3.50 mmol) followed by a saturated NH4Cl solution (3.0 mL) at room 
temperature.  The heterogeneous biphasic black reaction mixture was vigorously stirred at room 
temperature for 2 h and was then slowly acidified to pH 1-1.5 with an HCl solution (1.0 M, the 
mixture clears and the Zn clumps together near this pH).  The resulting mixture was vacuum 
filtered through a plug of SiO2 (1 in) with EtOAc (100 mL).  The filtrate was transferred to a 
separatory funnel, the water layer was removed, and the EtOAc layer was dried (Na2SO4) and 
concentrated by rotary evaporation (25 °C).  The resulting clear oil was re-filtered through a plug 
of SiO2 with a solution of EtOAc (0.10% TFA, 30 mL) and the filtrate was concentrated by 
rotary evaporation (20 °C).  The clear oil was dissolved in DCM (3.0 mL) and hexanes (40 mL) 
were slowly added.  The turbid solution was cooled to -5 °C for 15 h over which time a fluffy 
white solid crystallized.  This solid was isolated by vacuum filtration, washed with hexanes (10 
mL) and dried in vacuo.  An attempt to dissolve the white solid in CDCl3 for 1H NMR resulted in 
a turbid solution in which a small amount of a sticky pale yellow oil did not dissolve.  This 
solution was gravity filtered through a plug of sand (0.5 in, contained in a 5 3/4 in disposable 
pipette packed tightly with a plug of glass wool) with additional DCM (2.5 mL).   The filtrate 
was concentrated and dried in vacuo (20 °C) to afford 244 as a white powdery solid (47.5 mg, 
66%): Mp 140.5-142.0 °C; IR (ATR) 2981, 2913, 1787, 1763, 1694, 1411, 1347, 1247, 1215, 
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1191, 1016, 934, 857 cm-1; 1H NMR (CDCl3, 300 MHz) δ 8.19 (d, 2 H, J = 8.4 Hz), 7.46-7.35 
(m, 5 H), 7.29 (d, 2 H, J = 8.4 Hz), 5.38 (s, 2 H), 4.48 (q, 2 H, J = 7.2 Hz), 3.87 (s, 2 H), 1.40 (t, 
3 H, J = 7.2 Hz); 13C-NMR (CDCl3, 75 MHz) δ 165.5, 163.9, 162.2, 148.7, 148.3, 137.2, 135.8, 
131.3, 131.1 (2 C), 128.8 (4 C), 128.5, 128.3 (2 C), 67.2, 67.0, 39.8, 13.8; MS (EI) m/z 410 (M+, 
24), 303 (100); HRMS (EI) m/z calculated for C21H18N2O7 410.1114, found 410.1112. 
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4-[3-(ethoxycarbonyl)-2,4,6-trioxo-1,3,5-trihydropyrimidinyl]benzoic acid (241, DMA-
NB205-75).  To a solution of 244 (53.0 mg, 0.129 mmol) in THF (3.0 mL) was added 
Pd(OH)2/C (18.0 mg, 0.0256 mmol, 20%) and the resulting dark back suspension was placed 
under hydrogen (1 atm) for 2 h at room temperature.  At this time, due to low conversion, a 
second batch of Pd(OH)2/C (9.0 mg, 0.0128 mmol, 10%) was added and the reaction went to 
completion after an additional 2 h.  The reaction mixture was directly filtered through a 1 in plug 
of SiO2 (5 3/4 in disposable pipette, pre-treated once with a 100:0.1 solution of EtOAc:TFA and 
then flushed with EtOAc (10 mL)) with EtOAc (45 mL).  The filtrate was condensed by rotary 
evaporation (25 °C) and the resulting solids were dissolved in EtOAc (4.0 mL).  Hexanes were 
added (50 mL) and the solution was cooled to 0 °C for 30 min.  The resulting precipitate was 
isolated by vacuum filtration, washed with a 5:1 solution of hexanes:DCM (10 mL), hexanes (20 
mL) and dried in vacuo to afford 241 as a white powdery solid (31.8 mg, 77%): Mp 219-220 °C; 
IR (ATR) 2995, 2900, 2686, 1795, 1756, 1694, 1675, 1385, 1347, 1247, 1215, 1016 cm-1; 1H 
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NMR (DMSO-d6, 300 MHz) δ 13.20 (s, 1 H), 8.04 (d, 2 H, J = 8.1 Hz), 7.41 (d, 2 H, J = 8.1 Hz), 
4.41 (q, 2 H, J = 6.9 Hz), 3.97 (s, 2 H), 1.29 (t, 3 H, J = 6.9 Hz); 13C-NMR (DMSO-d6, 175 
MHz) δ 166.7, 165.1, 164.0, 149.3, 148.9, 138.2, 131.1, 130.0 (2 C), 129.2 (2 C), 65.9, 40.6, 
13.6; MS (EI) m/z 320 (M+, 97), 303 (9), 248 (18), 163 (100), 146 (31); HRMS (EI) m/z 
calculated for C14H12N2O7 320.0645, found 320.0638. 
4.4.3 Synthesis and identification of the structure of SID 861574 
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Phenylmethyl 4-isocyanatobenzoate (262).  To a mixture of 225 (600 mg, 2.64 mmol) in DCM 
(25 mL) was added a saturated NaHCO3 solution (25 mL) and the resulting biphasic mixture was 
vigorously stirred while cooling to 0 °C over 15 min (ice bath).  Stirring was stopped, the layers 
were allowed to separate and phosgene (2.78 mL, 5.28 mmol, 20% in toluene) was added in a 
single portion via syringe to the lower organic layer.  Stirring was resumed immediately and 
continued at 0 °C for 30 min.  The reaction mixture was then transferred to a separatory funnel, 
diluted with distilled water (30 mL) and the aqueous layer was extracted with DCM (2 X 60 
mL).  The DCM extracts were combined, dried (Na2SO4) and concentrated in vacuo to afford 
262 as a pale yellow-orange oil (658 mg, 98%).  This product was used crude for the next step: 
1H NMR (CDCl3, 300 MHz) δ 8.05 (d, 2 H, J = 8.7 Hz), 7.47-7.36 (m, 5 H), 7.15 (d, 2 H, J = 8.7 
Hz), 5.37 (s, 2 H); 13C-NMR (CDCl3, 75 MHz) δ 165.6, 138.1, 135.8, 131.3 (2 C), 128.7 (2 C), 
128.4, 128.3 (2 C), 127.5, 125.6, 124.8 (2 C), 67.0. 
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Diethyl-(2Z)-3-hydroxy-2-(N-{4-[benzyloxycarbonyl]phenyl}carbamoyl)pent-2-ene-1,5-
dioate (263, DMA-NB205-79).  To a solution of diethyl 3-oxopentane-1,5-dioate (72.7 µL, 
0.400 mmol) in dry ether (5.0 mL) was added NaH (11.1 mg, 0.440 mmol) in one portion at 
room temperature.  A hydrogen gas release was realized immediately and the initially white 
suspension cleared after 5 min.  The reaction mixture was cooled to 0 °C and a solution of 262 
(101 mg, 0.400 mmol) in dry ether (1.0 mL) was added dropwise over 5 min.  The resulting 
white suspension was warmed to room temperature over 5 min, heated to reflux for 2.5 h, cooled 
to room temperature, diluted with distilled water (10 mL) and the resulting suspension was 
acidified with an HCl solution (1.0 M, pH = 1-1.5).  The aqueous layer was extracted with ether 
(2 X 20 mL).  The ether layers were combined, dried (Na2SO4) and concentrated by rotary 
evaporation (25 °C).  The resulting white solids were dissolved in DCM (3.0 mL) and hexanes 
(30 mL) were slowly added at room temperature.  The resulting cloudy white solution was 
cooled at 0 °C for 1 h and a crystalline solid precipitated, which was isolated by vacuum 
filtration, washed with hexanes (40 mL) and dried in vacuo to afford 263 as clear crystalline 
needles (112 mg, 61%): Mp 96-97 °C; IR (ATR) 3125, 3070, 2982, 2937, 1718, 1681, 1586, 
1530, 1379, 1273, 1172, 1090, 1008 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 18.20 (s, 1 H), 
11.56 (s, 1 H), 8.08 (d, 2 H, J = 9.0 Hz), 7.64 (d, 2 H, J = 8.7 Hz), 7.48-7.35 (m, 5 H), 5.37 (s, 2 
H), 4.30 (q, 2 H, J = 7.2 Hz), 4.22 (q, 2 H, J = 7.2 Hz), 3.83 (s, 2 H), 1.35 (t, 3 H, J = 7.2 Hz), 
 225 
1.30 (t, 3 H, J = 7.2 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 186.6, 170.9, 168.2, 167.8, 165.9, 
141.1, 136.1, 130.9 (2 C), 128.6 (2 C), 128.3, 128.2 (2 C), 126.2, 120.5 (2 C), 96.3, 66.7, 61.5, 
61.4, 45.5, 14.2, 14.1; HRMS (ESI) m/z calculated for C24H25NO8Na 478.1478, found 478.1448. 
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Ethyl-1-(4-(benzyloxycarbonyl)phenyl)-4,6-dihydroxy-2-oxo-1,2-dihydropyridine-3-
carboxylate (264).  To a solution of diethyl 3-oxopentane-1,5-dioate (179 µL, 0.987 mmol) in 
distilled THF (20 mL) cooled to 0 °C was added NaH (56.4 mg, 2.35 mmol) in one portion.  The 
ice bath was immediately removed and the white suspension was slowly warmed to room 
temperature over 15 min.  At this time, hydrogen gas release ceased and the light suspension was 
re-cooled to 0 °C over 10 min.  To the reaction mixture was added, dropwise over 5 min, a 
solution of 262 (238 mg, 0.940 mmol) in THF (2.0 mL). The ice bath was immediately removed 
and the heterogeneous reaction mixture was warmed to room temperature over 20 min and to 
reflux for 2 h.  After 2 h, the reaction mixture cleared, became light yellow in color and was 
cooled to room temperature.  To the mixture was then added an HCl solution (1.0 M, 0.50 mL, to 
quench any un-reacted NaH) followed by deionized water (20 mL).  The biphasic mixture was 
neutralized (1.0 M HCl, pH 7-8) and then extracted with ether (1 X 30 mL).  The aqueous layer 
was acidified (1.0 M HCl, pH = 1-1.5) and the resulting cloudy solution was extracted with 
DCM (2 X 50 mL).  The DCM extracts were combined, dried (Na2SO4) and concentrated in 
vacuo.  The resulting light tan solids were recrystallized (2 X) by dissolving in 2-3 mL of DCM 
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and then slowly adding hexanes (20 mL) with cooling to 0 °C for 30 min.  After each 
recrystallization, the resulting tan solids were isolated by vacuum filtration, washed with a 2:1 
mixture of hexanes:DCM (20 mL) and dried in vacuo.  The product of the second 
recrystallization showed 264 (149 mg, 39%, ~92% pure by 1H NMR): Mp 180.5-182.0 °C; IR 
(ATR) 3082, 2982, 2693, 2441, 1718, 1636, 1586, 1485, 1424, 1334, 1265, 1236, 1103, 1003 
cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 13.14 (s, 1 H), 11.01 (br-s, 1 H), 8.06 (d, 2 H, J = 8.1 
Hz), 7.50-7.35 (m, 7 H), 5.39 (s, 2 H), 5.32 (s, 1 H), 4.18 (q, 2 H, J = 6.9 Hz), 1.21 (t, 3 H, J = 
6.9 Hz); 13C-NMR (DMSO-d6, 75 MHz) δ 174.4, 172.0, 165.6, 161.9, 160.2, 141.3, 136.6, 130.2 
(2 C), 130.1 (2 C), 129.5, 129.0 (2 C), 128.6, 128.4 (2 C), 89.6, 81.8, 66.8, 60.8, 14.6; HRMS 
(ESI) m/z calculated for C22H19NO7Na 432.1059, found 432.1064. 
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4-[3-(Ethoxycarbonyl)-4,6-dihydroxy-2-oxohydropyridyl]benzoic acid (260, DMA-NB245-
14).  To a clear solution of diethyl 3-oxopentane-1,5-dioate (229 µL, 1.26 mmol) and ethyl 4-
isocyanatobenzoate (200 mg, 1.05 mmol) in distilled THF (20 mL) cooled to 0 °C was added 
NaH (66.0 mg, 2.62 mmol) in one portion.  Hydrogen gas release was noted upon the addition of 
NaH.  The reaction mixture was stirred at 0 °C for 30 min and then warmed to room temperature 
for 30 min.  To the heavy white suspension was then added a sodium hydroxide solution (1.0 M, 
20 mL) and the biphasic mixture was vigorously stirred for 1 h at room temperature.  The THF 
layer was removed and the aqueous layer was washed with ether (2 X 40 mL) and acidified with 
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concentrated HCl to pH 0.0-0.5 at 0 °C.  The resulting white suspension was stirred at 0 °C for 
an additional 30 min following the acidification and the precipitate was isolated by vacuum 
filtration, washed with deionized water (50 mL) and dried in vacuo to afford 260 as a white 
powdery solid (291 mg, 87%): Mp 225-227 °C (dec); IR (ATR) 3082, 2969, 2863, 2699, 1687, 
1644, 1586, 1517, 1498, 1429, 1416, 1273, 1228, 1109 cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 
13.14 (s, 1 H), 13.00 (br-s, 1 H), 10.84 (br-s, 1 H), 8.00 (d, 2 H, J = 8.4 Hz), 7.32 (d, 2 H, J = 8.4 
Hz), 5.35 (s, 1 H), 4.21 (q, 2 H, J = 7.2 Hz), 1.22 (t, 2 H, J = 7.2 Hz); 13C-NMR (DMSO-d6, 75 
MHz) δ 174.3, 171.6, 166.9, 161.2, 159.5, 139.9, 130.6, 129.8 (2 C), 129.4 (2 C), 90.0, 81.1, 
60.6, 14.2; HRMS (ESI) m/z calculated for C15H13NO7Na 342.0590, found 342.0583. 
4.4.4 Synthesis of SID 861574 decomposition products and other related analogues 
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Diprop-2-enyl 3-oxopentane-1,5-dioate (268).  A suspension of dimethyl 1,3-acetone-
dicarboxylate (1.00 mL, 6.80 mmol), allyl alcohol (4.60 mL, 67.1 mmol) and ZnO (280 mg, 3.40 
mmol, 50 mol %) in dry toluene (5.0 mL) was heated to reflux for 27 h.  The heterogeneous, pale 
yellow reaction mixture was cooled to room temperature and then filtered through a 1 in plug of 
SiO2 with EtOAc (75 mL).  The cloudy white filtrate was concentrated by rotary evaporation (60 
°C) and the oily residue was chromatographed on SiO2 (10:1 hexanes:EtOAc).  The product 
fractions were combined and concentrated in vacuo to afford 268 as a clear oil (666 mg, 43%, 
90:10 mixture of keto- to enol- tautomers): IR (ATR) 2995, 2900, 2686, 1795, 1694, 1675, 1385, 
1347, 1215 cm-1; 1H NMR (CDCl3, 300 MHz) keto-tautomer δ 5.97-5.86 (m, 2 H), 5.38-5.25 (m, 
4 H), 4.65 (dt, 4 H, J = 5.7, 1.4 Hz), 3.66 (s, 4 H); enol-tautomer δ 12.01 (s, 1 H), 5.98-5.86 (m, 
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2 H), 5.38-5.25 (m, 4 H), 5.19 (s, 1 H), 5.47-4.67 (m, 4 H), 3.27 (s, 2 H); 13C NMR (CDCl3, 75 
MHz) keto-tautomer δ 195.3, 166.6 (2 C), 131.5 (2 C), 119.3 (2 C), 66.4 (2 C), 49.0 (2 C); enol-
tautomer δ 172.1, 170.2, 167.8, 132.0, 131.7, 119.0, 118.7, 92.1, 66.2, 65.2, 41.1; HRMS (ESI) 
m/z calculated for C11H14O5Na 249.0739, found 249.0749. 
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4-[4,6-Dihydroxy-2-oxo-3-(prop-2-enyloxycarbonyl)hydropyridyl]benzoic acid (267, DMA-
NB245-18).  To a clear solution of 268 (213 mg, 0.942 mmol) and 203 (150 mg, 0.785 mmol) in 
distilled THF (15.0 mL) cooled to 0 °C was added NaH (49.6 mg, 1.96 mmol) in one portion.  
Hydrogen gas release was noted upon the addition of NaH and the reaction mixture was stirred at 
0 °C for 30 min and then warmed to room temperature for 30 min.  To this white suspension was 
then added a sodium hydroxide solution (1.0 M, 15 mL) and the resulting clear biphasic mixture 
was vigorously stirred for 1 h at room temperature.  The THF layer was then removed and the 
aqueous layer was washed with ether (2 X 30 mL) and acidified with concentrated HCl to pH 
0.0-0.5 at 0 °C.  The resulting white suspension was stirred at 0 °C for an additional 1 h 
following the acidification.  The precipitate was isolated by vacuum filtration, washed with 
deionized water (50 mL) and dried in vacuo to afford 267 as a white powdery solid (208 mg, 
80%): 211-212 °C (dec); IR (ATR) 3088, 2855, 1694, 1636, 1586, 1493, 1424, 1273, 1191, 1103 
cm-1; 1H NMR (DMSO-d6, 300 MHz) δ 13.01 (br-s, 2 H), 10.72 (br-s, 1 H), 8.00 (d, 2 H, J = 8.4 
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Hz), 7.33 (d, 2 H, J = 8.4 Hz), 5.99-5.87 (m, 1 H), 5.47-5.36 (m, 2 H), 5.19 (dd, 1 H, J = 10.5, 
1.2 Hz), 4.67 (d, 2 H, J = 4.8 Hz); 13C NMR (DMSO-d6, 75 MHz) δ 174.2, 171.1, 166.9, 161.3, 
159.6, 140.0, 132.3, 130.5, 129.8 (2 C), 129.4 (2 C), 117.5, 89.9, 81.0, 64.7; MS (EI) m/z 331 
(M+, 82), 273 (24), 163 (47), 137 (93), 69 (100); HRMS (EI) m/z calculated for C16H13NO7 
331.0692, found 331.0695. 
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4-(4-Hydroxy-2,6-dioxo-1,5-dihydropyridyl)benzoic acid (265, DMA-NB245-24).   To a 
white suspension of 267 (100 mg, 0.302 mmol) and Pd(PPh3)4 (17.4 mg, 0.0151 mmol, 0.05 
mol%) in dry THF (5.0 mL) was added morpholine (266 µL, 3.02 mmol) at room temperature.  
The resulting heterogeneous light yellow reaction mixture was stirred at room temperature for 1 
h.  The reaction mixture was then diluted with a NaOH solution (1.0 M, 5.0 mL), followed by 
ether (10 mL) and the organic layer was removed.  The pale yellow/orange aqueous layer was 
washed with ether (2 X 10 mL), cooled to 0 °C and acidified to pH 0.0-0.5.  Upon acidification, 
a light yellow precipitate formed and the aqueous mixture was cooled to and gently stirred at 0 
°C for 30 min.  The resulting brown solid was removed by vacuum filtration and the filtrate was 
immediately extracted with EtOAc (3 X 40 mL).  The extracts were combined, dried (Na2SO4), 
vacuum filtered through a 1 in plug of SiO2, flushed through with EtOAc (100 mL) and the clear 
filtrate was concentrated in vacuo.  The resulting yellow solids were dissolved in EtOH (15.0 
mL), filtered through a small plug of glass wool and then diluted by slow addition of hexanes 
 230 
(100 mL) at room temperature.  The homogeneous pale yellow solution was brought to a boil 
and concentrated to 75 mL when a light yellow precipitate began to form.  At this time, the 
mixture was slowly cooled to room temperature and then to -5 °C for 10 h.  The crystallized 
solid was isolated by vacuum filtration, washed with hexanes (10 mL), dissolved in HPLC grade 
water (8.0 mL) with heating and the light orange solution was concentrated in vacuo to afford 
265 as an orange solid (55.1 mg, 74%): 240-245 °C (slow dec.); IR (ATR) 3459, 3075, 2894, 
1694, 1631, 1605, 1392, 1366, 1210, 1165, 1122 cm-1; 1H NMR (DMSO-d6, 300 MHz) major 
tautomer (83%) δ 13.04 (br-s, 1 H), 11.78 (br-s, 1 H), 7.98 (d, 2 H, J = 8.4 Hz), 7.26 (d, 2 H, J = 
8.4 Hz), 5.36 (s, 1 H), 3.66 (s, 2 H); distinct resonances for minor tautomer (17%) δ 5.25 (s, 1 
H), 10.43 (s, 1 H); 13C NMR (DMSO-d6, 75 MHz) major tautomer δ 168.8, 168.5, 166.9, 166.5, 
139.9, 130.3, 129.7 (2 C), 129.5 (2 C), 93.9, 37.4; MS (EI) m/z 247 (M+, 63), 219 (21), 163 (72), 
146 (100), 137 (42), 90 (51), 69 (66); HRMS (EI) m/z calculated for C12H9NO5 247.0481, found 
247.0483; LC/MS/UV data: Phenomenex C18 (4.6 X 100 nm) column, 1.0 mL/min, 254 nm, 
gradient elution with 15 to 45% acetonitrile in water containing 0.10% TFA, 1 mg sample/mL 
DMSO or MeOH; Retention  time = 9.96 min(MeOH), 3.29 (DMSO); MS(ESI+) m/z 248 [M + 
H]+.  This sample was found to have an IC50 > 50 µM against PLK1-PBD. 
 
4-(4-Hydroxy-2,6-dioxo-1,5-dihydropyridyl)benzoic acid (265, DMA-NB245-3). To a light 
yellow solution of 267 (20.0 mg, 0.0557 mmol) and Pd(PPh3)4 (3.2 mg,  0.00279 mmol, 5 mol%) 
in dry THF (1.5 mL) was added morpholine (48.2 µL, 0.557 mmol, 10 equiv.) at room 
temperature.  The resulting heterogeneous light orange reaction mixture was stirred at room 
temperature for 1 h, diluted with an NaOH solution (1.0 M, 2.0 mL) and stirred at room 
temperature for an additional 1.5 h.  The resulting light orange mixture was extracted with ether 
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(3 X 3.0 mL) and the aqueous layer was cooled to 0 oC and acidified with an HCl solution (1.0 
M, pH 0).  No precipitate formed upon acidification.  The aqueous solution was extracted with 
EtOAc (4 X 10 mL) and the EtOAc extracts were combined, dried (Na2SO4) and concentrated by 
rotary evaporation (25 oC).  The resulting light orange residue was dissolved in EtOAc (6.0 mL) 
and hexanes (30 mL) was slowly added at room temperature.  The resulting orange precipitate 
was isolated by vacuum filtration, washed with DCM (10 mL) and dried in vacuo to afford 265 
(9.3 mg, 68%).  This sample was found to have an IC50 = 2.079 µM against PLK1-PBD in an 
initial testing and an IC50 = 6.047 µM in a follow-up testing. 
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4-(1-(4-Carboxyphenyl)-4,6-dihydroxy-2-oxo-1,2-dihydropyridine-3-carboxamido)benzoic 
acid (266, DMA-NB245-67).  To a solution of 265 (200 mg, 0.809 mmol) and 203 (155 mg, 
0.809 mmol) in a 1:1 mixture of THF:ACN (10.0 mL) cooled to 0 oC was added DIPEA (0.270 
mL,1.62 mmol, 2 equiv.) in one portion.  An orange precipitate formed immediately upon 
addition of DIPEA and re-dissolved within 3 min.  After 5 min, the ice bath was removed.  The 
reaction mixture was warmed to room temperature over 45 min and was then diluted with a 1.0 
M NaOH solution (10 mL) to saponify the ethyl ester.  After 1.5 h, the deep red aqueous layer 
was diluted with de-ionized water (15 mL) and extracted with ether (3 X 20 mL).  The aqueous 
layer was cooled to 0 oC, acidified with concentrated HCl (pH = 0) and the resulting cloudy 
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purple solution was extracted with EtOAc (4 X 30 mL).  The EtOAc extracts were combined, 
dried (Na2SO4) and concentrated by rotary evaporation (30 oC).  The resulting solids were 
recrystallized from a boiling 1:7 mixture of THF:hexanes (150 mL) affording the desired product 
(188 mg, ~ 80% pure).  This product was further purified by a second recrystallization from a 
boiling 1:2 mixture of EtOAc:hexanes (75 mL), which was slowly cooled to -5 oC.  The resulting 
light tan solid was isolated by vacuum filtration, triturated with MeOH (5 mL) at 45 oC for 30 
min (to remove EtOAc and hexanes) and concentrated in vacuo to afford 266 solvated with 
approximately 5% MeOH (35.3 mg, 11%): Mp 275.0-276.5 oC (dec.); IR (ATR) 3221, 3107, 
2887, 2656, 2516, 1719, 1700, 1581, 1536, 1410, 1366, 1254, 1174, 1090 cm-1; 1H NMR 
(DMSO-d6, 300 MHz) δ 14.88 (br-s, 1 H), 12.42 (s, 1 H), 8.03 (d, 2 H, J = 8.4 Hz), 7.89 (d, 2 H, 
J = 8.7 Hz), 7.67 (d, 2 H, J = 8.7 Hz), 7.41 (d, 2 H, J = 8.1 Hz), 5.39 (s, 1 H); 13C NMR (DMSO-
d6, 100 MHz) δ 175.2, 169.5, 166.8 (2 C), 163.1, 160.8, 141.7, 139.7, 130.7, 130.6 (2 C), 129.9 
(2 C), 129.4 (2 C), 125.6, 119.5 (2 C), 89.8, 82.8; LC/MS/UV data: Phenomenex C18 (4.6 X 100 
nm) column, 1.0 mL/min, 254 nm, gradient elution with 15 to 45% acetonitrile in water 
containing 0.10% TFA, 1 mg sample/mL DMSO; Retention  time = 16.44 min; MS(ESI+) m/z 
411 [M + H]+. 
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4-[2-(Ethoxycarbonyl)acetylamino]benzoic acid (271, DMA-NB245-90).113  To a solution of 
ethyl malonylchloride (282 µL, 1.97 mmol, 90%) in dry ether (5.0 mL) was added 4-
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aminobenzoic acid (250 mg, 1.82 mmol) at room temperature.   The resulting light orange 
suspension was stirred at room temperature for 4 h before an additional (250 mg, 1.82 mmol) of 
4-aminobenzoic acid was added.  After 20 h, the reaction mixture was diluted with EtOAc (50 
mL), extracted with 1.0 M HCl (3 x 50 mL) and brine (2 X 50 mL).  The EtOAc layer was dried 
(Na2SO4), concentrated by rotary evaporation (40 oC) and the resulting orange solids were 
recrystallized by dissolving in boiling EtOAc (40 mL) to which hexanes (5 mL) were added 
upon dissolution of the product.  After slowly cooling to room temperature, the resulting light 
orange solid was isolated by vacuum filtration, washed with hexanes (20 mL) and dried in vacuo 
to afford 271 (309 mg, 63%): 1H NMR (DMSO-d6, 300 MHz) δ 12.74 (s, 1 H), 10.49 (s, 1 H), 
7.90 (d, 2 H, J = 8.7 Hz), 7.68 (d, 2 H, J = 8.7 Hz), 4.12 (q, 2 H, J = 7.2 Hz), 3.50 (s, 2 H), 1.20 
(t, 3 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 167.6, 167.0, 164.7, 142.9, 130.6 (2 C), 
125.5, 118.5 (2 C), 60.8, 43.8, 14.1; HRMS (TOF MS ES+) m/z calculated for C12H13NO5Na 
(M+Na) 274.0691, found 274.0692. 
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4-[4-(Ethoxycarbonyl)-3-oxobutanoylamino]benzoic acid (272, DMA-NB245-91).  A 
suspension of ZnO (297 mg, 3.65 mmol), 261 (994 µL, 5.47 mmol) and 4-aminobenzoic acid 
(500 mg, 3.65 mmol) in dry toluene was prepared at room temperature and heated to reflux for 
24 h.  At this time, the reaction mixture was cooled to room temperature, diluted with EtOAc (50 
mL) and filtered through a plug of SiO2 (1 in) with EtOAc (250 mL).  The solid remaining on top 
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of the SiO2 plug was found by 1H NMR (DMSO-d6) to contain the majority of the major product 
(possibly as the zinc salt).  These solids were then carefully removed and triturated with a boiling 
solution of 50:1 THF:AcOH (60 mL) for 30 min.  The hot suspension was vacuum filtered and 
the filtrate was concentrated in vacuo to afford crude 4-[(1-{[N-(4-
carboxyphenyl)carbamoyl]methyl}-2-(ethoxycarbonyl)vinyl)amino]benzoic acid (olefin position 
is uncertain) as a white solid (160 mg, ~65-70% pure): 1H NMR (DMSO-d6, 300 MHz) δ 12.53 
(br-s, 2 H), 10.41 (s, 1 H), 8.94 (s, 1 H), 7.94 (d, 2 H, J = 8.7 Hz), 7.89 (d, 2 H, J = 8.7 Hz), 7.71 
(d, 2 H, J = 8.7 Hz), 7.29 (d, 2 H, J = 8.7 Hz), 5.43 (s, 1 H), 3.99 (s, 2 H), 3.97 (q, 2 H, J = 7.2 
Hz), 1.13 (t, 3 H, J = 7.2 Hz).  The remainder of this solid was suspended in a 1.0 M HCl 
solution (20 mL) and stirred at room temperature for 2 h, at which time the remaining white solid 
was isolated by vacuum filtration, washed with deionized water (20 mL), dried in vacuo and 
suspended in EtOAc (2.5 mL) for chromatography on SiO2 (EtOAc).  The product (Rf = 0.66; 
SiO2; EtOAc) fractions were combined and concentrated by rotary evaporation (40 oC).  The 
resulting white solid was dissolved in MeOH (10 mL) and re-concentrated in vacuo to afford 272 
containing ~2% of 4-aminobenzoic acid (15.2 mg, 1%, ~95% pure): Mp 242-243 oC (dec); IR 
(ATR) 3334, 3208, 2975, 2667, 2548, 1735, 1683, 1597, 1534, 1409, 1308, 1258, 1169, 1025 
cm-1; keto-tautomer (83%):  1H NMR (DMSO-d6, 300 MHz) δ 12.71 (s, 1 H), 10.42 (s, 1 H), 
7.90 (d, 2 H, J = 8.7 Hz), 7.67 (d, 2 H, J = 8.7 Hz), 4.10 (q, 2 H, J = 7.2 Hz), 3.74 (s, 2 H), 3.71 
(s, 2 H), 1.18 (t, 3 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 198.1, 166.9, 166.8, 165.1, 
142.8, 130.5 (2 C), 125.5, 118.4 (2 C), 60.7, 51.6, 49.2, 14.0; distinguished resonances for major-
enol-tautomer (13%): 1H NMR (DMSO-d6, 300 MHz) δ 13.64 (s, 1 H), 10.43 (s, 1 H), 5.37 (s, 1 
H), 3.36 (s, 2 H); distinguished resonances for minor-enol-tautomer (4%): 1H NMR (DMSO-d6, 
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300 MHz) δ 11.93 (br-s, 1 H), 5.25 (s, 1 H), 3.39 (s, 2 H); HRMS (TOF MS ES+) m/z calculated 
for C14H15NO6Na (M+Na) 316.0797, found 316.0810. 
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274a 274b 274c 274d  
Allyl 1-(4-(ethoxycarbonyl)phenyl)-4,6-dihydroxy-2-oxo-1,2-dihydropyridine-3-carboxylate 
(274a).  To a solution of 268 (6.54 g, 28.9 mmol, 1.11 equiv.) in distilled THF (500 mL) cooled 
to 0 oC was added NaH in three 551 mg batches over 5 min (1.65 g, 65.4 mmol, 2.5 equiv.).  The 
ice bath was immediately removed and the resulting white suspension was slowly warmed to 
room temperature over 30 min.  At this time, gas release ceased, the light suspension was re-
cooled to 0 oC and a solution of 203 (5.00 g, 26.2 mmol) in THF (10.0 mL) was added dropwise 
over 5 min.  The ice bath was immediately removed.  The heterogeneous reaction mixture was 
warmed to room temperature over 30 min and heated to reflux for 2.45 h over which time 
reaction mixture became orange in color.  After cooling to 0 °C, a concentrated HCl solution 
(reaction mixture pH ~7-8, reaction mixture turned deep red upon neutralization) was added to 
the reaction mixture, followed by deionized water (500 mL) and ether (200 mL).  The organic 
layer was removed and the deep red aqueous layer was extracted with ether (2 X 300 mL).  The 
aqueous layer was then further acidified with an HCl solution (1.0 M, pH = 0.5-1.0) and the 
resulting heterogeneous solution was extracted with EtOAc (3 X 300 mL).  The EtOAc layers 
were combined, dried (Na2SO4) and concentrated by rotary evaporation (30 oC).  The resulting 
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orange/tan solids were triturated with DCM (100 mL) at room temperature for 15 min.  The 
remaining solids were isolated by vacuum filtration, washed with DCM (50 mL) and hexanes (50 
mL), and dried in vacuo to afford a mixture of ~3.5:1:2:trace 274a: 274b: 274c: 274d determined 
by 1H NMR integration (3.23 g, 35%).  The remaining dark red mother liquor was diluted with 
hexanes (250 mL) and cooled to -5 °C for 1 h.  The light yellow precipitate was isolated by 
vacuum filtration, washed with a 1:1 DCM:hexanes solution (30 mL) and hexanes (50 mL), and 
dried in vacuo to afford a second batch of this crude mixture (1.41 g, 15%).  The product mixture 
was carried on crude to the next step.  A LC/MS/ELS analysis was performed (ESI industries 
epic C18 column; 1.0 mL/min; 30 min run; gradient elution = 30 to 60% ACN in water, ELS/MS 
detection).  247a: 1H NMR (DMSO-d6, 300 MHz) δ 13.03 (br-s, 1 H), 11.89 (br-s, 1 H), 8.02 (d, 
2 H, J = 8.7 Hz), 7.36 (d, 2 H, J = 8.7 Hz), 5.99-5.86 (m, 1 H), 5.47-5.41 (m, 1 H), 5.35 (s, 1 H), 
5.20-5.16 (m, 1 H), 4.70 (dt, 2 H, J = 4.8, 1.5 Hz), 4.35 (q, 2 H, J = 7.2 Hz), 1.34 (t, 3 H, J = 7.2 
Hz); LC/MS (ESI+) m/z 360.2 [M+H]+; LC/ELS retention time 12.99 min. 247b: LC/MS (ESI+) 
m/z 360 [M+H]+; LC/ELS retention time 12.99 min.  247c: LC/MS (ESI+) m/z 372 [M+H]+; 
LC/ELS retention time 14.37 min.  247d: LC/MS (ESI+) m/z 348 [M+H]+; LC/ELS retention 
time 11.53 min. 
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General Procedure for the Optimization Experiments in Table 13.  To a solution of 
heterocycle (25 – 50 mg) and catalyst (5-100 mol%) in distilled THF was added the amine (1-10 
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equiv.) at room temperature.  The reaction mixture was stirred at room temperature or heated to 
the specified temperature for the specified time period.  At this time, a NaOH solution (1.0 M, 
2.0 mL) was added to the room temperature reaction mixture.  After 2 h, the biphasic mixture 
was diluted with deionized water (15 mL) and extracted with ether (3 X 20 mL).  The aqueous 
layer was then cooled to 0 oC and acidified slowly with a concentrated HCl solution just to pH 0.  
The resulting heterogeneous solution was stirred gently at 0 oC for 30 min, vacuum filtered (filter 
paper) and the isolated solids were washed with deionized water (10.0 mL).   The aqueous 
filtrate was extracted with EtOAc (3 X 20 mL).  The extracts were combined, dried (Na2SO4) 
and concentrated in vacuo.  The crude reaction mixtures were then analyzed by 1H NMR 
(DMSO-d6 or MeOD) and the respective product ratios were reported.  Products 277 and 278 
were observed in the crude reaction mixtures and their NMR characterization data is reported: 
4-(3-Allyl-4-hydroxy-2,6-dioxo-5,6-dihydropyridin-1(2H)-yl)benzoic acid (277). 1H NMR 
(DMSO-d6, 300 MHz) δ 12.89 (br-s, 1 H), 11.15 (s, 1 H), 7.98 (d, 2 H, J = 8.4 Hz), 7.25 (d, 2 H, 
J = 8.1 Hz), 5.82-5.73 (m, 1 H), 5.05-4.89 (m, 2 H), 3.74 (s, 2 H), 3.02 (d, 2 H, J = 6.6 Hz).  
4-(3,3-diallyl-2,4,6-trioxopiperidin-1-yl)benzoic acid (278).  1H NMR (MeOH-d4, 400 MHz) δ 
8.11 (d, 2 H, J = 6.3 Hz), 7.14 (d, 2 H, J = 6.3 Hz), 5.82-5.72 (m, 2 H), 5.20-5.15 (m, 4 H), 2.82-
2.67 (m, 4 H); 13C NMR (MeOH-d4, 100 MHz) δ  174.4, 172.2, 167.6, 166.2, 139.7, 131.6 (2 C), 
130.6, 130.1 (2 C), 128.7 (2 C), 118.7 (2 C), 54.5, 41.9, 1C in MeOD solvent peak. 
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2H-Pyran-2,4,6(3H,5H)-trione (282).109,110  To a 1.4:1 mixture of AcOH:Ac2O (25.8 mL) 
cooled to 0 oC was added 1,3-acetonedicarboxylic acid (10.0 g, 66.4 mmol) portion wise over a 
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20 min period.  The resulting light brown heterogeneous mixture was stirred at 0-5 °C for 3.5 h.  
At this time, the white solid was isolated by vacuum filtration, washed with AcOH (30 mL) 
followed by hexanes (100 mL), and was dried in vacuo to afford 282 (6.85 g, 81%): 1H NMR 
(Acetone-d6, 300 MHz) δ 10.98 (br-s, 1 H), 5.35 (s, 1 H), 3.70 (d, 2 H, J = 0.9 Hz); MS (EI) m/z 
128 (M+, 100), 120 (63), 116 (43). 
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Ethyl 4-(3-oxobutanamido)benzoate (284, DMA-NB245-72).114  To a suspension of 282 (1.00 
g, 7.81 mmol) in anhydrous ether (50 mL) cooled to 0 °C was added a solution of ethyl 4-
aminobenzoate (1.32 g, 7.81 mmol) in anhydrous ether (25 mL) dropwise over 30 min.  The 
resulting white suspension was stirred at 0 oC for 3 h and at room temperature for 16 h affording 
a pale yellow nearly homogeneous reaction mixture, which was diluted with hexanes (50 mL) 
and vacuum filtered.  The filtrate was cooled to 0 oC and hexanes (125 mL) was slowly added 
with stirring.  The resulting turbid solution was cooled to -5 oC for 40 h over which time a white 
solid crystallized, which was isolated by vacuum filtration, washed with hexanes (50 mL) and 
dried in vacuo to afford a nearly 1:1 mixture of 283 and 284 (1.14 g crude, ~50 %).  Compound 
283: 1H NMR (DMSO-d6, 300 MHz) δ 12.69 (br-s, 1 H), 10.45 (s, 1 H), 7.92 (d, 2 H, J = 8.7 
Hz), 7.70 (d, 2 H, J = 8.4 Hz), 4.28 (q, 2 H, J = 7.2 Hz), 3.17 (s, 2 H), 3.62 (s, 2 H), 1.31 (t, 3 H, 
J = 7.2 Hz).  After storage of the recrystallized solid at room temperature, it was found by 1H 
NMR that the mixture further decomposed to ~88% of 284 over 2 d and to ~95% after 4 d.  This 
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mixture was recrystallized from boiling wet ether (100 mL); however, the purity did not 
improve.  Complete decarboxylation was accomplished by refluxing the mixture in toluene (50 
mL) for 20 min.  Concentration of the mixture in vacuo afforded 284 (539 mg, 28%): keto 
tautomer (88%):  1H NMR (DMSO-d6, 300 MHz) δ 10.40 (s, 1 H), 7.91 (d, 2 H, J = 8.7 Hz), 
7.70 (d, 2 H, J = 8.7 Hz), 4.28 (q, 2 H, J = 7.2 Hz), 3.60 (s, 2 H), 2.21 (s, 3 H), 1.31 (t, 3 H, J = 
7.2 Hz); distinguished resonances for enol tautomer (12%): δ 13.61 (s, 1 H), 10.24 (s, 1 H), 5.23 
(s, 1 H), 1.94 (s, 3 H); MS (EI) m/z 249 (M+, 13), 165 (16), 146 (20), 137 (18), 120 (100).   
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4-(4-Carboxy-3-oxobutanamido)benzoic acid (279, DMA-NB245-70).  To a suspension of 
282 (250 mg, 1.95 mmol) in anhydrous ether (10 mL) cooled to 0 °C was added a solution of 4-
aminobenzoic acid (270 mg, 1.95 mmol) dissolved in anhydrous ether (25 mL) dropwise over 
30.  The resulting white suspension was slowly warmed to room temperature for 15 h, vacuum 
filtered and the resulting white solid was washed with wet ether (50 mL).  The crude solids were 
dissolved in THF (20 mL) at room temperature and hexanes (20 mL) was slowly added.  
Initially, a pale yellow solid precipitated which was removed by vacuum filtration.  The filtrate 
was diluted with hexanes (100 mL) and the resulting turbid solution was cooled to -5 °C for 3 h.  
The precipitate was isolated by vacuum filtration, washed with hexanes (30 mL) and dried in 
vacuo to afford 279 (176 mg, 34%, ~90% pure).  Product further crystallized from the mother 
liquor over 16 h at room temperature.  The precipitate was isolated by vacuum filtration, washed 
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with hexanes (30 mL) and dried in vacuo to afford an approximately 94:6 mixture of 279:285 
(54.1 mg, 10%, ~94% pure) as a white solid: IR (ATR) 3240, 2914, 2675, 2556, 1732, 1668, 
1627, 1592, 1428, 1286, 1258, 1174, 940 cm-1; keto tautomer (80%): 1H NMR (DMSO-d6, 300 
MHz) δ 12.71 (s, 1 H), 10.41 (s, 1 H), 7.89 (d, 2 H, J = 8.0 Hz), 7.67 (d, 2 H, J = 9.0 Hz), 3.71 
(s, 2 H), 3.62 (s, 2 H); 13C NMR (DMSO-d6, 75 MHz) δ 198.4, 168.4, 166.9, 165.1, 142.8, 130.5 
(2 C), 125.4, 118.4 (2 C), 51.6, 49.4;  distinguished resonances for major enol tautomer (14%): 
1H NMR (DMSO-d6, 300 MHz) δ 13.6 (s, 1 H), 5.38 (s, 1 H), 3.26 (s, 2 H); distinguished 
resonances for minor enol tautomer (6%): 1H NMR (DMSO-d6, 300 MHz) δ 5.18 (s, 1 H), 3.37 
(s, 2 H);  LC/MS/UV data: Phenomenex C18 (4.6 X 100 nm) column, 1.0 mL/min, 254 nm, 
gradient elution with 15 to 45% acetonitrile in water containing 0.10% TFA, 1 mg sample/mL 
DMSO; Retention  time = 4.94 min; MS(ESI+) m/z 266 [M + H]+.   
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4-(3-Oxobutanoylamino)benzoic acid (285, DMA-NB245-77).114  A mixture of 279 (127 mg, 
0.479 mmol) in toluene (20 mL) was heated to 110 oC.  The decarboxylation experiment was 
monitored over three heating cycles of 30 min (35%), 3 h (~98%), and 2.5 h (complete by 1H 
NMR) for a total heating time of 6 h.  The product was isolated and worked up as follows after 
each heating cycle.  Upon cooling to room temperature, the reaction mixture was diluted with 
hexanes (30 mL), further cooled to -5 oC for 1 h and vacuum filtered.  The isolated yellow 
crystalline solid was washed with hexanes (20 mL) and dried in vacuo to afford 285 (91.6 mg, 
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86%): keto tautomer (91%):  1H NMR (DMSO-d6, 300 MHz) δ 12.72 (s, 1 H), 10.37 (s, 1 H), 
7.90 (d, 2 H, J = 8.7 Hz), 7.68 (d, 2 H, J = 8.7 Hz), 3.60 (s, 2 H), 2.21 (s, 3 H); distinguished 
resonances for enol tautomer (9%): δ 13.63 (s, 1 H), 10.21 (s, 1 H), 5.23 (s, 1 H), 1.94 (s, 3 H); 
MS (EI) m/z 221 (M+, 32), 137 (100), 127 (14), 120 (98); LC/UV data: Phenomenex C18 (4.6 X 
100 nm) column, 1.0 mL/min, 254 nm, gradient elution with 15 to 45% acetonitrile in water 
containing 0.10% TFA, 1 mg sample/mL DMSO; Retention  time = 5.06 min.  
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Ethyl 4-(5-methoxy-3,5-dioxopentanamido)benzoate (287, DMA-NB245-75).  To a 
suspension of 286 (1.35 mL, 8.90 mmol) and ZnO (483 mg, 5.93 mmol) in dry toluene (30 mL) 
was added ethyl 4-aminobenzoate (1.00 g, 5.93 mmol, 1 equiv.) at room temperature.  The white 
suspension was heated to reflux for 2 h, cooled to room temperature, filtered through a plug of 
SiO2 (1 in) with EtOAc (150 mL), concentrated by rotary evaporation (40 oC) and the resulting 
yellow oil was chromatographed on SiO2 (2:1 hexanes:EtOAc).  The product (Rf = 0.20) 
fractions were combined, concentrated by rotary evaporation (30 oC) and the resulting oil was 
dissolved twice in MeOH (8.0 mL) followed by re-concentration in vacuo, to aid in the removal 
of residual EtOAc, to afford 287 as a white crystalline solid (1.15 g, 63%): Mp 68.5-72.0 oC; IR 
(ATR) 3321, 3195, 3115, 2988, 2956, 1745, 1681, 1594, 1536, 1316, 1279, 1247, 1146, 1003 
cm-1; keto tautomer (86%):  1H NMR (DMSO-d6, 300 MHz) δ 10.45 (s, 1 H), 7.92 (d, 2 H, J = 
8.7 Hz), 7.70 (d, 2 H, J = 8.7 Hz), 4.28 (q, 2 H, J = 7.2 Hz), 3.76 (s, 2 H), 3.72 (s, 2 H), 3.63 (s, 3 
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H), 1.30 (t, 3 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 198.0, 167.3, 165.3, 165.1, 
143.1, 130.3 (2 C), 124.6, 118.5 (2 C), 60.9, 52.3, 52.0, 49.4, 14.6; distinguished resonances for 
major enol tautomer (12%): 1H NMR (DMSO-d6, 300 MHz) δ 13.61 (s, 1 H), 10.43 (s, 1 H), 
5.39 (s, 1 H), 3.66 (s, 3 H), 3.39 (s, 2 H); 13C NMR (DMSO-d6, 100 MHz) δ 170.5, 169.3, 168.7, 
142.8, 119.0, 93.9, 52.4, 41.0; distinguished resonances for minor enol tautomer (2%): 1H NMR 
(DMSO-d6, 300 MHz) δ 11.81 (s, 1 H), 5.27 (s, 1 H); 13C NMR (DMSO-d6, 100 MHz) δ 171.9, 
171.4, 166.0, 118.2, 91.5, 51.7, 43.5; HRMS (TOF MS ES+) m/z calculated for C15H17NO6Na 
(M+Na) 330.0954, found 330.0953.  
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N-ethyl-4-(5-morpholino-3,5-dioxopentanamido)benzamide (288, DMA-NB245-82).  To a 
suspension of 287 (350 mg, 1.14 mmol) and ZnO (92.7 mg, 1.14 mmol) in toluene (20 mL) was 
added morpholine (100 µL, 1.14 mmol) at room temperature.  The resulting mixture was heated 
to reflux for 36 h, cooled to room temperature and vacuum filtered through a plug of SiO2 (2 in) 
with EtOAc (800 mL).  The cloudy filtrate was concentrated by rotary evaporation (40 oC) and 
the resulting light yellow solids were dissolved in EtOAc (4.0 mL) for chromatography on SiO2 
(EtOAc).  The product fractions (Rf = 0.26) were combined, concentrated by rotary evaporation 
(40 oC) and the resulting light orange oil was dissolved in MeOH (5.0 mL, to remove residual 
EtOAc), re-concentrated by rotary evaporation (40 oC) and further dried in vacuo to afford 288 
as a light orange solid (180 mg, 44%). The tautomeric ratios reported below as percentages 
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reflect the ratio of the tautomer in solution immediately after sample preparation vs. after 
equilibration (20 h) as measured by 1H NMR integration: Mp 133.5-134.5 oC; IR (ATR) 3271, 
3195, 3115, 2964, 2869, 1717, 1692, 1592, 1543, 1266, 1234, 1107 cm-1; keto tautomer (88% vs. 
80%):  1H NMR (DMSO-d6, 300 MHz) δ 10.45 (s, 1 H), 7.92 (d, 2 H, J = 8.7 Hz), 7.70 (d, 2 H, J 
= 8.7 Hz), 4.28 (q, 2 H, J = 7.2 Hz), 3.81 (s, 2 H), 3.69 (s, 2 H), 3.57-3.52 (m, 4 H), 3.46-3.44 
(m, 2 H), 3.38-3.32 (m, 2 H), 1.31 (t, 3 H, J = 7.2 Hz); 13C NMR (DMSO-d6, 100 MHz) δ 199.5, 
165.4, 165.3, 165.2, 143.1, 130.3 (2 C), 124.5, 118.5 (2 C), 66.1, 66.0, 60.5, 51.5, 48.5, 46.1, 
41.5, 14.2; distinguished resonances for major enol tautomer (0% vs. 12%): 1H NMR (DMSO-d6, 
300 MHz) δ 14.97 (s, 1 H), 5.62 (s, 1 H); 13C NMR (DMSO-d6, 100 MHz) δ 171.2, 170.1, 166.5, 
143.2, 118.9, 88.7, 43.8; distinguished resonances for minor enol tautomer (12 vs. 8%): 1H NMR 
(DMSO-d6, 300 MHz) δ 13.68 (s, 1 H), 10.37 (s, 1 H), 5.31 (s, 1 H); 13C NMR (DMSO-d6, 100 
MHz) δ 170.6, 165.8, 142.8, 93.1, 41.5; HRMS (TOF MS ES+) m/z calculated for 
C18H22N2O6Na (M+Na) 385.1376, found 385.1368. 
 
O
HN
O O
N
O OH
O
280
 
4-(5-Morpholino-3,5-dioxopentanamido)benzoic acid (280, DMA-NB245-88).  To a 
homogeneous yellow solution of 288 (120 mg, 0.331 mmol) in dioxane (10 mL) was added in 
one portion a 3.0 M LiOH solution (10 mL).  The resulting slightly heterogeneous pale yellow 
reaction mixture was stirred at room temperature for 6 h, cooled to 0 oC and acidified to pH 0 
with a concentrated HCl solution.  The resulting pale yellow homogeneous aqueous solution was 
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extracted with EtOAc (4 X 30 mL).  The extracts were combined, dried (Na2SO4) and 
concentrated by rotary evaporation (40 oC).  The resulting yellow residue was triturated with 
MeOH (10 mL) at 40 oC for 30 min and the heterogeneous solution was cooled to -5 oC for 1 h.  
The precipitate was isolated by vacuum filtration, washed with MeOH (5 mL, cooled to 0 oC) 
and dried in vacuo to afford 280 as a white solid (67.1 mg, 61%).  The tautomeric ratios reported 
below as percentages reflect the ratio of the tautomer in solution immediately after sample 
preparation vs. after equilibration (6 h) as measured by 1H NMR integration: Mp 177.5-178.5 oC; 
IR (ATR) 3290, 3202, 2975, 2924, 2863, 2662, 2548, 1683, 1596, 1545, 1407, 1314, 1295, 1226, 
1169, 1113 cm-1; keto-tautomer (90% vs. 82%):  1H NMR (DMSO-d6, 300 MHz) δ 12.75 (s, 1 
H), 10.43 (s, 1 H), 7.90 (d, 2 H, J = 8.7 Hz), 7.67 (d, 2 H, J = 8.7 Hz), 3.81 (s, 2 H), 3.69 (s, 2 
H), 3.75-3.52 (m, 4 H), 3.46-3.43 (m, 2 H), 3.38-3.34 (m, 2 H); 13C NMR (DMSO-d6, 100 MHz) 
δ 199.6, 167.0, 165.5, 165.3, 142.9, 130.5 (2 C), 125.5, 118.5 (2 C), 66.1 (2 C), 51.6, 48.5, 46.2, 
41.6; distinguished resonances for major-enol-tautomer (1% vs. 11%): 1H NMR (DMSO-d6, 300 
MHz) δ 14.98 (s, 1 H), 5.62 (s, 1 H); 13C NMR (DMSO-d6, 100 MHz) δ 171.4, 170.2, 166.5, 
143.0, 118.9, 88.8, 43.9; distinguished resonances for minor-enol-tautomer (8% vs. 7%): 1H 
NMR (DMSO-d6, 300 MHz) δ 13.71 (s, 1 H), 10.35 (s, 1 H), 5.31 (s, 1 H); HRMS (TOF MS 
ES+) m/z calculated for C16H18N2O6Na (M+Na) 357.1063, found 357.1054; LC/MS/UV data: 
Phenomenex C18 (4.6 X 100 nm) column, 1.0 mL/min, 254 nm, gradient elution with 15 to 45% 
acetonitrile in water containing 0.10% TFA, 1 mg sample/mL DMSO; Retention  time = 6.00 
min; MS(ESI+) m/z 375 [M + Na]+. 
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Ethyl 4-(4-{N-[4-(ethoxycarbonyl)phenyl]carbamoyl}-3-oxobutanoylamino)benzoate (289, 
DMA-NB245-78).  To a suspension of dimethyl 1,3-acetonedicarboxylate (0.40 mL, 2.64 mmol) 
and ZnO (0.215 mg, 2.64 mmol) in dry toluene (12 mL) was added ethyl 4-aminobenzoate (979 
mg, 5.81 mmol, 2.2 equiv.) at room temperature.  The reaction mixture was heated to reflux for 9 
h, cooled to room temperature and vacuum filtered 3 times through a plug of SiO2 (1 in) with 
EtOAc (~300 mL/filtration).  The cloudy filtrate was condensed by rotary evaporation (40 oC) 
after each filtration and this process was repeated until the filtrate was clear.  After the third 
filtration, the resulting white solids were dissolved in boiling EtOAc (25 mL) and diluted with 
hexanes (50 mL). The turbid solution was slowly cooled to room temperature and the resulting 
white crystalline solid was isolated by vacuum filtration, washed with hexanes (30 mL) and dried 
in vacuo.  The mother liquor was recrystallized 3 additional time utilizing the same procedure 
affording 289 (701 mg, 60%, total yield from 4 recrystallizations): Mp 194.0-195.0 oC; IR (ATR) 
3353, 3295, 3195, 3126, 2975, 1719, 1656, 1599, 1536, 1411, 1273, 1172, 1103 cm-1; keto 
tautomer (72%):  1H NMR (DMSO-d6, 300 MHz) δ 10.47 (s, 2 H), 7.92 (d, 4 H, J = 8.7 Hz), 
7.71 (d, 4 H, J = 9.0 Hz), 4.28 (q, 4 H, J = 7.2 Hz), 3.76 (s, 4 H), 1.31 (t, 6 H, J = 7.2 Hz); 13C 
NMR (DMSO-d6, 100 MHz) δ 198.9, 165.3 (2 C), 165.2 (2 C), 143.1 (2 C), 130.3 (4 C), 124.5 (2 
C), 118.5 (4 C), 60.5 (2 C), 51.8 (2 C), 14.2 (2 C); distinguished resonances for enol tautomer 
(28%): 1H NMR (DMSO-d6, 300 MHz) δ 13.70 (s, 1 H), 10.56 (s, 1 H), 10.41 (s, 1 H), 7.75 (d, 2 
H, J = 9.0 Hz), 5.42 (s, 1 H), 3.40 (s, 2 H); 13C NMR (DMSO-d6, 100 MHz) δ 170.8, 170.5, 
 246 
166.3, 143.2, 142.8, 124.5, 118.9, 118.5, 93.4, 43.4; HRMS (TOF MS ES+) m/z calculated for 
C23H24N2O7Na (M+Na) 463.1481, found 463.1440. 
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4-{4-[N-(4-carboxyphenyl)carbamoyl]-3-oxobutanoylamino}benzoic acid (290, DMA-
NB245-81).  To a solution of 289 (200 mg, 0.454 mmol) in dioxane (20 mL) was added a 4.0 M 
LiOH solution (20 mL) in one portion at room temperature.  The resulting heterogeneous yellow 
reaction mixture was stirred at room temperature for 2.5 h, cooled to 0 oC and acidified to pH 0 
with concentrated HCl (10 mL).  The resulting white oily suspension was stirred at 0 oC for 18 h; 
however, the suspension did not sufficiently coagulate to afford an isolable solid.  The mixture 
was warmed to room temperature and diluted with deionized water (100 mL) followed by EtOAc 
(150 mL) for extraction.  A white solid formed between the two layers, was isolated by vacuum 
filtration, washed with EtOAc (20 mL) and dried in vacuo to afford the product (81.7 mg, batch 
1).  The aqueous layer was extracted with EtOAc (3 X 150 mL).  The EtOAc layers were 
combined, dried (Na2SO4) and concentrated by rotary evaporation (40 oC).  The resulting light 
brown residue was triturated with boiling EtOAc (40 mL) for 30 min.  This mixture was cooled 
to room temperature and the resulting solid was isolated by vacuum filtration, washed with 
hexanes (30 mL) and dried in vacuo (52.7 mg, batch 2).  1H NMRs (DMSO-d6) of both batches 
of solid showed a similar composition for the isolated products with the major contaminants 
being residual solvents; dioxane and EtOAc.  The products from both batches were combined 
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and triturated with boiling MeOH (50 mL) for 30 min.  The white suspension was slowly cooled 
to room temperature, the resulting light pink solid was isolated by vacuum filtration, washed 
with MeOH (10 mL) and dried in vacuo to afford 290 solvated with ~4% dioxane (118 mg, 
68%): Mp 264.0-265.0 oC; IR (ATR) 3303, 3070, 2831, 2667, 2561, 1663, 1594, 1530, 1405, 
1316, 1292, 1172 cm-1; keto tautomer (77%): 1H NMR (DMSO-d6, 300 MHz) δ 12.72 (s, 2 H), 
10.45 (s, 2 H), 7.90 (d, 4 H, J = 8.7 Hz), 7.68 (d, 4 H, J = 8.7 Hz), 3.67 (s, 4 H); 13C NMR 
(DMSO-d6, 100 MHz) δ 199.0, 166.9 (2 C), 165.1 (2 C), 142.8 (2 C), 130.5 (4 C), 125.4 (2 C), 
118.4 (4 C), 51.8 (2 C); distinguished resonances for enol tautomer (23%): 1H NMR (DMSO-d6, 
300 MHz) δ 13.75 (br-s, 1 H), 10.53 (s, 1 H), 5.40 (s, 1 H), 3.39 (s, 2 H); 13C NMR (DMSO-d6, 
100 MHz) δ 170.8, 170.5, 166.2, 118.8, 93.3, 43.5. 
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N1,N3-Bis(4-(carbethoxy)phenyl)malonamide (292, DMA-NB245-80).113  To a solution of 
ethyl 4-aminobenzoate (882 mg, 5.24 mmol) in THF (15 mL) cooled to 0 oC was added malonyl 
chloride (0.250 mL, 2.49 mmol) in one portion and the reaction mixture turned heterogeneous 
and light yellow in color.  After stirring at 0 oC for 5 min, K2CO3 (861 mg, 6.23 mmol) was 
added, the ice bath was removed, the reaction mixture was warmed to room temperature for 2 h 
and was then diluted with EtOAc (100 mL) and washed with 1.0 M HCl (2 X 100 mL) followed 
by a saturated brine solution (2 X 100 mL).  The EtOAc layer was then dried (Na2SO4) and 
concentrated by rotary evaporation (40 oC).  The resulting light yellow solids were dissolved in 
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boiling EtOAc (100 mL) and then hexanes (100 mL) was added to precipitate the product.  The 
resulting suspension was slowly cooled to room temperature and then to -5 oC for 3 h.  The fluffy 
white precipitate was isolated by vacuum filtration, washed with hexanes (50 mL) and dried in 
vacuo to afford 292 (819.9 mg, 83%): 1H NMR (DMSO-d6, 300 MHz) δ 10.55 (s, 2 H), 7.93 (d, 
4 H, J = 8.7 Hz), 7.74 (d, 4 H, J = 8.7 Hz), 4.28 (q, 4 H, J = 7.2 Hz), 3.57 (s, 2 H), 1.31 (t, 6 H, J 
= 7.2 Hz); MS (EI) m/z 398 (M+, 80), 207 (57), 165 (82), 120 (90), 95 (100). 
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N1,N3-Bis(4-benzoic acid)malonamide (293, DMA-NB245-85).113  To a suspension of 292 
(250 mg, 0.627 mmol) in dioxane (20 mL) was added a 1.0 M LiOH solution (20 mL) at room 
temperature.  The resulting homogenous yellow reaction mixture was stirred at room temperature 
for 2.5 h, cooled to 0 oC and acidified with concentrated HCl (10 mL, reaction pH = 0).  After 1 
h at 0 oC, a white solid precipitated from the mixture which was isolated by vacuum filtration, 
washed with deionized water (30 mL) and recrystallized from boiling MeOH (50 mL).  After 
slowly cooling the suspension to room temperature, the recrystallized solid was isolated by 
vacuum filtration, washed with MeOH (10 mL) and dried in vacuo to afford 293 (45.8 mg, 21%, 
~93% pure).  This sample was recrystallized a second time from boiling MeOH (20 mL) to 
afford 293 as a white crystalline solid (17.1 mg, 8%):  1H NMR (DMSO-d6, 300 MHz) δ 12.73 
(s, 2 H), 10.50 (s, 2 H), 7.91 (d, 4 H, J = 8.7 Hz), 7.72 (d, 4 H, J = 8.7 Hz), 3.56 (s, 2 H); MS 
(EI) m/z 342 (M+, 42), 149 (100). 
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Diethyl 4,4'-carbonylbis(azanediyl)dibenzoate (294, DMA-NB245-86).115  To a solution of 
ethyl 4-isocyanatobenzoate (300 mg, 1.57 mmol) in anhydrous ether (20 mL) was added ethyl 4-
aminobenzoate (259 mg, 1.57 mmol) in one portion.  The resulting homogeneous reaction 
mixture became cloudy after ~ 1 h and a clear crystalline solid precipitated slowly over 40 h.   At 
this time, the reaction mixture was further diluted with ether (15 mL), stirred at room 
temperature for 15 min and vacuum filtered.  The resulting white solid was isolated by vacuum 
filtration, washed with ether (15 mL) and dried in vacuo to afford 294 (327 mg, 58%):  1H NMR 
(DMSO-d6, 300 MHz) δ 9.19 (s, 2 H), 7.90 (d, 4 H, J = 8.7 Hz), 7.60 (d, 4 H, J = 8.7 Hz), 4.28 
(q, 4 H, J = 7.2 Hz), 1.30 (t, 6 H, J = 7.2 Hz); MS (EI) m/z 356 (M+, 21), 311 (9), 165 (66), 120 
(100). 
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4,4'-Carbonylbis(azanediyl)dibenzoic acid (295, DMA-NB245-87).115  To a suspension of 294 
(220 mg, 617 mmol) in dioxane (10 mL) was added a 2.0 M LiOH solution (10 mL) at room 
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temperature.  The heterogeneous reaction mixture was stirred at room temperature for 8 h, cooled 
to 0 oC and acidified with concentrated HCl to pH 0.  The resulting turbid solution was cooled to 
-5 oC for 18 h.  The white precipitate was isolated by vacuum filtration, triturated with boiling 
MeOH (200 mL) for 1 h and dried in vacuo to afford 295 ~7% solvated with dioxane (164 mg, 
88%):  1H NMR (DMSO-d6, 300 MHz) δ 12.63 (s, 2 H), 9.24 (s, 2 H), 7.88 (d, 4 H, J = 8.7 Hz), 
7.58 (d, 4 H, J = 8.7 Hz). 
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SID 861574.  LC/MS/UV data: Phenomenex C18 (4.6 X 100 nm) column, 1.0 mL/min, 254 nm, 
gradient elution with 15 to 45% acetonitrile in water containing 0.10% TFA, 1 mg sample/mL 
DMSO; Retention time = 16.92 min; MS(ESI+) m/z 320 [M + H]+.  X-Ray crystal structure: A 
2.5 mg sample of SID 861574 was dissolved in a 1:1 mixture of MeOH:ACN (1.0 mL).  The 
solvent was slowly evaporated at 5 oC over several months and the resulting orange crystals were 
used for X-Ray crystallographic analysis. 
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APPENDIX A 
A.1 X-RAY CRYSTALLOGRAPHIC DATA FOR SID 861574 
 
Figure 22. X-Ray crystal structure of SID 861574  
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Table 1.  Crystal data and structure refinement for daw1016. 
Identification code  daw1016 
Empirical formula  C15 H13 N O7 
Formula weight  319.26 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 21.011(7) Å a= 90°. 
 b = 13.139(5) Å b= 94.689(7)°. 
 c = 10.438(4) Å g = 90°. 
Volume 2871.9(17) Å3 
Z 8 
Density (calculated) 1.477 Mg/m3 
Absorption coefficient 0.119 mm-1 
F(000) 1328 
Crystal size 0.29 x 0.26 x 0.14 mm3 
Theta range for data collection 1.83 to 27.50°. 
Index ranges -27<=h<=27, -17<=k<=17, -13<=l<=13 
Reflections collected 13676 
Independent reflections 3298 [R(int) = 0.0618] 
Completeness to theta = 27.50° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9835 and 0.9663 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3298 / 0 / 241 
Goodness-of-fit on F2 1.059 
Final R indices [I>2sigma(I)] R1 = 0.0527, wR2 = 0.1376 
R indices (all data) R1 = 0.0750, wR2 = 0.1513 
Largest diff. peak and hole 0.490 and -0.280 e.Å-3 
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Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for daw1016.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________
________  
 x y z U(eq) 
________________________________________________________________________
________   
C(1) 863(1) -1216(2) 5421(3) 60(1) 
N(1) 2641(1) 1769(1) 2492(1) 25(1) 
O(1) 5056(1) 1058(1) -711(2) 45(1) 
O(2) 4266(1) 855(1) -2255(2) 50(1) 
C(2) 696(1) -834(2) 4100(2) 49(1) 
O(3) 1211(1) -174(1) 3704(2) 46(1) 
C(3) 1208(1) 786(2) 4081(2) 33(1) 
O(4) 797(1) 1114(1) 4746(2) 46(1) 
C(4) 1715(1) 1427(1) 3640(2) 27(1) 
O(5) 1306(1) 2841(1) 4761(1) 36(1) 
C(5) 1730(1) 2458(2) 4007(2) 27(1) 
O(6) 3083(1) 3323(1) 2370(1) 34(1) 
C(6) 2185(1) 3128(1) 3615(2) 28(1) 
O(7) 2244(1) 182(1) 2421(1) 33(1) 
C(7) 2633(1) 2773(1) 2851(2) 26(1) 
C(8) 2187(1) 1054(1) 2850(2) 25(1) 
C(9) 3108(1) 1442(1) 1620(2) 26(1) 
C(10) 3748(1) 1436(2) 2036(2) 31(1) 
C(11) 4195(1) 1251(2) 1158(2) 32(1) 
C(12) 3993(1) 1054(1) -116(2) 28(1) 
C(13) 3344(1) 989(2) -500(2) 32(1) 
C(14) 2898(1) 1200(2) 367(2) 30(1) 
C(15) 4452(1) 964(1) -1127(2) 32(1) 
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Table 3.   Bond lengths [Å] and angles [°] for  daw1016. 
_____________________________________________________  
C(1)-C(2)  1.483(4) 
C(1)-H(1A)  0.9700 
C(1)-H(1B)  0.9700 
C(1)-H(1C)  0.9700 
N(1)-C(7)  1.372(2) 
N(1)-C(8)  1.410(2) 
N(1)-C(9)  1.458(2) 
O(1)-C(15)  1.313(3) 
O(1)-H(1O)  1.05(4) 
O(2)-C(15)  1.218(3) 
C(2)-O(3)  1.471(3) 
C(2)-H(2A)  0.9800 
C(2)-H(2B)  0.9800 
O(3)-C(3)  1.321(2) 
C(3)-O(4)  1.230(2) 
C(3)-C(4)  1.461(3) 
C(4)-C(5)  1.407(3) 
C(4)-C(8)  1.428(2) 
O(5)-C(5)  1.334(2) 
O(5)-H(5O)  0.90(3) 
C(5)-C(6)  1.386(3) 
O(6)-C(7)  1.321(2) 
O(6)-H(6O)  0.88(3) 
C(6)-C(7)  1.366(3) 
C(6)-H(6)  0.88(2) 
O(7)-C(8)  1.240(2) 
C(9)-C(10)  1.378(3) 
C(9)-C(14)  1.382(3) 
C(10)-C(11)  1.386(3) 
C(10)-H(10)  0.90(2) 
C(11)-C(12)  1.386(3) 
C(11)-H(11)  0.99(2) 
C(12)-C(13)  1.392(3) 
C(12)-C(15)  1.491(3) 
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C(13)-C(14)  1.383(3) 
C(13)-H(13)  0.94(2) 
C(14)-H(14)  0.97(2) 
 
C(2)-C(1)-H(1A) 109.5 
C(2)-C(1)-H(1B) 109.5 
H(1A)-C(1)-H(1B)109.5 
C(2)-C(1)-H(1C) 109.5 
H(1A)-C(1)-H(1C)109.5 
H(1B)-C(1)-H(1C)109.5 
C(7)-N(1)-C(8) 122.98(15) 
C(7)-N(1)-C(9) 118.58(15) 
C(8)-N(1)-C(9) 118.26(15) 
C(15)-O(1)-H(1O)105(2) 
O(3)-C(2)-C(1) 109.7(2) 
O(3)-C(2)-H(2A) 109.7 
C(1)-C(2)-H(2A) 109.7 
O(3)-C(2)-H(2B) 109.7 
C(1)-C(2)-H(2B) 109.7 
H(2A)-C(2)-H(2B)108.2 
C(3)-O(3)-C(2) 117.23(16) 
O(4)-C(3)-O(3) 121.52(18) 
O(4)-C(3)-C(4) 122.69(18) 
O(3)-C(3)-C(4) 115.79(17) 
C(5)-C(4)-C(8) 119.09(17) 
C(5)-C(4)-C(3) 118.01(17) 
C(8)-C(4)-C(3) 122.89(17) 
C(5)-O(5)-H(5O) 100.0(17) 
O(5)-C(5)-C(6) 116.40(17) 
O(5)-C(5)-C(4) 121.46(17) 
C(6)-C(5)-C(4) 122.14(17) 
C(7)-O(6)-H(6O) 108.6(19) 
C(7)-C(6)-C(5) 118.73(18) 
C(7)-C(6)-H(6) 120.6(13) 
C(5)-C(6)-H(6) 120.7(13) 
O(6)-C(7)-C(6) 125.76(17) 
 256 
O(6)-C(7)-N(1) 113.41(16) 
C(6)-C(7)-N(1) 120.83(17) 
O(7)-C(8)-N(1) 115.68(16) 
O(7)-C(8)-C(4) 128.11(17) 
N(1)-C(8)-C(4) 116.20(16) 
C(10)-C(9)-C(14) 121.65(17) 
C(10)-C(9)-N(1) 119.61(17) 
C(14)-C(9)-N(1) 118.63(16) 
C(9)-C(10)-C(11) 119.25(19) 
C(9)-C(10)-H(10) 121.7(14) 
C(11)-C(10)-H(10)119.0(14) 
C(10)-C(11)-C(12)119.74(19) 
C(10)-C(11)-H(11)117.7(13) 
C(12)-C(11)-H(11)122.3(12) 
C(11)-C(12)-C(13)120.19(17) 
C(11)-C(12)-C(15)121.93(18) 
C(13)-C(12)-C(15)117.78(18) 
C(14)-C(13)-C(12)119.96(19) 
C(14)-C(13)-H(13)119.9(15) 
C(12)-C(13)-H(13)120.1(15) 
C(9)-C(14)-C(13) 118.95(18) 
C(9)-C(14)-H(14) 120.9(13) 
C(13)-C(14)-H(14)120.1(13) 
O(2)-C(15)-O(1) 123.69(18) 
O(2)-C(15)-C(12) 121.29(19) 
O(1)-C(15)-C(12) 114.95(18) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 
daw1016. 
________________________________________________________________________
________  
 x  y  z  U(eq) 
________________________________________________________________________
________  
  
H(1A) 1248 -1623 5434 90 
H(1B) 516 -1631 5690 90 
H(1C) 934 -645 6004 90 
H(1O) 5306(18) 1010(30) -1540(30) 110(13) 
H(2A) 635 -1409 3504 59 
H(2B) 296 -449 4074 59 
H(5O) 1063(13) 2290(20) 4860(30) 63(8) 
H(6O) 3012(14) 3970(20) 2530(30) 65(9) 
H(6) 2183(9) 3770(16) 3847(18) 22(5) 
H(10) 3883(10) 1559(16) 2860(20) 36(6) 
H(11) 4651(11) 1329(16) 1460(20) 40(6) 
H(13) 3209(11) 804(17) -1350(20) 47(7) 
H(14) 2446(11) 1203(16) 90(20) 38(6) 
________________________________________________________________________
________  
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